# EDGAR Filing Document

**Accession Number:** 0002041886
**File Stem:** 0001683168-26-005016
**Filing Date:** 2026-6
**Character Count:** 843218
**Document Hash:** 0c5cfd0e62a4551ffea4d7c6c9dddcb0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001683168-26-005016.hdr.sgml**: 20260622

**ACCESSION NUMBER**: 0001683168-26-005016

**CONFORMED SUBMISSION TYPE**: 1-A

**PUBLIC DOCUMENT COUNT**: 176

**FILED AS OF DATE**: 20260622

**DATE AS OF CHANGE**: 20260622

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MYRXWALLET NORTH AMERICA Corp
- **CENTRAL INDEX KEY:** 0002041886
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMPUTER PROCESSING & DATA PREPARATION [7374]
- **ORGANIZATION NAME:** 06 Technology
- **EIN:** 331503628
- **STATE OF INCORPORATION:** WY
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** 1-A
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 024-12775
- **FILM NUMBER:** 261106374

**BUSINESS ADDRESS:**
- **STREET 1:** 732 S. 6TH STREET
- **STREET 2:** #5397
- **CITY:** LAS VEGAS
- **STATE:** NV
- **ZIP:** 89101
- **BUSINESS PHONE:** 702-546-8686

**MAIL ADDRESS:**
- **STREET 1:** 732 S. 6TH STREET
- **STREET 2:** #5397
- **CITY:** LAS VEGAS
- **STATE:** NV
- **ZIP:** 89101

## Part

[**Table of Contents**](#a_001)

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 1-A**

**Tier 2**

Offering Statement UNDER THE SECURITIES ACT OF 1933

**MyRXWallet North America Corporation**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Wyoming** | **7374** | **33-1503628** |
| (State or Other Jurisdiction<br> of Incorporation) | (Primary Standard<br> Classification Code) | (IRS Employer<br> Identification No.)<br>|

---

**732 S. 6th Street, #5397**

**Las Vegas, NV 89101**

**(702) 546-8686**

(Address, including zip code, and telephone number,<br> including area code, of registrant's principal executive offices)

**Northwest Registered Agent Service Inc.**

**30 N Gould St Ste N**

**Sheridan, WY 82801 USA**

(Name, address, including zip code, and telephone number,<br> including area code, of agent for service)

THIS OFFERING STATEMENT SHALL ONLY BE QUALIFIED UPON ORDER OF THE COMMISSION, UNLESS A SUBSEQUENT AMENDMENT IS FILED INDICATING THE INTENTION TO BECOME QUALIFIED BY OPERATION OF THE TERMS OF REGULATION A.

Please send copies of all correspondence to:

---

| | |
|:---|:---|
| **Corporate Counsel**<br> Law Office of Dan M Winder, P.C. 3507<br> 3705 W. Charleston Blvd.<br> Las Vegas, NV 89102<br> Phone: (702) 878-6000<br> Fax: (702) 474-0631<br> winderdanatty@gmail.com | **Business Legal Advisors, LLC**<br> Brian Higley, Esq.<br> Attorney at Law****<br> 14888 Auburn Sky Drive,<br> Draper, UT 84020<br> (801) 634-1984<br> brian@businesslegaladvisor.com |

---

**THIS OFFERING CIRCULAR IS PART OF AN OFFERING STATEMENT ON FORM 1-A FILED PUBLICLY WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION. THIS IS A PRELIMINARY OFFERING CIRCULAR AND IS SUBJECT TO COMPLETION OR AMENDMENT. THE INFORMATION CONTAINED HEREIN IS SUBJECT TO CHANGE, AND THE SECURITIES DESCRIBED HEREIN MAY NOT BE SOLD NOR MAY OFFERS TO BUY BE ACCEPTED PRIOR TO QUALIFICATION OF THE OFFERING STATEMENT BY THE SEC.**

**PRELIMINARY OFFERING CIRCULAR DATED JUNE 22, 2026**

**OFFERING CIRCULAR**

![](logo.jpg)

MyRxWallet

**MyRXWallet North America Corporation**

**732 S. 6th Street, #5397**

**Las Vegas, NV 89101**

**(702) 546-8686**

www.myrxwallet.io

**MAXIMUM GROSS OFFERING: $74,980,795**

In this offering, we are offering up to 882,127 shares of our common stock at $85 per share for maximum gross proceeds to us of up to $74,980,795, before deduction of offering expenses, assuming all shares are sold. This is a primary-only offering; no shares are being offered by selling shareholders. This offering will begin as soon as practicable after this offering circular has been qualified by the United States Securities and Exchange Commission (the "**SEC**" or the "**Commission**").

Our common stock is not now listed on any national securities exchange (such as Nasdaq or the NYSE) or quotation system (such as the OTC Markets) and there is no market for our securities. Although we intend to apply for quotation of our Common Stock on the OTCQB or OTCQX through a market maker, public trading of our common stock may never materialize and there is no guarantee that an active trading market will develop in our securities. Investors should be prepared to hold our shares indefinitely.

All of the shares being registered for sale by us will be sold at a fixed price, which will be $85. We, by determination of our board of directors, in our sole discretion, may issue common stock under this offering for cash, promissory notes, services, and/or other consideration without notice to subscribers. There is no minimum amount we are required to raise from the shares being offered by us. There are no arrangements to place the funds received in an escrow, trust, or similar arrangement and the funds will be available to us following deposit into our bank account. There is no guarantee that we will sell any of the securities being offered in this offering. Additionally, there is no guarantee that this offering will successfully raise enough funds to implement our company's business plan.

This primary offering will terminate upon the earliest of (i) such time as all of the common stock has been sold pursuant to the Offering Statement on Form 1-A (the "**Offering Statement**"), or (ii) 365 days from the qualified date of this offering circular, unless extended by our directors for an additional 90 days. We may, however, at any time and for any reason terminate the offering.

Our Chief Executive Officer, Olivia Trinh, beneficially owns a majority of the issued and outstanding shares of our Common Stock and, thus, she controls a majority of the voting power of our Company. For so long as Ms. Trinh owns a majority of the voting power of the Company, she will control the outcome of matters submitted to a stockholder vote, including the appointment of all directors of the Company.

We expect to commence the offer and sale of the shares of common stock being offered pursuant to this offering circular as soon as practicable or within two calendar days of the qualification date.

This Offering Circular follows the disclosure format of Form S-1, pursuant to the General Instructions of Part II(a)(1)(ii) of Form 1-A.

There is currently no trading market for our common stock. Our common stock is not currently listed on any national securities exchange, quotation system or the Nasdaq stock market and there is no market for our securities. There is no guarantee that an active trading market will develop in our securities.

***Concurrent Exchange Act Registration***

Concurrently with the qualification of this offering statement, we intend to file a registration statement on Form 8-A with the Securities and Exchange Commission to voluntarily register our common stock under Section 12(g) of the Securities Exchange Act of 1934, as amended (the "**Exchange Act**"). Upon effectiveness of the Form 8-A, we will become subject to the information and reporting requirements of the Exchange Act, including the requirements to file annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements, and beneficial ownership reports. We will also become subject to the other provisions of the Exchange Act applicable to issuers with a class of equity securities registered thereunder, including certain corporate governance requirements and the proxy rules.

***Emerging Growth Company/Smaller Reporting Company***

As an "emerging growth company" and "smaller reporting company" under the Exchange Act, we will be permitted to take advantage of certain reduced disclosure and other requirements that will apply for so long as we remain an emerging growth company or smaller reporting company.

**NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ADEQUACY OR ACCURACY OF THE OFFERING CIRCULAR. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.**

**GENERALLY, NO SALE MAY BE MADE TO YOU IN THIS OFFERING IF THE AGGREGATE PURCHASE PRICE YOU PAY IS MORE THAN 10% OF THE GREATER OF YOUR ANNUAL INCOME OR NET WORTH. DIFFERENT RULES APPLY TO ACCREDITED INVESTORS AND NON-NATURAL PERSONS. BEFORE MAKING ANY REPRESENTATION THAT YOUR INVESTMENT DOES NOT EXCEED APPLICABLE THRESHOLDS, WE ENCOURAGE YOU TO REVIEW RULE 251(D)(2)(I)(C) OF REGULATION A. FOR GENERAL INFORMATION ON INVESTING, WE ENCOURAGE YOU TO REFER TO WWW.INVESTOR.GOV.**

**THESE SECURITIES ARE SPECULATIVE AND INVOLVE A HIGH DEGREE OF RISK. YOU SHOULD PURCHASE SHARES ONLY IF YOU CAN AFFORD THE COMPLETE LOSS OF YOUR INVESTMENT. PLEASE REFER TO '[RISK FACTORS](#a_005)' BEGINNING ON PAGE 5.**

The date of this offering circular is June 22, 2026

The following table of contents has been designed to help you find important information contained in this offering circular. We encourage you to read the entire offering circular.

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
| [OFFERING CIRCULAR SUMMARY](#a_003) | 1 |
| [RISK FACTORS](#a_005) | 5 |
| [DILUTION](#a_006) | 29 |
| [PLAN OF DISTRIBUTION](#a_007) | 31 |
| [USE OF PROCEEDS](#a_008) | 35 |
| [DESCRIPTION OF BUSINESS](#a_009) | 37 |
| [DESCRIPTION OF PROPERTY](#a_010) | 64 |
| [MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS](#a_011) | 66 |
| [DIRECTORS, EXECUTIVE OFFICERS AND SIGNIFICANT EMPLOYEES](#a_012) | 69 |
| [EXECUTIVE COMPENSATION](#a_013) | 73 |
| [SECURITY OWNERSHIP OF MANAGEMENT AND CERTAIN SECURITYHOLDERS](#a_014) | 75 |
| [INTEREST OF MANAGEMENT AND OTHERS IN CERTAIN TRANSACTIONS](#a_015) | 76 |
| [DESCRIPTION OF SECURITIES](#a_016) | 80 |
| [LEGAL MATTERS](#a_017) | 83 |
| [EXPERTS](#a_018) | 83 |
| [INDEX TO FINANCIAL STATEMENTS](#a_019) | 83 |

---

You should rely only on the information contained in this offering circular or contained in any free writing offering circular filed with the Commission. We have not authorized anyone to provide you with additional information or information different from that contained in this offering circular filed with the Commission. We take no responsibility for and can provide no assurance as to the reliability of, any other information that others may give you. We are offering to sell, and seeking offers to buy, our common stock only in jurisdictions where offers and sales are permitted. The information contained in this offering circular is accurate only as of the date of this offering circular, regardless of the time of delivery of this offering circular or any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date.

i

**FORWARD LOOKING STATEMENTS**

This offering circular contains forward-looking statements that involve risk and uncertainties. We use words such as "anticipate", "believe", "plan", "expect", "future", "intend", and similar expressions to identify such forward-looking statements. Investors should be aware that all forward-looking statements contained within this filing are good faith estimates of management as of the date of this filing. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including the risks faced by us as described in the "[Risk Factors](#a_005)" section and elsewhere in this offering circular.

Forward-looking statements in this Offering Circular include, but are not limited to, statements about the Company's ability to satisfy the $1.15 billion in promissory note obligations to related parties, the expected method of satisfying those obligations, the potential dilution from conversion of the notes and payment of interest in stock, the terms and completion of anticipated Capped Call arrangements, and the Company's ability to maintain sufficient authorized shares to satisfy the notes. These forward-looking statements are subject to substantial risks including the risk that the notes may be called on demand, that the Noteholders may elect to receive interest in stock rather than cash, and that conversion and interest payments may result in dilution substantially greater than currently estimated.

ii

**OFFERING CIRCULAR SUMMARY**

*This summary highlights information contained elsewhere in this Offering Circular and does not contain all of the information that you should consider in making your investment decision. Before investing in our common stock, you should carefully read this entire Offering Circular, including our consolidated financial statements and the related notes and the information set forth under the headings "[Risk Factors](#a_005)" and "[Management's Discussion and Analysis of Financial Condition and Results of Operations](#a_011)," in each case included elsewhere in this Offering Circular. Unless otherwise stated, all references to "us," "our," "we," the "Company" and similar designations refer to MyRXWallet North America Corporation and its wholly owned subsidiaries, MyRxWallet DAO, LLC, and MyRxWallet Prana, Pvt. Ltd., and majority owned subsidiary, MyRxWallet Capital, Inc.*

This offering circular, and any supplement to this offering circular include "forward-looking statements." To the extent that the information presented in this offering circular discusses financial projections, information or expectations about our business plans, results of operations, products or markets, or otherwise makes statements about future events, such statements are forward-looking. Such forward-looking statements can be identified by the use of words such as "intends", "anticipates", "believes", "estimates", "projects", "forecasts", "expects", "plans" and "proposes". Although we believe that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. These include, among others, the cautionary statements in the "*[Risk Factors](#a_005)*" section and the "*[Management's Discussion and Analysis of Financial Position and Results of Operations](#a_011)*" section in this offering circular.

This summary only highlights selected information contained in greater detail elsewhere in this offering circular. This summary may not contain all of the information that you should consider before investing in our common stock. You should carefully read the entire offering circular, including "*[Risk Factors](#a_005)*" beginning on Page 5, and the financial statements, before making an investment decision.

Generally, no sale may be made to you in this offering if the aggregate purchase price you pay is more than 10% of the greater of your annual income or net worth. Different rules apply to accredited investors and non-natural persons. Before making any representation that your investment does not exceed applicable thresholds, we encourage you to review Rule 251(d)(2)(i)(C) of Regulation A. For general information on investing, we encourage you to refer to www.investor.gov.

Sale of these shares will commence within two calendar days of the qualification date, and it will be a continuous offering pursuant to Rule 251(d)(3)(i)(F).

***Overview***

MyRxWallet North America Corporation (the "**Company**," "**MyRxWallet**," or the "**Parent Company**") through its wholly owned subsidiary, MyRxWallet DAO, LLC plans to pioneer a decentralized, blockchain-based platform that empowers patients to securely manage and monetize their healthcare data. With the current state of healthcare technology struggling to protect patient data from increasing cybersecurity threats, MyRxWallet intends to offer a secure, advanced solution designed to prevent breaches and reward patients for their participation.

We are a start-up company recently formed in October 2024. Subsequent to the period covered by our audited financial statements, the Company deployed its EHR platform to production at ehr.myrxwallet.io. The platform is technically operational, with APIs, patient and provider portals, and Hyperledger blockchain infrastructure live. On April 17, 2026, the platform successfully completed all 317 sub-tests of the ONC Inferno v8.0.0 certification test suite administered by the Office of the National Coordinator for Health Information Technology (ONC) on the first attempt with zero failures, which is the required predicate for ONC Health IT Module Certification under 45 CFR 170.315(g)(10). The Company remains pre-commercial: there are no external users, no executed pilot or customer agreements, and no revenue as of the date of this Offering Circular. The Company intends to use a portion of the proceeds of this offering to hire additional engineers, programmers, and staff to further develop its platform, complete ONC Module Certification, and build its sales and commercial operations.

Our mission is to revolutionize healthcare data management by providing patients with full control over their personal health data while securing that data through blockchain technology. By enabling patients to monetize their health data, we aim to address deficiencies in traditional healthcare systems and enhance data security. We believe our platform will reshape the future of healthcare, putting privacy and ownership in the hands of patients.

***Risk Factor Summary***

Our business will be subject to numerous risks and uncertainties, including those described in "*[Risk Factors](#a_005)*" immediately following this offering circular summary and elsewhere in this offering circular. These risks represent challenges to the successful implementation of our strategy and to the growth and future profitability of our business. These risks include, but are not limited to, the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· The Company has failed to generate revenues or profits;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Significant competition;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Risks associated with and unique to the health care industry;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Geopolitical situation in countries we operate in;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Not getting paid by customers;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Stability of the internet and cybersecurity;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Increased costs associated with reporting obligations as a public company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Exposure of our intellectual property and confidential information;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Our management controls the voting of our outstanding securities; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· There is no market for our securities and there may never be.

***The Offering***

We are offering our common stock pursuant to rules mandated under the Jumpstart Our Business Startups Act of 2012 (the "**JOBS Act**"). These offering rules are often referred to as "Regulation A+." We are relying upon "Tier 2" of Regulation A+, which allows us to offer of up to $75 million in a 12-month period.

---

| | |
|:---|:---|
| **Issuer name** | MyRXWallet North America Corporation, Wyoming corporation. |
| **Securities being offered by the Company** | We are offering up to 882,127 shares of our common stock at $85 per share on a "best efforts" basis through our officers and directors for maximum gross proceeds to us of up to $74,980,795, before deduction of offering expenses, assuming all shares are sold. This is a primary-only offering; no shares are being offered by selling shareholders. |
| **Offering price per share** | We will sell the shares at a fixed price per share of $85. |
| **Number of shares of common stock outstanding before the offering of common stock** | 280,352,363 shares of our common stock are currently issued and outstanding (reflecting 283,295,363 shares issued less 2,943,000 shares held in treasury). |
| **Number of shares of common stock outstanding after the offering of common stock** | 281,234,490 shares of our common stock will be issued and outstanding if we sell all the shares we are offering herein (reflecting 280,352,363 shares currently outstanding plus 882,127 shares offered hereby). |
| **The minimum number of shares to be sold in this offering** | There is no minimum number of shares to be sold in this offering. We do not intend to use an escrow agent as this is a "best-efforts" offering and funds will be available immediately to us for use. |
| **Minimum investment** | The minimum investment amount for a single investor is in the cumulative principal amount of $500, unless waived by the Company in its sole discretion. |
| **Use of Proceeds** | The Company intends to use a significant portion of the 70% allocation of this offering, representing aggregate gross proceeds of $52,499,400, exclusively for mergers and acquisitions, legal fees, accounting expenses, research and development, capital investments and working capital. These acquisitions are designed to expand and vertically integrate the MyRxWallet ecosystem across healthcare, data infrastructure, and technology services.<br>In the event that any qualified shares remain unsold, the Company has several additional acquisition targets prepared to proceed immediately upon access to liquidity following qualification. Management may, if necessary, allocate a limited portion of the proceeds to transaction expenses directly associated with these acquisitions, including legal, accounting, and regulatory costs.<br>See "*[Use of Proceeds](#a_008)*" below. |
| **Termination of the Offering** | The offering will terminate upon the earliest of (i) such time as all of the common stock has been sold pursuant to the Offering Statement or (ii) 365 days from the qualified date of this offering circular, unless extended by our Board of Directors for an additional 90 days. We may, however, at any time and for any reason terminate the offering. |
| **Subscriptions** | All subscriptions once accepted by us are irrevocable. |
| **Registration Costs** | We estimate our total offering registration costs and selling expenses to be approximately $50,000. |
| **Risk Factors** | See "*[Risk Factors](#a_005)*" and the other information in this offering circular for a discussion of the factors you should consider before deciding to invest in shares of our common stock. |

---

You should rely only upon the information contained in this offering circular. We have not authorized anyone to provide you with information different from that which is contained in this offering circular. We are offering to sell common stock and seeking offers to common stock only in jurisdictions where offers and sales are permitted.

***Concurrent Exchange Act Registration and Ongoing Reporting Obligations***

Immediately upon qualification of this offering statement, we intend to file a registration statement on Form 8-A with the SEC to voluntarily register our common stock under Section 12(g) of the Exchange Act. This registration will make us a fully reporting public company subject to the periodic reporting and other requirements of the Exchange Act.

***What this means for our company:***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· *Periodic Reporting*: We will be required to file annual reports on Form 10-K within 90 days after our fiscal year end (with possible 15-day extension), quarterly reports on Form 10-Q within 45 days after each of our first three fiscal quarters (with possible 5-day extension), and current reports on Form 8-K to report specified material events within four business days.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· *First Form 10-K Deadline*: Our next fiscal year ends September 30, 2026. We will be required to file our first annual report on Form 10-K by December 29, 2026 (or January 13, 2027 if we file for an extension).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· *Proxy Statements*: We will be subject to the SEC's proxy rules and will be required to provide our stockholders with a proxy statement meeting SEC requirements in advance of any stockholder meeting.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· *Section 16 Reporting*: Our directors, executive officers, and beneficial owners of more than 10% of our common stock will be required to file reports of their ownership and changes in ownership with the SEC under Section 16 of the Exchange Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· *Sarbanes-Oxley Act Compliance*: We will be subject to the applicable provisions of the Sarbanes-Oxley Act of 2002, including Section 404(a) requiring management's annual assessment of our internal control over financial reporting. As an emerging growth company, we will be exempt from the Section 404(b) requirement for an auditor attestation on internal control over financial reporting for up to five years.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· *Increased Costs*: We estimate that compliance with Exchange Act reporting requirements will cost us approximately $300,000 to $500,000 annually in legal, accounting, and administrative costs.

***Why we are taking this step:***

Our Board of Directors believes that becoming a fully reporting Exchange Act company will:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Enhance our credibility with customers, partners, and investors;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Provide greater transparency to our stockholders;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Potentially improve liquidity for our stockholders;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Position us to pursue listing on a national securities exchange (such as Nasdaq or NYSE) in the future; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Facilitate our ability to raise additional capital through registered public offerings.

***Emerging Growth Company and Smaller Reporting Company Status:***

We qualify as both an "emerging growth company" under the JOBS Act and a "smaller reporting company" under Exchange Act rules. As a result, we will be permitted to take advantage of certain reduced disclosure obligations and extended transition periods for new accounting standards. We may remain an emerging growth company for up to five years following the completion of this offering, or until earlier if we have more than $1.235 billion in annual revenues, issue more than $1 billion in non-convertible debt over a three-year period, or become a "large accelerated filer."

**RISK FACTORS**

Please consider the following risk factors and other information in this offering circular relating to our business before deciding to invest in our common stock.

This offering and any investment in our common stock involves a high degree of risk. You should carefully consider the risks described below and all of the information contained in this offering circular before deciding whether to purchase our common stock. If any of the following risks actually occur, our business, financial condition and results of operations could be harmed. The trading price of our common stock could decline due to any of these risks, and you may lose all or part of your investment.

We consider the following to be the material risks for an investor regarding this offering. Our company should be viewed as a high-risk investment and speculative in nature. An investment in our common stock may result in a complete loss of the invested amount.

An investment in our common stock is highly speculative, and should only be made by persons who can afford to lose their entire investment in us. You should carefully consider the following risk factors and other information in this report before deciding to become a holder of our common stock. If any of the following risks actually occur, our business and financial results could be negatively affected to a significant extent.

**Summary of Principal Risk Factors**

***Risks Related to Our Financial Condition***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· We have a limited operating history, have incurred significant losses since inception, and have substantial doubt about our ability to continue as a going concern. As of September 30, 2025, we had an accumulated deficit of $39,534 and working capital of $35,821.

· We will require substantial additional capital to execute our business plan, and there is no assurance that additional financing will be available on acceptable terms, or at all. This offering has no minimum amount, so proceeds may be insufficient to fund our operations.

***Risks Related to Our Business and Operations***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· We were formed in October 2024, have generated minimal revenue ($166,788 from inception), and while our core EHR platform has been deployed to production, it remains pre-commercial with no external users or customer agreements; our AI/ML clinical decision support, biobank infrastructure, and other advanced platform capabilities remain under development with no assurance of successful completion or market acceptance.

· We face intense competition from established companies with significantly greater resources and have not yet demonstrated our ability to compete effectively or achieve market adoption.

· We have completed two significant acquisitions and plan additional acquisitions, which involve substantial integration risks, potential unknown liabilities, and diversion of management resources.

· We depend heavily on our Chief Executive Officer, and the loss of key personnel could severely disrupt our business.

***Risks Related to Technology and Cybersecurity***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Our AI, machine learning, and advanced analytics capabilities do not currently exist and are entirely unproven. While our core EHR platform and Hyperledger blockchain infrastructure have been deployed to production and have successfully completed ONC Inferno v8.0.0 testing, these technologies have not yet been tested at commercial scale with external users and may not function as intended under real-world operating conditions.

· Despite our security-focused platform design, any cybersecurity breach could result in significant liability, regulatory penalties, and reputational harm.

· Our planned use of open-source software components subject to copyleft licenses may require us to publicly disclose our proprietary source code if we fail to comply with applicable license terms, which could negate our competitive advantage.

***Risks Related to Healthcare Regulation***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· We operate in a heavily regulated industry and must comply with HIPAA, GDPR, India's DPDP Act, and other complex and evolving privacy and healthcare regulations. Non-compliance could result in substantial penalties and operational restrictions.

· Healthcare reform and regulatory changes could materially adversely affect our business model and customers.

***Risks Related to International Operations***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· We have substantial operations and approximately $107 million in commitments in India, exposing us to political, economic, currency, and legal risks, including difficulties in repatriating funds and enforcing contracts.

· Our land acquisitions in India have not yet closed, legal title has not transferred, and there are significant uncertainties regarding completion of these transactions.

***Risks Related to Corporate Governance and Control***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Our Chief Executive Officer beneficially owns approximately 71.47% of our voting stock, giving her control over all stockholder matters, which may conflict with other stockholders' interests.

· We have identified material weaknesses in our internal controls, including the lack of an audit committee with financial expertise.

· We have engaged in significant related party transactions, including share buybacks totaling approximately $1.15 billion from entities controlled by our CEO, which may not be on arm's-length terms.

· Since its founding in 2024, the Company has had two Chief Executive Officers, and while each transition was voluntary and orderly, leadership changes in a development-stage company may raise concerns about management stability and continuity of strategic vision.

 **

 ****

 ****

 **

 ****

***Risks Related to Our Common Stock and This Offering***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· There is no public market for our common stock, and an active trading market may never develop. Investors should be prepared to hold shares indefinitely.

· New investors will experience immediate dilution of approximately $84.70 per share, or 99.65% of the $85 offering price.

· We do not intend to pay dividends, so any return depends entirely on stock price appreciation.

· Our Board may issue preferred stock with rights senior to common stock that could adversely affect common stockholders.

***Risks Related to Share Repurchases and Promissory Notes***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· We have incurred substantial indebtedness ($1.15 billion) to entities controlled by our CEO through demand promissory notes that (i) are convertible at $125 per share into up to 10.6 million shares, (ii) require quarterly interest payments in common stock creating ongoing dilution, (iii) may be called for immediate payment at any time, and (iv) automatically renew indefinitely, creating conflicts of interest and threatening our ability to continue as a going concern.

**Risk Factors Related to Our Financial Condition**

***The Company has limited operating history and has a new business model in an emerging and rapidly evolving market.***

We are an early-stage development enterprise and lack any operating history to evaluate in assessing our future prospects. Our business and prospects in light of the risks and difficulties we will encounter as a development stage company in a new and rapidly evolving market must be seriously considered. We may not be able to successfully address these risks and difficulties, which could materially harm our business and operating results. In addition, we do not know if our business model will operate effectively during the next economic downturn. Furthermore, we are unable to predict the likely duration and severity of any potential adverse economic conditions in the U.S. and other countries, but the longer the duration the greater risks we face in operating our business. There can be no assurance, therefore, that current economic conditions or worsening economic conditions, or a prolonged or recurring recession, will not have a significant adverse impact on our operating and financial results.

***We have limited cash on hand and there is substantial doubt as to our ability to continue as a going concern.***

 ****

We are a start-up that was formed on October 16, 2024 in the State of Wyoming. To date, we have not generated any revenue, and we have incurred losses and cash flow deficits. As at September 30, 2025, we had cash on hand of $48,998 and we had working capital of $35,821. As noted in our financial statements, as of September 30, 2025, we had an accumulated deficit of $39,534. We anticipate that we will continue to report losses and negative cash flow. Our auditors have raised substantial doubt regarding our ability to continue as a going concern as a result of our historical recurring losses and negative cash flows from operations as well as our dependence on private equity and financings.

Our financial statements do not include any adjustments that might result from the outcome of this uncertainty. These adjustments would likely include substantial impairment of the carrying amount of our assets and potential contingent liabilities that may arise if we are unable to fulfill various operational commitments. In addition, the value of our securities, including common stock issued in this offering, would be greatly impaired. Our ability to continue as a going concern is dependent upon generating sufficient cash flow from operations and obtaining additional capital and financing, including funds to be raised in this offering. If our ability to generate cash flow from operations is delayed or reduced and we are unable to raise additional funding from other sources, we may be unable to continue in business even if this offering is successful.

***We are dependent on outside financing for continuation of our operations.***

The success of our services will depend largely on the continued development, operation, and maintenance of our blockchain infrastructure. The Company has deployed its Hyperledger blockchain infrastructure to production, with APIs and smart contract layers operational. However, this infrastructure has not yet been tested at commercial scale with external users. The blockchain infrastructure may be unable to support increased user demand, higher transaction volumes, or the expanded data loads anticipated as the platform grows. In addition, increasing numbers of users, bandwidth requirements, or problems caused by viruses, worms, malware, and similar programs may harm the performance of the platform. The blockchain has experienced, and is likely to continue to experience, significant growth in the number of users and amount of traffic in the broader ecosystem. These outages and delays could reduce the level of usage of our services and could adversely impact our business.

Our business depends significantly on effective and secure blockchain information systems and the continued successful operation of these technologies. The Company has deployed its Hyperledger blockchain infrastructure and core EHR platform to production. These systems require continual investment for maintenance, upgrades, and enhancement to meet our operational needs and to handle our expansion and growth. Any inability or failure to properly maintain these information systems, successfully update or expand processing capability, or develop new capabilities to meet our business needs in a timely manner could result in operational disruptions, loss of existing or prospective customers, difficulty in attracting new customers, impairment of the implementation of our growth strategies, delays in settling disputes with customers and providers, regulatory problems, increases in administrative expenses, loss of our ability to produce timely and accurate reports, and other adverse consequences. Furthermore, our business requires the secure transmission of confidential information over public networks. Because of the confidential information we store and transmit, security breaches could expose us to a risk of regulatory action, litigation, possible liability, and loss. Our security measures may prove inadequate to prevent security breaches, and our business operations and profitability would be adversely affected by cancellation of contracts, loss of members, and potential criminal and civil sanctions if security breaches occur.

Our failure to obtain future financing or to produce levels of revenue to meet our financial needs could result in our inability to continue as a going concern and, as a result, our investors could lose their entire investment.

**Risk Factors Related to Our Business**

***The markets that we are targeting for revenue opportunities are emerging within a well-established healthcare industry, are rapidly developing and may change before we can access them.***

The markets for blockchain products and services that we are targeting for revenue opportunities are changing rapidly; and the barriers to entry into the niche are high and require unique experience and qualification. We cannot provide assurance that we will be able to realize these revenue opportunities before they change or before other companies enter or even dominate the market. Furthermore, we have based certain of our revenue opportunities on statistics provided by third party industry sources. Such statistics are based on ever-changing customer preferences due to our rapidly changing industry. With the introduction of new technologies and the influx of new entrants to the market, we expect competition to emerge and intensify in the future, which could adversely affect our ability to increase sales, limit client attrition and maintain our prices.

***We may be unsuccessful in achieving broad market education and changing healthcare patient habits.***

Our success and future growth largely depend on our ability to increase healthcare patient awareness of our platform and offerings, and on the willingness of patient consumers to access information and use our platform as a place to centralize patient data and connect with healthcare providers. To effectively market our platform, we must educate patients about the various purchase options and the benefits of using our blockchain platform when seeking information about healthcare data options. We focus our marketing and education efforts on patients, physicians, pharmacists and other participants that interact with patients. However, we cannot assure you that we will be successful in changing healthcare habits or that we will achieve broad market education or awareness among patient consumers. Even if we are able to raise awareness among patient consumers, they may be slow in changing their habits and may be hesitant to use our platform for a variety of reasons, including:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· The Company is currently a pre-revenue, development-stage entity. Subsequent to September 30, 2025, the Company deployed its core EHR platform to production at ehr.myrxwallet.io. The Company's present activities include: (i) completing ONC Health IT Module Certification following the April 17, 2026 ONC Inferno v8.0.0 test suite completion (317/317 sub-tests passed, zero failures); (ii) developing additional platform capabilities including AI/ML clinical decision support, expanded blockchain functionality, and the MyRxToken program, none of which currently exist; (iii) maintaining corporate governance, regulatory compliance, and SEC reporting obligations; and (iv) managing its strategic transaction program, including the pending Indian land acquisitions and the Noah Therapeutics SPA. The Company has not yet commenced commercial operations, generated revenue from its platform, or onboarded any external users or customers. Upon receipt of sufficient funding from this offering, the Company intends to implement its business plan as described in this Offering Circular, subject to adjustment based on the actual funding level received and prevailing market and operational conditions at the time of implementation.

· perception that our platform does not provide adequate marketing;

· concerns about the privacy and security of the data that consumers share with or through our platform;

· competition and negative selling efforts from competitors, including competing platforms and price matching programs; and

· perception regarding the time and complexity of using our platform.

If we fail to achieve broad market education of our platform and/or fail to convince patient consumers to subscribe for our services, or if we are unsuccessful in changing marketing habits, our business, financial condition and results of operations would be adversely affected.

***Our business depends on the development and maintenance of the blockchain infrastructure.***

The success of our services will depend largely on the development and maintenance of our blockchain infrastructure. This includes maintenance of a reliable network backbone with the necessary speed, data capacity and security, as well as timely development of complementary products, for providing reliable internet access and services. The blockchain has experienced, and is likely to continue to experience, significant growth in the number of users and amount of traffic. The blockchain infrastructure may be unable to support such demands. In addition, increasing numbers of users, increasing bandwidth requirements or problems caused by viruses, worms, malware and similar programs may harm the performance of the platform. The backbone computers of the internet have been the targets of such programs. The blockchain has experienced a variety of outages and other delays as a result of damage to portions of its infrastructure, and it could face outages and delays in the future. These outages and delays could reduce the level of internet usage generally as well as the level of usage of our services, which could adversely impact on our business.

***The nature of our blockchain platform requires sophisticated encryption technology to defend against hacking due to the personal information as well as the financial transaction data that will be utilized by a consumer/patient.***

Potential investors should be aware of the difficulties normally encountered by companies developing and commercializing new technology and the high rate of failure of such enterprises. While the Company has successfully deployed its core EHR platform to production and completed ONC Inferno v8.0.0 testing, significant additional development work remains, including AI/ML clinical decision support, the MyRxToken program, biobank infrastructure, and the hyperscale data center. The likelihood of success of these remaining development programs must be considered in light of the problems, expenses, difficulties, complications, and delays encountered in connection with the development of new technology with limited personnel and financial means. These potential problems include, but are not limited to, unanticipated technical problems that extend the time and cost of product development, or unanticipated problems with the operation of our technology that also extend the time and cost of development.

***Failure to properly maintain effective and secure blockchain information systems, update or expand processing capability or develop new capabilities to meet our business needs could result in operational disruptions and possible loss of data critical to our operations.***

We may successfully complete the technical development for one or all of our remaining product development programs, but still fail to develop a commercially successful product for a number of reasons. The Company has deployed its core EHR platform to production and passed ONC Inferno v8.0.0 testing; however, technical deployment is only one prerequisite for commercial success. We may still fail to achieve market acceptance due to, among other reasons: (i) competing products from established EHR vendors with significantly greater resources, installed customer bases, and brand recognition; (ii) the absence of ONC Health IT Module Certification and CHPL listing, which many healthcare providers require before adopting an EHR system; (iii) ineffective distribution and marketing, as the Company has not yet established a sales organization or executed any pilot or customer agreements; (iv) lack of sufficient cooperation from potential partners, including healthcare providers, payers, and data partners whose participation is necessary for the platform to function as intended; and (v) demonstrations of the platform not aligning with or meeting the operational needs of target customers, including hospitals, clinics, and specialty providers who may have entrenched workflow requirements that our platform does not accommodate. Any one of these outcomes could prevent the Company from generating revenue or achieving profitability, and could have a material adverse effect on our business, financial condition, and results of operations.

These information systems and applications will require continual investment for maintenance, upgrades and enhancement to meet our operational needs and to handle our expansion and growth. Any inability or failure to properly maintain management information systems, successfully update or expand processing capability or develop new capabilities to meet our business needs in a timely manner could result in operational disruptions, loss of existing customers, difficulty in attracting new customers, impairment of the implementation of our growth strategies, delays in settling disputes with customers and providers, regulatory problems, increases in administrative expenses, loss of our ability to produce timely and accurate reports and other adverse consequences. To the extent a failure in maintaining effective information systems occurs, we may need to contract for these services with third-party management companies, which may be on less favorable terms to us and significantly disrupt our operations and information flow. Furthermore, our business requires the secure transmission of confidential information over public networks. Because of the confidential information we store and transmit, security breaches could expose us to a risk of regulatory action, litigation, possible liability and loss. Our security measures may prove inadequate to prevent security breaches and our business operations and profitability would be adversely affected by cancellation of contracts, loss of members and potential criminal and civil sanctions if security breaches occur.

***General economic conditions, industry cycles, financial, business and other factors affecting our operations, many of which are beyond our control, may affect our future performance.***

General economic conditions, industry cycles, financial, business and other factors may affect our operations. If we cannot generate sufficient cash flow from operations in the future, we may, among other things, be required to take one or more of the following actions:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· seek additional financing in the debt or equity markets;

· refinance or restructure all or a portion of our indebtedness;

· sell selected assets;

· reduce or delay planned capital expenditures; or

· discontinue operations.

In addition, any financing, refinancing or sale of assets might not be available on economically favorable terms, which may prevent us from future expansion and growth in new markets and, thus, negatively affect our business and financial condition.

***In the event that we are unable to successfully compete in the healthcare industry, we may not be able to achieve profitable operations.***

We face substantial competition in the healthcare industry. Due to our small size, it can be assumed that many of our competitors have significantly greater financial, technical, marketing and other competitive resources. Accordingly, these competitors may have already begun to establish brand-recognition with consumers. We will attempt to compete against these competitors by developing features that exceed the features offered by competitors. However, we cannot assure you that our platform will outperform competing platforms or those competitors will not develop new features that exceed what we provide. In addition, we may face competition based on price. If our competitors lower the prices on their platform services, then it may not be possible for us to market our platform at prices that are economically viable. Increased competition could result in:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Lower than projected revenues;

· Price reductions and lower profit margins; or

· The inability to develop and maintain our platform with features and usability sought by potential customers.

Any one of these results could adversely affect our business, financial condition and results of operations. In addition, our competitors may develop competing products and services that achieve greater market acceptance. It is also possible that new competitors may emerge and acquire significant market share. Our inability to achieve sales and revenue due to competition will have an adverse effect on our business, financial condition and results of operations.

***Our future growth depends significantly on our marketing efforts, and if our marketing efforts are not successful, our business and results of operations will be harmed.***

We have dedicated some, and intend to significantly increase, resources to marketing efforts. Our ability to attract and retain customers depends in large part on the success of these marketing efforts and the success of the marketing channels we use to promote our products and services. Our marketing channels include, but are not limited to, social media, traditional media such as the press, online affiliations, search engine optimization, search engine marketing, and offline partnerships.

While our goal remains to increase the strength, recognition and trust in our brand by increasing our customer base and expanding our products and services, if any of our current marketing channels becomes less effective, if we are unable to continue to use any of these channels, if the cost of using these channels was to significantly increase or if we are not successful in generating new channels, we may not be able to attract new customers in a cost-effective manner or increase the use of our products and services. If we are unable to recover our marketing costs through increases in the size, value or other product selection and utilization, it could have a material adverse effect on our business, financial condition, results of operations, cash flows and future prospects.

***We have made and expect to continue to make acquisitions that could disrupt our operations and harm our operating results.***

Our growth depends upon market growth, our ability to enhance our existing products, and our ability to introduce new products on a timely basis. We intend to continue to address the need to develop new products and enhance existing products through acquisitions of other companies, product lines, technologies, and personnel. Acquisitions involve numerous risks, including the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Difficulties in integrating the operations, systems, technologies, products, and personnel of the acquired companies, particularly companies with large and widespread operations and/or complex products;

· Diversion of management's attention from normal daily operations of the business and the challenges of managing larger and more widespread operations resulting from acquisitions;

· Potential difficulties in completing projects associated with in-process research and development intangibles;

· Difficulties in entering markets in which we have no or limited direct prior experience and where competitors in such markets have stronger market positions;

· Insufficient revenue to offset increased expenses associated with acquisitions; and

· The potential loss of key employees, customers, distributors, vendors and other business partners of the companies we acquire following and continuing after announcement of acquisition plans.

Acquisitions may also cause us to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Issue common stock that would dilute our current shareholders' percentage ownership;

· Use a substantial portion of our cash resources or incur debt;

· Significantly increase our interest expense, leverage and debt service requirements if we incur additional debt to pay for an acquisition;

· Assume liabilities;

· Record goodwill and nonamortizable intangible assets that are subject to impairment testing on a regular basis and potential periodic impairment charges;

· Incur amortization expenses related to certain intangible assets;

· Incur tax expenses related to the effect of acquisitions on our intercompany research and development cost sharing arrangement and legal structure;

· Incur large and immediate write-offs and restructuring and other related expenses; and

· Become subject to intellectual property or other litigation.

Mergers and acquisitions are inherently risky and subject to many factors outside of our control, and no assurance can be given that our previous or future acquisitions will be successful and will not materially adversely affect our business, operating results, or financial condition. Failure to manage and successfully integrate acquisitions could materially harm our business and operating results. Prior acquisitions could result in a wide range of outcomes, from successful introduction of new products and technologies to a failure to do so. Even when an acquired company has already developed and marketed products, there can be no assurance that product enhancements will be made in a timely fashion or that pre-acquisition due diligence will have identified all possible issues that might arise with respect to such products.

From time to time, we have made acquisitions that resulted in charges in an individual quarter. These charges may occur in any particular quarter, resulting in variability in our quarterly earnings. In addition, our effective tax rate for future periods is uncertain and could be impacted by mergers and acquisitions. Risks related to new product development also apply to acquisitions.

***Acquisitions, joint ventures or other strategic transactions create certain risks and may adversely affect our business, financial condition or results of operations.***

Acquisitions, partnerships and joint ventures are part of our growth strategy. We evaluate and expect in the future to evaluate potential strategic acquisitions of, and partnerships or joint ventures with, complementary businesses, services or technologies. We may not be successful in identifying acquisition, partnership and joint venture targets. In addition, we may not be able to successfully finance or integrate any businesses, services or technologies that we acquire or with which we form a partnership or joint venture.

We may not be able to identify suitable acquisition candidates or complete acquisitions in the future, which could adversely affect our future growth; or businesses that we acquire may not perform as well as expected or may be more difficult or expensive to integrate and manage than expected, which could adversely affect our business and results of operations. In addition, the process of integrating these acquisitions may disrupt our business and divert our resources.

In addition, acquisitions outside our current operating jurisdictions often involve additional or increased risks including, for example:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· managing geographically separated organizations, systems and facilities;

· integrating personnel with diverse business backgrounds and organizational cultures;

· complying with foreign regulatory requirements;

· fluctuations in exchange rates;

· enforcement and protection of intellectual property in some foreign countries;

· difficulty entering new foreign markets due to, among other things, customer acceptance and business knowledge of these new markets; and

· general economic and political conditions.

These risks may arise for a number of reasons: we may not be able to find suitable businesses to acquire at affordable valuations or on other acceptable terms; we may face competition for acquisitions from other potential acquirers; we may need to borrow money or sell equity or debt securities to the public to finance acquisitions and the terms of these financings may be adverse to us; changes in accounting, tax, securities or other regulations could increase the difficulty or cost for us to complete acquisitions; we may incur unforeseen obligations or liabilities in connection with acquisitions; we may need to devote unanticipated financial and management resources to an acquired business; we may not realize expected operating efficiencies or product integration benefits from an acquisition; we could enter markets where we have minimal prior experience; and we may experience decreases in earnings as a result of non-cash impairment charges.

We cannot ensure that any acquisition, partnership or joint venture we make will not have a material adverse effect on our business, financial condition and results of operations.

***Because of the unique difficulties and uncertainties inherent in technology development, we face a risk of business failure.***

Potential investors should be aware of the difficulties normally encountered by companies developing new technology and the high rate of failure of such enterprises. The likelihood of success must be considered in light of the problems, expenses, difficulties, complications and delays encountered in connection with the development of new technology with limited personnel and financial means. These potential problems include, but are not limited to, unanticipated technical problems that extend the time and cost of product development, or unanticipated problems with the operation of our technology or that with which we are licensing that also extend the time and cost of product development.

***Successful technical development of our products does not guarantee successful commercialization.***

We may successfully complete the technical development for one or all of our product development programs, but still fail to develop a commercially successful product for a number of reasons, including among others the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Competing products;

· Ineffective distribution and marketing;

· Lack of sufficient cooperation from our partners; and

· Demonstrations of the products not aligning with or meeting customer needs.

Our success in the market for the products we develop will depend largely on our ability to prove our products' capabilities. Upon demonstration, our products and/or technology may not have the capabilities they were designed to have or that we believed they would have. Furthermore, even if we do successfully demonstrate our products' capabilities, potential customers may be more comfortable doing business with a larger, more established, more proven company than us. Moreover, competing products may prevent us from gaining wide market acceptance of our products. Significant revenue from new product investments may not be achieved for a number of years, if at all.

***If we are unable to successfully manage growth, our operations could be adversely affected.***

Our progress is expected to require the full utilization of our management, financial and other resources, which to date has occurred with limited working capital. Our ability to manage growth effectively will depend on our ability to improve and expand operations, including our financial and management information systems, and to recruit, train and manage sales personnel. There can be no absolute assurance that management will be able to manage growth effectively.

If we do not properly manage the growth of our business, we may experience significant strains on our management and operations and disruptions in our business. Various risks arise when companies and industries grow quickly. If our business or industry grows too quickly, our ability to meet customer demand in a timely and efficient manner could be challenged. We may also experience development delays as we seek to meet increased demand for our products. Our failure to properly manage the growth that we or our industry might experience could negatively impact our ability to execute on our operating plan and, accordingly, could have an adverse impact on our business, our cash flow and results of operations, and our reputation with our current or potential customers.

 ****

***Cyberattacks and security breaches of our systems, or those impacting our customers or third parties, could adversely impact our brand and reputation and our business, operating results and financial condition.***

Our business involves the collection, storage, processing and transmission of confidential information, customer, employee, service provider and other personal data, as well as information required to access customer assets. Any actual or perceived security breach of our or our third-party partners may:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· harm our reputation and brand;

· result in our systems or services being unavailable and interrupt our operations;

· result in improper disclosure of data and violations of applicable privacy and other laws;

· result in significant regulatory scrutiny, investigations, fines, penalties, and other legal, regulatory and financial exposure;

· cause us to incur significant remediation costs;

· lead to theft or irretrievable loss of our or our customers' assets;

· reduce customer confidence in, or decreased use of, our products and services;

· divert the attention of management from the operation of our business;

· result in significant compensation or contractual penalties from us to our customers or third parties as a result of losses to them or claims by them; and

· adversely affect our business and operating results.

Further, any actual or perceived breach or cybersecurity attack directed at other similar institutions, whether or not we are directly impacted, could lead to a general loss of customer confidence in the use of our technology, which could negatively impact us including the market perception of the effectiveness of our security measures and technology infrastructure.

An increasing number of organizations, including large businesses, technology companies and financial institutions, as well as government institutions, have disclosed breaches of their information security systems, some of which have involved sophisticated and highly targeted attacks, including on their websites, mobile applications, and infrastructure. Attacks upon systems across a variety of industries are increasing in their frequency, persistence, and sophistication, and, in many cases, are being conducted by sophisticated, well-funded, and organized groups and individuals, including state actors. The techniques used to obtain unauthorized, improper, or illegal access to systems and information (including customers' personal data and digital assets), disable or degrade services, or sabotage systems are constantly evolving, may be difficult to detect quickly, and often are not recognized or detected until after they have been launched against a target. These attacks may occur on our systems or those of its third-party service providers or partners. Certain types of cyberattacks could harm us even if our systems are left undisturbed. For example, attacks may be designed to deceive employees and service providers into releasing control of our systems to a hacker, while others may aim to introduce computer viruses or malware into our systems with a view to stealing confidential or proprietary data. Additionally, certain threats are designed to remain dormant or undetectable until launched against a target and we may not be able to implement adequate preventative measures.

Although we do not have a past history of material security breaches or cyberattacks, and do not believe we are a target of such breaches or attacks, we have developed systems and processes designed to protect the data we manage, prevent data loss and other security breaches, and effectively respond to known and potential risks. We expect to continue to expend significant resources to bolster these protections, but there can be no assurance that these security measures will provide absolute security or prevent breaches or attacks. Threats can come from a variety of sources, including criminal hackers, hacktivists, state-sponsored intrusions, industrial espionage, and insiders. Certain threat actors may be supported by significant financial and technological resources, making them even more sophisticated and difficult to detect. As a result, our costs and the resources it devotes to protecting against these advanced threats and their consequences may increase over time.

Although we may maintain insurance coverage that we believe is adequate for our business, it may be insufficient to protect us against all losses and costs stemming from security breaches, cyberattacks, and other types of unlawful activity, or any resulting disruptions from such events. Outages and disruptions of our systems, including any caused by cyberattacks, may harm our reputation and our business, operating results, and financial condition.

***We are heavily reliant on Olivia Trinh, our Chairman and Chief Executive Officer, and the departure or loss of Ms. Trinh could disrupt our business.***

We depend heavily on the continued efforts of Olivia Trinh, Chairman, Chief Executive Officer and director. Ms. Trinh is essential to our strategic vision and day-to-day operations and would be difficult to replace. We cannot be certain that Ms. Trinh will desire to continue with us for the necessary time to complete the development of our business. The departure or loss of Ms. Trinh, or the inability to hire and retain a qualified replacement, could negatively impact our ability to manage our business.

***If we are unable to recruit and retain key management, technical and sales personnel, our business would be negatively affected.***

For our business to be successful, we need to attract and retain highly qualified technical, management and sales personnel. The failure to recruit key personnel when needed with specific qualifications and on acceptable terms or to retain good relationships with our partners might impede our ability to continue to develop, commercialize and sell our products. To the extent the demand for skilled personnel exceeds supply, we could experience higher labor, recruiting and training costs in order to attract and retain such employees. We face competition for qualified personnel from other companies with significantly more resources available to them and thus may not be able to attract the level of personnel needed for our business to succeed.

***In the event of employee or service provider misconduct or error, our business may be adversely impacted.***

Employee or service provider misconduct or error could subject us to legal liability, financial losses, and regulatory sanctions, and could seriously harm our reputation and negatively affect our business. Such misconduct could include engaging in improper or unauthorized transactions or activities, misappropriation of customer funds, and misappropriation of information, failing to supervise other employees or service providers, or improperly using confidential information.

Employee or service provider errors could expose us to the risk of material losses even if the errors are detected. Although we have implemented processes and procedures and provide trainings to our employees and service providers to reduce the likelihood of misconduct and error, these efforts may not be successful. Moreover, the risk of employee or service provider error or misconduct may be even greater for novel products and services.

This can lead to high risk of confusion among employees and service providers, particularly in a fast growth company like ours, with respect to compliance obligations particularly including confidentiality, data access, and conflicts. It is not always possible to deter misconduct and the precautions we take to prevent and detect this activity may not be effective in all cases. If we were found not to have met our regulatory oversight and compliance and other obligations, we could be subject to regulatory sanctions, financial penalties and restrictions on our activities for failure to properly identify, monitor and respond to potentially problematic activity, which could seriously damage our reputation. Our employees, contractors, and agents could also commit errors that subject us to financial claims for negligence, as well as regulatory actions, or result in financial liability. Further, allegations by regulatory or criminal authorities of improper transactions could affect our brand and reputation.

**Risks Related to the Healthcare Industry**

***The healthcare regulatory and political framework is uncertain and evolving, and we cannot predict the effect that further healthcare reform and other changes in government programs may have on our business, financial condition or results of operations.***

Healthcare laws and regulations are rapidly evolving and may change significantly in the future, which could adversely affect our financial condition and results of operations. For example, the Patient Protection and Affordable Care Act (the "**ACA**"), which includes a variety of healthcare reform provisions and requirements that may become effective at varying times through 2022, substantially changes the way healthcare is financed by both governmental and private insurers and may significantly impact our industry. Further changes to the ACA and related healthcare regulation remain under consideration. In addition, current proposals to implement a single payer or "Medicare for all" system in the U.S., if adopted would likely have a material adverse effect on our business. The full impact of recent healthcare reform and other changes in the healthcare industry and in healthcare spending is unknown, and we are unable to predict accurately what effect the ACA or other healthcare reform measures that may be adopted in the future will have on our business.

  ****

***The healthcare industry is rapidly evolving and the market for technology-enabled services that empower healthcare consumers is relatively immature and unproven. If we are not successful in promoting and improving the benefits of our platform, our growth may be limited, and our business may be adversely affected.***

The market for our products and services is subject to rapid and significant change and competition. The market for technology-enabled services that empower healthcare consumers is characterized by rapid technological change, new product and service introductions, evolving industry standards, changing customer needs, existing competition and the entrance of non-traditional competitors. In addition, there may be a limited-time opportunity to achieve and maintain a significant share of this market due in part to the rapidly evolving nature of the healthcare and technology industries and the substantial resources available to our existing and potential competitors. The market for technology-enabled services that empower healthcare consumers is relatively new and unproven, and it is uncertain whether this market will achieve and sustain high levels of demand and market adoption.

Our success depends to a substantial extent on the willingness of consumers to increase their use of technology platforms to manage their healthcare options, the ability of our platform to increase consumer engagement, and our ability to demonstrate the value of our platform to our potential customers. If customers do not recognize or acknowledge the benefits of our platform or our platform does not drive consumer engagement, then the market for our products and services might develop more slowly than we expect, which could adversely affect our operating results. In addition, we have limited insight into trends that might develop and affect our business. We might make errors in predicting and reacting to relevant business, legal and regulatory trends, which could harm our business. If any of these events occur, it could materially adversely affect our business, financial condition or results of operations.

Finally, our competitors may have the ability to devote more financial and operational resources than we can to developing new technologies and services, including services that provide improved operating functionality, and adding features to their existing service offerings. If successful, their development efforts could render our services less desirable, resulting in the loss of our existing customers or a reduction in the fees we earn from our products and services.

***Failure to comply with extensive and complex healthcare laws and regulations may have a material adverse effect on our business.***

 ****

Healthcare is an extremely complex and regulated industry in the U.S. There are many laws and regulations that could have a material effect on our business, including but not limited to, HIPAA, and federal and state regulations controlling patient, provider and intermediary relationships. We have taken, and will continue to take, precautions to ensure compliance with applicable statutes and regulations; however there is no guarantee we will be success in our efforts, and even an unintentional violation of law could have a material adverse effect on our operations and business.

***We are subject to privacy regulations regarding the access, use and disclosure of personally identifiable information. If we or any of our third-party vendors experience a breach of personally identifiable information, it could result in substantial financial and reputational harm, including possible criminal and civil penalties.***

State and federal laws and regulations govern the collection, dissemination, access and use of personally identifiable information, including HIPAA and the Health Information Technology for Economic and Clinical Health Act the "**HITECH**"), which govern the treatment of protected health information, and the Gramm-Leach Bliley Act, which governs the treatment of nonpublic personal information. Privacy regulation has become a priority issue in many states, including California, which in 2018 enacted the California Consumer Privacy Act broadly regulating the sale of California residents' personal information and providing California residents with various rights to access and delete data. In the provision of services to our customers, we and our third-party vendors may collect, access, use, maintain and transmit personally identifiable information in ways that are subject to many of these laws and regulations. Although we have implemented measures to comply with privacy laws, rules and regulations, we may experience data privacy incidents. Any unauthorized disclosure of personally identifiable information experienced by us, or our third-party vendors could result in substantial financial and reputational harm, including possible criminal and civil penalties. In many cases, we are subject to HIPAA and other privacy regulations because we are a business associate providing services to covered entities; as a result, the covered entities direct HIPAA compliance matters in the event of a security breach, which complicates our ability to address harm caused by the breach. Additionally, we may be required to report breaches to partners, regulators, state attorney generals, and impacted individuals depending on the severity of the breach, our role, legal requirements and contractual obligations. Continued compliance with current and potential new privacy laws, rules and regulations and meeting consumer expectations with respect to the control of personal data in a rapidly changing technology environment could result in higher compliance and technology costs for us.

***Although we do not provide medical care, we could be a party to medical malpractice claims, which could have a material adverse effect on our business.***

We do not provide medical care. Rather, we help connect consumers and employers to providers of medical care, products and services. However, we could be a party to lawsuits related to the service we provide, and that could include risk of medical malpractice claims which could increase our insurance premiums, expose us to legal defense cost, and/or impact the brand of the Company, which could lead to a reduction in the number of customers we have and could have a material adverse effect on our revenues and profits.

**Risks Related to Insiders and Control Persons**

***Insiders will continue to have substantial control over us and our policies after this offering and will be able to influence corporate matters.***

MyRxWallet Corporation owns 130,000,000 shares of our common stock representing 46.37% of our outstanding shares. Ms. Olivia Trinh has beneficial ownership over these shares. Z the Future, LLC owns 70,000,000 shares of our common stock representing 24.97% of our outstanding shares. Ms. Olivia Trinh also has beneficial ownership over these shares. Even after the offering, Ms. Trinh, whose interests may differ from other stockholders, will have the ability to exercise significant control over us. She is able to exercise significant influence over all matters requiring approval by our stockholders, including the election of directors, the approval of significant corporate transactions, and any change of control of our company. She could prevent transactions, which would be in the best interests of the other shareholders. Her interests may not necessarily be in the best interests of the shareholders in general.

***We may engage in transactions that present conflicts of interest.***

Our officers and directors may enter into agreements with us from time to time which may not be equivalent to similar transactions entered into with an independent third party. Our major shareholder, MyRxWallet Corporation, does not now, but will have an agreement with us to market and sell the products and services on our blockchain platform.

A conflict of interest arises whenever a person has an interest on both sides of a transaction. While we believe that it will take prudent steps to ensure that all transactions between us and any officer, director or majority shareholder are fair, reasonable, and no more than the amount it would otherwise pay to a third party in an "arms'-length" transaction, there can be no assurance that any transaction will meet these requirements in every instance.

***We have agreed to indemnify our officers and directors against lawsuits to the fullest extent of the law.***

The Company is a Wyoming corporation. Wyoming law permits the indemnification of officers and directors against expenses incurred in successfully defending against a claim. Wyoming law also authorizes corporations to indemnify their officers and directors against expenses and liabilities incurred because of their being or having been an officer or director. Our organizational documents provide for this indemnification to the fullest extent permitted by law.

We currently do not maintain any insurance coverage. In the event that we are found liable for damage or other losses, we would incur substantial and protracted losses in paying any such claims or judgments. Although we intend to acquire such coverage immediately upon resources becoming available, there is no guarantee that we can secure such coverage or that any insurance coverage would protect us from any damages or loss claims filed against us.

***We depend significantly on the services of the members of our management team, and the departure of any of those persons could cause our operating results to suffer.***

Our success depends significantly on the continued individual and collective contributions of our management team. The loss of the services of any member of our management team or the inability to hire and retain experienced management personnel could harm our business, financial condition, and results of operations.

***The Company has experienced leadership transitions since its founding, which may raise concerns about management stability and continuity.***

Since its founding in 2024, the Company has had two Chief Executive Officers in addition to its Co-Founder: Dr. Hanh Do, Do served as CEO from October 2024 through September 2025, and Olivia Trinh has served as CEO from October 2025 to the present. While each transition was voluntary and orderly, leadership changes in a development-stage company may raise concerns among investors about management stability, continuity of strategic vision, and institutional knowledge retention. The Company believes the current leadership team under Ms. Trinh provides the continuity and commitment necessary to execute the Company's business plan; however, there can be no assurance that additional executive changes will not occur, or that any such changes would not have a material adverse effect on the Company's operations, financing activities, and ability to execute its business plan.

***Members of our Board and our executive officers may have other business interests and obligations to other entities.***

Neither our directors nor our executive officers will be required to manage our company as their sole and exclusive function and they may have other business interests and may engage in other activities in addition to those relating to our company, provided that such activities do not compete with the business of our company. We are dependent on our directors and executive officers to successfully operate our company. Their other business interests and activities could divert time and attention from operating our business.

***Our officers and directors do not have any prior experience conducting a best-efforts offering or management a public company.***

 ****

Our officers and directors do not have any experience conducting a best effort offering or managing a public company. Consequently, we may not be able to raise any funds or run our public company successfully. If we are not able to raise sufficient funds, we may not be able to fund our operations as planned, and our business will suffer and your investment may be materially adversely affected. Also, our executive officer's and director's lack of experience of managing a public company could cause you to lose some or all of your investment.

**Risks Related to Legal Uncertainty**

***If we are unable to prevent unauthorized use or disclosure of our proprietary trade secrets and unpatented know-how, our ability to compete will be harmed.***

Proprietary trade secrets, copyrights, trademarks and unpatented know-how are also very important to our business. We will rely on a combination of patents, trade secrets, copyrights, trademarks, confidentiality agreements, and other contractual provisions and technical security measures to protect certain aspects of our intellectual property, especially where we do not believe that patent protection is appropriate or obtainable. We will require our employees and consultants to execute confidentiality agreements in connection with their employment or consulting relationships with us. We also will require our employees and consultants to disclose and assign to us all inventions conceived during the term of their employment or engagement while using our property or which relate to our business; however, these measures may not be adequate to safeguard our proprietary intellectual property and conflicts may, nonetheless, arise regarding ownership of inventions. Such conflicts may lead to the loss or impairment of our intellectual property or to expensive litigation to defend our rights against competitors who may be better funded and have superior resources. Our employees, consultants, contractors and other advisors may unintentionally or willfully disclose our confidential information to competitors. In addition, confidentiality agreements may be unenforceable or may not provide an adequate remedy in the event of unauthorized disclosure. Enforcing a claim, that a third party illegally obtained and is using our trade secrets, is expensive and time consuming, and the outcome is unpredictable. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how. Unauthorized parties may also attempt to copy or reverse-engineer certain aspects of our platform that we consider proprietary. As a result, third parties attempt to use our proprietary technology or information, and our ability to compete in the market would be adversely affected.

***We may not have sufficient financial resources to defend our intellectual property rights or otherwise successfully defend against claims that we have infringed on a third party's intellectual property and, as a result, it may adversely affect our business, financial condition and results of operations.***

Even if such claims are not valid, they could subject us to significant costs. In addition, it may be necessary in the future to enforce our intellectual property rights to determine the validity and scope of the proprietary rights of others. Litigation may also be necessary to defend against claims of infringement or invalidity by others. We may not have sufficient financial resources to defend our intellectual property rights or otherwise to successfully defend the company against valid or spurious claims that we have infringed upon the intellectual property rights of others. An adverse outcome in litigation or any similar proceedings could force us to take actions that could harm its business. These include: (i) ceasing to sell products that contain allegedly infringing property; (ii) obtaining licenses to the relevant intellectual property which we may not be able to obtain on terms that are acceptable, or at all; (iii) indemnifying certain customers or strategic partners if it is determined that we have infringed upon or misappropriated another party's intellectual property; and (iv) redesigning products that embody allegedly infringing intellectual property. Any of these results could adversely and significantly affect our business, financial condition and results of operations. In addition, the cost of defending or asserting any intellectual property claim, both in legal fees and expenses, and the diversion of management resources, regardless of whether the claim is valid, could be significant and lead to significant and protracted losses.

***Compliance with changing regulation of corporate governance and public disclosure may result in additional expenses.***

Changing laws, regulations and standards relating to corporate governance and public disclosure, including new SEC regulations, are creating uncertainty for companies such as ours. These new or changed laws, regulations and standards are subject to varying interpretations in many cases due to their lack of specificity, and as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies, which could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We are committed to maintaining high standards of corporate governance and public disclosure. As a result, we intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new or changed laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to practice, our reputation may be harmed.

**Risks Related to the Offering and the Market for our Stock**

***Because there is no minimum offering amount, funds raised may not be sufficient to complete the plans of the Company as set forth in "Use of Proceeds" in this Offering Circular.***

There is no minimum offering amount. If we do not raise the maximum proceeds, funds raised may not be sufficient to complete all plans of the Company as set forth in "*Use of Proceeds*" in this Offering Circular, which could inhibit our ability to commence generating revenue.

***We have the right to issue shares of preferred stock. If we were to issue preferred stock, it is likely to have rights, preferences and privileges that may adversely affect the common stock.***

We are authorized to issue 100,000,000 shares of "blank check" preferred stock, with such rights, preferences and privileges as may be determined from time-to-time by our board of directors. Our board of directors is empowered, without stockholder approval, to issue preferred stock in one or more series, and to fix for any series the dividend rights, dissolution or liquidation preferences, redemption prices, conversion rights, voting rights, and other rights, preferences and privileges for the preferred stock.

The issuance of shares of preferred stock, depending on the rights, preferences and privileges attributable to the preferred stock, could reduce the voting rights and powers of the common stock and the portion of our assets allocated for distribution to common stockholders in a liquidation event, and could also result in dilution in the book value per share of the common stock we are offering. The preferred stock could also be utilized, under certain circumstances, as a method for raising additional capital or discouraging, delaying or preventing a change in control of the Company, to the detriment of the investors in the common stock offered hereby.

***New investors in our common stock will experience immediate and substantial dilution after this Offering.***

If you purchase shares of common stock in this Offering, you will experience immediate dilution, because the price that you pay will be substantially greater than the adjusted pro forma net tangible book value per share that you acquire. This dilution is due in large part to our negative book value.

***If a market for our common stock does not develop, shareholders may be unable to sell their shares.***

Our common stock is not now listed on any national securities exchange (such as Nasdaq or the NYSE) or quotation system (such as the OTC Markets) and there is no market for our securities. Although we intend to apply for quotation of our Common Stock on the OTCQB or OTCQX through a market maker, public trading of our common stock may never materialize and there is no guarantee that an active trading market will develop in our securities. Investors should be prepared to hold our shares indefinitely.

***The market price of our common stock is likely to be highly volatile and could fluctuate widely in price in response to various factors, many of which are beyond our control.***

We are not listed on any exchange or quoted on any third-party service. If we are listed or quoted, our stock price will be subject to a number of factors, including:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Technological innovations or new products and services by us or our competitors;

· Government regulation of our products and services;

· The establishment of partnerships with other environmental companies;

· Intellectual property disputes;

· Additions or departures of key personnel;

· Issuances of our common stock;

· Our ability to execute our business plan;

· Operating results below or exceeding expectations;

· Financial condition of our joint venture partners;

· Whether we achieve profits or not;

· Loss or addition of any strategic relationship;

· Industry developments;

· Economic and other external factors; and

· Period-to-period fluctuations in our financial results.

Our stock price may fluctuate widely as a result of any of the above. In addition, the securities markets have from time-to-time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. These market fluctuations may also materially and adversely affect the market price of our common stock.

***Because we may be considered a penny stock and subject to the penny stock rules, if we are listed or quoted, the level of trading activity in our stock may be reduced.***

The Securities and Exchange Commission has adopted regulations which generally define "penny stock" to be any listed, trading equity security that has a market price less than $5.00 per share or an exercise price of less than $5.00 per share, subject to certain exemptions. The penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document that provides information about penny stocks and the risks in the penny stock market. The broker-dealer must also provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson in the transaction, and monthly account statements showing the market value of each penny stock held in the customer's account. In addition, the penny stock rules generally require that prior to a transaction in a penny stock, the broker-dealer make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser's written agreement to the transaction. If we are listed or quoted, these disclosure requirements may have the effect of reducing the level of trading activity in the secondary market for a stock that becomes subject to the penny stock rules which may increase the difficulty Purchasers may experience in attempting to liquidate such securities.

***We do not expect to pay dividends in the foreseeable future. Any return on investment may be limited to the value of our common stock.***

We do not anticipate paying cash dividends on our common stock in the foreseeable future. The payment of dividends on our common stock will depend on earnings, financial condition and other business and economic factors affecting it at such time as the board of directors may consider relevant. If we do not pay dividends, our common stock may be less valuable because a return on your investment will occur only if our stock price appreciates.

***We will have broad discretion in applying the net proceeds of this Offering and we may not use those proceeds in ways that will enhance our business operations.***

 ****

We have significant flexibility in applying the net proceeds we will receive in this Offering. We will use the proceeds that we receive from the sale of shares in this Offering for mergers and acquisitions, legal fees, accounting expenses, research and development, capital investments and working capital. As part of your investment decision, you will not be able to assess or direct how we apply these net proceeds. If we do not apply these funds effectively, we may lose significant business opportunities.

***Securities laws may restrict transferability of the securities sold in the Offering.***

 ****

The shares in this Offering have not been registered under the Securities Act of 1933, as amended (the "**Securities Act**") or registered or qualified under any state or foreign securities laws. Such securities are being issued based upon the Company's reliance upon an exemption from registration under the Securities Act for an offer and sale of securities that does not involve a public offering. Unless such securities are so registered, they may not be offered or sold except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state or foreign securities laws.

***You must make an independent investment analysis in connection with this Offering.***

No independent legal, accounting or business advisors have been appointed to represent the interests of prospective investors in connection with this offering. Neither the Company nor any of its officers, directors, employees or agents makes any representation or expresses any opinion with respect to the merits of an investment in the shares offered hereby. Each prospective investor is therefore encouraged to engage independent accountants, appraisers, attorneys and other advisors to (i) conduct due diligence review as the prospective investor may deem necessary and advisable, and (ii) provide advice with respect to the merits of an investment in the shares offered hereby and applicable risk factors as a prospective investor may deem necessary and advisable to rely upon. We will fully cooperate with any prospective investor who desires to conduct an independent analysis, so long as it determines, in our sole discretion, that cooperation is not unduly burdensome. Each prospective investor acknowledges that he, she or it has been informed and understands.

***Because we lack certain internal controls over financial reporting in that we do not have an audit committee and our Board of Directors has no technical knowledge of U.S. GAAP and internal control of financial reporting and relies upon the Company's financial personnel to advise the Board on such matters, we are subject to increased risk related to financial statement disclosures.***

We lack certain internal controls over financial reporting in that we do not yet have an audit committee, and our Board of Directors has little technical knowledge of U.S. GAAP and internal control of financial reporting and relies upon the Company's financial personnel and accounting firm to advise the Board on such matters. Accordingly, we are subject to increased risk related to financial statement disclosures.

***Risks Related to Becoming a Fully Reporting Company***

We will incur significantly increased costs and demands upon management as a result of becoming a public reporting company under the Exchange Act.

Upon effectiveness of our Form 8-A registration statement, we will become subject to the information and reporting requirements of the Exchange Act. We will incur significant legal, accounting, and other expenses that we did not incur as a private company or Regulation A-only issuer. These requirements will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. We estimate these additional costs will be approximately $300,000 to $500,000 annually.

We will need to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Hire additional accounting, financial reporting, and administrative personnel

· Implement more comprehensive compliance and reporting systems

· Maintain more extensive record-keeping

· Establish and maintain effective disclosure controls and procedures and internal control over financial reporting

· Engage outside legal counsel and accountants to assist with Exchange Act compliance

We currently lack adequate internal controls and may not be able to comply with our reporting obligations or maintain effective internal controls.

As disclosed elsewhere in this offering circular, we have identified material weaknesses in our internal control over financial reporting, including the lack of an audit committee with financial expertise and insufficient segregation of duties. As an Exchange Act reporting company, we will be required to maintain effective disclosure controls and procedures and internal control over financial reporting. Under Section 404(a) of the Sarbanes-Oxley Act, we will be required to include management's report on internal control over financial reporting in our annual reports beginning with our second annual report following our initial Exchange Act registration.

If we fail to develop and maintain effective controls, we may be unable to produce timely and accurate financial statements. This could result in:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Loss of investor confidence

· Decline in stock price

· Regulatory sanctions

· Litigation

· Delisting from any quotation system or exchange

Our management has limited experience as a public reporting company under the Exchange Act.

None of our officers or directors have experience managing a company subject to the extensive reporting and compliance requirements of the Exchange Act. This lack of experience may result in:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Failure to timely file required reports

· Inadequate or inaccurate disclosures

· Non-compliance with Exchange Act requirements

· Regulatory enforcement actions

We may need to hire experienced personnel or engage consultants, which will increase our operating costs.

**Risks Related to Share Repurchases and Promissory Notes**

***The Company has incurred substantial indebtedness to entities controlled by our CEO, which creates significant risks of dilution, conflicts of interest, and threatens our ability to continue as a going concern.***

On January 3, 2026, we entered into two share repurchase agreements with entities controlled by our Chief Executive Officer, Olivia Trinh, pursuant to which we repurchased an aggregate of 13,500,000 shares of our common stock for an aggregate purchase price of $1,147,500,000. We have no cash or other assets sufficient to pay this obligation, and accordingly issued promissory notes to these entities bearing interest at 7.5% per annum, with all principal and accrued interest due on demand by the Noteholder at any time within 24 months from February 4, 2026, with automatic 24-month renewal if not demanded.

This indebtedness represents more than 15 times the maximum gross proceeds we could raise in this offering and exponentially exceeds our total assets as of September 30, 2025, which were approximately $49,005. We have no realistic ability to repay these notes in cash. This creates numerous significant risks to investors:

**Conversion Dilution and Interest-in-Stock Payments.** The Amended Promissory Notes are convertible at the holder's option at a fixed conversion price of $125 per share. While this fixed price eliminates certain risks associated with the original variable conversion formula, full conversion of both notes would result in the issuance of up to 10,557,000 shares (representing approximately 3.7% dilution). More significantly, quarterly interest payments totaling approximately $21.5 million per quarter ($86,062,500 annually) are payable in shares of our common stock at the Noteholder's election, creating continuous dilution estimated at approximately 686,010 shares annually (based on the $125 conversion price). If the Noteholders consistently elect stock payment of interest, this ongoing dilution could be substantial over the life of the notes, particularly given the automatic 24-month renewal provision.

**Conversion Terms and Dilution Risk.** The Amended Promissory Notes are convertible at the holder's option into shares of our common stock at a fixed conversion price of $125 per share. While this fixed conversion price eliminates the 'death spiral' characteristics of the original conversion formula (which was based on 66% of recent trading prices), conversion at $125 per share would still result in substantial dilution to existing stockholders. If both notes are fully converted along with all accrued interest, up to 10,557,000 shares could be issued (7,820,000 shares under the MyRxWallet Corporation note and 2,737,000 shares under the Z the Future note), representing dilution of approximately 3.7% to existing stockholders (based on 284,177,490 shares outstanding after this offering). Additionally, because quarterly interest payments are payable in shares of our common stock (at the Noteholder's election), stockholders will experience ongoing dilution each quarter from interest payments, estimated at approximately 686,010 shares annually ($86,062,500 total annual interest divided by $125 per share) unless the Noteholders elect cash payment.

**Absence of Arms-Length Negotiation.** Because both sides of these transactions were controlled by Ms. Trinh, there was no arms-length negotiation of terms. The purchase price of $85 per share substantially exceeds the book value per share of our common stock, which was approximately $0.000143 as of September 30, 2025. We cannot assure you that the terms of these transactions, including the purchase price, interest rate, conversion terms, or payment terms, are terms that we could have obtained from an unrelated third party, or represent fair value to the Company.

**No Apparent Business Purpose.** We have received no proceeds or other consideration from these transactions, we simply exchanged our promissory notes for shares we had previously issued. These transactions do not appear to serve any operational business purpose, do not provide us with capital, and do not further our business plan. The transactions substantially increased our liabilities without any corresponding benefit and have materially worsened our financial condition.

**Going Concern Implications.** Our independent auditors have expressed substantial doubt about our ability to continue as a going concern based on our lack of revenue and limited resources. The addition of $1,147,500,000 in **demand note obligations**, which begin accruing interest immediately at $86,062,500 per year (payable in stock), dramatically worsens our financial condition and makes our ability to continue as a going concern even more doubtful. The fact that these notes are payable on demand at any time means we could be required to satisfy these obligations immediately, and unless we raise substantial capital or generate revenue far in excess of our current projections, we will have no choice but to satisfy these obligations through stock issuances, resulting in massive dilution. We cannot repay these obligations from operating cash flow, and unless we raise substantial capital or generate revenue far in excess of our current projections, we will have no choice but to satisfy these obligations through stock issuances, resulting in massive dilution.

**Questions About Transaction Approval.** The related-party share repurchase transactions with MyRxWallet Corporation and Z the Future, LLC were reviewed and approved on February 5, 2026 by the then-serving disinterested members of the Board of Directors - Dr. Rajan Kombu Subramanian, Ph.D. and Dr. Anuradha Cingeetham, Ph.D. - acting as Independent Directors outside the presence of the interested parties. Both Dr. Subramanian and Dr. Cingeetham were appointed to the Board of Directors on February 1, 2026 and ceased serving as directors on March 20, 2026. Their departures were not the result of any disagreement with the Company on any matter relating to its operations, policies, practices, or disclosures; rather, each indicated that continued service would have required cash compensation that the Company was not in a position to fund pending qualification of this offering and receipt of offering proceeds. Olivia Trinh and Binh Do each disclosed their conflicts of interest and recused themselves from all deliberations and voting. The Independent Directors reviewed the transaction documents, considered the terms, and unanimously determined that the arrangements were fair to and in the best interests of the Company. These actions were ratified at a duly called special meeting of the Board on February 12, 2026. Investors should note that Dr. Rajan Kombu Subramanian and Dr. Anuradha Cingeetham are no longer serving as directors of the Company as of the date hereof.

**Subordination of Other Stockholders' Interests.** As our largest creditor, Ms. Trinh's interests as a note holder may conflict with her duties as CEO and with the interests of other stockholders. In any bankruptcy, dissolution, or liquidation scenario, her claims as a creditor would be senior to the interests of equity holders. This creates an incentive for her to favor creditor recoveries over equity value.

**Ability to Force Additional Dilution Through Default.** If we fail to make any quarterly interest payment in shares, or fail to maintain sufficient authorized shares for conversion, or breach any other covenant, the notes provide for an additional 2% interest penalty on overdue amounts. The note holders could use any default as leverage to extract additional consideration or more favorable terms from the Company. Given Ms. Trinh's control of the Company, she would be negotiating with herself in any such scenario.

**Absence of Customary Protective Covenants.** The promissory notes do not appear to contain customary protective covenants limiting our ability to incur additional debt, make restricted payments, or engage in transactions with affiliates. This provides Ms. Trinh, as the controlling stockholder, with substantial flexibility to cause the Company to take actions that could further impair our ability to satisfy the notes or could advantage certain stakeholders over others.

**Impact on Future Financing.** The existence of $1.147 billion in debt to related parties will make it substantially more difficult for us to raise capital from third-party investors or lenders. Potential investors will be concerned about dilution from conversion of the notes, the related-party nature of the obligations, and the senior claim these creditors would have in any dissolution scenario. This may prevent us from raising capital on acceptable terms or at all, which would materially harm our business and prospects.

**Questions About Transaction Approval.** As described above, the related-party share repurchase transactions were reviewed and approved on February 5, 2026 by the then-serving disinterested members of the Board of Directors. Dr. Rajan Kombu Subramanian, Ph.D. was appointed to the Board on February 1, 2026 and ceased serving on March 20, 2026. Dr. Anuradha Cingeetham, Ph.D. was appointed to the Board on February 1, 2026 and ceased serving on March 20, 2026. Neither departure was the result of any disagreement with the Company on any matter relating to its operations, policies, practices, or disclosures. There can be no assurance that the disinterested directors had access to independent financial or legal advice regarding the fairness of the transactions, or that the Board approval process would withstand legal challenge.

These transactions, and the obligations they have created, represent a substantial risk to your investment. If you purchase shares in this offering, you should expect that substantial dilution from conversion and interest payments is likely, and that the interests of the note holders (controlled by our CEO) may conflict with your interests as a stockholder.

**Demand Note Structure Creates Payment Uncertainty.** The Amended Promissory Notes are payable on demand by the Noteholders at any time within 24 months from February 4, 2026. This demand structure means that at any time before February 4, 2028, the Noteholders (both controlled by our CEO) could demand immediate payment of the full $1,147,500,000 principal plus all accrued interest. We have no realistic ability to pay this amount in cash, which would force us to issue shares to satisfy the notes, resulting in immediate massive dilution. The automatic 24-month renewal provision means this demand right could continue indefinitely, creating ongoing uncertainty for other stockholders.

**Capped Call Creates Additional Related-Party Exposure.** The Amended Promissory Notes contemplate that the Company will enter into Capped Call Agreements with the Noteholders (entities controlled by our CEO) designed to provide anti-dilution protection. These Capped Calls would have a strike price of $125 and a cap of $200 per share. However, these arrangements would create additional exposure to related parties controlled by our CEO and may involve complex accounting, tax, and securities law implications. Settlement of the Capped Calls may occur through delivery of additional shares, treasury shares, or 'issuer-sponsored tokenized shares,' which could create additional dilution or valuation uncertainties. There is no assurance these Capped Call arrangements will be entered into on arm's-length terms or will function as intended.

**Risks Related to Technology and Cybersecurity**

Our planned use of open-source software components exposes us to intellectual property risks that could adversely affect our business and competitive position. We expect to incorporate open-source software components, including open-source machine learning libraries and frameworks such as TensorFlow, PyTorch, scikit-learn, Hugging Face Transformers, BioBERT, and ClinicalBERT, into our planned technology platform. Certain open-source licenses (including GPL, AGPL, and similar "copyleft" licenses) impose conditions that, if not complied with, could require us to make our proprietary source code publicly available, negating our competitive advantage. If we are found to be in violation of an open-source license, we could be required to release our proprietary source code, redesign our technology at significant cost and delay, or cease using affected components entirely. Any of these outcomes could materially harm our business, competitive position, and ability to generate revenue.

**DILUTION**

If you invest in our shares, your interest will be diluted to the extent of the difference between the offering price per share of our common stock and the as-adjusted net tangible book value per share of our capital stock after this offering. The following dilution analysis is based on our audited balance sheet as of September 30, 2025.

Reconciliation to Audited Balance Sheet (September 30, 2025):

Total assets: $48,998

Less: Total liabilities: ($13,177)

Less: Intangible assets and goodwill: $0

Historical net tangible book value: $35,821

Shares outstanding (September 30, 2025): 250,604,316

Historical net tangible book value per share: $0.000143

Pro Forma (assuming sale of all 882,127 primary shares at $85.00, less $50,000 offering expenses):

Net proceeds from offering: $74,930,795

Pro forma net tangible book value: $74,966,616

Pro forma shares outstanding: 251,486,443

Pro forma net tangible book value per share: $0.2981

Offering price per share: $85.00

Dilution per share to new investors: $84.70

Dilution as percentage of offering price: 99.65%

**Dilution and Capitalization Table**

The following table illustrates the dilution to the purchasers of the common stock offered in this offering.

---

| | |
|:---|:---|
|  | Assuming the sale of offered shares: |
|  | 882,127 shares |
| Offering Price Per Share | $85 |
| Book Value Per Share Before the Offering | $0.000143 |
| Book Value Per Share After the Offering | $0.2981 |
| Net Increase to Original Shareholders | $0.2980 |
| Decrease in Investment to New Shareholders | $84.70 |
| Dilution to New Shareholders (%) | 99.65% |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| Net Proceeds (net of commission & offering cost) | $7498105 | $18745220 | $37490440 | $56235575 | $74980795 |
| Offering - Primary Shares | 88213 | 220532 | 441064 | 661595 | 882127 |
| Offering Cost | $50000 | $50000 | $50000 | $50000 | $50000 |
| **Commission** | **10%** | **25%** | **50%** | **75%** | **100%** |
| Initial price to public | $85 | $85 | $85 | $85 | $85 |

---

The following table summarizes the differences between the existing shareholders and the new investors with respect to the number of shares of common stock purchased from the Company, the total consideration paid, and the average price per share paid, on a maximum offering basis:

**Maximum Offering**

---

| | | | |
|:---|:---|:---|:---|
| **PRIMARY SHARES OFFERED** | **PRICE TO <br> PUBLIC(1)** | **SHARES <br> OFFERING** | **PROCEEDS TO THE <br> COMPANY OR <br> SELLING SHAREHOLDER(2)** |
| Newly Issued Shares by Company | $85 | 882127 | $74980795 |
| TOTAL PRIMARY SHARES OFFERED |  | 882127 | $74980795 |

---

(1) The initial offering price is $85 per share. The maximum number of shares offered in this offering is 882,127, for an estimated maximum aggregate offering of 74,980,795.

(2) Does not include expenses of the offering, estimated to be $50,000 including legal, accounting and other costs of qualification.

**Impact of Promissory Note Conversions and Interest Payments.** The dilution analysis above does not reflect the potential dilution from conversion of the Amended Promissory Notes issued to MyRxWallet Corporation and Z the Future, LLC. If both notes are fully converted at the fixed conversion price of $125 per share, an additional 10,557,000 shares would be issued, which would reduce the net tangible book value per share and increase dilution to new investors. Additionally, quarterly interest payments on the notes are payable in shares of common stock at the Noteholder's election, which would result in the issuance of approximately 686,010 shares annually based on current interest rates and the $125 conversion price. This ongoing dilution from interest payments would further reduce net tangible book value per share over time.

**PLAN OF DISTRIBUTION**

This Offering Statement is part of the Form 1-A that we filed with the SEC, using a continuous offering process. This is a primary-only offering of 882,127 shares of common stock at $85.00 per share; there are no selling shareholders participating in this offering. All proceeds inure solely to the Company. Periodically, as we have material developments, we will provide an Offering Statement supplement that may add, update or change information contained in this Offering Statement. Any statement that we make in this Offering Statement will be modified or superseded by any inconsistent statement made by us in a subsequent Offering Statement supplement.

***Persons Selling Shares Under Rule 3a4-1***

The following persons are authorized to sell shares on behalf of the Company in reliance on Exchange Act Rule 3a4-1: (1) Olivia Trinh, Chairman, Chief Executive Officer, and Interim Chief Financial Officer; and (2) Scherri A. Harps, Independent Director. Each such person: (i) performs substantial duties for the Company other than in connection with transactions in securities; (ii) is not a broker-dealer or an associated person of a broker-dealer; and (iii) has not participated in selling an offering of securities of any issuer more than once in the past twelve months. Neither will receive any commission or transaction-based compensation for share sales. No other persons are authorized to sell shares without a subsequent amendment to this Offering Statement.

***Listing/Quotation***

Our common stock is not now listed on any national securities exchange (such as Nasdaq or the NYSE) or quotation system (such as the OTC Markets) and there is no market for our securities. Although we intend to apply for quotation of our Common Stock on the OTCQB or OTCQX through a market maker, public trading of our common stock may never materialize and there is no guarantee that an active trading market will develop in our securities. Investors should be prepared to hold our shares indefinitely.

***Pricing of the Offering***

Prior to the offering, there has been no market for our common shares. The offering price was determined by the Company. The principal factors considered in determining the offering price include:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· the information set forth in this Offering Statement and otherwise available;

· our history and prospects and the history of and prospects for the industry in which we compete;

· our past and present financial performance;

· our prospects for future earnings and the present state of our development;

· the general condition of the securities markets at the time of this offering;

· the recent market prices of, and demand for, publicly traded common stock of generally comparable companies; and

· other factors deemed relevant by us.

***Investment Limitations***

Generally, no sale may be made to you in this offering if the aggregate purchase price you pay is more than 10% of the greater of your annual income or net worth (please see below on how to calculate your net worth). Different rules apply to accredited investors and non-natural persons. Before making any representation that your investment does not exceed applicable thresholds, we encourage you to review Rule 251(d)(2)(i)(C) of Regulation A. For general information on investing, we encourage you to refer to <u>www.investor.gov</u>.

Because this is a Tier 2, Regulation A Offering, most investors must comply with the 10% limitation on investment in the Offering. The only investor in this offering exempt from this limitation is an "accredited investor" as defined under Rule 501 of Regulation D under the Securities Act (an "**Accredited Investor**"). If you meet one of the following tests you should qualify as an Accredited Investor:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· a bank, savings and loan association, insurance company, registered investment company, business development company, or small business investment company or rural business investment company;

· an SEC-registered broker-dealer, SEC- or state-registered investment adviser, or exempt reporting adviser;

· a plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political subdivisions, for the benefit of its employees, if such plan has total assets in excess of $5 million;

· an employee benefit plan (within the meaning of the Employee Retirement Income Security Act) if a bank, insurance company, or registered investment adviser makes the investment decisions, or if the plan has total assets in excess of $5 million;

· a tax-exempt charitable organization, corporation, limited liability corporation, or partnership with assets in excess of $5 million;

· a director, executive officer, or general partner of the Company, or any director, executive officer, or general partner of a general partner of the Company;

· an enterprise in which all the equity owners are accredited investors;

· an individual with a net worth or joint net worth with a spouse or spousal equivalent of at least $1 million, not including the value of his or her primary residence;

· an individual with income exceeding $200,000 in each of the two most recent calendar years or joint income with a spouse or spousal equivalent exceeding $300,000 for those years and a reasonable expectation of the same income level in the current year;

· a trust with assets exceeding $5 million, not formed only to acquire the securities offered, and whose purchases are directed by a person who meets the legal standard of having sufficient knowledge and experience in financial and business matters to be capable of evaluating the merits and risks of the prospective investment;

· an entity of a type not otherwise qualifying as accredited that own investments in excess of $5 million;

· an individual holding in good standing any of the general securities representative license (Series 7), the investment adviser representative license (Series 65), or the private securities offerings representative license (Series 82);

· a knowledgeable employee, as defined in rule 3c-5(a)(4) under the Investment Company Act, of the issuer of securities where that issuer is a 3(c)(1) or 3(c)(7) private fund; or

· a family office and its family clients if the family office has assets under management in excess of $5 million and whose prospective investments are directed by a person who has such knowledge and experience in financial and business matters that such family office is capable of evaluating the merits and risks of the prospective investment.

***Underwriters and Commissions***

The offering is being conducted on a best-efforts basis without any minimum number of shares or amount of proceeds required to be sold. We will not initially sell the Shares through commissioned broker-dealers but may do so after the commencement of the offering. Any such arrangement will add to our expenses in connection with the Offering. If we engage one or more commissioned sales agents or underwriters, we will amend this Form 1-A to describe the arrangement. No compensation will be paid to any principal, the officers, or any affiliated company or party with respect to the sale of the Shares. This means that no compensation will be paid with respect to the sale of the Shares to our officer or directors. We are relying on Rule 3a4-1 of the Securities Exchange Act of 1934, *Associated Persons of an Issuer Deemed not to be Brokers*. The applicable portions of the rule state that associated persons (including companies) of an issuer shall not be deemed brokers if they (a) perform substantial duties at the end of the offering for the issuer; (b) are not broker dealers; and (c) do not participate in selling securities more than once every 12 months, except for any of the following activities: (i) preparing written communication, but no oral solicitation; or (ii) responding to inquiries provided that the content is contained in the applicable registration statement; or (iii) performing clerical work in effecting any transaction. Neither we, our officers or directors, nor any affiliates conduct any activities that fall outside of Rule 3a4-1 and are, therefore, not brokers nor are they dealers.

We may engage a broker-dealer registered with the SEC and a member of the Financial Industry Regulatory Authority ("**FINRA**"), to perform the following administrative and technology related functions in connection with this offering, but not for underwriting or placement agent services:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Accept investor data from us;

· Review and process information from potential investors, including but not limited to running reasonable background checks for anti-money laundering ()"**AML** "), IRS tax fraud identification and USA PATRIOT Act purposes, and gather and review responses to customer identification information;

· Review subscription agreements received from prospective investors to confirm they are complete;

· Advise us as to permitted investment limits for investors pursuant to Regulation A;

· Contact us and/or our agents, if needed, to gather additional information or clarification from prospective investors;

· Provide us with prompt notice about inconsistent, incorrect or otherwise flagged (e.g. for underage or AML reasons) subscriptions;

· Serve as registered agent where required for state blue sky requirements;

· Transmit data to the Company's transfer agent in the form of book-entry data for maintaining our responsibilities for managing investors (investor relationship management, aka "**IRM**") and record keeping; and

· Keep investor details and data confidential and not disclose to any third party except as required by regulators, by law or in our performance under this Agreement (e.g. as needed for AML); and comply with any required FINRA filings including filings required under Rule 5110 for the offering.

***Offering Period and Expiration Date***

Our offering will terminate upon the earliest of (i) such time as all of the common stock has been sold pursuant to the Offering Statement or (ii) 365 days from the qualification date of this offering circular unless extended by our Board of Directors for an additional 90 days. We may however, at any time and for any reason terminate the offering.

***Procedures for Subscribing***

There is no minimum amount we are required to raise from the shares being offered by the Company. There are no arrangements to place the funds received in an escrow, trust, or similar arrangement and the funds will be available to us upon our acceptance of your subscription. As such, there are no arrangements for the return of funds to subscribers if all of the securities to be offered are not sold in this offering. Additionally, there is no guarantee that we will sell any of the securities being offered in this offering.

Any potential investor will have ample time to review the subscription agreement, along with their counsel, prior to making any final investment decision. We shall only deliver such subscription agreement upon request after a potential investor has had ample opportunity to review this Offering Statement.

***Right to Reject Subscriptions***. After we receive your complete, executed subscription agreement and the funds required under the subscription agreement have been transferred to our bank account, we have the right to review and accept or reject your subscription in whole or in part, for any reason or for no reason. This review process will typically be a delay of between 10 and 15 days between the time you sign your subscription agreement and send payment, and the time we decide whether to accept or reject the subscription. We will promptly return all monies from rejected subscriptions immediately to you, without interest or deduction.

***Acceptance of Subscriptions***. Upon our acceptance of a subscription agreement, we will countersign the subscription agreement and issue the shares subscribed. Once you submit the subscription agreement and it is accepted, you may not revoke or change your subscription or request your subscription funds. All accepted subscription agreements are irrevocable.

Under Rule 251 of Regulation A, non-accredited, non-natural investors are subject to the investment limitation and may only invest funds which do not exceed 10% of the greater of the purchaser's revenue or net assets (as of the purchaser's most recent fiscal year end). A non-accredited, natural person may only invest funds which do not exceed 10% of the greater of the purchaser's annual income or net worth (please see below on how to calculate your net worth).

***NOTE***: For the purposes of calculating your net worth, it is defined as the difference between total assets and total liabilities. This calculation must exclude the value of your primary residence and may exclude any indebtedness secured by your primary residence (up to an amount equal to the value of your primary residence). In the case of fiduciary accounts, net worth and/or income suitability requirements may be satisfied by the beneficiary of the account or by the fiduciary, if the fiduciary directly or indirectly provides funds for the purchase of the Shares.

In order to purchase Shares and prior to the acceptance of any funds from an investor, an investor will be required to represent, to the Company's satisfaction, that he is either an accredited investor or is in compliance with the 10% of net worth or annual income limitation on investment in this offering.

***No Escrow***

The proceeds of this offering will not be placed into an escrow account. We will offer our shares of common stock on a best-efforts basis. As there is no minimum offering, upon the approval of any subscription to this Offering Statement, the Company shall immediately deposit said proceeds into the bank account of the Company and may dispose of the proceeds in accordance with the "*Use of Proceeds*."

**USE OF PROCEEDS**

We estimate that, at a per-share price of $85, the aggregate gross proceeds from this Offering will be approximately $74,980,795, assuming the sale of all 882,127 shares of common stock qualified under this Offering Statement. This is a primary-only offering; all proceeds inure solely to the Company. There are no selling shareholders in this offering.

Because there is no minimum offering amount, we may raise substantially less than the maximum offering amount. The following table presents the anticipated use of net proceeds at five funding levels:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Use of Proceeds** | **10%<br> (~$7.4M)** | **25%<br> (~$18.7M)** | **50%<br> (~$37.4M)** | **75%<br> (~$56.2M)** | **100% (~$75.0M)** |
| Gross Proceeds | $7498105 | $18745220 | $37490440 | $56235575 | $74980795 |
| Less: Offering Expenses | $(50000) | $(50000) | $(50000) | $(50000) | $(50000) |
| Net Proceeds to Company | $7448105 | $18695220 | $37440440 | $56185575 | $74930795 |
| Strategic M&A / Acquisitions (70%) | $5213674 | $13086654 | $26208308 | $39329903 | $52451557 |
| EHR Platform Development (10%) | $744811 | $1869522 | $3744044 | $5618558 | $7493080 |
| Working Capital (10%) | $744811 | $1869522 | $3744044 | $5618558 | $7493080 |
| Legal / Accounting / Regulatory (5%) | $372405 | $934761 | $1872022 | $2809279 | $3746540 |
| Land Acquisition Deposits / Closing (5%) | $372405 | $934761 | $1872022 | $2809279 | $3746540 |

---

At lower funding levels (10%-25%), proceeds are insufficient to fund the full pending Indian land acquisition consideration of approximately $104.3 million. At these levels, proceeds are directed toward EHR platform development, working capital, and partial deposits. Full land acquisition closing requires substantially full or full offering proceeds. Management retains broad discretion over the allocation of net proceeds.

We estimate that, at a per-share price of $85, the aggregate gross proceeds from this Offering will be approximately $74,980,795, assuming the sale of all 882,127 shares of common stock qualified under this Offering Statement.

After deducting estimated offering expenses of approximately $50,000, the net proceeds to the Company from this Offering are expected to be approximately $74,930,795, assuming all shares are sold.

***Primary Use of Proceeds (to the Company)***

The Company intends to allocate approximately 70% of net proceeds from this offering toward strategic mergers and acquisitions, including the following pending land acquisition transactions and future healthcare facility and technology acquisitions.

<u>Pending Land Acquisitions - Material Terms:</u>

 ****

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Property** | **Counterparty** | **Total Consideration** | **Status** | **Affiliate?** |
| 216 Acres, Medak District, Telangana | Mr. Chendireddy Raji Reddy | ~$83,584,551 | Agreement 8/9/2025; Affidavit of Extension executed; closing contingent on offering proceeds | No |
| 147.07 Acres (Vemulapalli Farms), Andhra Pradesh | Raghu Vemulapalli | ~$12,222,539 | Agreement 8/20/2025; closing contingent on offering proceeds | No |
| 10 Acres, Medak District, Telangana | Smt. Architha Raj Kumar Ittaboiena | ~$7,055,862 | Agreement 8/16/2025; closing contingent on offering proceeds | No |
| 5 Acres, Siddipet District, Telangana | Pandi Venkatesh (Dr. P. Venkatesh) | ~$1,450,000 | Agreement 8/16/2025; closing contingent on offering proceeds | Subject to securities counsel determination (see *Conflicts of Interest*) |

---

 

Total aggregate pending land consideration: approximately $104,312,952. All transactions are with unaffiliated third parties except the 5-acre transaction involving Dr. P. Venkatesh, whose affiliate status is under review given his multi-role relationship with the Company (see *[Description of Business - Noah Therapeutics](#a_030)*). None of the properties are currently owned by the Company or any subsidiary. Title will transfer at the Indian sub-registrar's office only upon full cash payment. There can be no assurance that any of these acquisitions will close.

The Company has no pending acquisitions of a business for which specific offering proceeds have been earmarked at this time.

The Company intends to allocate the bulk of the net proceeds toward strategic mergers and acquisitions, including both pending and future transactions that expand and vertically integrate the MyRxWallet ecosystem.

These acquisitions are expected to include healthcare facilities, healthcare technology developers, AI purpose built, Web3 developers, blockchain company, staking and mining company, DAO providers, diagnostic laboratories, pharmaceutical manufacturers, medical devices manufacturing, wellness providers, bio-bank, and bio-blockchain data-center assets that collectively strengthen the MyRxWallet ecosystem.

A portion of the net proceeds will support ongoing corporate and platform initiatives. Specifically, we intend to use proceeds for working capital and for continued development of our EHR, data-encryption, blockchain-infrastructure, and AI-driven healthcare solutions.

We also plan to dedicate funds to market expansion—establishing new partnerships with global healthcare providers, insurers, and government agencies—while strengthening our regulatory-compliance programs to ensure adherence to HIPAA, GDPR, and the DPDP, and other international standards.

Additional funds will be allocated for recruiting key personnel, expanding legal and customer-support services, and implementing targeted marketing and brand-awareness campaigns through digital outreach and public-relations efforts.

The Company's management has historically operated with high capital efficiency and will continue to apply a disciplined, bootstrapped approach, focusing the majority of resources on value-accretive revenue acquisitions and technology development.

The Company does not intend to use any portion of the proceeds from this offering to repay or satisfy the promissory notes issued to MyRxWallet Corporation and Z the Future, LLC. These notes are payable on demand and may be satisfied through conversion into common stock at $125 per share or through payment of interest in common stock. Management expects that these notes will be satisfied through equity rather than cash payments.

**DESCRIPTION OF BUSINESS**

***The Company***

MyRxWallet North America Corporation (the "**Company**," "**MyRxWallet**," or the "**Parent Company**") is a Wyoming corporation that serves as the ultimate parent of a global network of subsidiaries collectively referred to as the MyRxWallet Ecosystem. Through its wholly owned subsidiary, MyRxWallet DAO, LLC, the Company plans to pioneer a decentralized, blockchain-based platform that is intended to empower patients to securely manage and monetize their healthcare data. The Company's platform is in the concept and design stage and has not been built, launched, or deployed as of the date of this Offering Circular. With the current state of healthcare technology struggling to protect patient data from increasing cybersecurity threats, MyRxWallet intends to offer a secure, advanced solution designed to prevent breaches and reward patients for their participation.

Our mission is to revolutionize electronic health record ("**EHR**") healthcare data management by providing patients with full control over their personal data while securing that data through blockchain technology. By enabling patients to monetize their health data, we aim to address deficiencies in traditional healthcare systems and enhance data security. We believe our platform will reshape the future of healthcare, putting privacy and ownership in the hands of patients.

***Corporate Organizational Structure***

![](orgstructure.jpg)

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Entity** | **Jurisdiction** | **Relationship** | **Ownership %** | **Notes** |
| MyRxWallet North America Corporation | Wyoming, USA | Registrant / Parent | Public Issuer | CIK 0002041886. Olivia Trinh beneficially owns ~71.48% of voting power. |
| MyRxWallet Prana Private Limited | India (Hyderabad) | Wholly-Owned Subsidiary | 100% | CIN U86900-TS-2025-PTC-201297. APAC operations, land acquisition program. |
| Bio-Blockchain Intelligence Pvt. Ltd. (f/k/a Clinrarc Services Pvt. Ltd.) | India | Majority-Controlled Subsidiary (via Prana) | Majority / Controlling | Acquired November 2025. Biobank/data intelligence. 8,875,740 NAC shares issued as consideration. |
| Noah Therapeutics Private Limited | India | Pending 70% Acquisition (via Prana) — NOT YET CLOSED | Pending 70% | SPA dated June 17, 2025. Not yet closed. 30% held by original promoters (not affiliated). |
| MyRxWallet DAO LLC | Wyoming, USA | 100% Acquired Subsidiary | 100% | Acquired October 27, 2025. $500M at $27.00/share. |
| MyRxWallet DAO, Inc. | Wyoming, USA | Affiliate — 100% Owned and Controlled by NAC (NOT a subsidiary) | 100% | Blockchain technology foundation. 9,259,259 shares subject to Rule 144. Chanh Trinh retains no interest, role, or involvement. Affiliate status arises solely from 100% ownership by MyRxWallet North America Corporation. |
| MyRxWallet Venture Capital Inc. | Wyoming, USA | Wholly-Owned Subsidiary | 100% | Formation completed March 2026. Strategic M&A arm. 2,958,580 shares issued ($250M at $84.50/share). |
| MyRxWallet Corporation | Wyoming, USA | Related Party — Principal Stockholder & Noteholder (NOT a subsidiary) | N/A | Controlled by CEO. 130M restricted shares. $850M Amended Promissory Note, Feb 4, 2026. |
| Z the Future, LLC | Wyoming, USA | Related Party — Principal Stockholder & Noteholder (NOT a subsidiary) | N/A | Controlled by CEO. 70M restricted shares. $297.5M Amended Promissory Note, Feb 4, 2026. |

---

***MyRxWallet DAO, LLC – Technology and Platform Operations***

MyRxWallet DAO, LLC, a Wyoming-organized limited liability company and a wholly-owned subsidiary of the Parent Company, is responsible for innovating, developing, licensing, maintaining, and supporting all proprietary software, blockchain protocols, artificial-intelligence models, and enterprise EHR/electronic medical record ("**EMR**") systems within the MyRxWallet ecosystem.

It functions as the technological backbone of the enterprise—managing smart-contract frameworks, decentralized-data infrastructure, and interoperability tools that connect patients, providers, clinics, hospitals, laboratories, and payers.

Through decentralized autonomous organizations ("**DAO**")-governed protocols, MyRxWallet DAO ensures transparency, security, and equitable participation in the monetization of health data across all MyRxWallet platforms.

***MyRxWallet Prana Pvt. Ltd. – Healthcare Assets and Infrastructure (India)***

MyRxWallet Prana Private Limited, headquartered in India, is a wholly-owned subsidiary formed to acquire, operate, and consolidate healthcare-related entities and facilities that comprise the broader MyRxWallet ecosystem. Its principal mission is to build the most comprehensive healthcare infrastructure in India—integrating hospitals, specialty clinics, diagnostic laboratories, pharmaceutical manufacturing, and wellness centers—while deploying the Company's proprietary EHR and blockchain technologies throughout these facilities.

By acquiring and modernizing legacy healthcare operations, MyRxWallet Prana seeks to demonstrate a patient-centric model in which technology, treatment, and recovery are delivered seamlessly, minimizing disruption to patients' lives and eliminating inefficiencies inherent in traditional healthcare systems.

This subsidiary also serves as the anchor for the Company's planned hyperscale "Bio-Blockchain Intelligence" data-center campuses in Andhra Pradesh and other strategic regions.

***MyRxWallet Venture Capital, Inc. – Strategic Investment and M&A Division***

MyRxWallet Venture Capital, Inc., a Wyoming-organized corporation and wholly-owned subsidiary (100%), functions as the Company's corporate-finance and investment arm.

Its mandate is to identify, evaluate, and acquire breakthrough healthcare and technology—both early-stage startups and established enterprises—that complement or enhance the Company's existing product stack.

MyRxWallet Capital seeks to acquire at least a controlling interest, or where strategic, full ownership, in such companies, enabling their integration into the MyRxWallet ecosystem or the adoption of their technologies within the Company's EHR and artificial intelligence ("**AI**") infrastructure.

Through disciplined due diligence, equity participation, and structured acquisition programs, MyRxWallet Capital provides the Company with a continuous pipeline of innovation while expanding its intellectual-property portfolio and long-term enterprise value.

***Clinrarc Bio-Bank Intelligence Pvt. Ltd. – Biobank and Data Intelligence (USA)***

The Company completed its acquisition of Bio-Bank Intelligence (formerly Clinrarc Services, Pvt. Ltd.) ("**Bio-Bank**") in November 2025, with MyRxWallet Prana Private Limited holding a majority and controlling stake. As a subsidiary within the MyRxWallet Ecosystem, Bio-Bank is strategically focused on building and operating advanced biobank infrastructure, secure data intelligence platforms, and blockchain-enabled biomedical specimen vaults. Headquartered in the USA with operations in India with global reach, Bio-Bank serves as the data and infrastructure backbone of MyRxWallet's healthcare innovation strategy.

Bio-Bank brings together a multidisciplinary team of biobank specialists, genomic scientists, data engineers, and regulatory experts. Bio-Bank specializes in the ethical collection, processing, and storage of biological samples (DNA, tissue, blood), while simultaneously managing large-scale genomic, clinical, and lifestyle datasets. Leveraging blockchain, encryption, and AI-driven analytics, its mission is to transform biological assets into actionable intelligence that accelerates drug discovery, precision medicine, and predictive healthcare.

to interface with Noah Therapeutics' CRO operations, creating a vertically aligned pipeline from biobank specimen to clinical therapy. The intended integration is contingent in its entirety on the Noah SPA closing, completion of this offering, and successful development of the Company's EHR and AI platform, and proceeds through the following four planned stages: Step 1 - Bio-Blockchain Intelligence: biobank specimen collection, genomic data generation, and blockchain-secured storage of biological and clinical data within the MyRxWallet ecosystem; Step 2 - MyRxWallet EHR & AI Platform: integration of biobank-derived data into the Company's planned EHR platform, enabling AI-driven predictive modeling, clinical trial design optimization, and analytical output generation; Step 3 - Noah Therapeutics CRO: clinical trial execution utilizing the pipeline data, together with regulatory submission management, investigator site coordination, and pharmacovigilance and safety reporting; Step 4 - Therapeutic Outcomes: patient access platform integration, provider portal connectivity, and treatment workflow management enabling data-driven clinical outcomes. Bio-Bank's infrastructure is planned to include biobank vaults, EHR integration, cloud-based data centers, and IoT-enabled logistics supply chains. The hyperscale data center and biobank vault, when completed, will adhere to international standards such as ISO 9001, CLIA, HIPAA, GDPR, and ICH-GCP. None of these integration steps currently exist; all are planned features subject to the closing of the Noah SPA and the successful completion of the Company's platform development program.

Bio-Bank also anchors MyRxWallet's bio-blockchain intelligence initiatives, supporting the creation of genomic databases, AI-powered analytics platforms, and secure patient-consent frameworks. By combining biobank infrastructure with advanced digital technologies, the subsidiary strengthens MyRxWallet's ability to deliver personalized medicine solutions, expand its intellectual property portfolio, and drive long-term enterprise value across the life sciences sector.

***Noah Therapeutics SPA***

On June 17, 2025, MyRxWallet Prana Private Limited entered into a Definitive Share Purchase Agreement (the "**Noah SPA**") to acquire 70% of Noah Therapeutics Private Limited, a contract research organization ("**CRO**") based in Hyderabad, Telangana, India. The remaining 30% is held by the original promoters of Noah Therapeutics, who are not affiliated with the Company. The total consideration for the 70% stake is 843,750 shares of Company common stock valued at approximately $20,250,000 in the aggregate. Partial consideration has been transferred prior to closing: 572,916 shares were issued to Noah Therapeutics Corporation on September 19, 2025, and 125,200 shares were issued to Venkatesh Pandi on September 19, 2025. The Noah SPA is filed as Exhibit 7.3 to this Offering Statement.

As of the date of this Offering Circular, the acquisition of Noah Therapeutics Pvt. Ltd. (India) has not yet closed. Noah Therapeutics is not currently a subsidiary of the Company or any of its subsidiaries, and all references in this Offering Circular to Noah Therapeutics as part of the MyRxWallet Ecosystem describe planned, not consummated, integration. There can be no assurance that the Noah Therapeutics acquisition will close on the expected terms, or at all.

In its existing independent operations, Noah Therapeutics maintains CRO service agreements with pharmaceutical sponsors in the ordinary course of business, including an executed Master Services Agreement with a major global pharmaceutical company. Because the Noah SPA has not yet closed, these agreements are not agreements of the Company or any of its current subsidiaries, and the Company makes no representation regarding the terms, enforceability, or ongoing status of such agreements. Upon closing of the Noah SPA, all material contracts of Noah Therapeutics will be reviewed and, to the extent required by applicable securities regulations, disclosed in a subsequent amendment to this Offering Statement.

Dr. Venkatesh Pandi holds multiple overlapping roles in connection with the MyRxWallet Ecosystem that collectively constitute a potential conflict of interest currently under review by the Company's securities counsel: (i) he serves as Managing Director of Noah Therapeutics Private Limited and is the selling party under the Noah SPA; (ii) he is the vendor in the pending 5-acre land acquisition in Siddipet District, Telangana, for aggregate consideration of approximately $1,450,000, and his affiliate status with respect to that transaction is subject to determination by the Company's securities counsel (see "[Description of Property](#a_010)" and "[Use of Proceeds](#a_008)"); (iii) he served as the introducer of the 216-acre Medak District selling group, in connection with which Raghavendra Verita Spaces LLP received a finder's fee consisting of 37,920 shares of Company common stock at $75.00 per share; and (iv) he is expected to assume a future operational role at MyRxWallet Prana Private Limited, contingent upon completion of this offering and receipt of development funding. Dr. Venkatesh Pandi does not hold any officer or director position at MyRxWallet North America Corporation as of the date of this Offering Circular. See "*[Interest of Management and Others in Certain Transactions](#a_015)*" and "*[Risk Factors - Risks Related to Corporate Governance and Control](#a_028)*."

***Integrated Mission***

Collectively, these subsidiaries allow MyRxWallet North America Corporation to function as a vertically integrated healthcare-technology enterprise—combining advanced data-management systems, large-scale healthcare infrastructure, and strategic investment capabilities.

The unified structure enables the Company to design, deploy, and scale end-to-end solutions that return ownership of health data to patients, empower providers with real-time intelligence, and replace legacy, siloed healthcare models with a decentralized, secure, and globally interoperable ecosystem.

***Healthcare's Current State of Problems***

The healthcare industry faces persistent and compounding challenges in securing and managing patient data. Despite widespread digitization, existing EHR systems remain fragmented, inefficient, and vulnerable to cyber threats. The following represent some of the most critical systemic problems that MyRxWallet seeks to address:

**Frequent Cybersecurity Breaches and Endpoint Attacks**

Hospitals and healthcare providers are increasingly targeted by hackers due to outdated cybersecurity defenses and weak endpoints. Many organizations continue to rely on legacy IT infrastructure that lacks modern encryption, intrusion detection, and zero-trust protocols. These vulnerabilities have resulted in a rising frequency of ransomware incidents, data theft, and operational downtime that disrupt patient care and expose sensitive medical records.

**Vulnerabilities in Legacy EHR Systems**

Major EHR providers continue to operate on architectures designed decades ago, which lack interoperability and modern data-security standards. These systems are particularly vulnerable to endpoint compromises and social-engineering attacks that exploit unpatched software and outdated user-access controls. Once infiltrated, a single endpoint can provide unauthorized access to entire patient databases, leading to massive data losses and compliance violations.

**Centralized Data Storage Risks**

Most EHR systems depend on centralized cloud or on-premise storage, creating a single point of failure that exposes millions of patient records to large-scale breaches. A single compromised administrator account or server misconfiguration can result in catastrophic data exposure. This structural flaw continues to drive escalating cybersecurity insurance costs and reputational risk for healthcare institutions.

**Large-Scale Data Compromises**

Recent breaches, such as those affecting UnitedHealth Group, Kaiser Permanente, and other national providers, have collectively exposed the medical information of more than 100 million patients.<sup>1 2</sup> These events underscore how traditional EHR ecosystems remain ill-equipped to prevent or contain systemic cyber incidents, particularly when patient data is concentrated in a limited number of centralized repositories.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. UnitedHealth Group / Change Healthcare breach – A catastrophic ransomware attack in 2024 compromised sensitive medical and financial data of over 192 million people, with lawsuits ongoing against UnitedHealth and its subsidiaries: Nebraska AG's lawsuit over Change Healthcare data breach.<sup>3</sup>

2. UnitedHealth subsidiary Episource breach – In early 2025, hackers accessed systems at Episource (owned by Optum/UnitedHealth), exposing the medical and personal data of over 5 million individuals: UnitedHealth subsidiary data breach hits 5M+.<sup>4</sup>

3. Kaiser Permanente breaches – Kaiser suffered multiple incidents, including unauthorized tracking technologies in 2023 that exposed data of 13.4 million users, and a 2024 email breach affecting 44,000 customers: Kaiser data breach incidents: what patients should know.<sup>5</sup>

**Data Fragmentation and Lack of Interoperability**

Patient data is dispersed across hospitals, laboratories, insurers, and third-party applications that cannot communicate effectively. The absence of standardized interoperability leads to incomplete medical histories, duplicate testing, and delayed treatment decisions. This fragmentation results in wasted resources, reduced care quality, and higher systemwide costs.

------

<sup>1</sup> https://www.cms.gov/newsroom/press-releases/cms-notifies-individuals-potentially-impacted-data-breach

<sup>2</sup> https://onerep.com/blog/kaiser-data-breach-what-patients-should-know

<sup>3</sup> https://ago.nebraska.gov/news/attorney-general-mike-hilgers-files-lawsuit-against-change-healthcare-critical-failures

<sup>4</sup> https://cybernews.com/security/unitedhealth-data-breach-episource/

<sup>5</sup> https://onerep.com/blog/kaiser-data-breach-what-patients-should-know

**Regulatory Complexity and Compliance Burden**

Healthcare providers must comply with an expanding array of data-protection regulations, including HIPAA in the United States, the General Data Protection Regulation ("**GDPR**") in Europe, and India's Digital Personal Data Protection Act ("**DPDP**"). Legacy EHR systems are not equipped to provide granular consent management, immutable audit trails, or real-time access logs—capabilities that regulators increasingly require. Non-compliance can result in substantial penalties and reputational damage.

**Administrative Inefficiency and Cost Overload**

Manual data entry, claims processing, and reconciliation tasks continue to consume an estimated 20–25% of U.S. healthcare expenditure.<sup>6</sup> Outdated systems lack automation, resulting in billing errors, payment delays, and increased administrative headcount. This inefficiency reduces profitability and diverts attention from clinical outcomes.

**Lack of Patient Data Ownership and Monetization Transparency**

Under current frameworks, patients rarely control how their medical data is stored, shared, or monetized. Health systems and third parties often sell or license de-identified data without compensating the individuals who generated it. This inequity has eroded patient trust and created ethical and regulatory scrutiny over secondary use of health data.

**Limited Use of Artificial Intelligence and Predictive Analytics**

Although healthcare generates vast volumes of data, most EHR platforms lack embedded AI capabilities to detect early-stage disease indicators or predict treatment outcomes. This under-utilization of data diminishes opportunities for preventive care, population-health management, and cost savings.

**Infrastructure Inequality in Emerging Markets**

Healthcare IT infrastructure in many developing regions remains outdated or nonexistent. Limited bandwidth, aging hardware, and lack of secure cloud access prevent reliable deployment of EHR systems. This widens the global digital divide and excludes billions of patients from secure digital health participation.

**Escalating Cyber-Insurance and Liability Exposure**

As cyber incidents grow in frequency and magnitude, healthcare organizations face rising insurance premiums and tightening underwriting standards. Without immutable audit trails or decentralized data verification, providers struggle to demonstrate compliance and limit post-breach liability.

------

<sup>6</sup> https://jamanetwork.com/journals/jama/fullarticle/2785479

***Our Solution***

MyRxWallet's solution is designed to address the systemic challenges of data security, fragmentation, and patient disempowerment through a comprehensive, proprietary, and purpose-built platform combining blockchain, AI, and decentralized infrastructure. Subsequent to the September 30, 2025 balance sheet date, the Company deployed its core EHR platform to production. The core EHR platform, FHIR-based interoperability APIs, patient and provider portals, and Hyperledger blockchain infrastructure are technically operational. On April 17, 2026, the platform completed all 317 sub-tests of the ONC Inferno v8.0.0 test suite with zero failures, which is the required predicate for ONC Health IT Module Certification under 45 CFR 170.315(g)(10). The Company is currently engaging ONC-Authorized Certification Bodies to complete Module Certification and achieve listing on the federal Certified Health IT Product List (CHPL). The Company remains pre-commercial with no external users, no executed pilot or customer agreements, and no revenue as of the date of this Offering Circular. Certain advanced capabilities described below - including AI/ML clinical decision support, the MyRxToken program, the biobank infrastructure, and the hyperscale data center - remain in the planning or early development stage and are contingent upon the successful completion of this offering and subsequent development funding.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Feature / Operation** | **Current Status** | **Key Steps Remaining** | **Contingencies** | **Est. Timeline** |
| EHR Core Platform | Deployed to production (ehr.myrxwallet.io); ONC Inferno v8.0.0 passed April 17, 2026 (317/317 sub-tests, zero failures); ACB engagement for Module Certification in process; pre-commercial (no external users) | Hire dev team; build architecture; MVP; HIPAA compliance; ONC certification | Full funding required | 12–24 months post-funding |
| AI / ML Engine | Does not exist; no code written | Data architecture; model training; biostatistician validation; FDA SaMD review | Full funding + data partnerships | 12–36 months post-funding |
| Blockchain EHR Infrastructure | Hyperledger infrastructure deployed and live in production; integrated with core EHR platform; smart contract layer operational | Protocol selection; smart contract layer; security audit | Full funding; partner agreements | 12–30 months post-funding |
| Biobank / Bio-Blockchain Infrastructure | Land agreements signed; no construction | Land closing; construction; CLIA/ISO certification; clinical staff | Full proceeds + land closing | 12–60 months post-funding |
| Noah Therapeutics CRO Integration | SPA executed; NOT YET CLOSED | SPA closing; system integration; regulatory alignment | Contingent on SPA closing | Post-acquisition closing |
| Hyperscale Data Center | Land agreements signed; no construction | Land registration; permits; construction; power infrastructure | Full proceeds + land closing | 24–48 months post-funding |
| MyRxToken Program | Concept stage | Blockchain development; legal review; ecosystem partner onboarding | Platform completion required | 24–42 months post-funding |

---

**Core Platform Features**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· *Advanced Security Features*: Our platform is designed to utilize *decentralized data sharding*, splitting encrypted data fragments across multiple blockchain nodes to ensure that no single dataset is ever vulnerable to compromise, eliminating centralized points of failure common in traditional EHR systems.

· *Tamper-Proof Ledger Technology*: MyRxWallet's planned blockchain ledger is intended to be immutable and auditable. Once data is recorded, it will not be able to be altered or deleted, ensuring trust, traceability, and integrity across all participants in the healthcare network.

· *Proprietary AI Algorithms*: Purpose-built for the healthcare sector, our planned AI system is intended to enhance diagnostic accuracy, streamline administrative workflows, and deliver predictive analytics to healthcare providers, improving both clinical outcomes and operational efficiency.

· *Decentralized Encryption*: Our planned decentralized data encryption algorithm is designed to play a key role in securing data across the board, from patients to providers, eliminating the vulnerabilities present in traditional centralized systems by removing single points of access, protecting against endpoint and ransomware attacks that plague legacy EHR platforms.

· Our planned proprietary AI algorithms are intended to optimize diagnostic accuracy, healthcare workflows, and predict patient outcomes, improving overall care. The platform's planned adaptive AI engine does not currently exist and has not been built, trained, or deployed as of the date of this Offering Circular. When developed, it is intended to learn from anonymized datasets to improve predictive modeling, automate workflows, and optimize resource utilization across hospitals, laboratories, and insurers. All AI capabilities described in this section are planned features contingent upon completion of this offering and subsequent development funding.

· *Monetization Model*: Patients are intended to be rewarded for securely sharing anonymized data through MyRxCoins or MyRxTokens, creating a planned transparent and ethical marketplace for healthcare insights designed to support research, medical devices, insurance modeling, and pharmaceutical innovation while preserving patient consent and data control.

· *Development Stage Status:* Summary of Platform Components: All platform capabilities described in this Offering Circular are in the concept and design stage. None have been built, launched, or deployed as of the date of this Offering Circular. The following table summarizes the development status of each principal platform component. All timelines and cost estimates are contingent on receipt of sufficient offering proceeds.

 ****

***Electronic Health Record (EHR) Platform Overview***

Our platform is in the development stage. We plan to use the funds from this offering to build out the platform, which we plan to call the "MyRxWallet."

The primary purpose is to create an integrated EHR solution that offers secure, accessible, and user-friendly healthcare management tools for patients and healthcare providers. The system is expected to serve as both a patient portal and a robust backend workflow for providers, facilitating seamless healthcare delivery across diverse needs.

 **

 ****

 ****

 **

 ****

***Key Features and Functionality of the Patient Portal***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·  ***User-Friendly Interface*** : A simple, intuitive design with easy navigation is planned, intended to ensure that patients of all ages and tech comfort levels will be able to manage their health records with ease.

·  ***Secure Access*** : Two-factor authentication and encrypted logins are planned to ensure that only authorized users will be able to access sensitive data.

·  ***Appointment Scheduling*** : Patients will be able to book appointments with their primary care physicians, specialists, and lab services directly from the portal, with reminders and follow-ups integrated.

·  ***Real-Time Health Data Access*** : Patients will be able to access lab results, imaging, prescriptions, visit summaries, and more as soon as they are available.

·  ***Prescription Management*** : The platform is designed to allow patients to manage prescriptions, request refills, view medication history, and receive reminders for medications.

·  ***Health Progress Monitoring*** : Planned AI-driven insights are intended to offer tailored health recommendations based on data trends, helping patients track key health indicators such as blood pressure, glucose levels, and cholesterol.

·  ***Telehealth Integration*** : Built-in telemedicine capability is planned, which will allow patients to consult with healthcare providers via video directly within the portal.

·  ***Blockchain-Secured Data*** : Each record update is planned to be immutably recorded on the blockchain, ensuring tamper-proof and verifiable patient data.

·  ***Consent Management*** : Patients will be able to manage who has access to their health records, with options for timed access for external providers.

***Optometry and Dental Care Features***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·  ***Vision Records and History*** :

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o The platform is designed to track patients' vision assessments, including refractive error, prescription history, and visual acuity.

o The platform will document past vision correction procedures, such as LASIK or cataract surgeries, with details on outcomes and recovery.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·  ***Prescription Management for Glasses and Contact Lenses*** :

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o The platform is planned to include integrated tools for optometrists to generate and manage prescriptions for glasses and contact lenses.

o Patients will be able to view and refill contact lens prescriptions through the patient portal, with reminders for eye exams and prescription renewals.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·  ***Optical Image Storage and Analysis*** :

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o The platform is designed to allow users to upload and store images from optical coherence tomography ()"**OCT** "), fundus photography, and other diagnostic imaging to monitor eye health over time.

o The platform is planned to integrate AI tools to assist in identifying and tracking signs of retinal disease, glaucoma, or macular degeneration.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·  ***Integration with Vision Insurance*** :

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o The platform is designed to simplify insurance verification for vision coverage, allowing providers to check eligibility for routine exams, contact lenses, and glasses.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·  ***Visual Field Testing and Monitoring*** :

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o The platform will document and track results from visual field tests, important for managing glaucoma and other vision impairments.

o The platform will enable patients to see their test history and receive educational resources on maintaining visual health.

***Dental Care-Specific Features***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·  ***Dental Charting and History*** :

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o The platform is planned to include comprehensive dental charting functionality to document the state of each tooth, restorations, and gum health.

o The platform will record detailed patient dental history, including past treatments like fillings, crowns, root canals, and extractions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·  ***Treatment Planning and Case Documentation*** :

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o The platform is planned to include tools for providers to create detailed treatment plans, including recommended procedures, estimated costs, and timelines.

o The platform will enable patients to view their treatment plans and understand recommended steps and costs through the portal.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·  ***Dental Imaging and X-Ray Integration*** :

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o The platform is planned to allow storage and viewing of dental x-rays, intraoral images, and 3D scans, and is designed to integrate with existing dental imaging systems.

o AI-assisted analysis is planned to detect early signs of cavities, bone loss, and other dental issues.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·  ***Preventive Care Reminders*** :

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o The platform is planned to provide automatic reminders for routine cleanings, exams, and other preventive services.

o Patients will receive prompts to schedule cleanings and exams, promoting better long-term dental health.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·  ***Insurance and Billing Integration*** :

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o The platform is planned to integrate with dental insurance systems for easy verification of coverage and benefits.

o The platform will include streamlined billing tools for providers to quickly manage patient claims, verify dental benefits, and track treatment approvals.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·  ***Patient Education Tools*** :

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o The platform is planned to provide access to educational resources on oral hygiene, preventive care, and post-treatment guidelines.

o Visual aids and articles will be available through the patient portal, helping patients understand treatment plans and recovery processes.

***Integration with Core EHR Platform***

Both optometry and dental features are planned to be seamlessly integrated into the MyRxWallet EHR, ensuring a unified experience for patients and providers across all specialties. This integration is designed to provide a comprehensive healthcare record that combines general health data with optometry and dental history, offering a full spectrum of patient health information.

**Patient Benefits**

 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Patients have a single point of access to all their healthcare data, including vision and dental records, enhancing their engagement and understanding of their overall health.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Opt-in notifications for vision exams, dental cleanings, and preventive visits help patients stay proactive about their healthcare needs.

**Provider Benefits**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Patients will have a single point of access to all their healthcare data, including vision and dental records, enhancing their engagement and understanding of their overall health.

· Opt-in notifications for vision exams, dental cleanings, and preventive visits are designed to help patients stay proactive about their healthcare needs.

**Provider Backend Workflow Application**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·  ***Integrated Patient Records*** : The platform is planned to provide a comprehensive view of each patient's health data, including visit history, lab results, imaging, medications, and chronic condition tracking.

·  ***Automated Documentation*** : The platform is designed to use natural language processing ()"**NLP**") to automate data entry, reducing time spent on documentation and improving accuracy.

·  ***Appointment Management*** : The platform is planned to include real-time scheduling, automated reminders, and no-show tracking to maximize efficiency in patient care.

·  ***Clinical Decision Support*** : The platform is designed to provide AI-driven clinical recommendations, flagging potential diagnoses or treatment options based on symptoms, lab results, and medical history.

·  ***Prescription and Pharmacy Integration*** : The platform is planned to allow providers to manage prescriptions, check for drug interactions, and send orders directly to pharmacies.

·  ***Billing and Coding Assistance*** : The platform is designed to provide automated coding suggestions based on treatment and diagnostic entries, streamlining the billing process and reducing errors.

·  ***Care Coordination*** : The platform is designed to facilitate care team communication, including task assignment, progress tracking, and secure messaging among all team members.

·  ***Analytics and Reporting*** : The platform is planned to include in-depth reports on patient populations, treatment outcomes, and operational metrics, allowing providers to make data-driven decisions.

·  ***Blockchain for Audit Trails*** : The planned blockchain integration is intended to ensure a verifiable and transparent record of all modifications made within a patient's EHR, supporting compliance and security.

***Technical Architecture and Infrastructure***

**System Architecture**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·  ***Cloud-Based System*** : A secure, cloud-native environment leveraging the Company's planned proprietary, enterprise-grade and hyperscale cloud infrastructure is intended to ensure continuous data accessibility, redundancy, and near-zero downtime. This infrastructure is planned to underpin all blockchain, AI, and healthcare data operations across the MyRxWallet ecosystem, providing scalable performance and full compliance with SOC 2, HIPAA, and GDPR standards.

·  ***Modular Microservices Design*** : Each functionality (e.g., patient data management, scheduling, billing) is planned to be developed as an independent microservice, improving scalability, maintainability, and fault isolation.

·  ***Blockchain Integration*** : A permissioned blockchain network (e.g., Hyperledger Fabric) will manage patient data updates, creating a tamper-proof log of all EHR interactions.

·  ***APIs and Interoperability*** : The platform is planned to use HL7 FHIR (Fast Healthcare Interoperability Resources) standards to ensure compatibility with other healthcare systems, promoting interoperability across the healthcare ecosystem.

·  ***Web3 Components*** : The platform is planned to integrate Web3 components to enable secure, decentralized identity management, allowing users to control access to their data directly.

**Machine Learning and Artificial Intelligence — Planned Technical Architecture**

None of the AI or machine learning capabilities described below have been developed, validated, or deployed as of the date of this Offering Circular. All capabilities are planned features contingent on receipt of sufficient offering proceeds and completion of development. The Company plans to incorporate the following categories of machine learning and artificial intelligence:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) *Supervised Learning Applications*. The platform is designed to employ supervised machine learning models for clinical classification and prediction tasks, including disease risk stratification, medication adherence scoring, and readmission prediction. These models are intended to be trained on labeled clinical datasets - including diagnoses, laboratory results, and medication records - to generate evidence-based treatment recommendations and flag potential adverse drug interactions within the EHR interface. Intended algorithms include gradient boosting classifiers and logistic regression models applied to structured clinical data, implemented using open-source libraries such as scikit-learn and TensorFlow as foundational development libraries. These outputs will function as advisory information only and will be subject to mandatory review by licensed clinicians prior to any clinical application. The Company does not currently possess these models and has not commenced development.

(ii) *Natural Language Processing*. The platform intends to incorporate NLP for automated clinical documentation, including structured data extraction from unstructured clinical notes, ICD-10 diagnostic coding assistance, and patient-provider communication summarization. The Company intends to deploy transformer-based NLP models to automate the extraction and structuring of unstructured physician notes, discharge summaries, and referral letters into standardized EHR data fields. Intended base architectures include BioBERT and ClinicalBERT, which are open-source, pre-trained models released under the Apache 2.0 license. The Company intends to fine-tune these models on its own de-identified clinical datasets to develop proprietary, domain-adapted versions. The Hugging Face Transformers library is anticipated to serve as the primary framework for NLP model development and deployment. The Company does not currently own any proprietary trained NLP models and has not commenced development.

(iii) *Algorithm Architecture*. The platform's AI inference infrastructure is planned to use a modular microservices architecture with separate endpoints for each AI task. The Company intends to use transformer-based architectures for language and sequence tasks, gradient-boosted tree models (including XGBoost) for structured clinical data, and deep neural networks built with PyTorch for imaging and genomic analysis applications. The isolation forest algorithm intended for anomaly detection is similarly available through open-source libraries. The Company does not currently own any proprietary trained models. The Company's intended proprietary advantage will derive from fine-tuning these open-source architectures on its own de-identified clinical datasets and integrating them within its proprietary EHR platform workflow. All such proprietary development is contingent upon completion of development funding.

(iv) *Anomaly Detection*. The platform is designed to include real-time anomaly detection for cybersecurity threat identification (including detection of unusual access patterns and potential data breaches) and clinical data quality monitoring (including identification of potentially erroneous or fraudulent data entries). The Company additionally intends to implement unsupervised clustering and isolation forest algorithms to identify anomalous billing patterns, duplicate claims, and potential fraud indicators within connected payor system data. Both statistical and neural network-based anomaly detection models are planned for integration within the platform's security and data-quality layers. All anomaly detection outputs will be reviewed by qualified compliance personnel prior to any adverse action. No claim will be flagged, denied, or escalated based solely on machine learning output without human review.

(v) *Federated Learning*. To address patient privacy obligations under HIPAA and GDPR, the Company intends to incorporate federated learning protocols that enable model training across distributed healthcare data sources without centralizing raw patient data, consistent with the HIPAA minimum necessary standard. Under the planned approach, model parameters rather than raw patient data would be aggregated across participating nodes. This approach is intended to enable learning from decentralized datasets while preserving patient data sovereignty and regulatory compliance. The Company acknowledges implementation challenges including data heterogeneity across participating institutions, system interoperability requirements, and potential exposure to adversarial model inputs - all of which will require mitigation prior to any deployment. No federated learning architecture currently exists within the Company's technology.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) *Healthcare Facility Intelligence*. The platform is planned to include facility-level operational intelligence tools for the healthcare facilities the Company intends to acquire and operate, including: (i) predictive maintenance for on-site medical and data center equipment; (ii) AI-driven energy management across the planned hyperscale data center and biobank infrastructure; (iii) computer vision and sensor-based monitoring for facility security and patient flow management; and (iv) AI-assisted inventory and supply chain management for medical consumables, laboratory supplies, and pharmaceutical inputs. The Company intends to develop certain of these capabilities in-house and engage qualified third-party vendors for others; the specific allocation between in-house development and third-party engagement has not yet been determined and will be disclosed in future amendments. None of these operational capabilities currently exist.

(vii) *Open-Source License Risk Disclosure*: The Company expects to incorporate open-source software components including TensorFlow, PyTorch, scikit-learn, Hugging Face Transformers, BioBERT, and ClinicalBERT. Certain open-source licenses (including GPL and AGPL copyleft licenses) impose conditions that, if not complied with, could require the Company to disclose its proprietary source code publicly. *See [Risk Factors — Risks Related to Technology and Cybersecurity](#a_031)*.

(viii) *Model Governance, Human Oversight, and Liability*. The Company intends to implement a formal model validation framework prior to any clinical or operational deployment, including internal back-testing, ongoing performance monitoring, and periodic recalibration. All machine learning outputs in clinical decision support and claims anomaly detection contexts will be presented to qualified human reviewers — licensed clinicians or compliance personnel, as applicable — as advisory information only and will not constitute autonomous clinical or financial decisions. No machine learning output will be used to make, deny, or escalate a clinical recommendation or claims determination without human review. The Company acknowledges that the use of machine learning in clinical and financial contexts carries inherent risks, including model error, algorithmic bias, data quality limitations, and regulatory uncertainty. Investors are directed to the Risk Factors section of this Offering Circular for a full discussion of material risks associated with the Company's intended use of artificial intelligence and machine learning. None of the machine learning capabilities described above currently exist within the Company's technology or operations. All are planned features subject to successful fundraising, technology development, execution of required data agreements, and applicable regulatory review, including but not limited to review under HIPAA and applicable FDA guidance on clinical decision support software.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ix) *Training Data Sources and Development Timeline*. The Company intends to train its supervised and NLP models using de-identified electronic health records, laboratory results, medication histories, and physician notes obtained through data sharing agreements with partner healthcare facilities, subject to executed HIPAA Business Associate Agreements. The Company does not currently possess a proprietary clinical training dataset and has not executed any data sharing agreements to date. For proof-of-concept development, the Company anticipates utilizing publicly available, annotated clinical corpora such as MIMIC-III/IV (PhysioNet Credentialed Access License). The Company does not share or sell training data to third parties and has no plans to do so. Initial proof-of-concept model development could commence within 12 to 18 months following completion of initial development funding. Full integration of ML capabilities into the EHR platform is estimated at 24 to 36 months post-funding, subject to execution of data sharing agreements and applicable regulatory review. These timelines are estimates subject to material uncertainty.

(x) *AI Model Validation Framework (Planned)*. The Company's adaptive AI engine does not currently exist. No proprietary AI model has been built, trained, or deployed as of the date of this Offering Circular. All AI capabilities described in this Offering Circular are planned features contingent upon completion of this offering and allocation of development funding. Upon completion of development, the Company intends to validate its AI models through the following planned steps: (i) internal testing against de-identified patient datasets using held-out test sets to assess baseline model performance prior to any deployment; (ii) k-fold cross-validation to evaluate model generalizability across different patient subpopulations and clinical settings; (iii) external review by qualified biostatisticians and clinical informatics professionals prior to any clinical application; (iv) compliance review against applicable FDA Software as a Medical Device ()"**SaMD**") guidance and applicable HIPAA privacy and de-identification standards under 45 CFR §§ 164.514(a)–(b); and (v) peer review through academic publication or structured clinical pilot programs prior to any commercial deployment. No third-party validation services have been engaged as of the date of this Offering Circular, and no validation timeline has been established. All validation activities described above are contingent on first securing funding from this offering and completing initial development of the underlying AI infrastructure. There can be no assurance that any validation process will result in models that perform to the Company's expectations or that satisfy applicable regulatory requirements.

**Security and Compliance**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·  ***Data Encryption*** : End-to-end encryption for all data at rest and in transit is planned, designed to ensure compliance with HIPAA and other healthcare regulations.

·  ***Two-Factor Authentication ("2FA")*** : The platform is planned to require 2FA for all users accessing the system, protecting against unauthorized access.

·  ***Role-Based Access Control ("RBAC")*** : The platform is designed to restrict data access based on user roles, ensuring sensitive data is visible only to authorized personnel.

·  ***Audit Trails*** : Planned blockchain integration is designed to create a complete audit trail of all system activity, supporting transparency and accountability.

·  ***Compliance*** : The platform is designed to adhere to HIPAA, GDPR, and other relevant regulations, with regular compliance audits planned to maintain standards.

**Development and Deployment Plan**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·  ***Phase 1: Core EHR Platform*** : The core EHR platform has been deployed to production subsequent to the September 30, 2025 balance sheet date. The platform is technically operational at ehr.myrxwallet.io, with APIs, patient and provider portals, and Hyperledger blockchain infrastructure live. The Company will use a portion of the proceeds of this offering to complete ONC Module Certification, expand platform capabilities, onboard commercial users, and develop additional features described herein.

·  ***Phase 2: AI-Driven Decision Support and Blockchain*** : We plan to integrate AI tools for clinical decision support and implement blockchain for secure data management.

·  ***Phase 3: Telehealth and Patient Engagement*** : We plan to add telehealth functionality, expand patient engagement features (e.g., personalized health insights), and refine user interfaces.

·  ***Phase 4: Full Provider Workflow and Reporting*** : We plan to complete the backend provider workflow application with comprehensive analytics, reporting, and coding assistance.

**Testing and Quality Assurance**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·  ***Unit Testing*** : Each component is planned to be individually tested to ensure it meets functionality standards.

·  ***Integration*** Testing: Cross-service interactions will be rigorously tested to verify seamless communication between modules.

·  ***Compliance Testing*** : We plan to verify compliance with all regulatory standards, especially HIPAA and GDPR, and the DPDP.

·  ***User Acceptance Testing ("UAT")*** : We plan to engage a select group of patients and providers to test the platform in real-world scenarios and provide feedback.

**Deployment and Maintenance**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·  ***Continuous Integration/Continuous Deployment ("CI/CD")*** : The platform is planned to use automated testing and deployment pipelines to streamline updates and ensure a smooth rollout of new features.

·  ***Monitoring and Maintenance*** : We plan to implement 24/7 system monitoring with proactive maintenance and regular security audits to detect and address vulnerabilities.

·  ***Data Backup and Disaster Recovery*** : We plan to implement scheduled backups and maintain a detailed disaster recovery plan to protect patient data in case of any unexpected events.

**User Training and Support**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·  ***Provider Training Program*** : We plan to offer in-depth training for healthcare providers to familiarize them with all features of the backend workflow, clinical decision tools, and secure data handling.

·  ***Patient Support Resources*** : We plan to provide user guides, video tutorials, and 24/7 support to help patients navigate the portal, access their health information, and make the most of its features.

·  ***Help Desk and Technical Support*** : We plan to provide dedicated support teams for real-time assistance, available for both patients and providers.

**Future Scalability and Enhancements**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·  ***AI and Machine Learning Expansion*** : We plan to further develop predictive analytics for early detection of health issues based on EHR data trends.

·  ***Remote Patient Monitoring*** : We plan to integrate with wearable devices to enable real-time monitoring of chronic conditions and health metrics.

·  ***Integration with Third-Party Health Services*** : We plan to allow patients and providers to connect with third-party services, like diagnostic labs or specialist networks, for enhanced care coordination.

·  ***Advanced Telemedicine Features*** : We plan to expand telehealth capabilities to include features like remote diagnostics and multi-provider consultations.

***NFT-Base Identity and Access Management***

 ****

Each patient, provider, or institutional participant will receive a non-fungible token ("**NFT**") upon registration on the MyRxWallet platform. This NFT is intended to serve as a secure, cryptographically protected credential embedded with multi-layer encryption to authenticate user access throughout the MyRxWallet ecosystem. This feature does not currently exist and is a planned development contingent upon completion of funding and platform development.

*MyRxToken Program - Closed-Loop Healthcare Rewards (Internal Use Only)*: MyRxTokens are a proprietary, closed-loop digital rewards unit designed exclusively for use within the MyRxWallet Ecosystem. MyRxTokens are NOT intended to be sold, traded, transferred, redeemed, or transacted upon outside of the MyRxWallet platform. MyRxTokens are not a cryptocurrency, are not listed or intended to be listed on any digital asset exchange, and are not designed to function as a medium of exchange, store of value, or investment instrument outside the platform. The MyRxToken program is structurally analogous to a closed-loop healthcare loyalty rewards program.

*Intrinsic Value Determination*: The platform intends to assign token values based on: (i) data contribution type and research utility (longitudinal genomic records earn more than routine demographic data); (ii) activity completion (preventive care, appointment adherence, medication compliance); and (iii) participation tier multipliers for sustained engagement. All token valuations are set by Company platform administrators. No external oracle, market mechanism, or third-party exchange determines the value of MyRxTokens.

Redemption is limited exclusively to within the MyRxWallet Ecosystem for: (i) reduced or waived co-pays at participating facilities; (ii) premium platform features; (iii) credits toward pharmaceutical or laboratory services; and (iv) donation to registered health research initiatives within the platform.

*Regulatory Note*: The Company has structured MyRxTokens as a closed-loop loyalty program intended to fall outside the definition of a security under the Howey test. The Company has not sought a no-action letter or formal SEC guidance regarding MyRxTokens and does not represent that MyRxTokens are definitively excluded from regulation as securities under current or future law.

Each NFT functions as more than an identity key — it is a personalized "MyRxWallet" that contains and manages all of the participant's digital healthcare assets, including medical records, genomic data, health tokens, and verified credentials. These NFTs are asset-backed within the ecosystem, reflecting the intrinsic value of the holder's verified data, earned rewards, and staking rights. Accordingly, every NFT carries a determinable monetary value, representing the participant's cumulative healthcare and data assets, which can be utilized within the MyRxWallet platform, exchanged for MyRxTokens, or redeemed in accordance with applicable securities and data-monetization laws.

Through this design, MyRxWallet transforms digital identity into a value-bearing instrument, merging personal data ownership with secure financial participation — enabling patients, providers, and institutions to directly benefit from their contributions to the ecosystem, while maintaining privacy, regulatory compliance, and full transactional transparency.

***Decentralized DAO Governance***

Through MyRxWallet DAO, LLC, the Company intends to operate a decentralized governance framework that will enable community-based oversight of the ecosystem. Token holders will be able to propose and vote on upgrades, partnerships, and monetization initiatives directly on-chain and off-chain. This governance model is designed to promote transparency, stakeholder participation, and regulatory alignment while ensuring that platform decisions will be driven by the community and not solely by centralized corporate management.

The DAO is also intended to function as a licensing and royalty hub, managing the intellectual property ("**IP**") rights and software licenses across all MyRxWallet subsidiaries. This is designed to allow the DAO to generate on-chain revenue streams from licensing, staking, and governance fees that circulate within the ecosystem.

***Hyperscale and Hyperledger Data Centers***

Through MyRxWallet Prana Pvt. Ltd., the Company plans to develop hyperscale data centers—covering approximately 156 acres for purpose-built AI, DAO, and Web3 infrastructure, approximately 216 acres planned for hyperscale enterprise-grade blockchain cloud infrastructure, and 50 plus acres planned for bio specimen and bio intelligence EHR technology development in India. These facilities are intended to host blockchain nodes, AI compute clusters, genomic databases, and secure health-data archives. They are planned to support both MyRxWallet's global operations and third-party healthcare partners requiring compliant, high-availability data infrastructure.

By owning and operating its own data centers, MyRxWallet intends to eliminate dependence on external cloud providers, achieving:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Lower operating costs;

· Enhanced security and compliance with the DPDP, HIPAA, and GDPR; and

· Direct control over system performance, uptime, and scalability

We believe this planned infrastructure is intended to anchor MyRxWallet's long-term expansion across Asia, Europe, and North America, providing a resilient backbone for the Company's AI-, blockchain-, and data-driven healthcare operations.

***Our Infrastructure Stack***

MyRxWallet's infrastructure strategy extends beyond traditional data hosting to form a global-scale digital and healthcare ecosystem, comprising the following components:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· *Clinical Research Organization ()"**CRO** ")*: A full-service research and development entity with approximately 60 full-time employees based in India, supporting clinical trials, drug development, and biotech analytics.

· *Hyperscale + Hyperledger Mega Data Centers*: Nearly 500 acres of combined infrastructure in Hyderabad, India, allocated as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o 215 acres dedicated to hyperscale blockchain-powered enterprise cloud computing;

o 155 acres supporting multi-purpose AI, Web3, DAO, and staking infrastructure;

o 50 acres designated for critical supply chain and logistics technologies; and

o Five acres devoted to a human genomic bio-bank enabling real-time specimen storage and data analysis and precision-medicine research.

Together, these integrated assets position MyRxWallet as a self-sustaining healthcare and technology ecosystem—one capable of withstanding future global health crises or geopolitical disruptions while providing sovereign control over healthcare data, computation, and innovation.

***Intercompany Revenue Model***

MyRxWallet's planned group structure is designed to create a self-sustaining ecosystem that is intended to capture revenue internally from strategic acquisitions rather than outsourcing to third parties:

---

| | | |
|:---|:---|:---|
| **Entity** | **Role in Ecosystem** | **Revenue Contribution** |
| MyRxWallet North America Corporation (Parent) | Oversees global strategy, governance, and equity financing. | Is planned to generate revenue from healthcare facilities, technology licensing, tokenization, and data-exchange fees. |
| MyRxWallet DAO, LLC | Will innovate and develop blockchain EHR technology, bio-genomics artificial intelligence, hyperscale DAO governance, IP licensing, and staking programs. | Is planned to earn recurring DAO transaction and governance fees. |
| MyRxWallet Prana Pvt. Ltd. (India) | Will manage healthcare facilities, and develop and operate data-center infrastructure. | Is planned to generate MSA and compute-service revenue from both internal entities and external healthcare clients. |
| MyRxWallet Venture Capital, Inc. | Will identify and acquire emerging healthcare and biotech startups. | Is planned to add value through equity appreciation, royalties, and technology integration. |

---

This planned vertically integrated model is designed to ensure that MyRxWallet retains most of its revenue within the consolidated group—capturing value at every stage of the data life cycle, from collection and encryption to analytics, storage, and monetization.

By integrating blockchain, AI, decentralized governance, and hyperscale infrastructure under one vertically aligned corporate structure, MyRxWallet intends to eliminate third-party dependency and create a closed-loop economic system designed to be secure, transparent, and self-sustaining. The result is intended to be a platform capable of delivering reliable, compliant, and patient-owned healthcare solutions at global scale.

We believe this solution will have a profound impact on the healthcare industry:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· *Market Share Growth*: By providing a superior, secure platform, MyRxWallet intends to capture a significant share of the healthcare data management market, increasing our market share as we secure more partnerships with healthcare providers and insurers.

· *Revenue from Tokenization*: Our planned patient rewards and monetization programs are designed to allow users to earn MyRxCoins or MyRxTokens when their data is shared. This is intended to incentivize users and ensure continuous engagement with the platform, further driving growth in market share and valuation.

· *Government and Institutional Adoption*: As the platform gains adoption by government agencies and global healthcare providers, we believe it will reduce the frequency of data breaches and improve healthcare outcomes, leading to rapid expansion.

· Increased market share and valuation driven by advanced security features.

· The role of the decentralized data encryption algorithm in significantly enhancing data security.

· The impact of the patient rewards and monetization programs, ensuring long term platform engagement and further boosting market share.

***Our Plan of Operation***

**Short-Term Plan: Year 1 (June 2026 through December 2026)**

*Principal Anticipated Challenges*: The Company anticipates the following principal challenges in executing its business plan: (i) the sufficiency of offering proceeds relative to the capital intensity of the land acquisition and infrastructure development program, which requires approximately $104.3 million in aggregate cash consideration for land alone; (ii) ONC EHR certification and FDA Software as a Medical Device ("**SaMD**") regulatory timelines, which are uncertain and may materially extend the timeline for platform launch and AI/ML feature deployment; (iii) the complexity of Indian land registration procedures and hyperscale data center construction permitting, which involve multiple governmental authorities and are subject to delays outside the Company's control; (iv) recruiting qualified blockchain, AI, and healthcare technology personnel in a highly competitive talent market; (v) the Noah Therapeutics SPA closing timeline under Indian corporate law, which involves closing conditions outside the Company's control; and (vi) evolving regulatory frameworks for digital health tokens and cross-border healthcare data sovereignty, which may require material modifications to the Company's planned platform and token program structure.

The following table sets forth the Company's nine principal operational objectives, together with the estimated funding required, personnel and expertise required, estimated timelines, key anticipated challenges, and measurable milestones for each. All amounts and timelines are estimates subject to material uncertainty and contingent on receipt of sufficient offering proceeds.

*Objective 1 — Complete Regulation A Offering*: Funding Required: approximately $50,000 in offering expenses. Personnel: securities counsel and auditors. Estimated Timeline: immediate upon qualification. Key Challenges: SEC qualification timeline and investor demand. Milestone: offering qualification effective.

*Objective 2 — Close All Pending Indian Land Acquisitions*: Funding Required: approximately $104.3 million in aggregate cash consideration. Personnel: Indian legal counsel, land surveyors, and title registrars. Estimated Timeline: 0–6 months post-funding. Key Challenges: Indian sub-registrar registration requirements, currency risk, and title documentation. Milestone: legal title registered at the Indian sub-registrar's office for all four parcels.

*Objective 3 — Commence Hyperscale Data Center Construction*: Funding Required: included in strategic M&A and construction budget (70% of net proceeds allocation). Personnel: civil engineers, data center architects, and permitting specialists. Estimated Timeline: 6–18 months post-funding. Key Challenges: government permits, contractor availability, and power infrastructure development. Milestone: all permits obtained and groundbreaking completed.

*Objective 4 — Build and Launch EHR Core Platform (Phase 1)*: Funding Required: approximately $3–5 million. Personnel: software engineers, clinical informatics specialists, UX designers, and HIPAA compliance officers. Estimated Timeline: 18–24 months post-funding. Key Challenges: ONC EHR certification, HIPAA compliance, and healthcare provider adoption. Milestone: minimum viable product deployed and first provider pilot program initiated.

*Objective 5 — Integrate AI/ML Clinical Decision Support*: Funding Required: approximately $2–3 million. Personnel: data scientists, biostatisticians, ML engineers, and FDA SaMD regulatory specialists. Estimated Timeline: 24–36 months post-funding. Key Challenges: clinical training data availability, FDA SaMD regulatory pathway, and model validation requirements. Milestone: first validated AI module deployed within the EHR platform.

*Objective 6 — Close Noah Therapeutics SPA and Integrate CRO*: Funding Required: SPA share consideration partially transferred prior to closing; post-closing integration estimated at approximately $500,000–$1,000,000. Personnel: clinical operations management, regulatory affairs specialists, and integration specialists. Estimated Timeline: 0–24 months (entirely contingent on SPA closing). Key Challenges: Indian Companies Act closing requirements and post-acquisition integration complexity. Milestone: Noah SPA fully closed and CRO operations integrated within the MyRxWallet Ecosystem.

*Objective 7 — Healthcare Facility and Strategic Acquisitions*: Funding Required: 70% of net offering proceeds (approximately $52.5 million at the maximum offering level). Personnel: M&A counsel, healthcare operations management, and due diligence teams. Estimated Timeline: 12–36 months post-funding. Key Challenges: acquisition target identification, healthcare facility licensing and regulatory approvals, and valuation. Milestone: first healthcare facility acquisition completed and integrated.

*Objective 8 — Launch MyRxToken Rewards Program*: Funding Required: included within the platform development budget. Personnel: blockchain developers, legal counsel, and product managers. Estimated Timeline: 30–42 months post-funding. Key Challenges: regulatory classification of the token program and patient participant adoption. Milestone: 10,000 active platform participants enrolled in the rewards program.

*Objective 9 — Hire Key Executive and Operational Personnel*: Funding Required: included in the working capital allocation. Personnel to be recruited: Chief Financial Officer, Chief Technology Officer, Chief Medical Officer, VP of Sales and Marketing, and clinical operations head. Estimated Timeline: 0–12 months post-funding. Key Challenges: competitive talent market and requirement for specialized blockchain and healthcare technology expertise. Milestone: full senior leadership team assembled.

Objectives 3 and 7 both draw from the 70% strategic M&A and acquisitions allocation of net proceeds. Management retains broad discretion over the allocation of proceeds between data center construction and healthcare facility acquisitions within this category, based on market conditions and strategic priorities at the time of deployment.

The Company is currently a pre-revenue, development-stage entity. Its present activities are limited to: (i) building foundational architecture and design specifications for its EHR technology platform through MyRxWallet DAO, LLC; (ii) maintaining corporate governance, regulatory compliance, and SEC reporting obligations; and (iii) managing its strategic transaction program, including the pending Indian land acquisitions and the Noah Therapeutics SPA. The Company has not yet commenced commercial operations, generated revenue, or deployed any technology platform. Upon receipt of sufficient funding from this offering, the Company intends to immediately implement its business plan as described in this Offering Circular, subject to adjustment based on the actual funding level received and prevailing market and operational conditions at the time of implementation.

**Strategic Rationale**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·  ***Capitalization*** : Completing the Regulation A offering is foundational, as it provides the capital needed for all subsequent steps.

·  ***Infrastructure*** : Data center planning and hardware engagement are critical for building a secure, scalable platform.

·  ***Partnerships & Talent*** : Strategic alliances and expert recruitment will accelerate technology development and market entry.

·  ***Market Entry*** : A robust go-to-market strategy and targeted hiring will position MyRxWallet for rapid adoption.

**Long-Term Plan: Years 2 & 3 (January 2027 through December 2028)**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.  ***Begin On-Site EHR Technology Development*** : Launch EHR technology development within our owned ecosystem, bio-bank, clinical research, soon pharmaceutical and medical device manufacturing, labs, hospitals and clinics to ensure alignment with MyRxWallet's healthcare objectives.

2.  ***Hire Key Executives for International Headquarters*** : Bring on executives to lead and expand operations at all international headquarters.

3.  ***Establish International Headquarters*** : The Company has fully formed MyRxWallet Prana Pvt. Ltd., a wholly owned subsidiary of MyRxWallet North America Corporation, which serves as the Asia-Pacific (APAC) regional headquarters. MyRxWallet Prana operates under its own Chief Executive Officer, Board of Directors, and governance committees; however, it reports regularly to the Parent Company's Chief Executive Officer and remains fully consolidated within the Parent's corporate structure and governance framework.

MyRxWallet Prana Pvt. Ltd. was initially capitalized through a $500 million equity issuance by MyRxWallet North America Corporation, establishing a robust financial foundation to execute large-scale infrastructure and acquisition initiatives. During 2025, MyRxWallet Prana successfully completed multiple strategic acquisitions, including its 156-acre and 216-acre land for its multi-purpose built hyperscale health-data center campuses, 5-acre, 10-acre and a lease agreement of an additional 40-acre land for logistics and bio-bank specimen and data intelligence facilities, a clinical research organization (CRO), and a health organization management services company. These acquisitions collectively form the backbone of the Company's integrated healthcare and technology ecosystem, enabling vertical control of operations from data infrastructure through patient care. This capitalization and acquisition program provide the resources necessary for MyRxWallet Prana to acquire, develop, and integrate assets in alignment with the Company's global expansion strategy and to support its long-term goal of establishing a decentralized, AI-driven healthcare platform worldwide.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.  ***Take International Headquarters Public*** : Execute IPOs for each regional headquarters, strengthening the company's international presence and market reach.

5.  ***Establish a Strong International Presence*** : Build brand recognition, client relationships, and market share in each key global region.

6.  ***Prepare company for both the Patient and Provider Portal Launch*** : Ready key executives to support the launch of MyRxWallet's patient portal and develop a go-to-market plan for the provider portal, ensuring comprehensive support for both patient and provider needs.

MyRxWallet Prana Pvt. Ltd. was initially capitalized through the issuance of Company common stock by MyRxWallet North America Corporation, with the capitalization valued at approximately $250 million based on a Board-determined price of $84.50 per share. The Company acknowledges that shares of common stock in a development-stage company are not the equivalent of cash and do not provide Prana with immediately liquid funds. The equity capitalization of Prana through Company shares serves the following strategic purposes: (i) establishing Prana's balance sheet with an equity asset base to support future financing, credit arrangements, or strategic partnerships in India; (ii) enabling Prana to use Company shares as consideration in its Indian acquisition program, allowing transactions to be structured as equity-for-equity exchanges rather than requiring immediate cash outlay; (iii) providing Prana with documented equity value to support engagement with Indian government authorities, land registrars, and healthcare facility acquisition counterparties; and (iv) building the capitalization framework that will be supplemented with cash proceeds from this offering upon successful completion. The Board valued the Company's common stock at $84.50 per share based on its assessment of the Company's strategic asset base, including committed land agreements totaling approximately $104 million. This valuation is not based on a formal third-party appraisal, and the market price of the Company's shares, if and when traded, may differ materially from the Board-determined value.

During 2025, MyRxWallet Prana entered into agreements for multiple strategic transactions, including land agreements for its planned hyperscale health-data center campuses (including 216-acre and 156-acre parcels in Telangana), a 40-acre land lease agreement for logistics and bio-bank specimen and data intelligence facilities, a Definitive Share Purchase Agreement to acquire 70% of Noah Therapeutics Private Limited (not yet closed; see "[Noah Therapeutics SPA](#a_030)" in the *[Description of Business](#a_009)* above), and the acquisition of a majority and controlling interest in Bio-Blockchain Intelligence Pvt. Ltd. (formerly Clinrarc Services Pvt. Ltd.). These agreements and transactions are intended to form the foundation of the Company's integrated healthcare and technology ecosystem.

*Prana Does Not Currently Own the Land*: MyRxWallet Prana Private Limited does not currently own any of the land parcels referenced above. In each case: (i) an Agreement of Sale has been executed establishing the binding intent to purchase; (ii) a portion of the consideration has been transferred in the form of Company common stock to the respective sellers; and (iii) the remaining cash consideration - which constitutes the substantial majority of the total purchase price - has not yet been paid. Title to each parcel will transfer to Prana at the Indian sub-registrar's office only upon full payment of the remaining cash consideration, contingent upon the successful completion of this offering. There can be no assurance that the offering will be completed, that sufficient proceeds will be raised, or that any of the land acquisitions will ultimately close. See "*[Description of Property](#a_010)*" and "*[Use of Proceeds](#a_008)*" for the material terms of each pending land acquisition agreement.

We believe this plan provides a structured path to achieving MyRxWallet North America Corp. short- and long-term objectives, from going public and expanding through acquisitions, to scaling internationally and solidifying the company's role as a healthcare delivery and technology leader.

***Conclusion***

We believe the MyRxWallet EHR Platform represents an advanced healthcare management solution designed to bridge the gap between patients and providers, facilitating secure, efficient, and patient-centered care. Built with cutting-edge technology, regulatory compliance, and scalability in mind, this platform is poised to become a vital tool for modern healthcare delivery.

MyRxWallet's sales and marketing strategy is centered around positioning our blockchain platform as a leading solution in the healthcare sector, focusing on education, partnerships, and data monetization incentives to drive adoption.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·  ***Thought Leadership and Educational Campaigns*** : We will establish MyRxWallet as an industry thought leader through white papers, webinars, and participation in healthcare conferences. By educating the market on the benefits of blockchain in healthcare data management, we aim to build trust and generate interest among healthcare providers, regulators, and patients.

·  ***Healthcare Provider Onboarding*** : Our dedicated sales teams will focus on direct engagement with hospitals, clinics, and private practices, demonstrating the platform's benefits through customized demos and case studies that showcase improved patient outcomes, reduced costs, and enhanced data security.

·  ***Patient and Provider Incentive Programs*** : MyRxWallet will reward patients for sharing their anonymized healthcare data with researchers and healthcare organizations through a tokenized rewards program. Providers will also be incentivized to adopt the platform through significant discounted onboarding fees and performance-based incentives tied to improvements in patient care and operational efficiency.

·  ***Collaborations with Key Opinion Leaders ("KOLs")*** : Partnering with influential healthcare professionals and industry experts, we will raise awareness of MyRxWallet's platform. By leveraging endorsements from trusted voices in the healthcare space, we will build credibility and encourage wider adoption.

·  ***Multi-Channel Marketing*** : We will launch a multi-channel marketing campaign using digital advertising, targeted social media outreach, and content marketing. Our approach will include tailored messaging for both healthcare providers and patients, highlighting the platform's unique ability to enhance data security, improve healthcare outcomes, and empower patients.

Through a strategic combination of educational outreach, targeted sales efforts, and incentivization, MyRxWallet will secure a strong foothold in the healthcare industry, driving widespread adoption and long-term growth.

***Employees***

The Company currently has no employees.

***Competition***

While we believe there are currently no direct competitors that offer the full suite of solutions as we do; however, there are several companies that offer components of telehealth or address conditions that compete with our solutions. These include companies whose primary business is providing and marketing telehealth and health and wellness management, such as the delivery of on-demand access to healthcare and wellness services. We compete with other providers that are larger in scale and generally provide telehealth on behalf of self-insured employers and insurance plans. Within parts of the behavioral health market, we also compete with public and private organizations with similar product offerings for consumers. Competition focuses on, among other factors, technology, breadth and depth of functionality, range of associated services, operational experience, customer support, extent of customer base, and reputation.

***Regulatory Environment***

Participants in the health care industry are required to comply with extensive and complex laws and regulations in the United States at the federal and state levels as well as applicable international laws. Although many regulatory and governmental requirements do not directly apply to our business, our customers are required to comply with a variety of laws, and we may be affected by these laws as a result of our contractual obligations. Similarly, there are a number of legislative proposals in the Unites States, both at the federal and state level, which could impose new obligations in areas affecting our business. We have attempted to structure our operations to comply with applicable legal requirements, but there can be no assurance that our operations will not be challenged or impacted by enforcement initiatives.

***Healthcare Reform***

Our business could be affected by changes in health care laws, including without limitation, the Patient Protection and the ACA, which was enacted in March 2010. The ACA has changed how health care services are covered, delivered and reimbursed through expanded coverage of individuals, changes in Medicare program spending and insurance market reforms. Ongoing government and legislative initiatives may bring about other changes.

While most of the provisions of the ACA and other health care reform legislation will not be directly applicable to us, they may affect the business of many of our customers, which may in turn affect our business. Although we are unable to predict with any reasonable certainty or otherwise quantify the likely impact of the ACA, any amendment or repeal of the ACA, or other health care reform on our business model, financial condition, or results of operations, negative changes in the business of our customers and the number of individuals they insure may negatively impact our business.

***Requirements Regarding the Privacy and Security of Personal Information***

***U.S.- HIPAA and Other Privacy and Security Requirements.*** There are many U.S. federal and state laws and regulations related to the privacy and security of personal health information. Additionally, regulations promulgated pursuant to HIPAA and its implementing regulations establishes privacy and security standards that limit the use and disclosure of protected health information and require the implementation of administrative, physical and technical safeguards to ensure the confidentiality, integrity and availability of individually identifiable health information in electronic form. Any health plan customers, as well as health care clearinghouses and certain providers with which we may have or may establish business relationships, are covered entities that are regulated under HIPAA. HITECH, which became effective on February 17, 2010, significantly expanded HIPAA's privacy and security requirements. Among other things, HITECH makes HIPAA's privacy and security standards directly applicable to "business associates," who are independent contractors or agents of covered entities that create, receive, maintain, or transmit protected health information in connection with providing a service for or on behalf of a covered entity. Under HIPAA and our contractual agreements with our customers, we are considered a "business associate" to our customers and thus are directly subject to HIPAA's privacy and security standards. In order to provide our covered entity customers with services that involve the use or disclosure of protected health information, HIPAA requires our customers to enter into business associate agreements with it. Such agreements must, among other things, require us to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· limit how we will use and disclose the protected health information;

· implement reasonable administrative, physical and technical safeguards to protect such information from misuse;

· enter into similar agreements with our agents and subcontractors that have access to the information;

· report security incidents, breaches and other inappropriate uses or disclosures of the information; and

· assist the customer in question with certain duties under the privacy standards.

In addition to HIPAA regulations, we may be subject to other state and federal privacy laws, including laws that prohibit unfair or deceptive practices and laws that place specific requirements on use of data. Such state laws can be similar to or even more protective than HIPAA, in which case we must comply with the more stringent law. As a result, it may be necessary to modify our planned operations in order to ensure we are in compliance with the stricter state laws.

  ****

***Data Protection and Breaches****.* In recent years, there have been a number of well-publicized data breaches involving the improper use and disclosure of individuals' personal information. Many states have responded to these incidents by enacting laws requiring holders of personal information to maintain safeguards and to take certain actions in response to a data breach, such as providing prompt notification of the breach to affected individuals and state officials. In addition, under HIPAA, we must report breaches of unsecured protected health information to our contractual partners within 60 days of discovery of the breach. Notification must also be made to HHS and, in certain circumstances involving large breaches, to the media. Under the GDPR, the data controller is required to report personal data breaches to the supervisory authority within 72 hours of discovery of the breach.

We have implemented and maintained physical, technical and administrative safeguards intended to protect all personal data and have processes in place to assist it in complying with all applicable laws, regulations and contractual requirements regarding the protection of these data and properly responding to any security breaches or incidents. However, we cannot be sure that these safeguards are adequate to protect all personal data or to assist us in complying with all applicable laws and regulations regarding the privacy and security of personal data and responding to any security breaches or incidents. Furthermore, in many cases, applicable state laws, including breach notification requirements, are not preempted by the HIPAA privacy and security standards and are subject to interpretation by various courts and other governmental authorities, thereby complicating our compliance efforts. Additionally, state and federal laws regarding deceptive practices may apply to public assurances we give to individuals about the security of services we provide on behalf of our contractual customers.

 **

 ****

 **

 ****

***Other Healthcare Regulations***

In addition to data privacy laws, our operations and arrangements with healthcare professionals, clients, and third-party payors may subject us to various federal and state healthcare laws and regulations, including without limitation fraud and abuse laws, such as the federal Anti-Kickback Statute; civil and criminal false claims laws; physician transparency laws; and state laws regarding the corporate practice of medicine and fee-splitting prohibitions. These laws may impact, among other things, our sales and marketing operations, and our interactions with healthcare professionals. We continually monitor legislative, regulatory and judicial developments related to licensure and engagement arrangements with professionals; however, new agency interpretations, federal or state legislation or regulations, or judicial decisions could require us to change how we operate, may increase our costs of services and could have a material adverse impact on our business, results of operations or financial condition.

***Other Requirements.*** In addition to HIPAA, numerous other U.S. state and federal laws govern the collection, dissemination, use, access to and confidentiality of individually identifiable health information and health care provider information. Some states also are considering new laws and regulations that further protect the confidentiality, privacy and security of medical records or other types of medical information. In many cases, these state laws are not preempted by the HIPAA privacy standards and may be subject to interpretation by various courts and other governmental authorities. Further, Congress and a number of states have considered or are considering prohibitions or limitations on the disclosure of medical or other information to individuals or entities located outside of the United States.

In addition to HIPAA regulations, we may be subject to other state and federal privacy laws, including laws that prohibit unfair or deceptive practices and laws that place specific requirements on use of data. Such state laws can be similar to or even more protective than HIPAA, in which case we must comply with the more stringent law. As a result, it may be necessary to modify our planned operations in order to ensure we are in compliance with the stricter state laws.

***Forward Stock Split***

On September 4, 2025, the Company's Board of Directors and a majority of shareholder votes approved a forward stock split of our common stock at a ratio of 1:3.5, effective September 16, 2025. On January 27, 2026, the amended and restated articles were filed with the Wyoming Secretary of State.

***Stock Repurchases and Promissory Notes***

*Disinterested Director Approval*: The related-party share repurchase transactions with MyRxWallet Corporation and Z the Future, LLC were reviewed and approved on February 5, 2026 by the then-serving disinterested members of the Board of Directors - Dr. Rajan Kombu Subramanian, Ph.D. and Dr. Anuradha Cingeetham, Ph.D. - acting as Independent Directors outside the presence of the interested directors. Both Dr. Subramanian and Dr. Cingeetham were appointed to the Board of Directors on February 1, 2026 and ceased serving as directors on March 20, 2026. Their departures were not the result of any disagreement with the Company on any matter relating to its operations, policies, practices, or disclosures; each indicated that continued service would have required cash compensation that the Company was not in a position to fund pending qualification of this offering. Olivia Trinh and Binh Do each disclosed their conflicts of interest and recused themselves from all deliberations and voting. The Independent Directors reviewed the transaction documents, considered the terms, and unanimously determined that the arrangements were fair to and in the best interests of the Company. These actions were ratified at a duly called special meeting of the Board on February 12, 2026. Note: The current Board consists of Olivia Trinh (Chairman and CEO) and Scherri A. Harps (Independent Director).

On January 3, 2026, we entered into a Stock Repurchase Agreement with MyRxWallet Corporation, Inc., a Wyoming corporation, an entity controlled by Olivia Trinh, our Chief Executive Officer. Pursuant to the agreement, we agreed to repurchase from MyRxWallet Corporation 10,000,000 shares of the Company's Common Stock at $85 per share for an aggregate total of $850,000,000, which was evidenced by a Promissory Note issued to MyRxWallet Corporation.

On February 5, 2026, the parties amended and restated the Promissory Note. Under the Amended Promissory Note: (i) the maturity structure was changed to a demand note whereby the Noteholder may demand payment at any time within 24 months from February 4, 2026, and if not demanded, the Note automatically renews for an additional 24 months on the same terms; (ii) interest accrues at 7.5% per annum ($63,750,000 annual interest; $15,937,500 quarterly), payable quarterly in arrears in the form of fully paid, non-assessable shares of the Company's common stock unless otherwise agreed by the parties; (iii) the conversion price was changed from a variable formula based on 66% of recent trading prices to a fixed price of $125 per share, with up to 7,820,000 shares issuable upon full conversion of principal and accrued interest; (iv) all overdue amounts bear interest at an additional 2%; and (v) the Company is required at all times to reserve sufficient shares of its Common Stock for full conversion of the Promissory Note.

The Amended Promissory Note also contemplates that the parties will enter into a Capped Call Agreement (an anti-dilution hedge) with a notional amount equal to the number of shares underlying the Note, a strike price of $125 per share, and a cap price of $200 per share. Settlement under the Capped Call may be in cash, shares, treasury shares, or issuer-sponsored tokenized shares. The Borrower may prepay the Note in whole or in part at any time without penalty.

On January 3, 2026, we entered into a Stock Repurchase Agreement with Z the Future, LLC, an entity controlled by Olivia Trinh, our Chief Executive Officer. Pursuant to the agreement, we agreed to repurchase from Z the Future 3,500,000 shares of the Company's Common Stock at $85 per share for an aggregate total of $297,500,000, which was evidenced by a Promissory Note issued to Z the Future.

On February 5, 2026, the parties amended and restated the Promissory Note. Under the Amended Promissory Note: (i) the maturity structure was changed to a demand note whereby the Noteholder may demand payment at any time within 24 months from February 4, 2026, and if not demanded, the Note automatically renews for an additional 24 months on the same terms; (ii) interest accrues at 7.5% per annum ($22,312,500 annual interest; $5,578,125 quarterly as stated in the Repurchase Agreement), payable quarterly in arrears in the form of fully paid, non-assessable shares of the Company's common stock unless otherwise agreed by the parties; (iii) the conversion price was changed from a variable formula based on 66% of recent trading prices to a fixed price of $125 per share, with up to 2,737,000 shares issuable upon full conversion of principal and accrued interest; (iv) all overdue amounts bear interest at an additional 2%; and (v) the Company is required at all times to reserve sufficient shares of its Common Stock for full conversion of the Promissory Note.

The Amended Promissory Note also contemplates that the parties will enter into a Capped Call Agreement (an anti-dilution hedge) with a notional amount equal to the number of shares underlying the Note, a strike price of $125 per share, and a cap price of $200 per share. Settlement under the Capped Call may be in cash, shares, treasury shares, or issuer-sponsored tokenized shares. The Borrower may prepay the Note in whole or in part at any time without penalty.

Note: We have identified an inconsistency in the Amended Promissory Note to Z the Future, LLC regarding the treatment of fractional shares upon conversion. One provision states fractional shares shall be rounded down or settled in cash in lieu, while another provision states fractional shares shall be rounded up to the nearest whole share. This inconsistency will need to be resolved prior to any conversion.

**DESCRIPTION OF PROPERTY**

The Company maintains its principal executive office through a commercial virtual office services arrangement at 732 South 6th Street, #5397, Las Vegas, Nevada 89101.

*Important Note on Land Ownership*: MyRxWallet Prana Private Limited does NOT currently own any of the land parcels described below. In each case, an Agreement of Sale has been executed, a portion of the consideration has been transferred in Company common stock, but the remaining cash consideration has not yet been paid. Title to each parcel will transfer at the Indian sub-registrar's office ONLY upon full payment of the remaining cash consideration from offering proceeds. There can be no assurance that this offering will be completed, that sufficient proceeds will be raised, or that any of the land acquisitions will close.

*Important Note on Land Ownership*: MyRxWallet Prana Private Limited does NOT currently own any of the land parcels described below. In each case, an Agreement of Sale has been executed, a portion of the consideration has been transferred in Company common stock, but the remaining cash consideration has not yet been paid. Title to each parcel will transfer at the Indian sub-registrar's office ONLY upon full payment of the remaining cash consideration from offering proceeds. There can be no assurance that this offering will be completed, that sufficient proceeds will be raised, or that any of the land acquisitions will close.

***Pending Land Acquisition Agreements - Material Terms***

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Property** | **Agreement**<br> **Date** | **Total**<br> **Consideration** | **Shares**<br> **Already Paid** | **Cash**<br> **Remaining** | **Payment Deadline / Title Transfer** | **Extension** |
| 216 Acres — Medak District, Telangana | 8/9/2025 | ~$83,584,551 (INR 727,18,56,000) | 1,374,358 NAC at $63.00 to Chendireddy Raji Reddy (10/16/2025) | ~$83,497,601 | 120 days from agreement; extended per Affidavit 12/11/2025. 1% penalty upon IPO closing. Title at sub-registrar upon full cash payment. | Selling party confirmed continued intent |
| 147.07 Acres (Vemulapalli Farms) — Andhra Pradesh | 8/20/2025 | ~$12,222,539 (INR 1,03,89,15,750) | 237,331 NAC at $51.50 to Raghu Vemulapalli (10/16/2025) | ~$12,210,321 | 120 days from agreement. Stamp duty 7.6% (~$854,737) payable to Govt of AP prior to registration. | Selling party confirmed continued intent |
| 10 Acres — Medak District, Telangana | 8/16/2025 | ~$7,055,862 (INR 65,76,00,000) | 161,278 NAC at $42.50 to Raj Kumar Yada (10/16/2025) | ~$7,049,020 | 120 days from agreement. Title at sub-registrar upon full cash payment. | Selling party confirmed continued intent |
| 5 Acres — Siddipet District, Telangana | 8/16/2025 | ~$1,450,000 (INR 12,65,64,984) | 37,129 NAC at $35.75 to Venkatesh Pandi (10/16/2025) | ~$1,448,674 | 120 days from agreement. Title at sub-registrar upon full cash payment. | Selling party confirmed continued intent |

---

All cash consideration is contingent on receipt of offering proceeds. Total aggregate pending cash consideration: approximately $104,205,616.

On August 9, 2025, MyRXWallet Prana Private Limited entered into an Agreement of Sale with Chendireddy Raji Reddy pursuant to which we agreed to purchase 216 acres abutting to NH-44 (Hyderabad to Nagpur Highway) situated at Village Chinnashivnoor, Mandal Chegunta of Medak District, Telangana, India, PIN: 502255 for total consideration of $83,584,551. The term of the agreement was until September 11, 2025 subject to a 120-day extension. The purchase has yet to close.

On August 15, 2025, MyRXWallet Prana Private Limited entered into an Agreement to Lease with Smt. Architha Raj Kumar Ittaboiena pursuant to which we agreed to lease 41 acres of land located in Village Kallakal, Mandal Manoharabad, Division Toopran, District Medak, State Telangana. Pin-502110 for 30 years. Subject to increases per the agreement, monthly rent in the amount of 41,000 rupees per acre is due to be paid quarterly beginning after the earlier of 12 months or the production of Solar Power (as defined in the agreement).

On August 16, 2025, MyRXWallet Prana Private Limited entered into an Agreement of Sale with Smt. Architha Raj Kumar Ittaboiena pursuant to which we agreed to purchase 10 acres situated at Village Kallakal, Mandal Manoharabad, Division Toopran, District Medak, State Telangana. Pin-502110 for a total consideration of $7,055,862. The agreement terminates 120 days from the date of the agreement. The purchase has yet to close.

On August 16, 2025, MyRXWallet Prana Private Limited (an entity owned by MyRxWallet Prana Pvt. Ltd.) entered into an Agreement of Sale with Pandi Venkatesh pursuant to which we agreed to purchase 24,675 square yards, situated at survey number 157/E/7/2/, 157/E/7/1, of Madharam Village, Wargal, Siddipet District for total consideration of $1,450,000. The agreement terminates 120 days from the date of the agreement. The purchase has yet to close.

Through MyRxWallet Prana Pvt. Ltd., the Company is developing two of the world's largest healthcare-focused hyperscale data centers—covering approximately 156 acres for purpose-built AI, DAO, Web3 and Blockchain, the 216 acres is purpose built for hyperscale enterprise grade blockchain cloud application infrastructure, the 50 plus acres is purpose built for bio specimen and biobank intelligence for the main EHR technology development in India, the five acres for implementing healthcare supply chain technology infrastructure. These facilities are designed to host blockchain nodes, AI compute clusters, genomic databases, and secure health-data archives. They will support both MyRxWallet's global operations and third-party healthcare partners requiring compliant, high-availability data infrastructure.

**Property Ownership and Encumbrances**

As described above, the Company has secured fully executed purchase agreements for multiple parcels of land in Hyderabad, India's technology and healthcare district. Some agreements were arranged through brokers, while others were negotiated directly with landowners. The Company does not currently hold title to these properties intended for data center development. Title transfer to MyRxWallet North America Corporation will occur only upon full payment to the sellers. Until payment is completed and title is transferred, the properties are not held in fee and remain subject to the terms of the respective purchase agreements. The sellers' brokers and legal counsel will facilitate the title transfer upon confirmation of payment. There are no known major encumbrances on these properties other than the requirement for full payment prior to transfer of ownership.

**Suitability, Adequacy, and Utilization**

The planned data centers, once construction commences, fully equipped with the appropriate equipment, resources and technology and becomes operational, are expected to provide substantial productive capacity and are suitable for the Company's intended use in healthcare technology, data management, and infrastructure operations. These facilities are integral to the Company's long-term strategy and will be utilized to support both internal operations and external partnerships.

**MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes included elsewhere in this Offering Circular. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those discussed under "*Risk Factors*" and elsewhere in this Offering Circular.

Unless otherwise indicated, the discussion below covers the period from our inception on October 16, 2024 through September 30, 2025, which is the period covered by our current consolidated financial statements.

***Results of Operations from inception (October 16, 2024) through September 30, 2025***

**Revenues**

We did not generate any revenues during the period from inception through September 30, 2025.

General and administrative expenses for the period from inception through September 30, 2025 were approximately $39,534. These expenses primarily consisted of professional fees, filing fees, and general corporate overhead. As a result, we incurred a net loss of approximately $39,534 for the period from inception through September 30, 2025.

***Liquidity and Capital Resources***

As of September 30, 2025, we had total assets of approximately $48,998, consisting primarily of cash and cash equivalents. As of the same date, we had total liabilities of approximately $13,177, consisting primarily of accounts payable and accrued liabilities. Accordingly, our working capital was approximately $35,821 as of September 30, 2025.

Since inception, our operations have been financed primarily through the issuance of common stock. Our ability to continue as a going concern will depend on our ability to raise additional capital (including through this offering) and/or generate revenue in the future. There can be no assurance that we will be able to raise additional capital on acceptable terms, or at all.

***Going Concern***

The Company has incurred operating losses since inception and has not generated revenue as of September 30, 2025. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Management's plans to alleviate the substantial doubt include raising capital through this offering and through other potential financing transactions.

***Cash Flows***

For the period from inception through September 30, 2025:

Net cash used in operating activities was approximately $26,357.

Net cash used in investing activities was $0.

Net cash provided by financing activities was approximately $75,355.

The effect of exchange rate changes on cash was immaterial (approximately $21).

Net cash used in operating activities was primarily attributable to our net loss, partially offset by the increase in accounts payable and accrued liabilities of approximately $10,833. Net cash provided by financing activities was primarily attributable to proceeds from issuances of common stock for cash.

***Off-Balance Sheet Arrangements***

As described in the notes to our consolidated financial statements, certain land acquisition agreements have been executed through MyRxWallet Prana Pvt. Ltd.; however, these purchases have not yet closed and legal title has not transferred. Because the Company does not currently have legal title to the land, the related land is not recognized as an asset in our consolidated financial statements as of September 30, 2025. The aggregate contracted value of these land acquisition agreements is $107,030,968.82. Any future closings, if completed, are expected to occur after the closing of this offering and are expected to be funded, in part, from offering proceeds. There can be no assurance that these acquisitions will be consummated.

**Promissory Note Amendments**

On February 5, 2026, subsequent to our fiscal year end, we amended the promissory notes issued to MyRxWallet Corporation and Z the Future, LLC (both entities controlled by our Chief Executive Officer). The amendments materially changed the economic terms of the notes, including:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Converting from a variable conversion price formula (66% of recent trading prices) to a fixed conversion price of $125 per share;

· Changing the maturity structure from a fixed maturity date to demand notes payable at the Noteholder's election within 24 months, with automatic 24-month renewal;

· Changing interest payment mechanics from standard quarterly cash payments to payments in fully paid, non-assessable shares of common stock (at the Noteholder's election); and

· Adding contemplated Capped Call arrangements designed to provide anti-dilution protection.

These amendments significantly alter the potential dilution impact of the notes. Under the original terms, conversion at 66% of recent market prices could have resulted in unlimited dilution if our stock price declined. Under the amended terms, maximum dilution from conversion is capped at 10,557,000 shares. However, the amended terms create new sources of ongoing dilution through quarterly interest payments in stock (estimated at 686,010 shares annually) and create payment uncertainty through the demand note structure.

Management considered these amendments to be beneficial overall because they eliminate the potential for unlimited dilution under the original variable conversion formula, despite the addition of stock-based interest payments and the demand maturity structure.

Other than the arrangements described above, we did not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources.

***Critical Accounting Policies***

Our significant accounting policies are described in the notes to our consolidated financial statements. The most significant accounting policies affecting our financial statements include the basis of consolidation, the use of estimates, cash and cash equivalents, foreign currency translation, and income taxes. Because we are in the early stages of operations and have limited operating history, our accounting policies may evolve as our operations develop.

***Recent Accounting Pronouncements***

See the notes to our consolidated financial statements for recently issued accounting standards.

***Impact of Becoming a Fully Reporting Company***

Upon qualification of this offering, we intend to voluntarily register our common stock under Section 12(g) of the Exchange Act by filing a Form 8-A registration statement. This will subject us to the full periodic reporting and compliance requirements applicable to Exchange Act reporting companies, including requirements from which Regulation A issuers are otherwise exempt.

We expect this decision will significantly increase our operating expenses. We estimate incremental annual costs of approximately $300,000 to $500,000, including:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Increased audit and accounting fees for PCAOB audits and quarterly reviews

· Legal fees for Exchange Act compliance and SEC filings

· Additional personnel costs for financial reporting and compliance staff

· Directors and officers insurance

· SEC filing fees

· Investor relations costs

· Transfer agent fees

· Compliance systems and software

These costs represent a substantial portion of our current operating budget and will require us to generate significant revenue to achieve profitability.

**DIRECTORS, EXECUTIVE OFFICERS AND SIGNIFICANT EMPLOYEES**

The following information sets forth the names, ages, and positions of our current directors, executive officers, and significant employees:

---

| | | | |
|:---|:---|:---|:---|
| **Name** | **Positions and Offices Held** | **Age** | **Appointment Date** |
| **Olivia Trinh** | Chairman, Chief Executive Officer, and Interim Chief Financial Officer | 21 | 8/2025 |
| **Scherri A. Harps** | Independent Director | 61 | 2/2026 |

---

Set forth below is a description of the background and business experience of each of our current executive officers, directors, and significant employees.

***Olivia Trinh, Founder, Chairman, Chief Executive Officer, and Interim Chief Financial Officer***

Olivia Trinh serves as Chairman, Chief Executive Officer, and Interim Chief Financial Officer of MyRxWallet North America Corporation. Ms. Trinh assumed the Interim CFO role in March 2026 upon the resignation of Binh Do. Ms. Trinh devotes approximately 95% of her professional time to the Company. The remaining 5% covers administrative obligations at MyRxWallet Corporation and Z the Future, LLC, which are solely holding and noteholder entities with no active independent operations.

*Outside Business Affiliations*: Ms. Trinh has the following outside business affiliations which require approximately 5% of her professional time, consisting solely of administrative obligations:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· MyRxWallet Corporation (Wyoming): Ms. Trinh serves as Chief Executive Officer. This entity holds 130,000,000 restricted shares of the Company and is a noteholder ($850,000,000 Amended Promissory Note). It has no independent operations.

· Z the Future, LLC (Wyoming): Ms. Trinh serves as Managing Director. This entity holds 70,000,000 restricted shares and is a noteholder ($297,500,000 Amended Promissory Note). It has no independent operations.

Olivia Trinh, CEO, Founder, and Chairman of MyRxWallet North America Corporation, MyRxWallet DAO, LLC, MyRxWallet Prana Pvt. Ltd., MyRxWallet Capital and MyRxWallet Corporation, brings 4 years of experience and a unique blend of expertise in public health and business administration to the forefront of healthcare innovation. From a young age, Olivia developed a deep passion for healthcare, inspired by a commitment to improving access, equity, and efficiency in patient-centered systems. Her academic training and background have provided her with the strategic insight and leadership skills necessary to bridge the gap between healthcare delivery and emerging technologies. By founding MyRxWallet, Olivia has established a mission-driven platform designed to empower patients, providers, and organizations with secure, blockchain-enabled solutions for managing and optimizing healthcare interactions.

Under Olivia's leadership, we believe MyRxWallet is positioned at the intersection of healthcare and technology, pioneering innovative approaches that enhance transparency, security, and accessibility in medical data management. Her vision emphasizes not only the technical advancement of blockchain-driven tools but also the human impact these solutions bring to communities in need. Guided by her lifelong dedication to healthcare, Olivia ensures that MyRxWallet remains steadfast in its commitment to innovation, equity, and improving the overall healthcare experience.

***Scherri A. Harps, Independent Director***

Scherri A. Harps, age 61, has served as an Independent Director of the Company since March 1, 2026. Ms. Harps holds a Bachelor of Science degree in Economics and Finance from the University of Southern California (1992) and has been a licensed California Real Estate Broker (License No. 01500058) since May 18, 2005. She holds a Certified New Home Specialist (CNHS) designation and a Residential Construction Certified (RCC) designation and is a member of the National Association of Home Builders and the National Association of Realtors.

Ms. Harps has approximately 20 years of experience in residential real estate sales, contract negotiation, and client relationship management. From February 2019 through May 2024, Ms. Harps served as a Broker/New Home Sales Consultant at Lennar Corporation, Corona, California, where she closed over $500 million in new home sales and was consistently recognized as a top performer. Prior to that, from December 2012 through April 2018, she served in a sales role at Williams Sonoma, San Francisco, California. Ms. Harps has not previously served as an officer, director, promoter, control person, or consultant for any other issuer of securities.

Ms. Harps has not been the subject of any criminal, regulatory, or civil proceedings of the type described in Item 401 of Regulation S-K. She is a U.S. citizen and has no family relationships with any other officer or director of the Company.

Harps's compensation arrangements are governed exclusively by the Independent Director Appointment Agreement effective March 1, 2026 (the "Director Agreement"), filed as Exhibit 6.8 to this Offering Statement. Ms. Harps serves the Company solely as a non-employee Independent Director and does not hold, and has never held, any officer or employee position with the Company.

On or about March 1, 2026, a separate document titled "Director of Mergers and Acquisition and Board Member Employment Agreement" (the "**M&A Agreement**") was generated from a generic executive employment template and executed in error. The M&A Agreement was never operated by either party: no compensation was paid or accrued thereunder, no equity was issued thereunder, no payroll relationship was established, and Ms. Harps did not perform services as an officer or employee of the Company at any time. On May 8, 2026, the parties entered into a Mutual Rescission, rescinding the M&A Agreement ab initio, as if it had never been executed. The Board of Directors ratified the rescission, reaffirmed Ms. Harps's independent director status, and confirmed that her relationship with the Company has at all times been governed solely by the Director Agreement, pursuant to a Unanimous Written Consent dated May 8, 2026.

*Equity Awards*. Pursuant to the Director Agreement, Ms. Harps received the following one-time grants of restricted common stock, recorded with Colonial Stock Transfer Co., Inc. on March 10, 2026, and included within the 280,352,363 shares currently outstanding: (a) Compensation Award: 25,000 shares of restricted common stock as compensation for her service as Independent Director; and (b) Bonus Award: 10,000 shares of restricted common stock as a one-time signing bonus in recognition of her acceptance of appointment. The Initial Awards total 35,000 shares, are fully vested upon issuance, and are not subject to any continued-service vesting condition. The Initial Awards were issued pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended.

*Deferred Compensation*. In further consideration of Ms. Harps's service prior to the Company having sufficient operating capital to pay current cash compensation, the Company shall accrue deferred compensation in favor of Ms. Harps at the rate of $14,583.33 per month (equivalent to an annualized rate of $175,000), commencing on the Effective Date and continuing until the Funding Trigger Date or earlier termination of her service. The aggregate accrued obligation is capped at $350,000.00 (representing approximately 24 months of monthly accrual). No further accrual shall occur once the cap is reached unless increased by separate written Board action. The "Funding Trigger Date" means the first date on which the Company has received cumulative cash proceeds of not less than US$5,000,000.00 from any combination of: (i) net proceeds from this Regulation A offering; (ii) net proceeds from any subsequent financing; or (iii) operating cash flow from revenue. Upon the Funding Trigger Date, the accrued balance shall be paid in 12 equal monthly cash installments commencing in the month following such date. The deferred compensation does not bear interest. The Deferred Compensation Balance shall be reflected on the Company's books as an unfunded accrued liability in accordance with U.S. GAAP, including ASC 710. If Ms. Harps's service is terminated prior to the Funding Trigger Date for any reason other than termination for Cause, the accrued balance through the date of termination remains a fixed obligation of the Company. If terminated for Cause, the obligation to pay the Deferred Compensation Balance is forfeited; the Initial Awards, having been fully vested upon issuance, are unaffected.

The Board of Directors has determined that Ms. Harps qualifies as an "independent director" within the meaning of the listing standards of the Nasdaq Stock Market LLC and applicable rules of the U.S. Securities and Exchange Commission. This determination is based on the absence of any material relationship between Ms. Harps and the Company, its officers, directors, or their affiliates, other than her service as a non-employee Independent Director and the compensation described above. The Board reaffirmed this independence determination in its Unanimous Written Consent dated May 8, 2026, expressly finding that none of the Harps Matters - including the rescission of the M&A Agreement - impairs Ms. Harps's independent director status. The Company does not currently have a third independent director or an audit committee with financial expertise.

*Rule 3a4-1 Share Sales*. Ms. Harps is identified in the Plan of Distribution as one of two persons authorized to sell shares on behalf of the Company in reliance on Exchange Act Rule 3a4-1. This authorization arises solely from her capacity as an Independent Director performing substantial duties for the Company other than in connection with transactions in securities. Ms. Harps (i) is not a broker-dealer or an associated person of a broker-dealer; (ii) has not participated in selling an offering of securities of any issuer more than once in the past twelve months; and (iii) will receive no commission or transaction-based compensation for any share sales.

***Revan Sakura Faye Adams, Executive Vice President of Sales and Marketing***

Revan Adams, age 21, was appointed Executive Vice President of Sales and Marketing of MyRxWallet North America Corporation effective June 5, 2026, pursuant to a Board Unanimous Written Consent dated June 12, 2026. Ms. Adams reports directly to the Chairman and Chief Executive Officer. In her role, Ms. Adams is responsible for leading the Company's commercial sales strategy and execution, marketing programs, customer acquisition, channel development, and revenue operations.

Ms. Adams is currently pursuing a Bachelor of Science in Marketing at the University of Nevada, Reno (expected May 2027). Her professional experience includes service as a Front Desk Attendant at Spa of the West, Reno, Nevada (October 2024 – May 2025) and as a Sales Associate at Chico's FAS, Las Vegas, Nevada (June 2024 – August 2024). Ms. Adams has not previously served as an officer, director, promoter, control person, or consultant for any other issuer of securities registered or required to be registered with the SEC.

Ms. Adams has not been the subject of any criminal, regulatory, or civil proceedings of the type described in Item 401 of Regulation S-K. She is a U.S. citizen and has no family relationships with any other officer or director of the Company.

*Compensation*. Ms. Adams's compensation is governed by the Employment Agreement dated May 20, 2026, fully executed June 4–5, 2026 (the "**Adams Employment Agreement**"), approved and ratified by the Board's Unanimous Written Consent dated June 12, 2026. The material terms of the Adams Employment Agreement are as follows: (i) annual base salary of $150,000, payable in accordance with the Company's standard payroll practices; (ii) a grant of 500,000 shares of restricted common stock of the Company (the "**Adams RSA**"), vesting in five equal annual installments of 100,000 shares commencing on the first anniversary of May 20, 2026, subject to continued employment, with full acceleration upon a Change of Control; (iii) severance equal to twelve months of base salary upon termination without Cause; and (iv) reimbursement of reasonable business expenses. The Adams Employment Agreement also contains customary confidentiality, non-solicitation, and non-competition covenants. Ms. Adams has not held, and does not currently hold, any director position at the Company.

***Term of Office***

Our directors are appointed for a one-year term until their successors are duly elected and qualified. Our officers are appointed by our board of directors and hold office until removed by the board, subject to their respective employment agreements.

***Family Relationships***

Aside from Olivia Trinh and Chanh Trinh, who are related as father and daughter (Chanh Trinh is the former co-founder of MyRxWallet DAO), there are no family relationships between or among the current directors, executive officers, or significant employees of the Company. Mr. Trinh previously sold his controlling interest in MyRxWallet DAO to MyRxWallet North America Corporation. Although he no longer holds any ownership or control, he provides assistance to the Company from time to time, as needed, pursuant to the terms of the sale agreement.

There are no other family relationships between or among the current directors, executive officers, or significant employees of the Company.

***Involvement in Certain Legal Proceedings***

During the past five years, none of our current directors, nominees for directors or current executive officers has been involved in any of the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. A petition under the federal bankruptcy laws or any state insolvency law was filed by or against, or a receiver, fiscal agent or similar officer was appointed by a court for the business or property of such person, or any partnership in which he was general partner at or within two years before the time of such filing, or any corporation or business association of which he was an executive officer at or within two years before the time of such filing; or

2. A conviction in a criminal proceeding (excluding traffic violations and other minor offenses).

***Director Independence***

We have determined that one of our directors, Scherri A. Harps, qualifies as an "independent director" within the meaning of Nasdaq listing standards. The Company does not currently have a second independent director or a constituted audit committee with financial expertise.

***Code of Ethics***

As of the date of this Offering Circular, our Board of Directors has not adopted a code of ethics with respect to our directors, officers and employees.

**EXECUTIVE COMPENSATION**

We are an "emerging growth company," as defined in the JOBS Act, and thus the following disclosures are intended to comply with the scaled disclosure requirements applicable to emerging growth companies and "smaller reporting companies," as such term is defined in the rules promulgated under the Securities Exchange Act, which require compensation disclosure for our principal executive officer and the two most highly compensated executive officers other than our principal executive officer, whom we refer to as our "named executive officers."

This section discusses the material components of the executive compensation program offered to our named executive officers. Our named executive officers for the year ended September 30, 2025 were as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Olivia Trinh, our current Chairman, Chief Executive Officer, and Interim Chief Financial Officer;

· Binh Do, our former President, Chief Financial Officer, and Director; and

This discussion may contain forward-looking statements that are based on our current plans, considerations, expectations and determinations regarding future compensation programs. Actual compensation programs that we adopt could vary materially from our historical practices and currently planned programs summarized in this discussion.

***Summary Compensation Table***

During the year ended September 30, 2025 no compensation awarded to and earned by our named executive officers (Olivia Trinh and Binh Do) for services rendered in all capacities.

The Company currently does have any agreements in place for compensation of its officers. The Company plans to enter into employment agreements with its management as soon as funds are available for that purpose. The future agreements will likely include the following:

***Future Compensation Agreements***

 ****

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Chief Executive Officer (CEO):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o Annual salary: $200,000

o Paid bi-weekly

o Eligible for performance bonuses based on milestone achievements

o Full family health plan

o 401K retirement plan

o Life insurance

o Year-end bonuses

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Other Executive Officers:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o Annual salary: $150,000 (each)

o Paid bi-weekly

o Eligible for performance bonuses based on milestone achievements

o Full family health plan

o 401K retirement plan

o Life insurance

o Year-end bonuses

Subsequent to September 30, 2025, Revan Adams was appointed as Executive Vice President of Sales and Marketing effective June 5, 2026. Her compensation is described in the biographical section above under "*Revan Adams, Executive Vice President of Sales and Marketing*." The Adams RSA of 500,000 restricted shares was approved by the Board's Unanimous Written Consent dated June 12, 2026.

***Outstanding Equity Awards***

During the year ended September 30, 2025, there were no unexercised options, stock that has not vested, and equity incentive plan awards outstanding for any of our named executive officers.

***Director Compensation***

During the year ended September 30, 2025, no compensation was earned by, paid to, or awarded to our non-employee directors. Subsequent to September 30, 2025, Ms. Scherri A. Harps was appointed as Independent Director effective March 1, 2026. Her compensation is governed solely by the Independent Director Appointment Agreement effective March 1, 2026, the material terms of which are described in the biographical section above under "*Scherri A. Harps, Independent Director*." A separate document titled "Director of Mergers and Acquisition and Board Member Employment Agreement," executed on or about March 1, 2026 from a generic template in error, was never operated by either party and was rescinded ab initio by Mutual Rescission executed May 8, 2026, ratified by the Board's Unanimous Written Consent of the same date. No compensation of any kind was paid, accrued, or earned under the M&A Agreement.

***Insider Trading Policy***

We have not adopted an insider trading policy as our securities are not trading.

***Policies and Practices Related to the Timing of Grants of Certain Equity Awards***

It is the board of director's practice to approve ordinary course annual equity grants during a scheduled meeting held each year. At this meeting, the board will approve each named executive officer's annual equity award, if any. At this time, we do not currently anticipate granting stock options to any of our named executive officers. We do not schedule our equity grants in anticipation of the release of material, non-public information, nor do we time the release of material nonpublic information based on equity grant dates.

**SECURITY OWNERSHIP OF MANAGEMENT AND CERTAIN SECURITYHOLDERS**

The following table and footnotes thereto set forth information regarding the number of shares of common stock beneficially owned by (i) each director, named executive officer, and executive officer of our company, (ii) each person known by us to be the beneficial owner of 10% or more of its issued and outstanding shares of common stock, and (iii) named executive officers, executive officers, and directors of the Company as a group as of June 18, 2026. In calculating any percentage in the following table of common stock beneficially owned by one or more persons named therein, the following table assumes 280,352,363 shares of common stock outstanding as of the date of this offering statement. Unless otherwise further indicated in the following table, the footnotes thereto and/or elsewhere in this Offering Circular, the persons and entities named in the following table have sole voting and sole investment power with respect to the shares set forth opposite the shareholder's name, subject to community property laws, where applicable. Unless otherwise indicated in the following table and/or the footnotes thereto, the address of our executive officers and directors in the following tables is: 732 S. 6th Street, #5397, Las Vegas, NV 89101.

---

| | | |
|:---|:---|:---|
| **Name of Beneficial Owner** | **Amount and<br> Nature of<br> Beneficial<br> Ownership<sup>(1)</sup>** | **Percent of**<br> **Class<sup>(1)</sup>** |
| **Named Executive Officers, Executive Officers, and Directors** |  |  |
| Olivia Trinh, Chairman, Chief Executive, and Interim Chief Financial Officer<sup>(2)</sup> | 202500000<sup>(2)</sup> | 72.23% |
| Binh Do (Former Director and Officer; resigned March 2026)(3) | 1500000 | \* |
| Scherri A. Harps, Director | 35000 | \* |
| **Named Executive Officers, Executive Officers, and Directors as a Group (3 Persons)** | **204035000** | **72.78%** |
| **10% Beneficial Owners** |  |  |
| **MyRxWallet Corporation<sup>(3)(5)</sup>**<br> 732 S. 6th Street, #5397, Las Vegas, NV 89101 | 130000000 | 46.37% |
| **Z the FUTURE, LLC<sup>(4)(5)</sup>**<br> 30 N Gould St #13001<br> Sheridan, WY 82801 | 70000000 | 24.97% |

---

\* <1%.

_____________________

<sup>(1)</sup> Under Rule 13d-3 of the Exchange Act, a beneficial owner of a security includes any person who, directly or indirectly, through any contract, arrangement, understanding, relationship, or otherwise has or shares: (i) voting power, which includes the power to vote, or to direct the voting of shares; and (ii) investment power, which includes the power to dispose or direct the disposition of shares. Certain shares may be deemed to be beneficially owned by more than one person (if, for example, persons share the power to vote or the power to dispose of the shares). In addition, shares are deemed to be beneficially owned by a person if the person has the right to acquire the shares (for example, upon exercise of an option) within 60 days of the date as of which the information is provided. In computing the percentage ownership of any person, the amount of shares outstanding is deemed to include the number of shares beneficially owned by such person (and only such person) by reason of these acquisition rights. As a result, the percentage of outstanding shares of any person as shown in the above table does not necessarily reflect the person's actual ownership or voting power with respect to the number of shares of common stock actually outstanding on June 18, 2026.

<sup>(2)</sup> Includes 2,500,000 shares held in Ms. Trinh's name, 130,000,000 shares held by MyRxWallet Corp., and 70,000,000 shares held by Z the Future, LLC.

<sup>(3)</sup> Olivia Trinh has voting and disposition authority over the shares held by MyRxWallet Corporation.

<sup>(4)</sup> Olivia Trinh has voting and disposition authority over the shares held by Z the Future, LLC.

<sup>(5)</sup> Does not include up to 10,557,000 shares issuable upon conversion of promissory notes issued to related parties at a conversion price of $125 per share, or shares issuable for quarterly interest payments on such notes, which could total approximately 686,010 shares annually if paid in stock.

**INTEREST OF MANAGEMENT AND OTHERS IN CERTAIN TRANSACTIONS**

Including the disclosure above described under the heading "**COMPENSATION OF DIRECTORS AND EXECUTIVE OFFICERS**", in accordance with Regulation S-K Item 404(d), the following are all transactions or series of similar transactions occurring during the past two fiscal years to which we were or will be a participant, in which the amount involved exceeded or will exceed the lesser of $120,000 or 1% of the average of our total assets at year-end for the last two completed fiscal years, and in which any person who was a director, executive officer, holder of 5% or more of any class of our capital stock, or any member of the immediate family of any of the foregoing persons, had or will have a direct or indirect material interest - whether or not such person is currently serving in such role. This disclosure includes transactions involving persons who have since departed the Company but were related parties at the time the transaction occurred, consistent with Instruction 1 to Item 404(a).

***MyRxWallet DAO, LLC Acquisition (October 27, 2025)***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) *What was sold*: MyRxWallet DAO, LLC, a Wyoming LLC (formed September 19, 2024), which is now the Company's technology and platform development subsidiary responsible for blockchain EHR protocols, smart contract frameworks, AI development initiatives, and decentralized data infrastructure.

(ii) *Valuation*: Aggregate transaction value of $500,000,000 at $27.00 per share of Company common stock, determined by mutual agreement at arm's length between Chanh Trinh (seller) and the Company's Board. No formal third-party appraisal was conducted.

(iii) *Shares issued*: 18,518,518 total shares allocated as: 9,259,259 shares to Chanh Trinh individually; and 9,259,259 shares to MyRxWallet DAO, Inc. (a separately incorporated affiliate, not a subsidiary of the Company). Both recipients received Rule 144 restricted shares.

(iv) *Family relationship*: Chanh Trinh is the father of Olivia Trinh, the Company's Chairman, CEO, and Interim CFO. This is a related-party transaction.

(v) *Continued involvement*: Following the closing, Chanh Trinh does not hold any officer, director, or management position at the Company. No advisory or consulting agreement exists as of the date of this filing.

(vi) *What was sold*: MyRxWallet DAO, LLC, a Wyoming LLC (formed September 19, 2024), which is now the Company's technology and platform development subsidiary responsible for blockchain EHR protocols, smart contract frameworks, AI development initiatives, and decentralized data infrastructure. Chanh Trinh was the founder and former sole shareholder of MyRxWallet DAO, LLC. Pursuant to the Share Exchange Agreement dated September 22, 2025, which closed October 27, 2025, Mr. Trinh sold his entire ownership interest in MyRxWallet DAO, LLC to the Company. Following closing, Mr. Trinh has no ownership, officer, director, management, promoter, or any other role or relationship with the Company, MyRxWallet DAO, LLC, or MyRxWallet DAO, Inc. The only ongoing connection between Mr. Trinh and the Company is his family relationship as the father of Olivia Trinh, the Company's Chairman, Chief Executive Officer, and Interim Chief Financial Officer.

(vii) *MyRxWallet DAO, Inc. shares*: As a condition of the acquisition, Mr. Trinh directed that 9,259,259 of the 18,518,518 total consideration shares be issued to MyRxWallet DAO, Inc., a separately incorporated blockchain technology foundation. Upon closing of the Share Exchange Agreement on October 27, 2025, MyRxWallet DAO, Inc. became 100% owned and controlled by MyRxWallet North America Corporation. MyRxWallet DAO, Inc. is therefore an affiliate of the Company solely by virtue of the fact that it is 100% owned and controlled by MyRxWallet North America Corporation. Mr. Trinh retains no interest, role, or involvement in MyRxWallet DAO, Inc. whatsoever following the closing. The 9,259,259 shares held by MyRxWallet DAO, Inc. are subject to Rule 144 restrictions and have not been registered for resale. Chanh Trinh currently holds 9,259,259 shares of MyRxWallet North America Corporation common stock (approximately 3.27% of issued shares as of the date of this Offering Circular), all of which are subject to Rule 144 restrictions, representing the sole remaining economic interest Mr. Trinh holds in any entity within the MyRxWallet ecosystem.

***Olivia Trinh - Share Award (October 1, 2025)***

Ms. Trinh received 2,500,000 shares at $85.00/share (aggregate value $212,500,000) in recognition of her service as Chairman, CEO, and Interim CFO simultaneously. The award was intended to compensate Ms. Trinh for the extraordinary breadth of responsibilities assumed at a critical stage of the Company's development. No cash compensation was paid during this period.

***Binh Do - Share Award (October 1, 2025)***

Mr. Do received 1,500,000 shares at $85.00/share (aggregate value $127,500,000) in recognition of his expanded responsibilities as President in addition to CFO and Director. Mr. Do resigned from all positions effective March 9, 2026. Although Mr. Do's voluntary resignation did not constitute a termination for Good Reason under his Employment Agreement - which would otherwise have triggered forfeiture and cancellation of his 1,500,000 restricted shares - the Company has elected to waive its contractual forfeiture rights and allow Mr. Do to retain his 1,500,000 shares. His 1,500,000 restricted shares remain issued and outstanding and are subject to Rule 144 restrictions. No clawback or further forfeiture obligation applies.

***Clinrarc Bio-Bank Intelligence Pvt. Ltd. Acquisition (November 2025)***

Through its wholly-owned subsidiary MyRxWallet Prana Private Limited, the Company acquired a majority and controlling interest in Clinrarc Bio-Bank Intelligence Pvt. Ltd. (formerly Clinrarc Services Pvt. Ltd.) in November 2025. The consideration for the acquisition consisted of 8,875,740 shares of Company common stock, valued by the Board of Directors at $84.50 per share, representing aggregate consideration of approximately $750,000,000. The Board determined the $84.50 per-share value based on: (i) the $27.00 per-share arm's-length baseline established in connection with the October 2025 MyRxWallet DAO, LLC acquisition; (ii) a material increase in the Company's committed asset base, including executed land acquisition agreements totaling approximately $104 million in the aggregate; and (iii) the strategic ecosystem value attributable to the Company's developing healthcare data and infrastructure program. This valuation was not based on a formal third-party appraisal, and the market price of the Company's common stock, if and when publicly traded, may differ materially from the Board-determined value. The shares were issued pursuant to the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended. A U.S.-domiciled Clinrarc counterpart entity is currently being organized in connection with related land acquisition agreements; full terms of that entity will be disclosed in a subsequent amendment to this Offering Statement.

In August 2025, Chanh Trinh (former co-founder MyRxWallet NAC and former Managing Director of MyRxWallet DAO, LLC) sold the company to MyRxWallet North America Corporation in an all-equity transaction for an aggregate valued of $500 million. The equity issuance was divided equally, with 50% issued to Chanh Trinh and 50% issued to MyRxWallet DAO, Inc.

***MyRxWallet Venture Capital Inc. Formation (October 2025 / March 2026)***

On October 21, 2025, the Company issued 2,958,580 shares of its common stock at $84.50 per share as the initial equity capitalization of MyRxWallet Venture Capital Inc., a newly formed Wyoming corporation that serves as the Company's strategic mergers and acquisitions arm. The aggregate capitalization at the time of share issuance was approximately $250,000,000. The Wyoming corporate formation was completed in March 2026. MyRxWallet Venture Capital Inc. is 100% owned by the Company; there are no minority owners. The Board of Directors determined the $84.50 per-share value based on: (i) the $27.00 per-share arm's-length baseline established in connection with the October 2025 MyRxWallet DAO, LLC acquisition; (ii) a material increase in the Company's committed asset base, including executed land acquisition agreements totaling approximately $104 million in the aggregate; and (iii) the strategic ecosystem value attributable to the Company's developing healthcare data and infrastructure program. This valuation was not based on a formal third-party appraisal, and the market price of the Company's common stock, if and when publicly traded, may differ materially from the Board-determined value. The shares were issued pursuant to the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended.

On October 1, 2025, Olivia Trinh received an award of 2,500,000 common shares.

On October 1, 2025, Binh Do received an award of 1,500,000 common shares.

On January 3, 2026, we entered into a Stock Repurchase Agreement with MyRxWallet Corporation, Inc., a Wyoming corporation, an entity controlled by Olivia Trinh, our Chief Executive Officer. Pursuant to the agreement, we agreed to repurchase from MyRxWallet Corporation 10,000,000 shares of the Company's Common Stock at $85 per share for an aggregate total of $850,000,000, which was evidenced by a Promissory Note issued to MyRxWallet Corporation.

On February 5, 2026, the parties amended and restated the Promissory Note. Under the Amended Promissory Note: (i) the maturity structure was changed to a demand note whereby the Noteholder may demand payment at any time within 24 months from February 4, 2026, and if not demanded, the Note automatically renews for an additional 24 months on the same terms; (ii) interest accrues at 7.5% per annum ($63,750,000 annual interest; $15,937,500 quarterly), payable quarterly in arrears in the form of fully paid, non-assessable shares of the Company's common stock unless otherwise agreed by the parties; (iii) the conversion price was changed from a variable formula based on 66% of recent trading prices to a fixed price of $125 per share, with up to 7,820,000 shares issuable upon full conversion of principal and accrued interest; (iv) all overdue amounts bear interest at an additional 2%; and (v) the Company is required at all times to reserve sufficient shares of its Common Stock for full conversion of the Promissory Note.

The Amended Promissory Note also contemplates that the parties will enter into a Capped Call Agreement (an anti-dilution hedge) with a notional amount equal to the number of shares underlying the Note, a strike price of $125 per share, and a cap price of $200 per share. Settlement under the Capped Call may be in cash, shares, treasury shares, or issuer-sponsored tokenized shares. The Borrower may prepay the Note in whole or in part at any time without penalty.

On January 3, 2026, we entered into a Stock Repurchase Agreement with Z the Future, LLC, an entity controlled by Olivia Trinh, our Chief Executive Officer. Pursuant to the agreement, we agreed to repurchase from Z the Future 3,500,000 shares of the Company's Common Stock at $85 per share for an aggregate total of $297,500,000, which was evidenced by a Promissory Note issued to Z the Future.

On February 5, 2026, the parties amended and restated the Promissory Note. Under the Amended Promissory Note: (i) the maturity structure was changed to a demand note whereby the Noteholder may demand payment at any time within 24 months from February 4, 2026, and if not demanded, the Note automatically renews for an additional 24 months on the same terms; (ii) interest accrues at 7.5% per annum ($22,312,500 annual interest; $5,578,125 quarterly as stated in the Repurchase Agreement), payable quarterly in arrears in the form of fully paid, non-assessable shares of the Company's common stock unless otherwise agreed by the parties; (iii) the conversion price was changed from a variable formula based on 66% of recent trading prices to a fixed price of $125 per share, with up to 2,737,000 shares issuable upon full conversion of principal and accrued interest; (iv) all overdue amounts bear interest at an additional 2%; and (v) the Company is required at all times to reserve sufficient shares of its Common Stock for full conversion of the Promissory Note.

The Amended Promissory Note also contemplates that the parties will enter into a Capped Call Agreement (an anti-dilution hedge) with a notional amount equal to the number of shares underlying the Note, a strike price of $125 per share, and a cap price of $200 per share. Settlement under the Capped Call may be in cash, shares, treasury shares, or issuer-sponsored tokenized shares. The Borrower may prepay the Note in whole or in part at any time without penalty.

Note: We have identified an inconsistency in the Amended Promissory Note to Z the Future, LLC regarding the treatment of fractional shares upon conversion. One provision states fractional shares shall be rounded down or settled in cash in lieu, while another provision states fractional shares shall be rounded up to the nearest whole share. This inconsistency will need to be resolved prior to any conversion.

Please see the risk factor titled "***[The Company has incurred substantial indebtedness to entities controlled by our CEO, which creates significant risks of dilution, conflicts of interest, and threatens our ability to continue as a going concern.](#a_029)***"

In addition, Patrick Mokros (Former co-founder and CEO of MyRxWallet NAC), David Hume (former co-founder and Chief of Staff), and members of MyRxWallet Prana Pvt. Ltd.—including Kishore K. (Co-Managing Director), Suresh Sura (Co-Managing Director), Venkatratnam Pappoppu (Co-Managing Director), Pavuluri Chaitanya (M&A Special Strategic Advisor), and Raj Kumar Yadav Ittaboiena (Public Affairs Director)—participated in and provided operational and advisory support for:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· the acquisition of ClinRARC Services Pvt. Ltd. (now Biobank Intelligence, Inc.) for an aggregate value of $750 million; and

· multiple land-acquisition transactions totaling approximately 400 acres, with an aggregate value of approximately $110 million, intended for data-center development, biobanking vault infrastructure, supply-chain logistics, and critical-care healthcare warehousing.

These individuals received no compensation, were granted no equity, and did not receive any direct or indirect material benefit in connection with the transactions described above. Their involvement was strictly limited to advisory and operational functions, and they are no longer affiliated with the Company.

***Revan Adams — Employment Agreement and Restricted Stock Award (June 2026)***

On June 5, 2026, the Company entered into the Adams Employment Agreement with Revan Adams, the Company's Executive Vice President of Sales and Marketing, approved and ratified by the Board's Unanimous Written Consent dated June 12, 2026 (reviewed by Independent Director Scherri A. Harps acting outside the presence of interested officers). The material terms of the transaction are: (i) annual base salary of $150,000; (ii) a grant of 500,000 shares of restricted common stock vesting in five equal annual installments of 100,000 shares commencing on the first anniversary of May 20, 2026, subject to continued employment and with full acceleration upon a Change of Control; (iii) severance equal to twelve months of base salary upon termination without Cause; and (iv) reimbursement of reasonable business expenses. The aggregate value of the 500,000 RSA shares at the Board-determined price of $85.00 per share is $42,500,000. Ms. Adams does not hold any director position and has no family relationship with any other officer or director of the Company.

**DESCRIPTION OF SECURITIES**

*The following is a summary of the rights of our capital stock as provided in our Amended and Restated Articles of Incorporation (the "Articles of Incorporation"). For more detailed information, please see our Articles of Incorporation, which have been filed as an exhibit to the Offering Statement of which this Offering Circular is a part.*

Our authorized capital stock consists of 750,000,000 shares of common stock, with a par value of $0.0001 per share, and 100,000,000 shares of preferred stock, par value $0.0001 per share. As of the date of this offering statement, there were 283,295,363 shares of our common stock issued, of which 280,352,363 shares are outstanding (with 2,943,000 shares held in treasury), held by 113 stockholders of record. As of the date of this offering statement, there are no outstanding shares of preferred stock.

***Common Stock***

Our common stock is entitled to one vote per share on all matters submitted to a vote of the stockholders, including the election of directors. Except as otherwise required by law or provided in any resolution adopted by our board of directors with respect to any series of preferred stock, the holders of our common stock will possess all voting power. Generally, all matters to be voted on by stockholders must be approved by a majority (or, in the case of election of directors, by a plurality) of the votes entitled to be cast by all shares of our common stock that are present in person or represented by proxy, subject to any voting rights granted to holders of any preferred stock. Holders of our common stock representing 50% of our capital stock issued, outstanding and entitled to vote, represented in person or by proxy, are necessary to constitute a quorum at any meeting of our stockholders. A vote by the holders of a majority of our outstanding shares is required to effectuate certain fundamental corporate changes such as liquidation, merger or an amendment to our Articles of Incorporation. Our Articles of Incorporation do not provide for cumulative voting in the election of directors.

Subject to any preferential rights of any outstanding series of preferred stock created from time to time by our board of directors, upon liquidation, dissolution or winding up, the holders of shares of our common stock will be entitled to receive pro rata all assets available for distribution to such holders.

In the event of any merger or consolidation with or into another company in connection with which shares of our common stock are converted into or exchangeable for shares of stock, other securities or property (including cash), all holders of our common stock will be entitled to receive the same kind and number of shares of stock and other securities and property (including cash). Holders of our common stock have no pre-emptive rights, no conversion rights and there are no redemption provisions applicable to our common stock.

***Preferred Stock***

Our board of directors is authorized by our articles of incorporation to divide the authorized shares of our preferred stock into one or more series, each of which must be so designated as to distinguish the shares of each series of preferred stock from the shares of all other series and classes. Our board of directors is authorized, within any limitations prescribed by law and our articles of incorporation, to fix and determine the designations, rights, qualifications, preferences, limitations and terms of the shares of any series of preferred stock including, but not limited to, the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The number of shares constituting that series and the distinctive designation of that series, which may be by distinguishing number, letter or title;

2. The dividend rate on the shares of that series, whether dividends will be cumulative, and if so, from which date(s), and the relative rights of priority, if any, of payment of dividends on shares of that series;

3. Whether that series will have voting rights, in addition to the voting rights provided by law, and, if so, the terms of such voting rights;

4. Whether that series will have conversion privileges, and, if so, the terms and conditions of such conversion, including provision for adjustment of the conversion rate in such events as the Board of Directors determines;

5. Whether or not the shares of that series will be redeemable, and, if so, the terms and conditions of such redemption, including the date or date upon or after which they are redeemable, and the amount per share payable in case of redemption, which amount may vary under different conditions and at different redemption dates;

6. Whether that series will have a sinking fund for the redemption or purchase of shares of that series, and, if so, the terms and amount of such sinking fund;

7. The rights of the shares of that series in the event of voluntary or involuntary liquidation, dissolution or winding up of the corporation, and the relative rights of priority, if any, of payment of shares of that series; and

8. Any other relative rights, preferences and limitations of that series.

***Provisions in Our Articles of Incorporation and By-Laws That Would Delay, Defer or Prevent a Change in Control***

Our Articles of Incorporation authorize our board of directors to issue a class of preferred stock commonly known as a "blank check" preferred stock. Specifically, the preferred stock may be issued from time to time by the board of directors as shares of one or more classes or series. Our board of directors, subject to the provisions of our Articles of Incorporation and limitations imposed by law, is authorized to adopt resolutions; to issue the shares; to fix the number of shares; to change the number of shares constituting any series; and to provide for or change the following: the voting powers; designations; preferences; and relative, participating, optional or other special rights, qualifications, limitations or restrictions, including the following: dividend rights, including whether dividends are cumulative; dividend rates; terms of redemption, including sinking fund provisions; redemption prices; conversion rights and liquidation preferences of the shares constituting any class or series of the preferred stock.

In each such case, we will not need any further action or vote by our shareholders. One of the effects of undesignated preferred stock may be to enable the board of directors to render more difficult or to discourage an attempt to obtain control of us by means of a tender offer, proxy contest, merger or otherwise, and thereby to protect the continuity of our management. The issuance of shares of preferred stock pursuant to the board of director's authority described above may adversely affect the rights of holders of common stock. For example, preferred stock issued by us may rank prior to the common stock as to dividend rights, liquidation preference or both, may have full or limited voting rights and may be convertible into shares of common stock. Accordingly, the issuance of shares of preferred stock may discourage bids for the common stock at a premium or may otherwise adversely affect the market price of the common stock.

***Dividend Policy***

We have never declared or paid any cash dividends on our common stock. We currently intend to retain future earnings, if any, to finance the expansion of our business. As a result, we do not anticipate paying any cash dividends in the foreseeable future.

***Options and Warrants***

We have not issued and do not have outstanding any options or warrants to purchase shares of our common stock.

***Market Information***

Our common stock is not now listed on any national securities exchange (such as Nasdaq or the NYSE) or quotation system (such as the OTC Markets) and there is no market for our securities. Although we intend to apply for quotation of our Common Stock on the OTCQB or OTCQX through a market maker, public trading of our common stock may never materialize and there is no guarantee that an active trading market will develop in our securities. Investors should be prepared to hold our shares indefinitely.

***Securities Authorized for Issuance under Equity Compensation Plans***

We do not have any equity compensation plans. We plan to adopt an equity compensation plan in the near future and to reserve 5,000,000 shares of common stock under the plan.

***Exchange Act Registration***

Concurrently with the qualification of this offering statement, we intend to file a registration statement on Form 8-A with the SEC to register our common stock under Section 12(g) of the Exchange Act. Upon effectiveness of the Form 8-A, our common stock will become subject to the periodic reporting requirements of the Exchange Act, including the requirements to file annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K.

This registration is voluntary and is not required for Regulation A offerings. However, our Board of Directors believes the benefits of Exchange Act reporting status—including enhanced credibility, transparency, and potential for future exchange listing—outweigh the significant additional costs and administrative burdens.

The Form 8-A registration will also subject our directors, executive officers, and beneficial owners of more than 10% of our common stock to the reporting and "short-swing" profit recovery provisions of Section 16 of the Exchange Act.

**LEGAL MATTERS**

The legality of the issuance of the shares of Common Stock offered by this Offering Circular will be passed upon for us by Business Legal Advisors, LLC of Draper, Utah.

**EXPERTS**

No expert or counsel named in this Offering Circular as having prepared or certified any part of this Offering Circular or having given an opinion upon the validity of the securities being registered or upon other legal matters in connection with the registration or offering of the Common Stock was employed on a contingency basis, or had, or is to receive, in connection with the offering, a substantial interest, direct or indirect, in the registrant or any of its parents or subsidiaries. Nor was any such person connected with the registrant or any of its parents or subsidiaries as a promoter, managing or principal underwriter, voting trustee, director, officer, or employee.

The financial statements of the Company as of September 30, 2025, which include an explanatory paragraph relating to our ability to continue as a going concern, included in this Offering Circular have been audited by LAO Professionals, an independent auditor, as stated in their report appearing herein. Such financial statements have been so included in reliance upon the reports of such firm given its authority as experts in accounting and auditing.

**INDEX TO FINANCIAL STATEMENTS**

---

| | |
|:---|:---|
| [Report of Independent Registered Public Accounting Firm](#a_020) (PCAOB ID: 7057) | F-1 |
| [Audited Balance Sheets as of September 30, 2025](#a_021) | F-2 |
| [Statements of Operations for the Period from October 16, 2024 (Inception) to September 30, 2025](#a_022) | F-3 |
| [Statements of Stockholders' Deficit and Parent's Net Investment for the Period from October 16, 2024 (Inception) to September 30, 2025](#a_023) | F-4 |
| [Statements of Cash Flows for the Period from October 16, 2024 (Inception) to September 30, 2025](#a_024) | F-5 |
| [Notes to Financial Statements](#a_025) | F-6 |

---

**REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

<br> **To the Board of Directors and Stockholders of MyRxWallet North America Corporation**

**<u>Opinion on the Financial Statements</u>**

We have audited the accompanying consolidated balance sheets of MyRxWallet North America Corporation (the 'Company') as of September 30, 2025, and the related consolidated statements of operations, comprehensive income, changes in stockholders' equity and cash flows for period ended September 30, 2025, and the related notes (collectively referred to as the "financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as of September 30, 2025, and the results of its operations and its cash flows for each of the period ended September 30, 2025, in conformity with accounting principles generally accepted in the United States of America.

**<u>Going Concern</u>**

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 4, the Company suffered an accumulated deficit of $39,534. These matters raise substantial doubt about the Company's ability to continue as a going concern. Management's plans with regards to these matters are also described in Note 4 to the financial statements. These financial statements do not include any adjustments that might result from the outcome of this uncertainty.

**<u>Basis for Opinion</u>**

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

**<u>Critical Audit Matters</u>**

Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. Communication of critical audit matters does not alter in any way our opinion on the financial statements taken as a whole and we are not, by communicating the critical audit matters, providing separate opinions on the critical audit matter or on the accounts or disclosures to which they relate. There was no Critical Audit Matter to be communicated.

/S/ Lateef Awojobi

**LAO PROFESSIONALS**

(PCAOB ID 7057)

Lagos, Nigeria

We have served as the Company's auditor since 2025.

January 22, 2026

**MYRXWALLET NORTH AMERICA CORPORATION<br> CONSOLIDATED BALANCE SHEETS (AUDITED)<br> FOR THE FISCAL YEARS ENDED SEPTEMBER 30, 2025**

---

| | |
|:---|:---|
|  | **September 30, <br> 2025** |
|  | **(Audited)** |
| **Assets** |  |
| **Current assets:** |  |
| &nbsp;&nbsp;&nbsp;Cash | $48998 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses, current | – |
| **Total assets** | $**48998** |
| **Liabilities and Stockholders' Deficit** |  |
| **Current liabilities:** |  |
| &nbsp;&nbsp;&nbsp;Accounts payable | $13177 |
| &nbsp;&nbsp;&nbsp;Accrued expenses, related party | – |
| **Total Current liabilities** | **13177** |
| &nbsp;&nbsp;&nbsp;Accrued interest – non-current | – |
| **Total liabilities** | **13177** |
| **Stockholders' Equity (Deficit):** |  |
| &nbsp;&nbsp;&nbsp;Preferred stock, par value shares authorized, 25,000,000 issued and |  |
| &nbsp;&nbsp;&nbsp;Common stock, par value $0.0001, 300,000,000 shares authorized; 250,604,316 shares issued and outstanding, as of September 30, 2025 | 25060 |
| &nbsp;&nbsp;&nbsp;Additional paid-in capital | 50294 |
| &nbsp;&nbsp;&nbsp;Accumulated deficit | (39534) |
| Total stockholders' equity (deficit) | 35821 |
| **Total liabilities and stockholders' equity (deficit)** | $**48998** |

---

The accompanying notes are an integral part of these consolidated financial statements.

**MYRXWALLET NORTH AMERICA CORPORATION<br> CONSOLIDATED STATEMENT OF OPERATIONS (AUDITED)<br> FOR THE PERIOD FROM OCTOBER 16, 2024 (INCEPTION) THROUGH SEPTEMBER 30, 2025**

---

| | |
|:---|:---|
|  | **September 30,**<br> **2025** |
|  | **(Audited)** |
| **Revenue** |  |
| &nbsp;&nbsp;&nbsp;Sales | $– |
| **Total Revenue** | **–** |
| **Operating expenses** |  |
| &nbsp;&nbsp;&nbsp;General and administrative | 39533.80 |
| **Total operating expenses** | **39533.80** |
| **Operating income (loss)** | **(39533.80)** |
| **Other income (expense):** |  |
| &nbsp;&nbsp;&nbsp;Interest income (expense) |  |
| **Total other income (expense)** | **–** |
| Interest income (expense) |  |
| **Income (loss) before provision for income taxes** | **(39533.80)** |
| &nbsp;&nbsp;&nbsp;Provision (benefit) for income taxes | **–** |
| **Net income (loss)** | $**(39533.80)** |
| Net loss per common share, basic and diluted | $(0.00) |
| Weighted average number of common shares outstanding basic and diluted | 249808034 |

---

The accompanying notes are an integral part of these consolidated financial statements.

**MYRXWALLET NORTH AMERICA CORPORATION<br> CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY (DEFICIT)<br> FOR THE PERIOD FROM OCTOBER 16, 2024 (INCEPTION) THROUGH SEPTEMBER 30, 2025**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Preferred Stock** | **Preferred Stock** | **Common Stock** | **Common Stock** | | | |
|  | **Shares** | **Amount** | **Shares** | **Amount** |<br>**Additional**<br>**Paid-in**<br>**Capital** |<br>**Accumulated**<br>**Deficit** | **Total**<br>**Stockholders'**<br>**Equity**<br>**(Deficit)** |
| **September 30, 2024** |  | $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;– |  | $– | $– | $– | $– |
| &nbsp;&nbsp;&nbsp;September 30, 2024 |  | **–** | **–** | **–** | **–** | **–** | **–** |
| **September 30, 2024** |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Common Stock |  |  | 250604316 | 25060 | 50294 |  |  |
| &nbsp;&nbsp;&nbsp;Net loss |  | – | – | – | – | (39534) | (39534) |
| **September 30, 2025** |  | $**–** | **250604316** | $**25060** | $**50294** | $**(39534)** | $**(39534)** |

---

The accompanying notes are an integral part of these consolidated financial statements.

**MYRXWALLET NORTH AMERICA CORPORATION<br> CONSOLIDATED STATEMENT OF CASH FLOWS (AUDITED)<br> FOR THE PERIOD FROM OCTOBER 16, 2024 (INCEPTION) THROUGH SEPTEMBER 30, 2025**

---

| | |
|:---|:---|
|  | **September 30,**<br> **2025** |
|  | **(Audited)** |
| **Operating Activities:** |  |
| &nbsp;&nbsp;&nbsp;Net loss | $(39534) |
| **Change in assets and liabilities:** |  |
| &nbsp;&nbsp;&nbsp;Accounts payable | 13177 |
| **Net cash provided by (used in) operating activities** | $**(26357)** |
| **Investing Activities:** |  |
| &nbsp;&nbsp;&nbsp;Property, plant and equipment | – |
| **Net cash used in investing activities** | $**–** |
| **Financing Activities:** |  |
| &nbsp;&nbsp;&nbsp;Opening balance |  |
| &nbsp;&nbsp;&nbsp;Stock issued for cash | 25060 |
| &nbsp;&nbsp;&nbsp;Additional paid in capital | 50294 |
| **Net cash provided by (used in) financing activities** | $**75355** |
| **Net increase (decrease) in cash** | **48998** |
| **Cash at beginning of the period** | **–** |
| **Cash at end of the period** | $**48998** |

---

The accompanying notes are an integral part of these consolidated financial statements.

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<br> FOR THE YEARS ENDED SEPTEMBER 30, 2025<br> (In U.S. dollars)**

**Note 1 – Organization and Nature of Operations**

MyRxWallet North America Corporation (the "Company") was incorporated on October 16, 2024. The Company is in the development stage and has not generated revenues since inception. The Company's activities to date have consisted primarily of organizational activities, preparation for a Regulation A offering, professional fees, and related administrative costs.

The Company has one wholly owned subsidiary, MyRxWallet Prana Private Limited ("Prana"), organized in India. These consolidated financial statements include the accounts of the Company and Prana. All material intercompany balances and transactions have been eliminated in consolidation.

**Note 2 – Summary of Significant Accounting Policies**

Basis of Presentation. The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP"). The consolidated financial statements are Audited and, in the opinion of management, include all normal recurring adjustments necessary for a fair presentation.

Accounts Payable.

Accounts payable and accrued liabilities of approximately $13,177 as of September 30, 2025 consisted primarily of unpaid professional fees payable to The Doney Law Firm (approximately $10,871) and BD Tax Group (approximately $2,306).

Use of Estimates.

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingencies. Actual results could differ from those estimates.

Cash and Cash Equivalents. The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. There were no cash equivalents as of September 30, 2025.

Foreign Currency Translation. The functional currency of the Company is the U.S. dollar. The functional currency of Prana is the Indian Rupee ("INR"). Prana's assets and liabilities are translated to U.S. dollars at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at average exchange rates during the period. Translation adjustments are recorded in accumulated other comprehensive income (loss). For purposes of these Audited consolidated financial statements, management used an exchange rate of INR 85 = USD 1.00 to translate Prana bank activity and the Prana cash balance as of September 30, 2025.

Income Taxes. The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for temporary differences. Management has not recorded material deferred tax balances for the period presented.

**Note 3 – Potential Acquisitions and Business Combinations**

Management has evaluated potential acquisitions and strategic transactions, including potential acquisitions of foreign operating entities and certain land-related opportunities. As of September 30, 2025, no such acquisition had been consummated that required recognition in these consolidated financial statements. Any future transactions may be subject to additional terms and conditions, including the successful closing of the Company's offering and other liquidity events.

**Note 4 – Going Concern**

The Company has incurred losses since inception and, as of September 30, 2025, had not generated revenues. These conditions raise substantial doubt about the Company's ability to continue as a going concern for a period of twelve months from the date these financial statements are issued. Management's plans to alleviate this substantial doubt include raising additional capital through equity and/or debt financings, including proceeds from the planned offering. These consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

**Note 5 – Stockholders' Equity**

The Company is authorized to issue 300,000,000 shares of common stock, par value $0.0001 per share, and 25,000,000 shares of preferred stock, par value $0.0001 per share. As of September 30, 2025, the Company had 250,604,316 shares of common stock issued and outstanding and no preferred shares issued or outstanding.

**Note 6 – Related Party Transactions**

During the period from inception through September 30, 2025, the Company advanced approximately $1,200 to Prana to fund initial set-up and professional costs. The intercompany receivable/payable is eliminated in consolidation.

Office space is provided free of charge by the Company's President and Chief Financial Officer. The Company recognized no rent expense for the period presented.

Based on the Prana bank activity provided, Prana incurred approximately INR 88,033 of payments during August and September 2025, which management has classified as legal and professional services in these draft financial statements (approximately $1,036 translated at INR 85 = USD 1). The remaining Prana cash balance included in consolidated cash at September 30, 2025 was approximately INR 15,801 (approximately $186).

**Note 7 – Commitments and Contingencies**

The Company (through its subsidiary) has entered into and/or evaluated certain land purchase and lease agreements in India in connection with potential future projects. As of September 30, 2025, legal title had not transferred, and no land assets were recorded on the consolidated balance sheet. Management has disclosed the aggregate contracted value of these land-related agreements as approximately $107,030,968.82. Any future closings, if consummated, are expected to occur after the closing of the Company's offering and are subject to the satisfaction of applicable closing conditions, including funding.

**Note 8 – Subsequent Events**

Management evaluated subsequent events through the date these financial statements were available to be issued. Subsequent to September 30, 2025, the Company completed certain equity transactions, including issuances of common stock in connection with acquisitions and compensation arrangements, and also repurchased shares that are held as treasury stock. These events are considered subsequent events and are not reflected in the accompanying consolidated financial statements as of September 30, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· October 20, 2025 – issuance of 9,259,259 common shares in connection with the acquisition of MyRxWallet DAO LLC.

· October 20, 2025 – issuance of 9,259,259 common shares to Chanh Trinh.

· October 21, 2025 – issuance of 8,875,740 common shares in connection with the acquisition of Clinrarc Pvt. Ltd.

· October 21, 2025 – issuance of 2,958,580 common shares in connection with MyRxWallet Prana Pvt. Ltd.

· October 21, 2025 – issuance of 2,958,580 common shares in connection with MyRxWallet Venture Capital Inc.

· October 31, 2025 – repurchase of 13,500,000 common shares (10,000,000 shares from MyRxWallet Corporation and 3,500,000 shares from Z the Future, LLC) held as treasury stock.

· October 31, 2025 – issuance of common shares for officer compensation (2,500,000 shares to Olivia Trinh and 1,500,000 shares to Binh Do).

No other subsequent events requiring recognition in the consolidated financial statements were identified.

**PART III - EXHIBITS**

***Exhibits***

The following exhibits are included as part of this Offering Statement:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Exhibit**<br> **Number** | **Exhibit Description** | **Form** | **File No.** | **Exhibit** | **Filing**<br> **Date** | **Filed**<br> **Herewith** |
| 2.1 | Amended and Restated Articles of Incorporation filed March 10, 2026 |  |  |  |  | X |
| 2.2 | [Bylaws](myrxwallet_ex0202.htm) |  |  |  |  | X |
| 4.1 | [Subscription Agreement](myrxwallet_ex0401.htm) |  |  |  |  | X |
| 6.1 | [Amended Promissory Note Issued to Z the Future, LLC dated February 4, 2026](myrxwallet_ex0601.htm) |  |  |  |  | X |
| 6.2 | [Amended Repurchase Agreement with Z the Future, LLC dated February 4, 2026](myrxwallet_ex0602.htm) |  |  |  |  | X |
| 6.3 | [Amended Promissory Note Issued to MyRxWallet Corporation, Inc. dated February 4, 2026](myrxwallet_ex0603.htm) |  |  |  |  | X |
| 6.4 | [Amended Repurchase Agreement with MyRxWallet Corporation, Inc. dated February 4, 2026](myrxwallet_ex0604.htm) |  |  |  |  | X |
| 6.5 | [Agreement to Lease dated August 13, 2025 with Smt. Architha Raj Kumar Ittaboiena](myrxwallet_ex0605.htm) |  |  |  |  | X |
| 6.6 | [Agreement of Sale dated August 9, 2025 with Chendireddy Raji Reddy](myrxwallet_ex0606.htm) |  |  |  |  | X |
| 6.7 | [Agreement of Sale dated August 16, 2025 with Smt. Architha Raj Kumar Ittaboiena](myrxwallet_ex0607.htm) |  |  |  |  | X |
| 6.8 | [Agreement of Sale dated August 16, 2025 with Pandi Venkatesh](myrxwallet_ex0608.htm) |  |  |  |  | X |
| 6.9+ | [Mutual Rescission of Director of Mergers and Acquisition and Board Member Employment Agreement, dated May 12, 2026, by and between MyRxWallet North America Corporation and Scherri A. Harps](myrxwallet_ex0609.htm) |  |  |  |  | X |
| 6.10+ | [Independent Director Appointment Agreement effective March 1, 2026, by and between MyRxWallet North America Corporation and Scherri A. Harps (controlling agreement governing Ms. Harps's service as non-employee Independent Director)](myrxwallet_ex0610.htm) |  |  |  |  | X |
| 7.1 | [Share Exchange Agreement dated September 22, 2025 with MyRxWallet DAO, LLC and Chanh Trinh](myrxwallet_ex0701.htm) |  |  |  |  | X |
| 7.2 | [Share and Asset Purchase Agreement dated September 24, 2025 with Clinrarc Pvt. Ltd.](myrxwallet_ex0702.htm) |  |  |  |  | X |
| 7.3 | [Share Purchase Agreement dated June 17, 2025, between MyRxWallet Prana Private Limited and Noah Therapeutics Private Limited](myrxwallet_ex0703.htm) |  |  |  |  | X |
| 10.1 | [Power of Attorney](myrxwallet_ex1001.htm) |  |  |  |  | X |
| 11.1 | Consent of Business Legal Advisors, LLC (included in [Exhibit 12.1](myrxwallet_ex1201.htm)) |  |  |  |  | X |
| 11.2 | [Consent of LAO Professionals](myrxwallet_ex1102.htm) |  |  |  |  | X |
| 12.1 | [Opinion of Business Legal Advisors, LLC as to the legality of the securities being offered](myrxwallet_ex1201.htm) |  |  |  |  | X |
| 15.1 | [Investor Presentation — MyRxWallet North America Corporation, Regulation A+ Tier 2 Offering, Maxim Group LLC, June 2026](myrxwallet_ex1501.htm) |  |  |  |  | X |
| 15.2 | [Investor Presentation — MyRxWallet North America Corporation, Pepperdine Graziadio Business School Most Fundable Companies Competition, Version 3, 2026](myrxwallet_ex1502.htm) |  |  |  |  | X |

---

____________

+ Management compensatory arrangement.

**SIGNATURES**

Pursuant to the requirements of Regulation A, the registrant has duly caused this Form 1-A to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Las Vegas, State of Nevada, on June 22, 2026.

---

| | |
|:---|:---|
| **MyRXWallet North America Corporation** | **MyRXWallet North America Corporation** |
| By: | */s/ Olivia Trinh* |
| Name: | Olivia Trinh |
|  | Chairman, Chief Executive Officer,<br> and Interim Chief Financial Officer<br> (Principal Executive Officer and Principal Financial and Accounting Officer) |

---

Pursuant to the requirements of Regulation A, this Form 1-A has been signed by the following persons in the capacities indicated on June 22, 2026:

---

| | |
|:---|:---|
| Name | Title |
| */s/ Olivia Trinh* | Chief Executive Officer, Interim Chief Financial Officer, and Chairman |
| Olivia Trinh |  |
| */s/ Scherri A. Harps* | Director |
| Scherri A. Harps |  |

---

## Ex1A-2B

**Exhibit 2.1**

![](image_147.jpg)

WY Secretary of State FILED: 03/10/2026 01:00 PM Original ID: 2024 - 001539485 Amendment ID: 202tHMl6437108 AMENDED AND RESTATED ARTICLES OF INCORPORATION MyRxWallet North America Corporation, a corporation organized and existing under the laws of the State of Wyoming, hereby certifies as follows: 1. Profit Corporation Articles of Incorporation were filed with the Secretary of State of Wyoming on October 16, 2024, under the name of MyRxWallet North America Corporation. 2. Pursuant to Article 10 of the Wyoming Business Corporation Act, these Amended and Restated Articles of Incorporation restate, integrate, and further amend the provisions of the Articles of Incorporation of this corporation. 3. These Amended and Restated Articles were approved in accordance with W . S . 17 - 16 - 1003 by the board of directors of the company and by a majority of shareholders of the company in a manner required by the Wyoming Business Corporation Act and consolidates all amendments into a single document . 4. The text of the Amended and Restated Articles oflncorporation as heretofore amended or supplemented is hereby restated and further amended to read in its entirety as follows: ARTICLES OF INCORPORATION OF MYRXWALLET NORTH AMERICA CORPORATION ARTICLE I. NAME The name of the corporation is MyRxWallet North America Corporation (the "Corporation"). The name and address of the incorporator is as follows: Northwest Registered Agent Service Inc., 30 N Gould St Ste N Sheridan, WY 82801. The Authorized Signer was and currently is Nat Smith from Northwest Registered Agent Service, Inc. ARTICLE II. REGISTERED OFFICE The address of the Corporation's registered office in the State of Wyoming is 30 N Gould St Ste R Sheridan, WY 82801 USA. The name of the registered agent at such address is Registered Agents Inc. ARTICLE III. PURPOSE ೦ et \ ೦ eee,i ೦೦ ೦ t ೦ \ o \ ee'6"' ೦೦೦ The Corporation is authorized to issue two classes of shares to be designated, respectively, ' Stock" and "Preferred Stock". The number of shares of Common Stock authorized to be issued is Seven The purpose or purposes of the corporation is to engage in any lawful act or activity for w £@ corporations may be organized under the Wyoming Business Corporation Act. :: ARTICLE IV. CAPITAL STOCK

![](image_148.jpg)

Hundred and Fifty Million (750,000,000). The number of shares of Preferred Stock authorized to be issued is One Hundred Million (100,000,000). The Common Stock shall each have par value of $0.0001 per share. The Preferred Stock shall each have par value of $0.0001 per share. Section 1. Authorized Shares The Corporation is authorized to issue two classes of shares designated as "Common Stock" and "Preferred Stock." • Common Stock: 750,000,000 shares, par value $0.0001 per share. • Preferred Stock: 100,000,000 shares, par value $0.0001 per share. All shares of the Corporation shall be non - assessable when issued as fully paid. Section 2. Authority to Establish Series of Preferred Stock The Board of Directors is authorized, subject to the limitations prescribed by law and this Article IV, to divide the Preferred Stock into one or more series and to determine, by filing a Certificate of Designation with the Wyoming Secretary of State, the designation, powers, preferences, rights, qualifications, limitations, and restrictions of each such series. This authority includes, without limitation, the power to establish: • Interest rights (cash, property, securities, or digital tokens) • liquidation preferences • conversion rights • redemption provisions • voting rights • token - enabled or blockchain - represented securities • sinking fund provisions • anti - dilution adjustments • any other lawful terms No further stockholder approval shall be required for the creation of any series of Preferred Stock unless expressly required by law. Section 3. Series A Preferred Stock (Token - Enabled) The Corporation hereby authorizes a series of Preferred Stock designated "Series A Preferred Stock." The number of shares constituting the Series A shall be fixed by the Board of Directors in a Certificate of Designation. (a) Digital Token Representation Each share of Series A Preferred Stock may be represented by one hundred (100) digital security tokens, designated "MyRx - A Tokens." • MyRx - A Tokens are digital representations of the economic and governance rights of the underlying Series A Preferred Stock. • MyRx - A Tokens do not constitute a separate class of securities. • The total number ofMyRx - A Tokens shall not exceed 100 x the number of issued and outstanding Series A Preferred Shares.

![](image_149.jpg)

• The Corporation may utilize blockchain - based transfer agent systems or smart - contract registries to record token ownership. (b) Form of Interests • Interests on Series A Preferred Stock may be paid in: • cash • property • securities of the Corporation • MyRx - A Tokens • or any combination thereof as determined by the Board of Directors. (c) Conversion and Redemption Series A Preferred Stock may include conversion rights into Common Stock or tokenized equivalents, and may be redeemable at the option of the Corporation, as set forth in the applicable Certificate of Designation. (d) Voting Rights Series A Preferred Stock shall have only such voting rights as are expressly provided in the Certificate of Designation or required by law. Section 4. Voting Rights of Common Stock Each holder of Common Stock shall be entitled to one vote per share on all matters submitted to stockholders, except as otherwise required by law or by the rights of any series of Preferred Stock. Section 5. Consideration for Shares Shares of Common Stock and Preferred Stock may be issued for such consideration as determined by the Board of Directors, including cash, promissory notes, services, property, securities, or digital assets, to the fullest extent permitted by law. Section 6. Non - Assessability All shares issued as fully paid shall be non - assessable, and no stockholder shall be personally liable for the debts or obligations of the Corporation. Section 7. Forward Stock Splits and Corporate Actions (a) Forward Stock Split. Effective as of September 16, 2025, each share of Common Stock issued and outstanding immediately prior to such date shall be split and converted into 3.5 shares of Common Stock (a l - for - 3.5 split). The Corporation shall make appropriate adjustments to its records to reflect the split. Fractional shares, if any, shall be handled in accordance with the policies adopted by the Board of Directors or as required by law. (b) Other Corporate Actions. Any forward stock split, reverse stock split, recapitalization, or similar corporate action not otherwise provided for herein shall be effected only by amendment to the Articles of Incorporation or by Board resolution where permitted by law. No such action shall modify the rights of any series of Preferred Stock unless expressly provided in the amendment or resolution. No such action

![](image_150.jpg)

shall modify the rights of any series of Preferred Stock unless expressly provided in the amendment or resolution. Section 8. Future Increase of Authorized Shares Although the Corporation is currently authorized to issue 300,000,000 shares of Common Stock and 25,000,000 shares of Preferred Stock, nothing in this Article IV shall limit the authority of the Board of Directors, subject to stockholder approval where required by law, to amend the Articles of Incorporation at any future time to increase the number of authorized shares of either class if the Board determines such an increase to be advisable and in the best interests of the Corporation, including for purposes of enhancing liquidity, increasing public float, facilitating mergers and acquisitions, or supporting future capital - raising activities. Any such amendment may be adopted at the discretion of the Board of Directors and shall not affect the rights of any existing shares or series unless expressly provided in the amendment. ARTICLEV. BOARD OF DIRECTORS (a) Number. The number of directors, constituting the entire Board of Directors shall be fixed from time to time by vote of a majority of the entire Board of Directors, provided, however, that the number of directors shall not be reduced so as to shorten the terms of any director at any time in office. (b) Vacancies. Vacancies on the Board shall be filled by the affirmative vote of the majority of the remaining directors, though less than a quorum of the Board of Directors, or by election at an annual meeting or at a special meeting of the stockholders called for that purpose. ARTICLE VI. BY - LAWS In furtherance and not in limitation of the powers conferred by statute, the Board of Directors is expressly authorized to make, alter, amend or repeal the Bylaws of the Corporation. ARTICLE VII. AMENDMENT No amendment or restatement of this Articles of Incorporation shall be valid unless approved by holders of a majority of the voting rights of the Corporation which shall expressly include voting rights associated with the outstanding shares of Common Stock and Preferred Stock of the Corporation. ARTICLE VIII. LIABILITY To the fullest extent permitted by the Wyoming Business Corporation Act as the same exists or as may hereafter be amended, no director of the Corporation shall be personally liable to the Corporation or its stockholders for or with respect to any acts or omissions in the performance of his or her duties as a director of the Corporation. Any amendment or repeal of this Article VIII will not eliminate or reduce the effect of any right or protection of a director of the Corporation existing immediately prior to such amendment or repeal. ARTICLE IX. COMBINATIONS WITH INTERESTED STOCKHOLDERS

![](image_151.jpg)

Election Not to Be Subject to the Restrictions in WBCA 17 - 18 - 104(b) Related to Restrictions on Business Combinations. The Corporation elects not to be subject to the restrictions in WBCA 17 - 18 - 104(b). Election Not to Be Subject to the Restrictions in WBCA 17 - 18 - 105 Through 17 - 18 - 111 Related to Takeover Protection Provisions. The Corporation elects not to be subject to the restrictions in WBCA 17 - 18 - 105 through 17 - 18 - 111. ARTICLEX. SHAREHOLDER ACTION WITHOUT A MEETING Any action required or permitted by the Wyoming Business Corporation Act to be taken at a shareholders' meeting may be taken without a meeting, and without prior notice, if consents in writing setting forth the action so taken are signed by the holders of outstanding shares having not less than the minimum number of votes that would be required to authorize or take the action at a meeting at which all shares entitled to vote on the action were present and voted. The written consent shall bear the date of signature of the shareholder(s) who signs the consent and be delivered to the corporation for inclusion in the minutes or filing with the corporate records. I, THE UNDERSIGNED, being the Executive Officer of MyRxWallet North America Corporation pursuant to the Wyoming Business Corporation Act, do make this certificate, hereby declaring and certifying, under penalties of perjury, that this is my act and deed and the facts herein stated are true, and accordingly have hereunto set my hand this December 29th day of 2025. Dated: March 10, 2026 By: o ೦ r - wd Olivia Trinh, CEO

## Ex1A-2B

**Exhibit 2.2**

![](image_168.jpg)

![](image_169.jpg)

![](image_170.jpg)

Corporate Bylaws - Page 3 of 16 8. REGULAR MEETINGS . The meetings of the Board or any committee may be held at the Corporation's principal office or at any other place designated by the Board or its committee, including by means of remote communication . The annual meeting of the Board will be held without notice immediately after the adjournment of the annual meeting of shareholders . 9. SPECIAL MEETINGS . Special meetings of the Board may be held at any place and at any time and may be called by the Chairman of the Board, the President, Vice President, Secretary, or Treasurer, or at least two directors . Any special meeting of the Board must be preceded by at least forty - eight hours' notice of the date, time, place, and purpose of the meeting, unless these Bylaws require otherwise . 10. ACTION BY DIRECTORS WITHOUT A MEETING . Any action which may be taken at a meeting of the Board, or its committee, may be taken without a meeting, provided all directors or committee members unanimously agree, and such unanimous consent is filed with the minutes of the proceeding and sets forth the action taken taken by the Board . 11. NOTICE OF MEETINGS . The regular meetings of the Board shall be held without notice of the date, time, place, or purpose of the meeting, provided the meeting of the Board follows the adjournment of the annual shareholder meeting . Notice may be given personally, by facsimile, by mail, or in any other lawful manner, so long as the method for notice comports with Article 8 of these Bylaws . Oral notification is sufficient only if a written record of the notice is included in the Corporation's minute book . Notice is effective at the earliest of : a. b. Receipt; Delivery to the proper address or telephone number of the director(s) as shown in the Corporation's records; or Five days after its deposit in the United States mail, as evidenced by the postmark, if correctly addressed and mailed with first - class postage prepaid. c. 12. QUORUM . A simple majority of the Board constitutes a quorum, and a quorum is necessary at all meetings to constitute a quorum to transact business . 13. DIRECTORS, MANNER OF ACTING . The act of the majority of the Board present at a meeting at which a quorum is present when the vote is taken shall be the act of the Board unless the Articles of Incorporation require a greater percentage . 14. WAIVER OF NOTICE . A director waives the notice requirement if that director attends or participates in the meeting, unless a director attends for the express purpose of promptly objecting to the transaction of any business because the meeting was not lawfully called or convened . A director may waive notice by a signed writing, delivered to the Corporation for inclusion in the minutes before or after the meeting . 15. REGISTERING DISSENT . A director who is present at a meeting at which an action on a corporate matter is taken is presumed to have assented to such action, unless the director expressly dissents to the action . A valid dissent must be entered in the meeting's minutes, filed

![](image_171.jpg)

Corporate Bylaws - Page 4 of 16 with the meeting's acting Secretary before its adjournment, or forwarded by registered mail to the Corporation's Secretary within twenty - four (24) hours after the meeting's adjournment . These options for dissent do not apply to a director who voted in favor of the action or failed to express such dissent at the meeting . 16. EXECUTIVE AND OTHER COMMITTEES . The Board may create committees to delegate certain powers to act on behalf of the Board, provided the Board passes a resolution indicating such creation or delegation . The Board may delegate to a committee the power to appoint directors to fill vacancies on the Board . All committees must record regular minutes of their meetings and keep the minute book at the corporation's office . The creation or appointment of a committee does not relieve the Board or its members from their standard of care described in Section 2 . 03 of these Bylaws . Notwithstanding the power to create committees, no committee may be empowered to issue shares, recommend shareholder actions, nor amend these Bylaws . 17. REMUNERATION . The Board may adopt a resolution which results in directors being paid a reasonable compensation for their services rendered as directors of the Corporation . Directors may also be paid a fixed sum and expenses, if any, for attendance at each regular or special meeting of such Board . Nothing contained in these Bylaws precludes a director from receiving compensation for serving the Corporation in any other capacity, including any services rendered as an officer or employee . If the Board accordingly passes a resolution, then committee members may be allowed like compensation for attending committee meetings . A resolution of the Board that grants compensation to a director may be challenged by a shareholder, provided the shareholder requests a special shareholder meeting specifically addressing the resolution related to director compensation . Any Board resolution that relates to director compensation can be overturned by a majority vote of shareholders . 18. LOANS . The Corporation may not make loans to the directors, unless first approved by the holders of two - thirds of the voting shares . The Corporation may not make loans secured by its own shares . 19. ADVANCE EXPENSE . The Corporation shall pay for or reimburse the reasonable expenses incurred by a director who is a party to a proceeding which arises from the business operations of the Corporation . 20. INDEMNIFICATION . Provided the director complies with the standard of care described in Section 2 . 03 of these Bylaws, the Corporation shall indemnify any director made a party to a proceeding, brought or threatened, as a consequence of the director acting in their official capacity . 21. ACTION OF DIRECTORS BY COMMUNICATIONS EQUIPMENT. Any action which may be taken at a meeting of the Board, or a committee, may be taken by means of a telephone or video conference or similar communications equipment which allows all persons

![](image_172.jpg)

Corporate Bylaws - Page 5 of 16 participating in the meeting to hear each other at the same time . A director participating in a meeting by this means is deemed to be present in person at the meeting . ARTICLE 3 Shares 1. AUTHORITY TO ISSUE . The Corporation is authorized to issue any class of shares or securities convertible into shares of any class . Before any shares of the Corporation may be issued, the Board must pass a resolution which authorizes the issuance, sets the minimum consideration for the shares or security (or a formula to determine the minimum consideration), and fairly describes any non - monetary consideration . The authorized number of shares shall be as listed in the Corporation's Articles of Incorporation . 2. RESTRICTIONS . Shares may only be issued in accordance with the Corporation's Articles of Incorporation, and through the process described in these Bylaws . Any issuance of shares in excess of the amount described in the Articles of the Corporation must be authorized by the Board and approved by the affirmative vote by a majority of shareholders . Any restriction on the transferability of shares shall be fully furnished to the shareholder, upon shareholder request, and without any charge to the shareholder . No shareholder has a preemptive right to subscribe to any subsequent or additional issuance of shares . 3. SHARE CERTIFICATES . The Corporation need not provide shareholders any share certificates that certify the shares of the Corporation's shares held by the shareholder . Consequently, the Board may authorize the issuance of some or all shares of any class or series of shares without certificates, provided that the Board shall provide to a shareholder, upon that shareholder's request, a written statement that contains the information required to be on share certificates . If share certificates are issued, then each share certificate must contain on its face : a. b. c. d. The name and state of formation of the Corporation ; The name of the shareholder (or person to whom the shares are issued) ; The class of shares and the number of shares it represents ; The signature of the president, vice president, chief executive officer, chief operating officer, chief financial officer, chairman of the Board, or vice - chairman of the Board ; and The counter signature of the Secretary, assistant secretary, treasurer, assistant treasurer, or any other officer . e. For the sake of clarity, in the event that an individual serves multiple roles within the Corporation, that person cannot countersign any document which that person has already signed in their official or individual capacity . If an officer who has signed or whose facsimile signature appears on any share certificate ceases to be an officer before the certificate is issued to the

![](image_173.jpg)

Corporate Bylaws - Page 6 of 16 shareholder, it may be issued by the Corporation and is valid as if the person were an officer on the date of issuance. The certificate may be sealed with the Corporation's seal. 4. MUTILATED, LOST, OR DESTROYED CERTIFICATES. In the instance of any mutilation, loss, or destruction of any share certificate, another may be issued in its place on proof of such mutilation, loss or destruction. The Board may impose conditions on such issuance and may require the giving of a satisfactory bond or indemnity to the Corporation. The Board may establish other procedures as they deem necessary. 5. FRACTIONAL SHARES OR SCRIP. The Corporation may: a. Issue fractions of a share which entitle the holder to exercise voting rights, to receive dividends, and to participate in any of the Corporation's assets in the event of liquidation ; Arrange for the disposition of fractional interests by those entitled thereto ; Pay the fair market value, in cash, of fractions of a share as of the time when those entitled to receive such shares are determined ; or Issue scrip in a form which entitles the holder to receive a certificate for the full share upon surrender of such scrip aggregating a full share . b. c. d. 6. TRANSFER . So long as there is no transferability restriction on the shares, as described in Section 3 . 02 of these Bylaws, the shares of the Corporation are freely transferable . Transfers of shares must be made upon the corporation's share transfer books . Share transfer books shall be kept in the manner described in Article 7 of these Bylaws . Before a new certificate is issued, the old certificate must be surrendered for cancellation . The Board may, by resolution, open a share register in any state of the United States, and may employ an agent or agents to keep such register, and to record transfers or shares therein . 7. REGISTERED OWNER . The Corporation shall recognize an individual as the registered owner of given shares, provided that individual is determined as the shareholder of record by the record date as set out in Sections 4 . 08 and 4 . 09 of these Bylaws . Shareholders may agree to confer the right to vote or represent their shares to third parties, including trustees, proxies, or fiduciaries . The Board may resolve to adopt a procedure by which a shareholder of the Corporation may certify in writing to the Corporation that all or a portion of the shares registered in the shareholder's name are held for the account of a specified person or persons . The resolution must set forth : a. b. c. d. The classification of shareholders who may certify; The purpose or purposes for which the certification may be made; The form of certification and information to be contained therein; If the certification is with respect to a record date or closing of the share transfer books, the date within which the certification must be received by the Corporation; and Other provisions with respect to the procedure as are deemed necessary or desirable. e.

![](image_174.jpg)

![](image_175.jpg)

Corporate Bylaws - Page 8 of 16 b. c. d. e. f. g. h. Proof of notice of meeting (or filing of waiver); Reading of minutes of last annual meeting; Officer reports; Committee reports; Election of directors; Disclosures to Shareholders; Miscellaneous business. 4 . 04 SPECIAL MEETINGS . Special shareholder meetings, for any purpose, may be called at any time by the President, the Board, or the Secretary . The Secretary may only call a special shareholder meeting if the Secretary has received a written request from the holders of at least one - tenth of all shares entitled to vote at the meeting . 5. NOTICE . The Secretary shall cause notice to be given to each shareholder of record at least ten (10) days, but no more than sixty (60) days, before the shareholders' meeting . Notice shall be by writing, electronic transmission, or by personal delivery, and shall state the time, place, and purpose of the meeting (including instructions for how to remotely or electronically attend and participate) . Notice is considered given to a shareholder when it is personally provided to the shareholder, left at the shareholder's residence or usual place of business, mailed to the shareholder's address of record, or by electronic transmission to the shareholder's address or number of record on file with the Corporation . A single notice may be delivered to multiple shareholders sharing the same address, unless the Corporation receives a request from a shareholder that more than a single notice be delivered . Notice by electronic transmission shall be considered ineffective if the Corporation is unable to deliver two consecutive notices and the individual responsible for sending notices to shareholders is made aware of the delivery failures . A shareholder meeting, and any actions taken by shareholders, shall not be invalidated due to an inadvertent failure to deliver notice . 6. WAIVER OF NOTICE . A shareholder who is entitled to notice may waive the notice requirement if they provide a signed written waiver of the required notice, before or after the stated meeting time, or the shareholder is present at the meeting in person or by proxy . 7. ADJOURNED MEETING . If any shareholder meeting is adjourned to a different date, time, or place, notice need not be given of the new date, time, and place if the new date, time, and place is announced at the meeting before adjournment . But if the adjournment is for more than thirty (30) days or if a new record date for the adjourned meeting is, or must be fixed, then notice must be given pursuant to the requirements of Section 4 . 05 , to those persons who are shareholders as of the new record date . 8. SHAREHOLDER LIST . At least ten (10) days before each shareholder meeting, a complete record of the shareholders entitled to vote at the meeting must be made and maintained in the books and records of the Corporation . This list must be arranged by voting group (if any), in alphabetical order, and include number of shares held by and the address of each shareholder

![](image_176.jpg)

Corporate Bylaws - Page 9 of 16 and in a legible and reproducible format . This record must be kept on file at the Corporation's principal office for a period of ten (10) days prior to the meeting . The records must also be kept open for inspection at shareholder meetings . 4.09. CLOSING OF TRANSFER BOOKS & FIXING RECORD DATE. In order to determine which shareholders are entitled to notice of or to vote at any shareholder meeting, or any adjournment thereof, or entitled to receive payment of any dividend, the Board may require that the share transfer books must be closed for not more than twenty (20) days prior to the meeting . Instead of closing the share transfer books, the Board may fix in advance a record date for determination of such shareholders . The record date must not be more than seventy (70) days or less than ten (10) days prior to the date of the meeting, adjournment, or payment . 4 . 10 . SHAREHOLDER LIABILITY . Shareholders shall not be personally liable for the debts and acts of the Corporation solely due to the fact that the shareholders own shares of the Corporation . Nevertheless, shareholders are personally liable to the Corporation or its creditors for any delinquencies in payments of the agreed upon price or consideration for the shares . In the event that a subscription price or consideration for shares has not been fully paid, the following people are not personally liable for the unpaid balance : a. A transferee or assignee who acquires the shares or subscription in good faith and without knowledge or notice of the nonpayment; A person who holds the shares as a fiduciary, although the estate in the hands of the fiduciary is liable for the nonpayment; and A pledgee or other person who holds shares as security . b . c . 11. VOTING RIGHTS . Each outstanding share is entitled to one (1) vote on each matter submitted to a vote at a shareholder meeting, provided the shares are held in compliance with any payment plan, subscription, share purchase agreement, or fiduciary capacity . Agreements between or among the shareholders of the Corporation which may limit, restrict, or otherwise affect the normal governance or operations of the Corporation, directors, officers, or shareholders are permitted . For the sake of clarity and to avoid future confusion, "normal governance or operations" shall include the rights to call meetings, vote on matters, and take action on behalf of the Corporation . 12. VOTING FOR DIRECTORS . Unless otherwise provided in the Articles of Incorporation , directors are elected by a plurality of the votes cast by the shares entitled to vote in the election at a meeting at which a quorum is present . 13. PROXIES. A shareholder may vote either in person or by proxy, signed in writing by the shareholder or the shareholder's duly authorized attorney - in - fact. No proxy is valid after eleven (11) months from the date signed, unless the proxy states otherwise . A proxy is revocable by a shareholder at any time, unless the proxy states that it is irrevocable and is coupled with an interest.

![](image_177.jpg)

Corporate Bylaws - Page 10 of 16 14. QUORUM . When a majority of all outstanding shares which may vote on a given matter is present, in person or by proxy, a quorum exists for the purposes of the matter subjected to a vote . If a quorum is present at a shareholder meeting, then a majority vote of all shares comprising the quorum at the meeting is sufficient to approve or deny any matter properly brought before the meeting . 15. ACTION BY SHAREHOLDERS WITHOUT A MEETING . Any action which may be taken at any annual or special shareholder meeting may be taken without a meeting and without prior notice if one or more shareholders entitled to vote on the matter consent to the action in writing, setting forth the action so taken and at least the minimum number of votes necessary to take such action . Such consent must also be signed by all the shareholders which support such action and consent . In the event any consent to action without a shareholder meeting is submitted to the Corporation is deficient under this Section of these Bylaws, the Corporation may notify shareholders of the pending action . 16. CORPORATION'S ACCEPTANCE OF VOTES . The Corporation shall accept votes by the shareholders in the following manner : a. If the name signed on a vote, consent, waiver, or proxy appointment corresponds to the name of a shareholder, the corporation if acting in good faith is entitled to accept the vote, consent, waiver, or proxy appointment and give it effect as the act of the shareholders . If the name signed on a vote, consent, waiver, or proxy appointment does not correspond to the name of its shareholder, the corporation if acting in good faith is nevertheless entitled to accept the vote, consent, waiver, or proxy appointment and give it effect as the act of the shareholder if : b. i. the shareholder is an entity and the name signed purports to be that of an officer or agent of the entity; the name signed purports to be that of an administrator, executor, guardian, or conservator representing the shareholder and, if the corporation requests, evidence of fiduciary status acceptable to the corporation has been presented with respect to the vote, consent, waiver, or proxy appointment; the name signed purports to be that of a receiver or trustee in bankruptcy of the shareholder and, if the corporation requests, evidence of this status acceptable to the corporation has been presented with respect to the vote, consent, waiver, or proxy appointment; the name signed purports to be that of a pledgee , beneficial owner, or attorney - in - fact of the shareholder and, if the corporation requests, evidence acceptable to the corporation of the signatory's authority to sign for the shareholder has been presented with respect to the vote, consent, waiver, or proxy appointment; ii. iii. iv.

![](image_178.jpg)

Corporate Bylaws - Page 11 of 16 v. two or more persons are the shareholder as co - tenants or fiduciaries and the name signed purports to be the name of at least one of the co - owners and the person signing appears to be acting on behalf of all the co - owners. c. The corporation is entitled to reject a vote, consent, waiver, or proxy appointment if the secretary or other officer or agent authorized to tabulate votes, acting in good faith, has reasonable basis for doubt about the validity of the signature on it or about the signatory's authority to sign for the shareholder. The corporation and its officer or agent who accepts or rejects a vote, consent, waiver, or proxy appointment in good faith and in accordance with the standards of this section are not liable in damages to the shareholder for the consequences of the acceptance or rejection. Corporate action based on the acceptance or rejection of a vote, consent, waiver, or proxy appointment under this section is valid unless a court of competent jurisdiction determines otherwise. d. e. ARTICLE 5 Officers 1. DESIGNATIONS . The Corporation shall have a President, a Secretary, and a Treasurer, who will be elected by the directors at their first meeting after the annual shareholder meeting . The Corporation may also have one or more Vice - Presidents (one shall serve as Executive Vice - President) and Assistant Secretaries and Assistant Treasurers as the Board may designate . Per these Bylaws, an elected officer will hold office for one year or until a successor is elected and qualified . The same person may hold any two or more offices concurrently, except the offices of President, Vice - President, and Secretary shall be held by separate individuals . 2. APPOINTMENT AND TERM OF OFFICE . The officers of the Corporation shall be appointed by the Board for a term as determined by the Board . The designation of a specified term grants to the officer no contractual rights, and the Board can remove the officer at any time prior to the termination of such term . If no term is specified, they shall hold office until they resign, die, or until they are removed in the manner provided in Section 5 . 03 . 3. REMOVAL OF OFFICERS . Any officer or agent may be removed by the Board at any time, with or without cause . Such removal shall be without prejudice to the contract rights, if any, of the person so removed . Appointment of an officer or agent shall not of itself create contract rights . 4. THE PRESIDENT . The President shall preside over all meetings of shareholders and directors, shall have general supervision of the Corporation's affairs, and perform all other duties as are incident to the office or are properly required by a resolution passed by the Board .

![](image_179.jpg)

Corporate Bylaws - Page 12 of 16 5. VICE PRESIDENT . During the absence or disability of the President, the Executive Vice - President (if any) may exercise all functions of the President . Each Vice - President shall have such powers and fulfill such duties as may be assigned by a resolution of the Board . If there is no Vice President, then the Treasurer shall perform such duties of the President . 6. SECRETARY AND ASSISTANT SECRETARIES. The Secretary must: a. b. c. d. e. f. g. h. Issue notices for all meetings and actions of the Board or shareholders; Accept all requests for special meetings of the Board or shareholders; Accept all notices of proxy appointments and revocations; Keep the minutes of all meetings; Accept delivery of any dissent announced at any meeting of the Board or shareholders; Acknowledge and execute any share certificates; Have charge of the corporate seal and books; and Make reports and perform duties as are incident to the office, or are properly required of him or her by the Board of Directors . The Assistant Secretary , or Assistant Secretaries (in the order designated by the Board), will perform all of the duties of the Secretary during the absence or disability of the Secretary, and at other times may perform such duties as are directed by the President or the Board . 5.07 . THE TREASURER. The Treasurer shall : a. Have custody of the Corporation's monies and securities and maintain regular books of account ; Disburse the Corporation's funds in payment of the just demands against the Corporation or as may be ordered by the Board, taking proper vouchers for such disbursements ; and Provide the Board with an account of all his or her transactions as Treasurer and of the financial conditions of the office properly required of him or her by the Board . b. c. The Assistant Treasurer, or Assistant Treasurers (in the order designated by the Board), must perform all of the duties of the Treasurer in the absence or disability of the Treasurer, and at other times may perform such other duties as are directed by the President or the Board . 8. DELEGATION . In the absence or inability to act of any officer and of any person authorized to act in their place, the Board may delegate the officer ' s powers or duties to any other officer, director, or other person, subject to Section 5 . 01 of these Bylaws . Vacancies in any office arising from any cause may be filled by the Board , subject to Section 5 . 01 of these Bylaws , at any regular or special board meeting . 9. OTHER OFFICERS . The Board may appoint other officers and agents as it deems necessary or expedient . The term, powers, and duties of such officers will be determined by the Board and described in the resolution authorizing the appointment .

![](image_180.jpg)

Corporate Bylaws - Page 13 of 16 10. LOANS . No loans may be made by the Corporation to any officer, unless first approved by a two - thirds majority vote of all the outstanding the voting shares entitled to vote on the matter . 11. BONDS . The Board may resolve to require any officer to give bonds to the Corporation, with sufficient surety or sureties, conditioned upon the faithful performance of the duties of their offices and compliance with other conditions as required by the Board . 12. SALARIES . Officers' salaries will be fixed from time to time by the Board . Officers are not prevented from receiving a salary by reason of the fact that he or she is also a director of the Corporation . 13. INDEMNIFICATION . Officers shall be indemnified by the Corporation, so long as the officer acted in a manner substantially similar to and consistent with the standard of care for directors, as described in Section 2 . 03 of these Bylaws . Any officer indemnification shall be limited to proceedings that are directly related to or have arisen out of the officer's acts on behalf of the Corporation . ARTICLE 6 Capital & Finance 6 . 01 . DIVIDENDS . Dividends may be declared by the Board and paid by the Corporation out of the net earnings of the corporation unreserved and unrestricted earned surplus of the Corporation, or out of the unreserved and unrestricted net earnings of the current fiscal year, or in treasury shares of the Corporation, subject to the conditions and limitations imposed by the state of formation . The share transfer books may be closed by the Board pursuant to Sections 3 . 07 and 4 . 08 of these Bylaws . The Board, without closing the Corporation's books, may declare dividends payable only to holders of record at the close of business on any business day not more than ninety (90) days prior to the date on which the dividend is paid . 2. RESERVES . The Board may, in its absolute discretion, set aside out of the Corporation's earned net surplus, such sum or sums as it deems expedient for dividend, maintaining any corporate property, or any other purpose, before making any distribution of earned surplus . 3. DEPOSITORIES . The Corporation's monies must be deposited in the Corporation's name in a bank or trust company or trust companies designated by resolution of the Board . Corporate monies may be drawn out only by check or other order for payment signed by such persons and in such manner as may be determined by resolution of the Board . ARTICLE 7 Books and Records 1. MEETING MINUTES . As required by these Bylaws, the Corporation must keep a complete and accurate accounting and minutes of the proceedings of its shareholders and Board .

![](image_181.jpg)

Corporate Bylaws - Page 14 of 16 2. SHAREHOLDER LIST . The Corporation must keep a list of its shareholders, including the names and addresses of all shareholders and the number and class of the shares held by each at its registered office or principal place of business, or at the office of its transfer agent or registrar . 3. ACCOUNTING RECORDS. The Corporation shall maintain appropriate accounting records . 4. OTHER RECORDS . The Corporation shall keep a copy of the following records at its principal office : a. b. c. its Articles of Incorporation, as originally filed, and as currently in effect; a copy of these Bylaws currently in effect; the minutes of all shareholders' meetings, and records of all action taken by shareholders without a meeting, for the past three (3) years; all written communications within the past three (3) years to shareholders as a group; a list of the names and business addresses of its current officers and directors; its most recent annual report delivered to the relevant state authority; and all quarterly or annual financial statements (balance sheet and income statement) prepared for periods ending during the last three (3) years . d. e. f . g. 5. LEGIBILITY OF RECORDS . Any books, records, and minutes may be in written form or any other form capable of being converted into written form within a reasonable time . 6. RIGHT TO INSPECT . Any shareholder or shareholder representative has the right, upon written request delivered to the Corporation, to inspect and copy during usual business hours the following documents of the Corporation : a. b. c. d . e. These Bylaws; Minutes of the shareholder proceedings; Annual statements of affairs; Any voting trust agreements; and Any documents kept in accordance with Article 7 herein. The Corporation acknowledges and agrees that any obligation to produce corporate documents under this Article of these Bylaws shall attach to the Secretary as part of the duties described in Section 5 . 06 of these Bylaws . 7 . 07 . ENHANCED INSPECTION . Any individual or group which comprises at least five (5) percent of the outstanding shares, may submit to the Corporation a written request to inspect and copy the following documents during usual business hours : a. b. c. The books of account and share ledger of the Corporation; The statement of affairs for the Corporation; and The list of shareholders .

![](image_182.jpg)

Corporate Bylaws - Page 15 of 16 ARTICLE 8 Notices 1. MAILING OF NOTICE . Except as may otherwise be required by law, any notice to any shareholder or director may be delivered personally or by mail . If mailed, the notice will be deemed to have been delivered on the close of business of the fifth business day following the day when deposited in the United States mail with postage prepaid and addressed to the recipient's last known address in the records of the Corporation . 2. E - NOTICE PERMITTED . Any communications required by these Bylaws, or any other laws, may be made by digital or electronic transmission to the recipient's known electronic address or number as known to the Corporation at the time of notice . 3. DUTY TO NOTIFY . All shareholders, directors, officers, employees, and representatives of the Corporation are required to notify the Corporation of any changes to the individual's contact information . Pursuant to the obligations under this Section of these Bylaws, the individual must notify the Corporation that electronic transmissions of notice are impracticable, impossible, frustrated, or otherwise improper and ineffective . ARTICLE 9 Special Corporate Acts 1. EXECUTION OF WRITTEN INSTRUMENTS . All contracts, deeds, documents, and instruments that acquire, transfer, exchange, sell, or dispose of any assets of the Corporation must be executed by the President to bind the Corporation . This Section does not apply to any checks, money orders, notes, or other financial instruments for direct payment of corporate funds which are subject to Section 9 . 02 of these Bylaws . 2. SIGNING OF CHECKS OR NOTES . All authorizations to distribute, pay, or immediately draw upon the financial resources of the Corporation must be signed by the Treasurer, including any expense reimbursement or compensation payments to directors, officers, employees, representatives, service providers, or contractors of the Company . 3. SPECIAL SIGNING POWERS . To duly bind the Corporation to an agreement or instrument in the event the President holds an interest which exists outside of the capacity of being President, then any agreement involving such interest must be signed by an officer pursuant to either Section 5 . 05 or 9 . 02 of these Bylaws . 4. SHAREHOLDER APPROVAL . Shareholder approval is required prior to any merger, consolidation, share - exchange, conversion, or dissolution, and any loans provided under Sections 2 . 18 or 5 . 10 of these Bylaws . In the event of any dissent by shareholders, the Corporation must comply with Section 9 . 05 of these Bylaws .

![](image_183.jpg)

## Ex1A-4

**Exhibit 4.1**

**MYRXWALLET NORTH AMERICA CORPORATION**

**SUBSCRIPTION AGREEMENT**

*Regulation A Tier 2 Offering*

 

This Subscription Agreement (this "Agreement") is entered into as of the date set forth on the signature page hereof, by and between MyRXWallet North America Corporation, a Wyoming corporation (the "Company"), and the undersigned subscriber ("Subscriber").

**RECITALS**

The Company is offering up to 882,127 shares of its common stock, par value $0.0001 per share (the "Shares"), at a price of $85.00 per share (the "Offering Price"), for maximum gross proceeds of up to $74,980,795 (the "Offering"), pursuant to an Offering Statement on Form 1-A (File No. [●]) qualified by the United States Securities and Exchange Commission (the "SEC") under Regulation A of the Securities Act of 1933, as amended (the "Securities Act"), and the Offering Circular forming Part II thereof, dated June [●], 2026, as the same may be amended or supplemented from time to time (the "Offering Circular").

**AGREEMENT**

In consideration of the mutual covenants and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

**1. SUBSCRIPTION**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1 <u>Subscription for Shares</u>. Subject to the terms and conditions of this Agreement, Subscriber hereby irrevocably subscribes for and agrees to purchase the number of Shares set forth on the signature page hereof at the Offering Price of $85.00 per Share, for the aggregate purchase price set forth on the signature page hereof (the "Subscription Amount"). The minimum investment amount is $500 (approximately 5 Shares), unless waived by the Company in its sole discretion.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2 <u>Payment</u>. Subscriber shall deliver to the Company the Subscription Amount in immediately available funds by wire transfer, ACH, or such other method as designated by the Company, in accordance with the payment instructions set forth on the signature page hereof or as separately provided by the Company. Funds will be available to the Company immediately upon deposit into the Company's bank account. There is no escrow arrangement; funds are not held in trust for the benefit of subscribers.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.3 <u>No Minimum Offering</u>. There is no minimum number of Shares required to be sold and no minimum aggregate offering amount required to be raised. The Company may accept subscriptions and deploy funds at any time following acceptance of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.4 <u>Acceptance or Rejection</u>. The Company reserves the right to accept or reject this subscription, in whole or in part, in its sole and absolute discretion, for any reason or for no reason. The Company's acceptance or rejection of this subscription will typically occur within 10 to 15 business days of receipt of this Agreement and the Subscription Amount. If rejected, the Company will promptly return all funds to Subscriber, without interest or deduction. Upon acceptance, the Company will countersign this Agreement and cause the Shares to be issued to Subscriber in book-entry form through the Company's transfer agent, Colonial Stock Transfer Co., Inc.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.5 <u>Irrevocability</u>. Once submitted by Subscriber and accepted by the Company, this subscription is irrevocable. Subscriber may not revoke, cancel, or modify this subscription or request the return of the Subscription Amount after acceptance.

**2. REPRESENTATIONS AND WARRANTIES OF SUBSCRIBER**

Subscriber hereby represents and warrants to the Company as follows, as of the date of this Agreement and as of the date of acceptance:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1 <u>Legal Capacity</u>. Subscriber has full legal capacity, power, and authority to execute and deliver this Agreement and to perform Subscriber's obligations hereunder. If Subscriber is an entity, this Agreement has been duly authorized, executed, and delivered and constitutes a valid and binding obligation of Subscriber, enforceable against Subscriber in accordance with its terms.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2 <u>Investment Limitations — Non-Accredited Natural Persons</u>. If Subscriber is a natural person who is not an "accredited investor" as defined in Rule 501(a) of Regulation D under the Securities Act, Subscriber represents and warrants that the aggregate purchase price paid by Subscriber for Shares in this Offering does not exceed 10% of the greater of Subscriber's annual income or net worth (as calculated in accordance with Rule 251(d)(2)(i)(C) of Regulation A). For purposes of this calculation, "net worth" means the difference between total assets and total liabilities, excluding the value of Subscriber's primary residence and, to the extent applicable, any indebtedness secured by Subscriber's primary residence up to the value of such residence.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3 <u>Investment Limitations — Non-Accredited Non-Natural Persons</u>. If Subscriber is an entity that is not an "accredited investor," Subscriber represents and warrants that the aggregate purchase price paid by Subscriber for Shares in this Offering does not exceed 10% of the greater of Subscriber's annual revenue or net assets as of its most recently completed fiscal year end.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.4 <u>Accredited Investor Status</u>. If Subscriber is an "accredited investor" as defined in Rule 501(a) of Regulation D under the Securities Act, Subscriber so indicates on the signature page hereof and represents and warrants that Subscriber satisfies at least one of the criteria for accredited investor status set forth in the Offering Circular under "*Plan of Distribution — Investment Limitations*."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.5 <u>Review of Offering Circular</u>. Subscriber has received, carefully read, and understands the Offering Circular in its entirety, including without limitation the "*Risk Factors*" section beginning on page 5 of the Offering Circular, the "*Dilution*" section, and the "*Use of Proceeds*" section. Subscriber has had the opportunity to ask questions of, and receive answers from, the Company and its management concerning the terms and conditions of this Offering and to obtain any additional information that Subscriber deemed necessary.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.6 <u>Investment Risk</u>. Subscriber understands that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) an investment in the Shares is speculative and involves a high degree of risk, including the risk of a complete loss of Subscriber's investment;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) the Company is a development-stage enterprise with a limited operating history, no revenues as of the date of the Offering Circular, and substantial doubt about its ability to continue as a going concern;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) there is currently no public trading market for the Shares, and there is no assurance that any market will develop or that Subscriber will be able to sell the Shares;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) the Shares are subject to immediate and substantial dilution, estimated at approximately $84.70 per Share, or 99.65% of the Offering Price, based on the pro forma net tangible book value per share after the Offering;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) the Company has incurred approximately $1,147,500,000 in demand promissory note obligations to entities controlled by its Chief Executive Officer, which may be converted into common stock or satisfied through stock-based interest payments, resulting in substantial ongoing dilution;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) the Company's Chief Executive Officer beneficially owns a majority of the Company's voting stock and controls all stockholder matters; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) all subscriptions once accepted are irrevocable and Subscriber must be prepared to hold the Shares indefinitely.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.7 <u>No Reliance</u>. Subscriber has not relied upon any representations, warranties, or statements made by any person other than those expressly set forth in the Offering Circular. No independent legal, accounting, or business advisors have been appointed to represent Subscriber's interests in connection with this Offering.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.8 <u>No Solicitation</u>. Subscriber was not solicited to invest through any form of general solicitation or general advertising other than the Offering Circular and materials filed with the SEC as part of the Offering Statement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.9 <u>Residence / Principal Office</u>. Subscriber is a resident of, or has its principal place of business in, a jurisdiction listed in Item 5 of Part I of the Offering Statement in which the Company has indicated it intends to offer the Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.10 <u>No Undisclosed Information</u>. Subscriber is not aware of any material information regarding the Company that has not been publicly disclosed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.11 <u>Tax Matters</u>. Subscriber acknowledges that neither the Company nor any of its agents has made any representation regarding the U.S. federal, state, local, or foreign tax consequences to Subscriber of purchasing, holding, or disposing of the Shares, and Subscriber has consulted its own tax advisors regarding such matters.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.12 <u>Anti-Money Laundering</u>. The funds used to purchase the Shares are not derived from any illegal activity. Subscriber is not a "Specially Designated National" or "Blocked Person" identified by the U.S. Office of Foreign Assets Control, and the purchase of Shares by Subscriber does not violate any applicable anti-money laundering, anti-terrorism, or economic sanctions laws.

**3. REPRESENTATIONS AND WARRANTIES OF THE COMPANY**

The Company hereby represents and warrants to Subscriber as follows, as of the date of acceptance of this Agreement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1 <u>Organization</u>. The Company is a corporation duly organized, validly existing, and in good standing under the laws of the State of Wyoming.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2 <u>Authorization</u>. The execution, delivery, and performance of this Agreement by the Company have been duly authorized by all necessary corporate action. This Agreement constitutes the valid and binding obligation of the Company, enforceable against the Company in accordance with its terms.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.3 <u>Valid Issuance</u>. The Shares, when issued in accordance with this Agreement, will be duly and validly authorized, issued, fully paid, and non-assessable, free and clear of any liens or encumbrances other than restrictions on transfer under applicable federal and state securities laws.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.4 <u>Offering Circular</u>. The Offering Circular, as of its qualification date and as of the date of this Agreement, does not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.

**4. RESTRICTIONS ON TRANSFER**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1 <u>Securities Laws</u>. The Shares have been registered under the Securities Act by virtue of the qualification of the Offering Statement pursuant to Regulation A. Notwithstanding the foregoing, the Shares may be subject to restrictions on resale under applicable state securities laws and under such circumstances as the Company determines appropriate, and Subscriber agrees to comply with all applicable securities laws in connection with any resale of the Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2 <u>No Registration Rights</u>. Subscriber has no right to require the Company to register the Shares for resale under the Securities Act or any state securities law.

**5. USE OF PROCEEDS**

Subscriber acknowledges that the Company intends to use the net proceeds of this Offering as described in the "*Use of Proceeds*" section of the Offering Circular, including allocation of approximately 70% of net proceeds toward strategic mergers and acquisitions, approximately 10% toward EHR platform development, approximately 10% toward working capital, approximately 5% toward legal, accounting, and regulatory costs, and approximately 5% toward land acquisition deposits and closing costs. Subscriber further acknowledges that the Company retains broad discretion over the allocation of proceeds within these categories, that there is no minimum offering amount, and that proceeds raised may be less than the maximum amount and may be insufficient to implement the Company's full business plan.

**6. NO ESCROW; NO RETURN OF FUNDS**

Subscriber understands and acknowledges that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) there is no escrow, trust, or similar arrangement for the proceeds of this Offering;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) upon acceptance of this subscription, all funds will be deposited into the Company's operating bank account and will be immediately available to the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) there is no minimum offering amount and no provision for the return of funds if less than a specified amount is raised; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) if this subscription is rejected, in whole or in part, only the rejected portion of the funds will be returned to Subscriber.

**7. MISCELLANEOUS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.1 <u>Entire Agreement</u>. This Agreement, together with the Offering Circular, constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements, representations, warranties, and understandings of the parties with respect thereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.2 <u>Amendments</u>. This Agreement may not be amended, modified, or waived except by a written instrument signed by both parties; provided, however, that the Company may amend or supplement the Offering Circular in accordance with applicable law, and any such amendment or supplement shall be incorporated herein by reference.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.3 <u>Severability</u>. If any provision of this Agreement is held to be invalid or unenforceable, such provision shall be modified to the minimum extent necessary to make it valid and enforceable, and the remaining provisions shall continue in full force and effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.4 <u>Governing Law</u>. This Agreement shall be governed by and construed in accordance with the laws of the State of Wyoming, without regard to conflict of law principles.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.5 <u>Jurisdiction</u>. Each party hereby irrevocably consents to the exclusive jurisdiction of the state and federal courts located in Clark County, Nevada, for the resolution of any dispute arising out of or relating to this Agreement, and waives any objection to the laying of venue in such courts.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.6 <u>Counterparts; Electronic Signatures</u>. This Agreement may be executed in counterparts, each of which shall be deemed an original and all of which together shall constitute one and the same instrument. Electronic signatures shall be deemed valid and binding to the same extent as original signatures.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.7 <u>Notices</u>. All notices required or permitted under this Agreement shall be in writing and delivered to the Company at 732 S. 6th Street, #5397, Las Vegas, Nevada 89101, Attention: Chief Executive Officer, or by email to olivia@myrxwallet.io, and to Subscriber at the address set forth on the signature page hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.8 <u>Headings</u>. Section headings are for convenience only and shall not affect the interpretation of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.9 <u>No Waiver</u>. Failure by either party to exercise any right or remedy under this Agreement shall not constitute a waiver of such right or remedy.

[*Signature Page to Follow*]

**SIGNATURE PAGE**

**SUBSCRIBER INFORMATION**

---

| | |
|:---|:---|
| Full Legal Name of Subscriber: | ______________________________________________ |
| Entity Type (if applicable): | ☐ Individual ☐ Joint Tenants ☐ Corporation ☐ LLC ☐ Trust ☐ Other: ____________ |
| Address: | ______________________________________________ |
| City, State, Zip: | ______________________________________________ |
| Country of Residence / Principal Office: | ______________________________________________ |
| Email Address: | ______________________________________________ |
| Phone Number: | ______________________________________________ |
| Social Security No. / EIN: | ______________________________________________ |
| Number of Shares Subscribed: | ______________________________________________ |
| Aggregate Subscription Amount ($85.00 × Shares): | $_____________________________________________ |
| Date: | ______________________________________________ |

---

------

**ACCREDITED INVESTOR STATUS (Check if applicable)**

☐ Subscriber is an "accredited investor" as defined in Rule 501(a) of Regulation D under the Securities Act.

*(If checked, please indicate the basis for accredited investor status):*

 

☐ Natural person with individual net worth, or joint net worth with spouse or spousal equivalent, exceeding $1,000,000, excluding primary residence.

☐ Natural person with individual income exceeding $200,000 in each of the two most recent calendar years (or joint income with spouse or spousal equivalent exceeding $300,000), with reasonable expectation of the same for the current year.

☐ Entity with total assets exceeding $5,000,000 not formed for the specific purpose of acquiring the securities offered.

☐ Bank, savings institution, registered investment company, business development company, or small business investment company.

☐ Registered broker-dealer, investment adviser, or exempt reporting adviser.

☐ Natural person holding a Series 7, Series 65, or Series 82 license in good standing.

☐ Other (describe): ___________________________________________________________

**INVESTMENT LIMITATION CERTIFICATION(Complete if NOT an accredited investor)**

I certify that the aggregate purchase price I am paying for Shares in this Offering does not exceed 10% of the greater of my annual income or net worth (for a natural person) or 10% of the greater of my annual revenue or net assets (for an entity), calculated in accordance with Rule 251(d)(2) of Regulation A.

**PAYMENT INSTRUCTIONS**

Payment shall be made by [wire transfer / ACH / check] as directed by the Company. Please contact the Company at olivia@myrxwallet.io or (702) 546-8686 for current payment instructions.

**SUBSCRIBER SIGNATURE**

---

| | |
|:---|:---|
| Signature: | ______________________________________________ |
| Print Name: | ______________________________________________ |
| Title (if entity): | ______________________________________________ |
| Date: | ______________________________________________ |

---

 

*If joint subscription, both subscribers must sign:*

---

| | |
|:---|:---|
| Co-Subscriber Signature: | ______________________________________________ |
| Print Name: | ______________________________________________ |
| Date: | ______________________________________________ |

---

**ACCEPTANCE BY THE COMPANY**

The Company hereby accepts the foregoing subscription for __________ Shares of common stock at $85.00 per Share.

**MyRXWallet North America Corporation**

---

| | |
|:---|:---|
| By: | ______________________________________________ |
| Name: | Olivia Trinh |
| Title: | Chairman, Chief Executive Officer, and Interim Chief Financial Officer |
| Date of Acceptance: | ______________________________________________ |

---

------

*This Subscription Agreement is part of the Offering Statement on Form 1-A filed with the United States Securities and Exchange Commission. Prospective investors should read the entire Offering Circular carefully before making an investment decision. Investment in the Shares involves a high degree of risk. See "Risk Factors" beginning on page 5 of the Offering Circular.*

 

*NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ADEQUACY OR ACCURACY OF THE OFFERING CIRCULAR. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.*

## Ex1A-6

**Exhibit 6.1**

**AMENDED PROMISSORY NOTE**

**OF**

**Z THE FUTURE, LLC**

**Principal Amount:** $297,500,000.00

**Repurchase Price:** $85 per share of common stock

**Conversion Price:** $125/share

**Annual Interest Rate: 7.5%**

**Annual Interest Amount:** $22,312,500.00

**Quarterly Interest Payment Term:** $11,156,250.00 (cash or equity)

**Total Interest Due Per Agreement:** $44,625,000.00

**Total Amount Due at Maturity:** $342,125,000.00

**Shares Issuable Upon Full Conversion:** 2,737,000 per share of common stock

**Date: February 4, 2026**

FOR VALUE RECEIVED, MyRxWallet North America Corporation (the "Borrower") hereby unconditionally promises to pay to the order of Z the Future, LLC a Wyoming Corporation (the "Noteholder") the principal amount of $297,500,000.00 (the "Loan"), together with all accrued interest thereon, as provided in this Promissory Note (this "Note").

1. Payment Dates and Maturity

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Payment Date: The aggregate unpaid principal amount of the Loan, all accrued and unpaid interest, and all other amounts payable under this Note shall be due and payable on demand from the Noteholder. The Noteholder may demand payment at any time within twenty-four (24) months from the date of this Note. If the Noteholder does not exercise its redemption rights within this period, this Agreement shall automatically renew for an additional twenty-four (24) months on the same terms and conditions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Prepayment: The Borrower may prepay the Loan in whole or in part at any time or from time to time without penalty or premium by paying the principal amount to be prepaid together with accrued interest thereon to the date of the prepayment.

2. Interest

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Interest Rate: The principal amount outstanding under this Note from time to time shall bear interest at a rate per annum (the "Interest Rate") equal to seven and one-half percent (7.5%).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Interest Payment Dates: Interest shall be payable quarterly, in arrears, in the form of fully paid and non-assessable shares of the Borrower's common stock, unless otherwise agreed by the parties.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Default Interest: If any amount payable hereunder is not paid when due (without regard to any applicable grace period), whether at stated maturity, by acceleration, or otherwise, such overdue amount shall bear interest at the Interest Rate plus two percent (2%) (the "Default Rate").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Computation of Interest: All computations of interest hereunder shall be made on the basis of a year of 365/366 days, as the case may be, and the actual number of days elapsed. Interest shall begin to accrue on the Loan on the date of this Note. For any portion of the Loan that is repaid, interest shall not accrue on the date on which such payment is made.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) Interest Rate Limitation: If at any time the Interest Rate payable on the Loan shall exceed the maximum rate of interest permitted under applicable law, such Interest Rate shall be reduced automatically to the maximum rate permitted.

3. Interest and Redemption Provisions

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A. Accrual of Unpaid Amounts: Any unpaid principal, interest, or Interests shall accrue and compound until paid in full.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B. Interest Priority: The Borrower shall pay all accumulated Interests on this Note before declaring or paying any Interests on its common stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;C. Redemption/Liquidation Priority: All accrued Interests must be paid in full prior to any redemption or liquidation of the Note.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;D. Ongoing Interests: Interests shall continue to accrue and be payable until the Note is fully redeemed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E. Payment Frequency: Interests and interest shall be paid quarterly, unless otherwise agreed in writing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;F. Payment Form: Payments may be made, at the Noteholder's election, in cash or in fully paid and non-assessable shares of the Borrower's common stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;G. Compliance: All terms and payments under this Note shall comply with applicable federal and state securities laws, SEC regulations, PCAOB standards, and any other relevant regulatory requirements.

4. Conversion Option

**Conversion at Noteholder's Election:**

At any time while any portion of the principal or accrued interest under this Note remains outstanding, the Noteholder may, at their sole discretion, elect to convert all or any part of the unpaid principal and accrued interest into fully paid and non-assessable shares of the Borrower's common stock (the "Conversion Shares"). Such conversion shall be effected by delivering written notice to the Borrower specifying the amount to be converted and the date of conversion.

**Conversion Price:**

The "Conversion Price" shall be $125.00 per share of the Borrower's common stock, as adjusted for stock splits, stock combinations, recapitalizations, and similar transactions affecting the common stock. The number of shares issuable upon conversion shall equal the aggregate principal and accrued but unpaid interest (or other amounts then outstanding and elected to be converted) divided by the Conversion Price. No fractional shares shall be issued; any fractional share shall be rounded down to the nearest whole share or settled in cash in lieu thereof.

**Conversion Price:**

The "Conversion Price" shall be $125.00 per share of the Borrower's common stock, as adjusted for stock splits, stock combinations, recapitalizations, and similar transactions affecting the common stock. The number of shares issuable upon conversion shall equal the aggregate principal and accrued but unpaid interest (or other amounts then outstanding and elected to be converted) divided by the Conversion Price. No fractional shares shall be issued; any fractional share shall be rounded down to the nearest whole share or settled in cash in lieu thereof.

**MyRxWallet Anti-Dilution Capped Call Agreement**

**Noteholder:** Z the Future LLC ("Affiliate Counterparty")

**Purpose:** To economically offset dilution arising from the conversion of the Senior Convertible Promissory Notes.

**Notional Amount:** Equal to the number of shares underlying the $297,500,000.00 Notes.

**Strike Price:** $125.00 per share

**Cap Price:** $200.00 per share

**Term:** Matches maturity of the Notes.

**Settlement:** Cash settlement; share settlement; or delivery of treasury shares; or delivery of issuer-sponsored tokenized shares of the same class recorded on the Borrower's master securityholder file. Any tokenized settlement shall be treated as delivery of the underlying shares and effected in compliance with applicable federal and state securities laws.

**Effect:** Issuer receives value if the stock price exceeds the cap price, offsetting dilution.

**Accounting: Treated as an intercompany equity hedge; no derivative liability expected. Partial Conversion and Payment:**

The Noteholder may elect to receive payment of any portion of the outstanding principal and accrued interest in cash, and convert the remaining balance into Conversion Shares, at their discretion.

**Mechanics and Adjustments:**

The Borrower shall deliver the Conversion Shares to the Noteholder within five (5) business days of receipt of the conversion notice. If the Borrower's common stock is not listed or quoted on a trading market at the time of conversion, the conversion price shall be determined by mutual agreement between the Borrower and the Noteholder, or, failing such agreement, by an independent third-party valuation.

**Fractional Shares:**

No fractional shares shall be issued upon conversion. Any fractional share shall be rounded up to the nearest whole share.

**Reservation of Shares:**

The Borrower shall at all times reserve and keep available out of its authorized but unissued shares of common stock, solely for the purpose of effecting conversions under this Note, such number of shares as shall be sufficient to effect the conversion of the entire outstanding principal and accrued interest under this Note.

5. Anti-Dilution Protection; Capped Call Agreement"

To mitigate potential dilution resulting from conversions of this Note, the Borrower and certain of its affiliated entities may enter into one or more capped call or similar anti-dilution hedge transactions (each, a "Capped Call Agreement"). Any such Capped Call Agreement shall be entered into for the sole purpose of economically offsetting the dilutive effect of the issuance of shares of the Borrower's common stock upon conversion of this Note.

The principal economic terms of the Capped Call Agreement are expected to include:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· **Notional Amount:** Equal to the number of shares underlying this Note.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· **Strike Price:** USD $125.00 per share.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· **Cap Price:** USD $200.00 per share (subject to adjustment by the Borrower).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· **Term:** To match the maturity of this Note.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· **Settlement:** Cash settlement, share settlement, or settlement in treasury shares.

· **Purpose and Effect:** The Capped Call Agreement is intended to reduce or eliminate dilution upon
 conversion of this Note and to provide economic value to the Borrower if the market price of its common
 stock exceeds the applicable cap price.

· **Accounting Treatment:** Expected to be accounted for as an intercompany equity hedge without recognition
 of derivative liability under applicable accounting standards.

No rights are conferred upon the Noteholder by the existence, terms, or performance of any Capped Call Agreement, and the entry into, amendment of, or termination of any Capped Call Agreement shall not be deemed to modify the terms of this Note or the Conversion Option.

6. Events of Default

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Failure to Pay: The Borrower fails to pay (i) any principal amount of the Loan when due; (ii) any interest on the Loan within two (2) Business Days after the date such amount is due; or (iii) any other amount due hereunder within two (2) Business Days after such amount is due.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Bankruptcy; Insolvency: (i) The Borrower institutes a voluntary case seeking relief under any law relating to bankruptcy, insolvency, reorganization, or other relief for debtors. (ii) An involuntary case is commenced seeking the liquidation or reorganization of the Borrower under any law relating to bankruptcy or insolvency, and such case is not dismissed or vacated within sixty (60) days of its filing. (iii) The Borrower makes a general assignment for the benefit of its creditors. (iv) The Borrower is unable, or admits in writing its inability, to pay its debts as they become due. (v) A case is commenced against the Borrower or its assets seeking attachment, execution, or similar process against all or a substantial part of its assets, and such case is not dismissed or vacated within sixty (60) days of its filing.

7. Remedies

Upon the occurrence and during the continuance of an Event of Default, the Noteholder may, at its option, by written notice to the Borrower declare the outstanding principal amount of the Loan, accrued and unpaid interest thereon, and all other amounts payable hereunder immediately due and payable; provided, however, if an Event of Default described in Section 5(b)(i), 5(b)(iii) or 5(b)(iv) shall occur, the outstanding principal amount, accrued and unpaid interest, and all other amounts payable hereunder shall become immediately due and payable without notice, declaration, or other act on the part of the Noteholder.

8. Expenses

The Borrower shall reimburse the Noteholder on demand for all reasonable and documented out-of-pocket costs, expenses, and fees, including the reasonable fees and expenses of counsel, incurred by the Noteholder in connection with the negotiation, documentation, and execution of this Note and the enforcement of the Noteholder's rights hereunder.

9. Notices

All notices and other communications relating to this Note shall be in writing and shall be deemed given upon the first to occur of (x) deposit with the United States Postal Service or overnight courier service, properly addressed and postage prepaid; (y) transmittal by electronic communication (including email, internet or intranet websites, or facsimile properly addressed (with written acknowledgment from the intended recipient such as "return receipt requested" function, return e-mail, or other written acknowledgment)); or (z) actual receipt by an employee or agent of the other party. Notices hereunder shall be sent to the following addresses, or to such other address as such party may specify in writing from time to time:

&nbsp;&nbsp;&nbsp;&nbsp;(a) If to the Borrower:

MyRxWallet North America Corporation

Name: Binh Do

Title: President & CFO

Address: 2475 South Jones Blvd., Suite 9,

Las Vegas, Nevada 89146

Email: binh@myrxwallet.app

&nbsp;&nbsp;&nbsp;&nbsp;(b) If to the Noteholder:

Name: Olivia Trinh

Title: CEO

Z the Future, LLC

30 N Gould St #13001

Sheridan, WY 82801 USA

Email: olivia@myrxwallet.io

10. Governing Law

This Note and any claim, controversy, dispute, or cause of action (whether in contract, tort, or otherwise) based on, arising out of, or relating to this Note and the transactions contemplated hereby shall be governed by and construed in accordance with the laws of the State of Wyoming.

&nbsp;&nbsp;&nbsp;&nbsp;11. Disputes

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Submission to Jurisdiction: (i) The Borrower irrevocably and unconditionally (A) agrees that any action, suit, or proceeding arising from or relating to this Note may be brought in the courts of the State of Wyoming, and in the United States District Court for the District of Wyoming, and (B) submits to the exclusive jurisdiction of such courts in any such action, suit, or proceeding. Final judgment against the Borrower in any such action, suit, or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. (ii) Nothing in this Section 10(a) shall affect the right of the Noteholder to bring any action, suit, or proceeding relating to this Note against the Borrower or its properties in the courts of any other jurisdiction. (iii) Nothing in this Section 10(a) shall effect the right of the Noteholder to serve process upon the Borrower in any manner authorized by the laws of any such jurisdiction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Venue: The Borrower irrevocably and unconditionally waives, to the fullest extent permitted by law, (i) any objection that it may now or hereafter have to the laying of venue in any action, suit, or proceeding relating to this Note in any court referred to in Section 10(a) and (ii) the defense of inconvenient forum to the maintenance of such action, suit, or proceeding in any such court.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Waiver of Jury Trial: THE BORROWER HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY RELATING TO THIS NOTE OR THE TRANSACTIONS CONTEMPLATED HEREBY, WHETHER BASED ON CONTRACT, TORT, OR ANY OTHER THEORY.

&nbsp;&nbsp;&nbsp;&nbsp;12. Successors and Assigns

This Note may be assigned or transferred by the Noteholder to any individual, corporation, company, limited liability company, trust, joint venture, association, partnership, unincorporated organization, governmental authority, or other entity.

&nbsp;&nbsp;&nbsp;&nbsp;13. Integration

This Note constitutes the entire contract between the Borrower and the Noteholder with respect to the subject matter hereof and supersedes all previous agreements and understandings, oral or written, with respect thereto.

&nbsp;&nbsp;&nbsp;&nbsp;14. Amendments and Waivers

No term of this Note may be waived, modified, or amended, except by an instrument in writing signed by the Borrower and the Noteholder. Any waiver of the terms hereof shall be effective only in the specific instance and for the specific purpose given.

&nbsp;&nbsp;&nbsp;&nbsp;15. No Waiver; Cumulative Remedies

No failure by the Noteholder to exercise and no delay in exercising any right, remedy, or power hereunder shall operate as a waiver thereof; nor shall any single or partial exercise of any right, remedy, or power hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, or power. The rights, remedies, and powers herein provided are cumulative and not exclusive of any other rights, remedies, or powers provided by law.

&nbsp;&nbsp;&nbsp;&nbsp;16. Severability

If any term or provision of this Note is invalid, illegal, or unenforceable in any jurisdiction, such invalidity, illegality, or unenforceability shall not affect any other term or provision of this Note or render such term or provision invalid or unenforceable in any other jurisdiction.

&nbsp;&nbsp;&nbsp;&nbsp;17. Counterparts

This Note and any amendments, waivers, consents, or supplements hereto may be executed in counterparts, each of which shall constitute an original, but all of which taken together shall constitute a single contract. Delivery of an executed counterpart of a signature page to this Note by facsimile or in electronic ("pdf" or "tif" or any other electronic means that reproduces an image of the actual executed signature page) format shall be as effective as delivery of a manually executed counterpart of this Note.

&nbsp;&nbsp;&nbsp;&nbsp;18. Electronic Execution

The words "execution," "signed," "signature," and words of similar import in this Note shall be deemed to include electronic and digital signatures and the keeping of records in electronic form, each of which shall be of the same effect, validity, and enforceability as manually executed signatures and paper-based recordkeeping systems, to the extent and as provided for under applicable law, including the Electronic Signatures in Global and National Commerce Act (15 U.S.C. §§ 7001-7031), the Uniform Electronic Transactions Act (UETA), or any state law based on the UETA, including the Wyoming Electronic Signatures and Records Act (WY. State Tech. §§ 301 to 309).

**IN WITNESS WHEREOF,** each of the parties has executed this Promissory Note Agreement as of the day and year first above written.

/ Signature page follow /

---

| | |
|:---|:---|
| Dated: February 4, 2026 | Dated: February 4, 2026 |
| Borrower (Issuer / Maker) | Lender (Noteholder) |
| By: <u>/s/ Binh Do</u> | By: <u>/s/ Olivia Trinh</u> |
| Binh Do, President and CFO | Olivia Trinh, Managing Director |
| MyRxWallet North America Corp. | Z the Future, LLC |

---

## Ex1A-6

**Exhibit 6.2**

**COMMON STOCK REPURCHASE AGREEMENT**

**OF**

**Z THE FUTURE, LLC**

**Principal Amount:** $297,500,000.00

**Repurchase Price:** $85 per common stock

**Conversion Price:** $125/share

**Annual Interest Rate: 7.5%**

**Annual Interest Amount:** $22,312,500.00

**Interest Payment Term:** Quarterly payments of $11,156,250.00 (cash or equity)

**Total Interest Due Per Agreement:** $44,625,000.00

**Total Amount Due at Maturity:** $342,125,000.00

**Shares Issuable Upon Full Conversion:** 2,737,000 per common stock

THIS STOCK REPURCHASE AGREEMENT (this "Agreement") is made and entered into as of January 3, 2026, by and between MyRxWallet North America Corporation, Inc., a Wyoming corporation (the "Company"), and Z the Future, LLC (the "Stockholder").

**RECITALS**

**WHEREAS,** apart from the Stockholder's other shareholdings of shares of the Company's common stock, the Stockholder is the holder of 73,500,000 shares (the "Shares") of the Company's common stock, par value $0.0001 per share (the "Common Stock"), which the Stockholder purchased from the Company pursuant to that certain Stock Purchase Agreement dated as of October 30, 2024 between the Company and the Stockholder.

**WHEREAS,** the Stockholder desires to sell, and the Company desires to repurchase the Shares, on the terms and subject to the conditions set forth in this Agreement (the "Repurchase").

**WHEREAS,** the Board of Directors of the Company has authorized the Share Repurchase; and

**WHEREAS,** it is the intention of the Parties that the Share Repurchase be a private sale of securities that is exempt from the registration and prospectus delivery requirements of the Securities Act of 1933, as amended.

**NOW, THEREFORE, IN CONSIDERATION** of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and the Stockholder agree as follows:

**<u>SECTION 1</u>**

**REPURCHASE OF SHARES**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.1 Repurchase.** At the Closing (as defined below), MyRxWallet North America Corporation, Inc. (the "Company") hereby agrees to repurchase from Z the Future, LLC (the "Stockholder"), and the Stockholder hereby agrees to sell, assign and transfer to the Company, the Stockholder's right, title and interest in and to 3,500,000 Shares, at a price per Share $85.00, with an aggregate amount of $297,500,000.00, and the Company shall issue to the Stockholder a promissory note in the principal amount equal to the Purchase Price, substantially in the form attached hereto as Exhibit A (the "Note"), and subject to terms and conditions therein.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.2 Closing.** The closing of the Repurchase (the "Closing") shall take place at the offices of the Company at 2475 South Jones Blvd., Suite 9, Las Vegas, Nevada, 89146, or remotely by exchange of documents and signatures (or their electronic counterparts), at such date, time and place as the Company and the Stockholder shall mutually agree.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.2.1 At the Closing:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (a) The Company shall deliver to the Stockholder the Note evidencing the Purchase Price; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Stockholder shall deliver to the Company an executed stock power with or without a medallion signature guarantee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.3 Termination of Rights as the Stockholder.** At the Closing and upon delivery of the Note, the Shares shall cease to be outstanding for any and all purposes, and the Stockholder shall no longer have any rights as a holder of the Shares, including any rights in respect of the Shares that the Stockholder may have had under the Company's Certificate of Incorporation or otherwise. For greater certainty, the foregoing termination of rights shall have no application or effect in respect of the Stockholder's rights as a holder of other shares of the Company's common stock.

**<u>SECTION 2</u>**

**REPRESENTATIONS AND WARRANTIES**

In connection with the transactions provided for hereby, the Stockholder represents and warrants to the Company as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.1 Ownership of Shares.** The Stockholder has good and marketable right, title and interest (legal and beneficial) in and to all of the Shares, free and clear of all liens, pledges, security interests, charges, claims, equity or encumbrances of any kind. Upon paying for the Shares in accordance with this Agreement, the Company will acquire good and marketable title to the Shares, free and clear of all liens, pledges, security interests, charges, claims, equity or encumbrances of any kind.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.2 Authorization.** The Stockholder has all necessary power and authority to execute, deliver and perform the Stockholder's obligations under this Agreement and all agreements, instruments and documents contemplated hereby and to sell and deliver the Shares being sold hereunder, and this Agreement constitutes a valid and binding obligation of the Stockholder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.3 No Conflict.** The execution and delivery of this Agreement and the consummation of the transactions contemplated hereby will not result in a breach by the Stockholder of, or constitute a default by the Stockholder under, any agreement, instrument, decree, judgment or order to which the Stockholder is a party or by which the Stockholder may be bound.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.4 Experience and Evaluation.** By reason of the Stockholder's business or financial experience or the business or financial experience of the Stockholder's professional advisers who are unaffiliated with the Company and who are not compensated by the Company, the Stockholder has the capacity to protect the Stockholder's own interests in connection with the sale of the Shares to the Company. The Stockholder is capable of evaluating the potential risks and benefits of the sale hereunder of the Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.5 Access to Information.** The Stockholder has received all of the information that the Stockholder considers necessary or appropriate for deciding whether to sell the Shares hereunder and perform the transactions contemplated hereby. The Stockholder further represents that the Stockholder has had an opportunity to ask questions and receive answers from the Company regarding the business, properties, prospects and financial condition of the Company and to seek from the Company such additional information as the Stockholder has deemed necessary to verify the accuracy of any such information furnished or otherwise made available to the Stockholder by or on behalf of the Company.

**<u>SECTION 3</u>**

**SUCCESSORS AND ASSIGNS**

Except as otherwise provided herein, the terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties (including transferees of any Shares). Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.

**<u>SECTION 4</u>**

**GOVERNING LAW**

All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of Wyoming, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings arising with respect to the transactions contemplated hereunder shall be commenced exclusively in the state and federal courts sitting in the State of Wyoming. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the State of Wyoming, Borough of Manhattan for the adjudication of any dispute hereunder and hereby irrevocably waives, and agrees not to assert in any action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof.

**<u>SECTION 5</u>**

**ENTIRE AGREEMENT**

This Agreement contains the entire understanding of the parties, and there are no further or other agreements or understandings, written or oral, in effect between the parties relating to the Shares (and the purchase and sale thereof), except as expressly referred to herein. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right.

**<u>SECTION 6</u>**

**AMENDMENTS AND WAIVERS**

No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in the case of an amendment, by the parties or, in the case of a waiver, by the party against whom enforcement of any such waived provision is sought.

**<u>SECTION 7</u>**

**FURTHER ACTION**

Each party hereto agrees to execute any additional documents and to take any further action as may be necessary or desirable in order to implement the transactions contemplated by this Agreement.

**<u>SECTION 8</u>**

**SURVIVAL**

The representations and warranties herein shall survive the Closing.

**<u>SECTION 9</u>**

**SEVERABILITY**

Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement shall be held to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Agreement.

**<u>SECTION 10</u>**

**NOTICES**

Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication is delivered via facsimile at the facsimile number or email at the email address as set forth on the signature page attached hereto at or prior to 5:30 p.m. (Wyoming time) on a Business Day, (b) the next Business Day after the time of transmission, if such notice or communication is delivered via facsimile at the facsimile number or email at the email

address as set forth on the signature pages attached hereto on a day that is not a Business Day or later than 5:30 p.m. (Wyoming time) on any Business Day, (c) the second (2nd) business day following the date of mailing, if sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given.

**<u>SECTION 11</u>**

**COUNTERPARTS**

This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

**<u>SECTION 12</u>**

**WAIVER OF JURY TRIAL**

**WAIVER OF JURY TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.**

**<u>SECTION 13</u>**

**ELECTRONIC EXECUTION**

The words "execution," "signed," "signature," and words of similar import in this Agreement shall be deemed to include electronic and digital signatures and the keeping of records in electronic form, each of which shall be of the same effect, validity, and enforceability as manually executed signatures and paper-based recordkeeping systems, to the extent and as provided for under applicable law, including the Electronic Signatures in Global and National Commerce Act (15 U.S.C. §§ 7001-7031), the Uniform Electronic Transactions Act (UETA), or any state law based on the UETA, including the Wyoming Electronic Signatures and Records Act (N.Y. State Tech. §§ 301 to 309).

**IN WITNESS WHEREOF,** each of the parties has executed this Stock Repurchase Agreement as of the day and year first above written.

---

| | |
|:---|:---|
| Dated: February 4, 2026 | Dated: February 4, 2026 |
| Borrower (Issuer / Maker) | Lender (Noteholder) |
| By: <u>/s/ Binh Do</u> | By: <u>/s/ Olivia Trinh</u> |
| Binh Do, President and CFO | Olivia Trinh, Managing Director |
| MyRxWallet North America Corp. | Z the Future, LLC |

---

## Ex1A-6

**Exhibit 6.3**

**AMENDED PROMISSORY NOTE**

**OF**

**MYRXWALLET CORPORATION**

**Principal Amount:** $850,000,000.00

**Repurchase Price:** $85 per share of common stock

**Conversion Price:** $125/share

**Annual Interest Rate: 7.5%**

**Annual Interest Amount:** $63,750,000.00

**Quarterly Interest Payment:** $15,937,500 per payment

**Total Interest Due at Maturity:** $127,500,000.00

**Total Amount Due at Maturity:** $977,500,000.00

**Shares Issuable Upon Full Conversion:** 7,820,000 common stock ($125/share)

**February 4, 2026**

FOR VALUE RECEIVED, MyRxWallet North America Corporation (the "Borrower") hereby unconditionally promises to pay to the order of MyRxWallet Corporation a Wyoming Corporation (the "Noteholder") the principal amount of $850,000,000.00 (the "Loan"), together with all accrued interest thereon, as provided in this Promissory Note (this "Note").

1. Payment Dates and Maturity

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Payment Date: The aggregate unpaid principal amount of the Loan, all accrued and unpaid interest, and all other amounts payable under this Note shall be due and payable on demand from the Noteholder. The Noteholder may demand payment at any time within twenty-four (24) months from the date of this Note. If the Noteholder does not exercise its redemption rights within this period, this Agreement shall automatically renew for an additional twenty-four (24) months on the same terms and conditions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Prepayment: The Borrower may prepay the Loan in whole or in part at any time or from time to time without penalty or premium by paying the principal amount to be prepaid together with accrued interest thereon to the date of the prepayment.

2. Interest

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Interest Rate: The principal amount outstanding under this Note from time to time shall bear interest at a rate per annum (the "Interest Rate") equal to seven and one-half percent (7.5%).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Interest Payment Dates: Interest shall be payable quarterly, in arrears, in the form of fully paid and non-assessable shares of the Borrower's common stock, unless otherwise agreed by the parties.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Default Interest: If any amount payable hereunder is not paid when due (without regard to any applicable grace period), whether at stated maturity, by acceleration, or otherwise, such overdue amount shall bear interest at the Interest Rate plus two percent (2%) (the "Default Rate").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Computation of Interest: All computations of interest hereunder shall be made on the basis of a year of 365/366 days, as the case may be, and the actual number of days elapsed. Interest shall begin to accrue on the Loan on the date of this Note. For any portion of the Loan that is repaid, interest shall not accrue on the date on which such payment is made.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) Interest Rate Limitation: If at any time the Interest Rate payable on the Loan shall exceed the maximum rate of interest permitted under applicable law, such Interest Rate shall be reduced automatically to the maximum rate permitted.

3. Interest and Redemption Provisions

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A. Accrual of Unpaid Amounts: Any unpaid principal, interest, or Interests shall accrue and compound until paid in full.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B. Interest Priority: The Borrower shall pay all accumulated Interests on this Note before declaring or paying any Interests on its common stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;C. Redemption/Liquidation Priority: All accrued Interests must be paid in full prior to any redemption or liquidation of the Note.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;D. Ongoing Interests: Interests shall continue to accrue and be payable until the Note is fully redeemed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E. Payment Frequency: Interests and interest shall be paid quarterly, unless otherwise agreed in writing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;F. Payment Form: Payments may be made, at the Noteholder's election, in cash or in fully paid and non-assessable shares of the Borrower's common stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;G. Compliance: All terms and payments under this Note shall comply with applicable federal and state securities laws, SEC regulations, PCAOB standards, and any other relevant regulatory requirements.

4. Conversion Option

**Conversion at Noteholder's Election:**

At any time while any portion of the principal or accrued interest under this Note remains outstanding, the Noteholder may, at their sole discretion, elect to convert all or any part of the unpaid principal and accrued interest into fully paid and non-assessable shares of the Borrower's common stock (the "Conversion Shares"). Such conversion shall be effected by delivering written notice to the Borrower specifying the amount to be converted and the date of conversion.

**Conversion Price:**

The "Conversion Price" shall be $125.00 per share of the Borrower's common stock, as adjusted for stock splits, stock combinations, recapitalizations, and similar transactions affecting the common stock. The number of shares issuable upon conversion shall equal the aggregate principal and accrued but unpaid interest (or other amounts then outstanding and elected to be converted) divided by the Conversion Price. No fractional shares shall be issued; any fractional share shall be rounded down to the nearest whole share or settled in cash in lieu thereof.

**MyRxWallet Anti-Dilution Capped Call Agreement**

Noteholder: MyRxWallet Corporation ("Affiliate Counterparty")

Purpose: To economically offset dilution arising from the conversion of the Senior Convertible Promissory Notes.

Notional Amount: Equal to the number of shares underlying the $850,000,000.00 Notes. Strike Price: $125.00 per share

Cap Price: $200.00 per share

Term: Matches maturity of the Notes.

Settlement: Cash settlement; share settlement; or delivery of treasury shares; or delivery of issuer-sponsored tokenized shares of the same class recorded on the Borrower's master securityholder file. Any tokenized settlement shall be treated as delivery of the underlying shares and effected in compliance with applicable federal and state securities laws.

Effect: Issuer receives value if the stock price exceeds the cap price, offsetting dilution.

**Accounting: Treated as an intercompany equity hedge; no derivative liability expected.**

**Partial Conversion and Payment:**

The Noteholder may elect to receive payment of any portion of the outstanding principal and accrued interest in cash, and convert the remaining balance into Conversion Shares, at their discretion.

**Mechanics and Adjustments:**

The Borrower shall deliver the Conversion Shares to the Noteholder within five (5) business days of receipt of the conversion notice. If the Borrower's common stock is not listed or quoted on a trading market at the time of conversion, the conversion price shall be determined by mutual agreement between the Borrower and the Noteholder, or, failing such agreement, by an independent third-party valuation.

**Fractional Shares:**

No fractional shares shall be issued upon conversion. Any fractional share shall be round down round down or cash in lieu.

**Reservation of Shares:**

The Borrower shall at all times reserve and keep available out of its authorized but unissued shares of common stock, solely for the purpose of effecting conversions under this Note, such number of shares as shall be sufficient to effect the conversion of the entire outstanding principal and accrued interest under this Note.

5. Anti-Dilution Protection; Capped Call Agreement"

To mitigate potential dilution resulting from conversions of this Note, the Borrower and certain of its affiliated entities may enter into one or more capped call or similar anti-dilution hedge transactions (each, a "Capped Call Agreement"). Any such Capped Call Agreement shall be entered into for the sole purpose of economically offsetting the dilutive effect of the issuance of shares of the Borrower's common stock upon conversion of this Note.

The principal economic terms of the Capped Call Agreement are expected to include:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· **Notional Amount:** Equal to the number of shares underlying this Note.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· **Strike Price:** USD $125.00 per share.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· **Cap Price:** USD $200.00 per share (subject to adjustment by the Borrower).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· **Term:** To match the maturity of this Note.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· **Settlement:** Cash settlement; share settlement; settlement in treasury shares; or delivery of tokenized shares of the same
class of the Borrower's master security file (issuer-sponsored tokenized securities). Any tokenized settlement shall be treated
as delivery of the underlying shares and effected in compliance with applicable federal and state securities laws.

· **Purpose and Effect:** The Capped Call Agreement is intended to reduce or eliminate dilution upon conversion of this Note and
to provide economic value to the Borrower if the market price of its common stock exceeds the applicable cap price.

· **Accounting Treatment:** Expected to be accounted for as an intercompany equity hedge without recognition
 of derivative liability under applicable accounting standards.

No rights are conferred upon the Noteholder by the existence, terms, or performance of any Capped Call Agreement, and the entry into, amendment of, or termination of any Capped Call Agreement shall not be deemed to modify the terms of this Note or the Conversion Option.

6. Events of Default

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Failure to Pay: The Borrower fails to pay (i) any principal amount of the Loan when due; (ii) any interest on the Loan within two (2) Business Days after the date such amount is due; or (iii) any other amount due hereunder within two (2) Business Days after such amount is due.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Bankruptcy; Insolvency: (i) The Borrower institutes a voluntary case seeking relief under any law relating to bankruptcy, insolvency, reorganization, or other relief for debtors. (ii) An involuntary case is commenced seeking the liquidation or reorganization of the Borrower under any law relating to bankruptcy or insolvency, and such case is not dismissed or vacated within sixty (60) days of its filing. (iii) The Borrower makes a general assignment for the benefit of its creditors. (iv) The Borrower is unable, or admits in writing its inability, to pay its debts as they become due. (v) A case is commenced against the Borrower or its assets seeking attachment, execution, or similar process against all or a substantial part of its assets, and such case is not dismissed or vacated within sixty (60) days of its filing.

7. Remedies

Upon the occurrence and during the continuance of an Event of Default, the Noteholder may, at its option, by written notice to the Borrower declare the outstanding principal amount of the Loan, accrued and unpaid interest thereon, and all other amounts payable hereunder immediately due and payable; provided, however, if an Event of Default described in Section 5(b)(i), 5(b)(iii) or 5(b)(iv) shall occur, the outstanding principal amount, accrued and unpaid interest, and all other amounts payable hereunder shall become immediately due and payable without notice, declaration, or other act on the part of the Noteholder.

8. Expenses

The Borrower shall reimburse the Noteholder on demand for all reasonable and documented out-of-pocket costs, expenses, and fees, including the reasonable fees and expenses of counsel, incurred by the Noteholder in connection with the negotiation, documentation, and execution of this Note and the enforcement of the Noteholder's rights hereunder.

9. Notices

All notices and other communications relating to this Note shall be in writing and shall be deemed given upon the first to occur of (x) deposit with the United States Postal Service or overnight courier service, properly addressed and postage prepaid; (y) transmittal by electronic communication (including email, internet or intranet websites, or facsimile properly addressed (with written acknowledgment from the intended recipient such as "return receipt requested" function, return e-mail, or other written acknowledgment)); or (z) actual receipt by an employee or agent of the other party. Notices hereunder shall be sent to the following addresses, or to such other address as such party may specify in writing from time to time:

&nbsp;&nbsp;&nbsp;&nbsp;(a) If to the Borrower:

MyRxWallet North America Corporation

Name: Binh Do

Title: President & CFO

Address: 2475 South Jones Blvd., Suite 9,

Las Vegas, Nevada 89146

Email: binh@myrxwallet.app

&nbsp;&nbsp;&nbsp;&nbsp;(a) If to the Noteholder:

MyRxWallet Corp.

Name: Olivia Trinh

Title: Chairman and CEO

Address: 2475 South Jones Blvd., Suite 9,

Las Vegas, Nevada 89146

Email: olivia@myrxwallet.app

10. Governing Law

This Note and any claim, controversy, dispute, or cause of action (whether in contract, tort, or otherwise) based on, arising out of, or relating to this Note and the transactions contemplated hereby shall be governed by and construed in accordance with the laws of the State of Wyoming.

11. Disputes

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Submission to Jurisdiction: (i) The Borrower irrevocably and unconditionally (A) agrees that any action, suit, or proceeding arising from or relating to this Note may be brought in the courts of the State of Wyoming, and in the United States District Court for the District of Wyoming, and (B) submits to the exclusive jurisdiction of such courts in any such action, suit, or proceeding. Final judgment against the Borrower in any such action, suit, or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. (ii) Nothing in this Section 10(a) shall affect the right of the Noteholder to bring any action, suit, or proceeding relating to this Note against the Borrower or its properties in the courts of any other jurisdiction. (iii) Nothing in this Section 10(a) shall effect the right of the Noteholder to serve process upon the Borrower in any manner authorized by the laws of any such jurisdiction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Venue: The Borrower irrevocably and unconditionally waives, to the fullest extent permitted by law, (i) any objection that it may now or hereafter have to the laying of venue in any action, suit, or proceeding relating to this Note in any court referred to in Section 10(a) and (ii) the defense of inconvenient forum to the maintenance of such action, suit, or proceeding in any such court.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Waiver of Jury Trial: THE BORROWER HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY RELATING TO THIS NOTE OR THE TRANSACTIONS CONTEMPLATED HEREBY, WHETHER BASED ON CONTRACT, TORT, OR ANY OTHER THEORY.

12. Successors and Assigns

This Note may be assigned or transferred by the Noteholder to any individual, corporation, company, limited liability company, trust, joint venture, association, partnership, unincorporated organization, governmental authority, or other entity.

13. Integration

This Note constitutes the entire contract between the Borrower and the Noteholder with respect to the subject matter hereof and supersedes all previous agreements and understandings, oral or written, with respect thereto.

14. Amendments and Waivers

No term of this Note may be waived, modified, or amended, except by an instrument in writing signed by the Borrower and the Noteholder. Any waiver of the terms hereof shall be effective only in the specific instance and for the specific purpose given.

15. No Waiver; Cumulative Remedies

No failure by the Noteholder to exercise and no delay in exercising any right, remedy, or power hereunder shall operate as a waiver thereof; nor shall any single or partial exercise of any right, remedy, or power hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, or power. The rights, remedies, and powers herein provided are cumulative and not exclusive of any other rights, remedies, or powers provided by law.

16. Severability

If any term or provision of this Note is invalid, illegal, or unenforceable in any jurisdiction, such invalidity, illegality, or unenforceability shall not affect any other term or provision of this Note or render such term or provision invalid or unenforceable in any other jurisdiction.

17. Counterparts

This Note and any amendments, waivers, consents, or supplements hereto may be executed in counterparts, each of which shall constitute an original, but all of which taken together shall constitute a single contract. Delivery of an executed counterpart of a signature page to this Note by facsimile or in electronic ("pdf" or "tif" or any other electronic means that reproduces an image of the actual executed signature page) format shall be as effective as delivery of a manually executed counterpart of this Note.

18. Electronic Execution

The words "execution," "signed," "signature," and words of similar import in this Note shall be deemed to include electronic and digital signatures and the keeping of records in electronic form, each of which shall be of the same effect, validity, and enforceability as manually executed signatures and paper-based recordkeeping systems, to the extent and as provided for under applicable law, including the Electronic Signatures in Global and National Commerce Act (15 U.S.C. §§ 7001-7031), the Uniform Electronic Transactions Act (UETA), or any state law based on the UETA, including the Wyoming Electronic Signatures and Records Act (WY. State Tech. §§ 301 to 309).

IN WITNESS WHEREOF, the Borrower and Lender has caused this Promissory Note to be duly executed as of February 4, 2026.

---

| | |
|:---|:---|
| Dated: February 4, 2026 | Dated: February 4, 2026 |
| Borrower (Issuer / Maker) | Lender (Noteholder) |
| By: <u>/s/ Binh Do</u> | By: <u>/s/ Olivia Trinh</u> |
| Binh Do, President and CFO | Olivia Trinh, CEO |
| MyRxWallet North America Corp. | MyRxWallet Corporation |

---

## Ex1A-6

**Exhibit 6.4**

**STOCK REPURCHASE AGREEMENT**

**OF**

**MYRXWALLET CORPORATION**

**Principal Amount:** $850,000,000.00

**Repurchase Price:** $85 per share of common stock

**Conversion Price:** $125/share

**Annual Interest Rate: 7.5%**

**Annual Interest Amount:** $63,750,000.00

**Quarterly Interest Payment:** $15,937,500 (cash or equity)

**Total Interest Due at Maturity:** $127,500,000.00

**Total Amount Due at Maturity:** $977,500,000.00

**Estimated Share Issued After Conversion:** 7,820,000 common stock Date: February 4, 2026

THIS STOCK REPURCHASE AGREEMENT (this "Agreement") is made and entered into as of January 3, 2026, by and between MyRxWallet North America Corporation, Inc., a Wyoming corporation (the "Company"), and MyRxWallet Corporation, Inc., a Wyoming corporation (the "Stockholder").

**RECITALS**

**WHEREAS,** apart from the Stockholder's other shareholdings of shares of the Company's common stock, the Stockholder is the holder of 140,000,000 shares (the "Shares") of the Company's common stock, par value $0.0001 per share (the "Common Stock"), which the Stockholder purchased from the Company pursuant to that certain Stock Purchase Agreement dated as of October 30, 2024 between the Company and the Stockholder;

**WHEREAS**, the Stockholder desires to sell, and the Company desires to repurchase, 10,000,000 of the Shares (the "Sale Shares") at a price per share of USD $85.00 (the "Per Share Purchase Price"), upon the terms and subject to the conditions set forth in this Share Repurchase Agreement (the "Share Repurchase").

**WHEREAS,** the Board of Directors of the Company has authorized the Share Repurchase; and

**WHEREAS,** it is the intention of the Parties that the Share Repurchase be a private sale of securities that is exempt from the registration and prospectus delivery requirements of the Securities Act of 1933, as amended.

**NOW, THEREFORE, IN CONSIDERATION** of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and the Stockholder agree as follows:

**<u>SECTION 1</u>**

**REPURCHASE OF SHARES**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.1 Repurchase.** At the Closing (as defined below), MyRxWallet North America Corporation, Inc. (the "Company") hereby agrees to repurchase from MyRxWallet Corporation (the "Stockholder"), and the Stockholder hereby agrees to sell, assign and transfer to the Company, the Stockholder's right, title and interest in and to 10,000,000 Shares, at a price per Share $85.00, with an aggregate amount of $850,000,000.00, and the Company shall issue to the Stockholder a promissory note in the principal amount equal to the Purchase Price, substantially in the form attached hereto as Exhibit A (the "Note"), and subject to terms and conditions therein.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.2 Closing.** The closing of the Repurchase (the "Closing") shall take place on January 3, 2026 at the offices of the Company at 2475 South Jones Blvd., Suite 9, Las Vegas, Nevada, 89146, or remotely by exchange of documents and signatures (or their electronic counterparts), at such date, time and place as the Company and the Stockholder shall mutually agree.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.2.1 At the Closing:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (a) The Company shall deliver to the Stockholder the Note evidencing the Purchase Price; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Stockholder shall deliver to the Company an executed stock power with or without a medallion signature guarantee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.3 Termination of Rights as the Stockholder.** At the Closing and upon delivery of the Note, the Shares shall cease to be outstanding for any and all purposes, and the Stockholder shall no longer have any rights as a holder of the Shares, including any rights in respect of the Shares that the Stockholder may have had under the Company's Certificate of Incorporation or otherwise. For greater certainty, the foregoing termination of rights shall have no application or effect in respect of the Stockholder's rights as a holder of other shares of the Company's common stock.

**<u>SECTION 2</u>**

**REPRESENTATIONS AND WARRANTIES**

In connection with the transactions provided for hereby, the Stockholder represents and warrants to the Company as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.1 Ownership of Shares.** The Stockholder has good and marketable right, title and interest (legal and beneficial) in and to all of the Shares, free and clear of all liens, pledges, security interests, charges, claims, equity or encumbrances of any kind. Upon paying for the Shares in accordance with this Agreement, the Company will acquire good and marketable title to the Shares, free and clear of all liens, pledges, security interests, charges, claims, equity or encumbrances of any kind.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.2 Authorization.** The Stockholder has all necessary power and authority to execute, deliver and perform the Stockholder's obligations under this Agreement and all agreements, instruments and documents contemplated hereby and to sell and deliver the Shares being sold hereunder, and this Agreement constitutes a valid and binding obligation of the Stockholder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.3 No Conflict.** The execution and delivery of this Agreement and the consummation of the transactions contemplated hereby will not result in a breach by the Stockholder of, or constitute a default by the Stockholder under, any agreement, instrument, decree, judgment or order to which the Stockholder is a party or by which the Stockholder may be bound.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.4 Experience and Evaluation.** By reason of the Stockholder's business or financial experience or the business or financial experience of the Stockholder's professional advisers who are unaffiliated with the Company and who are not compensated by the Company, the Stockholder has the capacity to protect the Stockholder's own interests in connection with the sale of the Shares to the Company. The Stockholder is capable of evaluating the potential risks and benefits of the sale hereunder of the Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.5 Access to Information.** The Stockholder has received all of the information that the Stockholder considers necessary or appropriate for deciding whether to sell the Shares hereunder and perform the transactions contemplated hereby. The Stockholder further represents that the Stockholder has had an opportunity to ask questions and receive answers from the Company regarding the business, properties, prospects and financial condition of the Company and to seek from the Company such additional information as the Stockholder has deemed necessary to verify the accuracy of any such information furnished or otherwise made available to the Stockholder by or on behalf of the Company.

**<u>SECTION 3</u>**

**SUCCESSORS AND ASSIGNS**

Except as otherwise provided herein, the terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties (including transferees of any Shares). Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.

**<u>SECTION 4</u>**

**GOVERNING LAW**

All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of Wyoming, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings arising with respect to the transactions contemplated hereunder shall be commenced exclusively in the state and federal courts sitting in the State of Wyoming. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the State of Wyoming and U.S. District Court for the District of Wyoming for the adjudication of any dispute hereunder and hereby irrevocably waives, and agrees not to assert in any action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof.

**<u>SECTION 5</u>**

**ENTIRE AGREEMENT**

This Agreement contains the entire understanding of the parties, and there are no further or other agreements or understandings, written or oral, in effect between the parties relating to the Shares (and the purchase and sale thereof), except as expressly referred to herein. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right.

**<u>SECTION 6</u>**

**AMENDMENTS AND WAIVERS**

No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in the case of an amendment, by the parties or, in the case of a waiver, by the party against whom enforcement of any such waived provision is sought.

**<u>SECTION 7</u>**

**FURTHER ACTION**

Each party hereto agrees to execute any additional documents and to take any further action as may be necessary or desirable in order to implement the transactions contemplated by this Agreement.

**<u>SECTION 8</u>**

**SURVIVAL**

The representations and warranties herein shall survive the Closing.

**<u>SECTION 9</u>**

**SEVERABILITY**

Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement shall be held to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Agreement.

**<u>SECTION 10</u>**

**NOTICES**

Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication is delivered via facsimile at the facsimile number or email at the email address as set forth on the signature page attached hereto at or prior to 5:30 p.m. (Wyoming time) on a Business Day, (b) the next Business Day after the time of transmission, if such notice or communication is delivered via facsimile at the facsimile number or email at the email

address as set forth on the signature pages attached hereto on a day that is not a Business Day or later than 5:30 p.m. (Wyoming time) on any Business Day, (c) the second (2nd) business day following the date of mailing, if sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given.

**<u>SECTION 11</u>**

**COUNTERPARTS**

This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

**<u>SECTION 12</u>**

**WAIVER OF JURY TRIAL**

**WAIVER OF JURY TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.**

**<u>SECTION 13</u>**

**ELECTRONIC EXECUTION**

The words "execution," "signed," "signature," and words of similar import in this Agreement shall be deemed to include electronic and digital signatures and the keeping of records in electronic form, each of which shall be of the same effect, validity, and enforceability as manually executed signatures and paper-based recordkeeping systems, to the extent and as provided for under applicable law, including the Electronic Signatures in Global and National Commerce Act (15 U.S.C. §§ 7001-7031), the Uniform Electronic Transactions Act (UETA), or any state law based on the UETA, including the Electronic Signatures in Global and National Commerce Act (15 U.S.C. §§ 7001–7031) and the Wyoming Uniform Electronic Transactions Act (Wyo. Stat. §§ 40-21-101 to 40-21-119).

**IN WITNESS WHEREOF,** MyRxWallet North America Corporation has caused this Convertible Promissory Note to be duly executed in its corporate name by the manual signature of its President, CFO and Director.

---

| | |
|:---|:---|
| Dated: February 5, 2026 | By: <u>/s/ Binh Do</u> |
|  | Binh Do,<br> President, CFO and Director |

---

## Ex1A-6

**Exhibit 6.5**

![](image_058.jpg)

I 600 ೦೦ dt1 ೦ 11 ೦ 1 TELANGANA 0 I I 1 - · or Whom Tran Id : 250813151621327201 Date: 13AUG 2025,03:25PM Purchased By: VENKATRATNAM l'OPPOPPU S/o BULL!RAMAlAH POPPOPPU R / o HYDERABAD MIS. MYRXWAUET PRANA PRIVATE UMIT ೦ REEMENT TO LEASE GOPA SREEMANTH LICENSED STAMP VENDOR Lie.No. IS - 10 - 038/2019 Ron.No. 1 5 - 10 - 081/2025 ShopNo: 7, Plot No : 44 , Scr iling ampally , Madhapur , Hyderabad Ph 9703416341 I This Lease Agreement is made at Hyderabad on this 15 th AUGUST 2025 (hereinafter referred I> as " Execution Date") and shall be effective from the Effective Date, by and between: A mt. Arcbitha Raj Kumar lttaboiena (Aadhaar No: 6144 2950 6533, Pan No: ೦ HP07396Q, DIN no.07575022), W/o Raj Kumar Yadav, age 47 years, Resident of: II.No. 168/3rt, Suknal Cottage, Vijayanagar Colony, Meena Gardens, Hyderabad, Telangana - 500057 y.ereinafter referred to as the VENDOR. which expression shall mean and include all their legal heirs, executors, successors, administrators, representatives, assignees of the first part . • AND : Lts MylbWallet Prana Private Limited, Represented by its Directors ; 1 . VENKATA fATNAM POPPOPPU (Aadbaar No : 3179 3673 9502 , PAN No : AILPP 4689 B, DIN : 07812464), S/o Bulli Ramaiab Poppoppu, aged 54 years, Resident of HNo 2 - 63 , f lat No 204 , Block - B, Sai Durga Avenue, Nizampet, Hyderabad, Telangana, 500090 . 2 . Suresb S (Aadbaar No : 3869 5022 4901 , PAN No : BKIPS 1400 F, DIN : 06777788), S/o Sura : ೦೦ - ೦ Page 10116 ೦ ೦ • \ - 0 ೦೦೦ I I ೦ ... , . ೦ ೦

![](image_059.jpg)

Venkatesbwara Rao, aged 47 years, Resident of HNo 3 - 6 - 54 , F l at No 4 D, Anatba Sai Apartment, Vivekana odh a Nagar Colony, Road n o 22 , Kukatpa ll y, Hy d erabad, Tela n gana, 500072 . The Lessee and the Lessor are hereinafter collectively referred to as "Parties" and individually as "Party" . WHEREAS: The Lessor is the legal and absolute owner of Premises (The Lessors is owner of the property bearing SY . NO : 325 , 326 , 327 , 328 & 329 admeasuring 41 acres (out of 59 . 27 acres) as a land parcel situated at Village Kallakal , Manda! Manoharabad, Division Toopran, District Medak, State Telangana . Pin - 502110 . Hereinafter referred to as the "Said Property & quot ; and is competent to deal with the same in any manner whatsoever) . 2 The Lessee is engaged in Data centers / solar power installation unjt and intends to operate . The Lessors desire and have agreed to give on lease the "Said Property" for the business and Data center usage of the Lessee and its group companies . from the Land . 3 Based on various mutual discussions, the Lessor has agreed to lease the Premises to Lessee, on the terms and conditions which have been mutually agreed hereunder between the Parties to this Lease Agreement . Now, The re fore, The Pa r ties He r eby Agree as Fo ll ows : 1. DEFINITIONS AND INTERPRETATION: In this Lease Deed (including the Recitals, Schedules and Annexures) unless the context otherwise requires or unless otherwise expressly provided: a. "Business" shall mean the business of the Lessee of providing holistic Data centers / solar power installation unit. b. "Date of Handover" shall be 5 months from phase 1. for installation of solar panels c. "Lease Commencement date" shall mean [ 12 months from phase 1] or the date of signing of the Lease Deed by both Parties, whichever is later. d. "Lease Period" shall mean the tenn of 1o+1o+10 [Thirty] years commencing from the Rent Commencement Date, e. Rent of Rs:40 , 000/ - [forty one thousand rupees] per acre . f. "Lock - in" shall be for 10 [ten] years from the date of Rent Commencement. g. "Rent Commencement Date" shall mean 12 months from phase 1. h. "Rent Free period for installation of so l ar panels" shall mean 12 months [TWELE] of the date of handover and positioning for installing the Solar panels . The Lessee shall carry out the installation of sol : ೦ : ls during the Rent Free/Fit - out R'io i . e . 12 months from the ೦ Page2o.f16 V

![](image_060.jpg)

date of handover till the Rent Commencement Date [ 12 months from phase 1 ] . During such time no rent shall be payable by the Lessee to the Lessor . 1 . "Schedule Property" shall have the meaning ascribed to in Annexure A . J. "Payment of Levies" shall mean that All outgoings , i . e . past , present and future , Levies pertaining to the land, shall be paid by the Lessor . If any new Levy becomes applicable , then the Lessor shall solely be Hable to pay . The Monthly Rent shall be exclusive of electricity , generator maintenance charges and water charges , which the Lessee must pay along with the OST on Rent amount to the authority . 2. Lease Term 1. The Lessor , in consideration of Monthly Rent (defined Later), hereby lease the Premises , as defined in detailed in Annexure B , attached hereto , to the Lessee with all the attached rights of common passage , way, air and easement for a period of 30 [ 10 + 10 + 10 ] years . 2. The Parties based on their mutual discussion and on mutually agreed terms may extend this Lease Term for a further period as per the terms to be agreed i . e . , [l 0 + 10 ]year . 3. Monthly Rent 1. During the Lease Term , the Lessee shall pay the lease rent on quarterly basis ("Quarterly Rent") to the Lessor in consideration of lease of Land . The amount of quarterly Rent for each period under the Lease Agreement shall be as per "Annexure - B , attached hereto" . 2. The Lessee shall also pay the applicable taxes on the quarterly Rent to the Lessor . quarterly Rent for said Land shall be paid by the Lessee to the Lessor in advance on or before the 10 th day of every calendar month . The Quarterly Rent shall start from expiration , i . e . after [ 12 ] Fifteen months or production of Solar Power or whichever is earlier from the Effective which is also a Rent - Free Period ("Instalation of solar panels & operation of the same Lease Commencement Date") . 3. The Parties agree that there shall be a [ 3 ] % increase in quarterly Rent after completion over the last quarterly Rent paid . 4. The quarterly Rent payable by the Lessee to the Lessor shall be subject to deduction of applicable taxes [TDS] at source and other statutory deductions and appropriate certificates for such deductions shall be provided by the Lessee to Lessor within the period prescribed under the Applicable Law . 5. The quarterly Rent and other amounts payable by the Lessee to the Lessor under ೦೦ :::.••• Agr;:shall be paid bycbeque/de ೦ and draft/RTGS in favor of the Page3o f 16 S S .

![](image_061.jpg)

Nala Converssion Cbages That the total land area of 41 acres (equivalent to 165 , 921.11 square meters) is subject to BASE Land value I.e Considered @ S,00 , 000 per acres. this lend is falls under GHMC LIMITES . the charges for Nala conversion shall be 1 . 5 % of 1 squire meters i.e 307 , 000 of hole 41 Acre, which shall pure government fee the Incidental charges shall be extra at actual. (subject to authorities approval) 4. Miscellaneous Payments of the Land 1. All outgoings, i . e . past, present and future, such as incidences of ground rent , conversion charges, land taxes, local levies, property tax , assessment, cesses or statutory dues , any other taxes and penalties pertaining to the Land, shall be paid by the Lessor, as applicable . If any new payment with respect to the Land becomes applicable after the Effective Date then the Lessor shall solely be liable to pay such payment with regards to the tenancy Land . 2. The quarterly Rent shall be exclusive of electricity and water charges for consumption of electricity and water in the Premises which the Lessee shall be responsible to pay promptly every month without default to the concerned agencies upon receipt of the bills . The Lessor shall be liable towards the pa y ment of the water and electricity charges / penalties for the period prior to the Effective Date . 4. Improvements/ Alteration 1. The Lessee shall be allowed to install solar panels / any other utilization of the related land parcel, at its own cost , with the consent of Lessor to meet the busines s needs and such consents will not be unreasonably withheld . However, if any land usage is required to be made in compliance of directions of any Government Authority , cost of such changes shall be borne by the Lessor . 2. The Lessee shall be entitled to furnish the Land parcel with necessary , signboards and other apparatus which are required for operating lessee's business from the Land . 4. Nature of use and Enjoyment 1. The Lessee shall use the Premises or parts thereof only for setting up and operating lessee's business 2. The Lessee shall obtain at its cost all the necessary licenses, p e rmits and sanctions , as per applicable laws , rules and regulations for operating lessee ' s busines s . The Lessor shall provide necessary support by way of docwnents , signatures and/or personal visits for obtaining such licenses , permits and sanctions within a period of thirty (30) days from the date of intimation thereof by the Lessee to the Lessor . The Lessor shall obtain all necessary licenses and permission required for commercial use of the property and for leasing the structure to ೦ see for its business us . ೦ , - ೦ . ೦ . Page 4 of16 H , v . . . . 4 ., . - a ,. i _ ._ ೦ , ೦ .

![](image_062.jpg)

7. Representation and Warranties 1. Lessee hereby represents and warrants to the Lessor that : a) lt has full power and authority to enter into this Lease Agreement, and this Lease Agreement when executed and delivered by the Lessee, will constitute a valid and legally binding obligations of the Lessee ; and b) It has obtained all requisite corporate and regulatory consents, approvals, permissions required by it to enter into and perform this Lease Agreement and that the execution and performance of this Lease Agreement does and shall not contravene or violate any Applicable Law . 2. The Lessor hereby represents and warrants to Lessee that : a) It has the power and authority to execute this Lease Agreement and perform and observe all its terms ; b) On execution, this Lease Agreement constitutes the valid and legall y binding obligation of Lessor enforceable in accordance with its terms and conditions ; c) The Lessor has a good, clear, absolute, unrestricted, free from all encumbrances, charges, claims, and marketable title and ownership rights to the Premises ; d) It is not bound by any contract, arrangement or understanding (written or unwritten) which may restrict his/her right or ability to enter into or perform this Lease Agreement ; e) It does not require any prior consent from any third party including but not limited to Government Authority, court or any judicial or administrative department in the nature of any pending litigation, enquiry, etc . to execute and perform this Lease Agreement ; f) Lessor is in compliance with all applicable laws, rules and regulations, etc . in relation to development, construction and use of the Premises ; g) Lessor shall ensure not to enter any such contract/ activity which may cause restriction/harm to the business of the lessee . For example, leasing adjacent premise to les see's competitors or to any business which may cause inconvenience to patient s under lessee's care . 8. Covenants and Obligations of the Lessor 1. The Lessor covenants with the Lessee as follows : a) The Lessor covenants that the Lessee shall have quiet, peaceful, unfettered access, possession and enjoyment of the Premises . b) The Lessor shall ensure that the Lessee's customers, employees, authorized representatives , business associates and visitors shall have absolute, unrestricted, unfettered and unconditional access, use and enjoyment of the Premises at all times 24 (twenty - four) hours a day, 7 (seven) days a week and 365 (three sixty - five) days in a year . c) The Lessor shall allow Lessee to install signage / identity / brand / display boards of its business along with the other consultants performing services from the Premises, at the front and road - side facade of the Premises without any additional co: ೦ ; the Lessee by the Lessor. ೦ statutory pe • si s I ೦ / Page 5 of 16 r ೦ I \ \ - - - -

![](image_063.jpg)

approvals / sanctions, if required, shall be obtained by the Lessee at its own cost with the help of the Lessor . d) The Lessor shall assist and cooperate with the Lessee in relation to exercise of Lessee's rights under this Lease Agreement including procurement of any government approval , if required, by the Lessee for the business . e) If, at any given point in time , the Lessee is unable to secure any certification from the governmental authorities due to lack of permissions on the property or because of any other deficiency on the part of the Lessor , this Lease Deed s hall stand void and the Lessor shall refund the entire amount paid by the Le ss ee within 30 days . f) Any restriction/regulation by the Government Authority on the use of the Land by any person shall immediately be brought to the notice of the Lessee so as to enable the Lessee to make alternative arrangements . 9. Covenants and Obligations of the Lessee 1. The Lessee covenants with the Lessor as follows : a) The Lessee shall use the Premises as per purpose of use provided hereunder in this Lease Agreement . b) The Lessee shall , without default, pay electricity and water conswnption charges as per the actual consumption from the Effective Date and on the ba s i s of the bills received from the concerned agencies for the said period . c) The Lessee shall always observe and perform all the terms and conditions , covenants and provisions on which the Premises is given on lease . d) Upon the expiry or earlier termination of the Lease Term , the Lessee shall, as per the provisions of this Lease Agreement, peacefully hand over the physical possession of the Land subject to reasonable wear and tear . 9. Protection of the Lessee's Leaseholds in case of sale 1. During the Term , if Lessor decides to sell the Land or any portion thereof (" Sale Property ") , the Lessor shall ensure that prior to the transfer of the Sale Property , an FRR [first right to refusal] to the lessee for the period of 30 da y s working days to decide , if the lessee says no then the lessor has full rights offered to prospective buyer, the proposed buyer has executed and lodged with Lessee an undertaking accepting the leasehold right of Lessee on the Sale Property for the unexpired period of this Lease Agreement and given his consent for compliance of all the terms and conditions of this Lease Agreement The Lessor shall also ensure before the transfer of the Sale Property that the buyer agrees to execute a fresh lease deed with the Lesso ೦೦೦ same terms as mentioned i ೦ this Lease Agreement . 1 s: . s P a g e 6of16

![](image_064.jpg)

11. Indemnities 1. The Lessor hereby agrees and undertakes to indemnify and hold harmless the Lessee, its directors , official s , representative s, employee s and agents from and against all demands, claims, actions or causes of actions, losses, damages , liabilities , penalties, interest , costs , reasonable attorneys' fees and expenses (including costs and expenses incurred in prosecuting actions for indemnification) (Collectively referred as 'Losses'), actually incurred or actually suffered by Lessee , its directors, officials, representatives, employees and agents due to the following : a) any willful misrepresentation or breach of any representation or warranty , or agreement, covenant or obligations on the part of Lessor under or pursuant to this Lease Agreement . b) Any third - party claim which is in relation to the Land . 112 If at any given point in time, the governmental norms require the property to have NOC from authorities or any other similar or relevant certification , the Lessor shall at his own cost procure the licenses/certification . In any case, if the Lessor fails to procure the License/Certification, the Lessee shall obtain the necessary License / Certification and the costs shall be adjusted/recovered by the Lessee from the Lessor against the monthly Rent payable (prior intimation shall be provided to the Lessor) . 11 . 3 The Lessee hereby agrees and undertakes to indemnify and hold harmless the Lessor, from and against all Losses actually incurred or actually suffered by the Lessor due to the following ; a) any willful misrepresentation or willful breach of any representation or warranty, or agreement , covenant or obligations on the part of the Lessee under or pursuant to this Lease Agreement . b) Any third - party claim which may arise due to the violation of this Lease Agreement and violation of Applicable Laws in relation to the operations of the Land . 12. Termination 1. This Lease Agreement between the Parties shall be for Term commencing from [ 12 months from phase 1 ] and shall stand terminated unless renewed as per this Lease Agreement . On such completion of the Lease Term , the Lessee shall give peaceful possession of the Premises to the Lessor on " as is where is" basis subject to normal wear and tear and shall remove all the equipment/movable assets installed by it in the Premises at their own cost . 2. However , this Lease Agreement can be terminated prior to this period of [ 10 ] years ೦ per fue prov : i s given herein below : ೦ 1 1 ೦ Page 7 0116 V s.s

![](image_065.jpg)

a) If the Lessor commits a material breach and/ or misrepresentation of any of his obligations provided under this Lease Agreement which remains uncured (in case such breach is capable of being cured) for a period of 30 (thirty) days from the date of notice given by Lessee for cure of such breach, Lessee may at its discretion, terminate this Lease Agreement by giving 30 (thirty) days' written notice to Lessor . On such termination, Lessee shall take the possession of all the equipment/moveable assets owned by it and installed in the Land . b) During the Lease Term, if there is any defect in the title of the Land and / or if any objections and / or claims / objections are received by the Lessee , the Lessee shall inform the Lessor of such defect in the title of the Land and / or any objection / claims received and the Lessor shall within a period of 30 (thirty) days from the date of receipt of the letter of the Lessee rectify any defects and I or settle all objections / claims with regards to the Land . If the Lessor fails to settle any claims / objections received with regard to the Land, then notwithstanding anything contained in this Lease Agreement, the Lessee shall have the option to forthwith terminate the Lease Agreement . The Lessee shall remove all the movable assets from the Land and shall be entitled to receive compensation from the Lessor at the time of vacation of the Land . c) If at any time after the Lease Rent becomes due and payable to the Lessors , the same or any part thereof is in arrears and remains, unpaid by the Lessee for a period of three (3) consecutive months, the Lessors may give 90 (Ninety) days' prior notice in writing (the "Eviction Notice") calling upon the Lessee to pay such outstanding amounts or vacate the Schedule Property with immediate effect within ninety (90) days from the date of such Eviction - Notice . Despite the receipt of such Eviction Notice, if the Lessee fails or neglects to pay, the Lease Rent after the expiry of the said ninety (90) days ; the Lessee shall deliver the peaceful and, vacant possession of the Schedule Property to the Lessors . 12 . 3 The Lessee may terminate this Lease Agreement post lock in for its convenience by giving (90 ] days prior written notice to the Lessor . The Lessee shall vacate the Land and will take the possession of the equipment/movable assets belonging to the Lessee and installed in the Land . 12 . 4 Notwithstandinganything contained in this Lease Agreement , on occurrence and/or continuation of a Force Measure Event which shall include but not limit to any event outside the reasonable control of a Party including, any physical natural disaster or any other act of God , riot, war, invasion, act of foreign enemies, acts of terrorism, rebellion, insurrection of military or usurped power, pandemic, epidemic, ೦ - Page8of16 ೦

![](image_066.jpg)

COVID - 19 restrictions, compulsory acquisition by any governmental or competent authority, acts of the governmental or competent authority including non - issuance of approvaV consent for operating business, change in the legaV regulatory regime, an which in any manner affects the Lessee's enjoyment of its rights, temporarily or otherwise, or if the Land is damaged or destroyed to such an extent so as to become unfit, temporarily or otherwise for the business use of the Lessee for a continuous period of 30 (thirty) days then the Parties may upon mutual discussion renegotiate the terms of this Lease Agreement including the Monthly Rent . Further, if such a Force Measure Event continues beyond 45 [Forty - Five] days, the Lessee may forthwith terminate this Lease Agreement and take the possession of aU the equipment/moveable assets belonging to the Lessee and installed in the Land . 13. Sub - Letting/Assignment 1. The Lessee shall be entitled to assign the lease, or transfer/assign the same to any of its group companies/ subsidiaries or companies which are relevant to its business purposes or to any other company provided however that the terms and conditions agreed upon by the Lessee herein shall apply mutates to the intending lessee ; Provided further that any such sub - letting or assignment shall not be inconsistent with or constitute a breach of the provisions of this Lease Deed . However, the Lessee continues to be responsible to all the obligations of this Lease Deed . If any subletting to third parties, the Lessee shall take prior written permission from the Lessors 14. Lease Agreement Registration 1. This Lease Agreement shall be registered with the appropriate authority in Sub Registrar Hyderabad. The cost of the registration including stamp duty shall be borne by the Lessee. 15. Consultancy & Advisory Services I. Appointment of Advisor : The Lessee and Lessor hereby acknowledge and confirm that Raghavendra Verita Spaces UP ("Advisor") has been exclusively appointed as the Real Estate Advisor in respect of the said property for the purposes of this lease transaction. II. Scope of Services: The Advisor shall provide complete real estate advisory and consultancy services, including but not limited to, property identification, evaluation, facilitation of negotiations between the partie s, coordination of documentation, assistance in legal and statutory compliance, and overall facilitation of the lease execution process until successful completion. ill. Service Fee: In consideration of the services rendered by the Advisor, the Parties agree that the Advisor shall be entitled to a one - time professional service fee equivalent to thirty (30) days of the monthly lease rental value i.e 16,40000/ - plus applicable GST for the said property . Such fee shall be fayable by the [spe ify ೦ /' ೦ ೦ ೦ , 1. • p .,. < Pa ge 9 of 16 erabad ೦ S - S

![](image_067.jpg)

party - Lessor/Lessee/Both, as applicable] within seven (7) days of execution of this Agreement to Lease , irrespective of any subsequent termination or modification of this Agreement. IV. Acknowledgment: The Parties expressly acknowledge and agree that the Advisor 's role is integral to the completion of this lease transaction, and that the above - stated service fee is fair, reasonable , and payable in full upon the occurrence of the fee trigger event as stated herein. 16. General 1. This Lease Agreement shall be governed and enforced according to the laws of the Republic of India . Subject to below given arbitration clause , competent court in Hyderabad shall have exclusive jurisdiction on all disputes ari s ing out of this or in connection with this Lease Agreement . 2. All the disputes arising out of or in connection with this Lease Agreement including the termination thereof during the subsistence of this Lease Agreement and any time thereafter shall be settled by the s ole arbitrator mutuaJly appointed by both the Parties . The proceedings shall be held in accordance with the Indian Arbitration and Conciliation Act , 1996 and Rules framed thereunder , as amended from time to time. The seat of arbitration shall be at Hyderabad and the proceedings shall be in English language only. The arbitrators ' award shall be substantiated in writing which shall be final and binding on both the Partie s and enforceable in any competent court of law. 3. The content of this Lease Agreement , information related to the Parties and information disclosed by the Parties to each other (" Confidential Information ") , before the execution of this Lease Agreement and during the validity of this Lease Agreement, s hall remain confidential . The Parties may disclose the Confidential Information to their employees , directors , consultants , agents , auditors , tax and legal advisors and investors on need to know basis . Provisions of this article s hall not be applicable on any Confidential Information which is already in public domain or hereafter, through no fault of the Party making such disclosure , becomes public knowledge or is required to be disclo s ed pursuant to appUcabJe law s, rule s and regulations . 4. Any notice , consents , claim and other communications (" Notices") to be given hereunder by any Party to the other shall be in writing , in English language and shall be deemed given upon : (i) deli v ery, if handed personally ; or (ii) if s ent by mail (certified or regi s tered mail , return receipt requested , postage prepaid) or by an internationally recognized courier service , upon the receipt of the same by the other Party as evident from the tracking report of the courier service ; or (iii) if by electronic mail , upon the expiry of 24 (twenty four) hours from transmission . Notices to the Parties shall be sent to their respective addresse s first mentioned in this Lease Agreement or any other addresses subsequentl y notified by them . 5. No waiver , relaxation , or inaction by any Party a t any time to require performance of any of the pro ೦ : ೦ of this Lease Agreement X \ al in any way affi ೦ ೦೦ s h ೦ ' Pag e 10 o f16 o/

![](image_068.jpg)

, or prejudice the right of such Party to require performance of that provision . Any waiver or acquiescence by any Party of any breach of any of the provisions of this Lease Agreement shall not be construed as a waiver or acquiescence of any right under or arising out of this Lease Agreement or of the subsequ . ent breach and shall not be deemed a continuous waiver unless it is specifically mentioned in the waiver . 6. If any provision of this Lease Agreement is determined to be invalid or unenforceable under the Applicable Law , in whole or in part, such invalidity or unenforceability shall attach only to such provision or part of such provision and the remaining part of such provision and all other provisions of this Lease Agreement shall continue to remain in full force and effect . In such event , the Parties undertake to endeavour in good faith to replace the invalid, illegal or unenforceable provision by a valid, legal and enforceable provision which contains, as nearly as possible, the rights and obligations contained in the provision to be replaced . 7. No variation including any amendment, supplement, deletion or replacement of this Lease Agreement (or of any of the docu . ments referred to in this Lease Agreement) shall be valid unless it is made by an instrument in writing and signed by each Party . 16 . 8 In no event will either Party be liable to the other for any delay or failure to perform its obligations hereunder (including payment obligations), which delay or failure to perform is due to causes a Force Measure Event . In every case, the delay or failure to perform mu . st be beyond the control and without the fault or negligence of the Party claiming excusable delay or waiver. 16.9 Save as otherwise expressly provided in this Lease Agreement, any Person who is : ೦ = : ೦೦ r ;e Agreement shall n ೦ ave any rights to enforce any term of ೦ /' 1 Pagell of16

![](image_069.jpg)

SCHEDULE OF PROPERTY All the land admeasuring 41 Acres in total bearing survey no ' s detailed , situated SY . NO : 325 , 326 , 327 , 328 & 329 admeasuring 41 acres (out of 59 . 27 acres) as a land parcel situated at Village Kallakal ,Mandal Manoharabad, Division Toopran, District Medak,State Telangana . Pin - 502110 . EAST BY WEST BY NORTH BY SOUTH BY IN WITNESS whereof this Lease Agreement bas been executed by the Parties on the date and place first above written . LESSOR Witness: . I Smt. A tha Raj Kumar lttaboieoa LESSOR LESSEE 2 . SURESHS Witness: Page 12 of16

![](image_070.jpg)

Annexure - B Rent Payable (Break - Up) Rent shall be payable by the Lessee to the Lessor at Quarterly : Rent Calculation is as follows: 40,000 X 41 acres= INR 16,40,000/ per month. Quarterly i.e. - 49,20,000/ - [rupees Forty nine lakh Twenty thousand only per quarterly) from the rent commencement date Rent shall be Payable to the Lessor in the Bank Account Details as mentioned below: Bank Name Account Name Account Number - IFSC Branch Address Page13 of 16

![](image_071.jpg)

Area Land Map Page 14 of 16

![](image_072.jpg)

- - - - • - c . . - .. . - _, · - - - - ,....... - .. - - . . _ . . f.illll'! -- - s E w SLNO Parucu"9rs Sy . NO 01 325 02 ೦ 6 03 327 - 328 14 - 33 04 13 - 11 329 05 12 - 05 330 06 - 27 Page 15 of16

![](image_073.jpg)

Purpose ACR - GTS Sy .No Particulars S.No Lease 17 - 28 325 1 Lease 11 - 06 326 2 Lease 10 - 24 327 3 Lease 14 - 33 328 4 Lease 13 - 11 329 5 Below are the details the Land owner with Survey numbers & land extent: The Indjvidual Landowner Smt. Architba Raj Kumar Ittaboiena to act as their lawful representative for the purposes of this Agreement to Lease. Note: The total extent of the land measures Acres 69 . 27 (Sixty - Nine Acres and Twenty - Seven Guntas), which is the absolute property of Smt . Architha Raj Kumar Ittaboiena . Out of the sa id total extent, an extent of Acres 59 . 27 (Fifty Nine Acres Twenty Seven Gunta) comprised in Survey No . 325 , 326 , 327 , 328 & 329 . Out of which only, From the said extent, an area of Acres 41 (Ten Acresonl ೦ ೦ eed for Lease unde ೦ i s A gre e m e n h - t - l . . L ೦೦೦ - - 1 Page 16 of16

## Ex1A-6

**Exhibit 6.6**

![](image_094.jpg)

t ೦ i ೦ ! ೦ ••f.. ೦ :: . - 0 . ೦ J'. ೦ 2, ೦ f1 ೦ r - i ೦ .. , . ೦ . . eoor \ - orn dH•ll.:WI TELANGANA Tran I ೦ : 250326204530732798 Date: 26 MAR 2025. 08:50 PM Purchased By: CH. RJJ1 REDDY S / o BAPU REDDY Rio HYDERABAD For \ 1J,om ••s ೦ F 0 BL . 44A148 f ೦ o.:t.1 ETIKALA DBANALAXMI LICENSED STAMP VENDOR Lie. No. 1 707022/2021 Ren . No. 1707037 /2 024 Chegunt11 Ph 6301810225 AGREEMENT OF SALE THIS AGREEMENT . OF SALE IS MADE ON THIS 09 TH DAY OF AUGUST , 2025 AT ೦ ECUNDERBA ೦ BY AND BETWEEN : - 1 M r . CHENDI ೦ DDY RAJI REDDY (AADHAAR NO . 9787 - 2345 - 0911 & PAN : AMRPC 6639 G) S/o Late CH . BAPU REDDY , Age : 51 years, Occupation : Business . R/ 0 . H . NO . 1 - 4 - 177 / 10 / 4 , GREEENWOOD COLONY, OLD ALWAL, VENKATARAMANA COLONY , ALWAL, DIST MEDCHAL - MALKAJGERY, HYDERABAD, TELANGANA, PIN - 500010 , Mobile : W 7 674014571 . Hereinafter referred to as FIRST PARTY / VENDOR which expression shall m 6 ,fm and include all their legal heirs, executors, administrators, representatives, assignees, successors m estate, agents, successors and nofninees in Office etc . , of the One Part . Contd ... P/ 2 I I • a

![](image_095.jpg)

:: 2 :: IN FAVOUR OF M/ s MyRxWallet Prana Private Limited, Registered Office address is Wework, Raheja Mindspace, Sy . No . 64 , Building No . 9 , Madhapur, Shaikpet, Hyderabad, Telangana, India, PIN : 500081 . CIN U 86900 - TS - 2025 - PTC - 201297 . Represented by its Directors : (1) Mr. VENKATARATNAM POPPOPPU (Aadhaar No. 3179 - 3673 - 9502, PAN NO. A I LPP4689B AND D I N : 07812464) S/o Bulli Ramaiah Poppoppu , aged 54 years, Resident of H . No . 2 - 63 , Flat No . 204 , Block - B, Sai Durga avenue, Nizampet, Hyderabad, Telangana, P I N : 500090 . MO BILE : _ (2) Mr. SURESH SURA (Aadhaar No.3869 - 5022 - 4901, PAN No.BK IP S1400F AND DIN : 06777788) S/o Sura Venkateshwara Rao , aged 47 years, Resident of H . No . 3 - 6 - 54 , Flat No . 4 D, Anantha Sai Apartment, Vive k anandha Nagar Colony, Road No . 22 , Kukatpally, Hyderabad, Telangana, PIN : 500072 . MOB I LE : _ Hereinafter referred to as SECOND PARTY/ VENDEES which expression shall mean and include all their legal he i rs, executors, administrators, representatives, assignees, successors in estate, agents, successors and nominees in Office etc . , of the Second Part . W H EREAS the FIRST PA R TY, SECOND PARTY and Other Parties involved have come to a mutual agreement to execute this sale of a total land extent admeasuring approximately 216 Ac r es (Refer ANNEXURE - A) abutting to NH - 44 (Hyderabad to Nagpur Highway) situated at Village Chinnashivnoo r , Mandal Chegunta of Medak District, Te l angana, I ndia, PIN : 502255 for a cumulative total sale consideration including the stamp duty and consultation fee the amount to be paid to the land owners wou l d be Rs . 727 , 18 , 56 , 000 . 00 (Indian Rupees Seven Hundred Twenty Seven Crore s Eighteen Lakhs and Fifty Six Thousand Only) ~ $83 , 584 , 551 . 00 USD (E i ghty Three Million - Five Hundred Eighty Four T h ousand - F i ve Hundred and Fifty One US Dollars @ Dolla r Current price INR 87 / - per USD) . The details of this total sum amount have been outlined below in points 1 - 7 . The extent of land may be increased or decreased depending upon physical possession available in accordance with the survey of land records and registration of s ೦೦೦ ... P/ 3 ೦೦ C) - ೦

![](image_096.jpg)

AMOUNT IN USD AMOUNT IN INR PARTICULARS SL . NO . 356,322/ - 3, 10,00,000 ! - PRICE PER ACRE 1 76,965,517 / - 669,60,00,000 / - PRICE PER 216 ACRES 2 NOTE: Calculated Current US Dollar Price in INR.87/ - per USD :: 3 :: Whereas the above mentioned F IR ST PARTY is the representative of the land owners of the schedu l ed property for the purpose of signing this agreement and to execute this agreement of sale on their behalf as the FIRST PARTY has got consents from the other Pattadars . The land owners who will be signing the Sale Deeds at the registrar office (Refer ANNEXURE - A) are the absolute ow n ers and possessors of the scheduled property abutting to NH - 44 (Hyderabad to Nagpur Highway) situated at Village Chinnashivnoor, Mandal Chegunta of Medak District, Telangana, India, PIN : 502255 . Whereas the F IR ST PARTY is representing both (a) Mr . Chendireddy Raji Reddy as a individual owning land parcel including (b) the other land owners for the apportion of the scheduled property, who have jointly herein offered to sell the total 216 Acres approximately (Refer ANNEXURE - A) of the scheduled property abutting to NH - 44 (Hyderabad to Nagpur Highway) situated at Village Chinnashivnoor, Mandal Chegunta of Medak District, Telangana, India, PIN : 502255 , in its entirety to the SECOND PARTY for a total consideration as per the details given below : - Whereas the SECOND PARTY herein agreed to purchase the schedule property for the said lump sum sale consideration from the FIRST PARTY . The FIRST PARTY has assured the SECOND PARTY that either all the Sale Deeds have to be executed by the Pattadars / Owners / AGPA holders in the SECOND PARTY's / NOMINEE's names directly or transfer the other Pattadar's land on FIRST PARTY's name first /SPV's name and then to th e SECOND PARTY's / NOMINEE ' S names as per the mutual consent and convenient of the both the parties. ೦ bbY td ... P/4

![](image_097.jpg)

:: 4 :: WHEREAS the FIRST PARTY has furnished all the certified copies of P attadar Pass Books(Bhu Bharathi/Dharani), Sale Deeds, ECs, All Pahanies, Kasra Pahanies, Link Documents, Agreement of Sales, Legal Opinions, Valuation Report issued by M/S B . E . Reddy & Associates, Hyderabad and Location Sketch Map/Digital Survey Map of the Schedule Property, etc . , to the SECOND PARTY to verify the title and source of title, etc . On satisfying all the terms and conditions, the SECOND PARTY has agreed to purchase the aforesaid property through the FIRST PARTY . WHEREAS the SECOND PARTY assured and agreed to pay an amount of Rs . 669 , 60 , 00 , 000 / - (Rupees Six Hundred Sixty Nine Crores and Sixty Lakhs only) to the FIRST PARTY towards total sale consideration for purchase of the above agriculture land for an extent approximately 216 Acres (Refer ANNEXURE - A) of the scheduled property abutting to NH - 44 (Hyderabad to Nagpur Highway) situated at Village Chinnashivnoor, Mandal Chegunta of Medak District, Telangana, Indi a, PIN : 502255 either by way of single payment or on the pro - rata basis against the extent of land registered or by way purchase of SPVs(Special Purpose Vehicles) meant for this land within the period of 90 days from the date of this agreement and another 30 days will be exten ded subject to maximum of total 120 days only as per the mutual consent and convenient of both the parties, post which it is null and void repeat treated as invalid : PAYMENT DETAILS Committed date of p a yment from the date of this A reement of Sale is AMOUNTININR PARTICULARS SL. NO . First cutoff date: 09.11.2025 i.e., within the period 90 days. Second cutoff date: 09.12 .2 025 i.e. , within the period of extension for 30 days. Validity period of this a eement is 120 da s 669 , 60,00,000/ - (Rupees Six Hundred Sixty Nine Crores and Sixty Lakhs only) Total sale consideration for purchase of the above agriculture land for an extent approximately 216 Acres 1 Note: - Either by way of single payment or on pro - rata basis against the extent of land registered or by way purchase of SPVs(Special Purpose Vehicles) meant for this l and within the period of 90 days from the date of this agreement and another 30 days will be extended sub·ect to maximum of total 120 da s onl from the this a reement

![](image_098.jpg)

AMOUNT IN USD AMOUNT IN INR PARTICULARS SL. NO. 5.85 Million USD 50 ,89,00,000/ - Stamps and Registration Duty @ 7.6 % on total sale consideration INR. 669,60,00,000/ - I Note: - Calcu l ated Current US Dollar Price in JNR. 87 / - oer USD : 5 : : : In order to have records straight and to avo id future claims, complications and disputes, this Agreement of Sale is executed on the terms and conditions hereinafter set forth . NOW THIS AGREEMENT OF SALE FURTHER WITNESSES AS FOLLOWS 1. The SECOND PARTY wil l go ahead with the purchase and carry out the registration process of the scheduled prop erty on or before 90 days from the date of this agreement and another 30 days will be extended subject to maximum of total 120 days only as per the mutual consent and convenient of both the parties, post which it is null and void . 2. The SECOND PARTY will have to pay a Stamp and Registration Duty of 7 . 6 % of the total sale consideration to the Gov ernme nt of Telangana prior to the registration to book a slot at the Tahasildar / Sub - Registrar/ SRO office to carry out the registration of the sale deed . The details amount is given below : - 3 . The said sale consideration does not include the consultation and facilitation fee payable to M/s RAGHAVENDRA VERITA SPACES LLP towards facilitating the agreement of sale, which stands at I % of the total sale consideration plus 18 % applicable GST . The total payable fee would be Rs 6 , 69 , 60 , 000 / - (Indian Rupees Six Crores Sixty - Nine Lakh Sixty Thousand Only)~ $7 , 697 , 701 . 15 (i . e . , approx . 7 . 70 million USD @INR 87 / -) , Seven Million Seven Hundred Thousand US Dollars (considered current market doUar price i.e., INR 87 / - per USD). 4. The SECOND PARTY will hav e to account for the o u t of pocket expenses to be paid at the time of registration on pro - rata basis which will be hanilled;:::aVertra w Spac ೦ C7 . ೦ U7 e_ /6

![](image_099.jpg)

AMOUNT IN USD AMOUNT IN INR PARTICULARS SL . NO . 3 56, 3 22 / - 3 , 10 , 00 , 000 / - PRICE PER A C RE 76,965,517 / - 669,60,00,000/ - PR I CE PER 216 ACRES 1 5,849,379/ - 50,88,96,000 / - STAMP DUTY (@ 7.6% 2 769,655/ - 6,69,60,000/ - CONSULTAT I ON FEE Cm 1 % 3 86,584 551/ - 727, 1 8,56,000/ - NOTE: !)Calculated Current US Dollar Price in INR.87 / - per USD 2)Any Incidenta l and unforeseen charges shall be paid extra at the time of registration at SRO by the SECOND PARTY as per the actual only. :: 6 :: 5 . The Total Sale Consideration including the stamp duty, consultation f ee, out of pocket expenses and the amount to be paid to the FIRST PARTY / LAND OWNERS is mentio n ed below : - 6. That the SECOND PARTY assured and agreed to pay the total sale consideration including Stamp Duty, Consultation Fee etc . , in INDIAN RUPEES only irrespective of value of USD to the FIRS T PA R TY from the time to time . 7. That in pursuance of this Agreement of Sale, either the FIRST PARTY shall form one or more SPVs(SPECIAL PURPOSE VEHICLES) to transfer the above said agriculture land into SPVs by the Pattadars first, then transfer of the entire SPVs to the SECOND PARTY phase wise OR transfer of above said agriculture land to the SECOND PARTY by the FIRST PARTY / LAND OWNERS(Pattadars) directly as per the mutual con sent and convenient of both the parties. 8. That the SECOND PARTY assured and agreed to pay an amount of Rs . 669 , 60 , 00 , 000 / - (Rupees Six Hundred Sixty Nine Crores and Sixty Lakhs only) to the FIRS T PARTY towards total sale consideration for purchase of the above agriculture land for an exte nt approximately 216 Acres (Refer ANNEXURE - A) of the scheduled property abutting to NH - 44 (Hyderabad to Nagpur H ighway) situated at Village Chinnashivnoor, Mandal Chegunta of Medak District, T elangana, India, PIN : 502255 either by way of single payment OR on the pro - rata basis against the extent of land registered OR by way of purchase of SPVs(Special Purpose Vehicles) meant for this agriculture land within the period of 90 days from the date of this agreement and another 30 days will be extended subject to maximum of total 120 days only as per the mutual consent and convenient of both the parties, post which it is n 11 / : / } ; 1 ; ೦ !, ೦ , ..: ... P / 7 ೦೦ ೦ <;;.su;JZ

![](image_100.jpg)

Committ e d date of p ay ment from the d a te of this Ae:reement of Sal e i s AMOUNTININR PARTICULARS SL . NO. First cutoff date: 09 . 11.2025 i.e., within the period 90 days. Second cutoff date: 09 . 12.2025 i . e . , within the period of extension for 30 days. Validity period of this ae:reement is 120 days 669,60 , 00,000/ - (Rupees Six Hundred Sixty Nine Crores and Sixty Lakhs only) Total sale consideration for purchase of the a b ove agriculture land for an extent approximately 216 Acres 1 N ote: - Either by way of single payment or o n pro - rata basis agai n st the extent of land registered or by way purchase of SPVs(Special Purpose V e hicles) meant for this land within the period of 90 days from the date of this agreement and another 30 days will be ex t ended subject to maximum of total 120 day s only from the this a ೦ eement :: 7 : : 9. That the SECOND PARTY shall be paid the total sale consideration to the F I RST PARTY on or before execution of Registered Sale Deed against extent of land registered OR transfer of SPVs from time to time within the stipulated time of 90 days extended up to maximum of 120 days from the date of t his Agreement of Sale . If the SECON D PARTY fails to pay within the stipulated as stated above, this Agreement of Sale shall stands Terminated/ Cancelled without any notice of intimat i on from the F I RST P ARTY and the SECON D PARTY is liable to pay 1 % of the total sale consideration to the F I RST PARTY as 'BREAK I NG CHARGES' wit h out fail . There upon the FIRST PARTY is at liberty to enter into Agreement of Sale OR Sale the schedule property to any third party of its choice . 10. That both the PARTIES agreed that time is the essence of this Agreement of Sale ; this Agreement o f Sale shall be valid till 09 / 11 / 2025 and the same will be extended subject to maximum of total 120 days i . e . , up to 09 . 12 . 2025 only as per the mutual consent and convenient of both the parties, post which it is null and void . 11. That the said total sale cons i deration does not include the Land Zone Conversion Fee that needs to be paid to the government or the facilitation charges, land leveling and other development charges that need to be paid to Raghavendra Verita Spaces LLP / the FIRST PARTY for taking care of the land zone conversion process, leveling and development, in case any portion of the proposed l and needs to be converted to better suit the SECOND PARTY's end utility as per mutual consent and convenient of the both the dJ _ - . ೦೦ 1 •.i.. - t - H • •~ ೦ Prcl,., ೦ . ೦ . . 1r " . " " .._.. ,............... d ... P/8 g . g

![](image_101.jpg)

AMOUNT IN USD AMOUNTININR PARTICULARS SL. NO . 356,322/ - 3, 10,00,000/ - Land Value per Acre 1 76,965,517 / - 669,60,00,000/ - Tota l Land Value for 216 Acres 2 3,078,21/ - 26, 78,40,000 / - NALA Conversion Fee @ 4% 3 NOTE: - 1) Calculated Current US Dollar Price in INR.87/ - per USD 2) That the above is illustrative . The actual fee will be charged as per the prevailing government rates in accordance with the law at the time of conversion, etc. 3) In addition to the above any other Incidental, Miscellaneous and Unforeseen charges shall be paid extra as per the actual bv the SECOND PARTY :: 8 : : 12 . That the area outside Hyderabad/HMDA - which applies to Medak District, Chegunta Mandal, Chinnasivnoor village - the app li cab l e NALA Conversion Fee is@ 4 % on the l and value . 13. That the all app l ication/processing charges, cess or local body charges including layout approval by DTCP/MAUD, mutation entries, development funds, stamp duty and registration fees if application and any other professional fee for legal, survey or liaison work shall also be borne and paid in full as per the actual by the SECOND PARTY for initiating and benefitting from the conversion process in addition to the above total dale consideration . 14. That the FIRST PARTY hereby assure that the Pattadars from whom they have entered into Agreement of Sale and got consent to purchase the aforesaid property, have got absolute right, marketable title and possession over the aforesaid property, hence they are authorized to enter into this Agreement of Sale . 15. That the FIRST PARTY has handed over all the certified copies of Pattadar Pass Books(Bhu Bharathi/Dharani), Sale Deeds, ECs, All Pahanies, Kasra Pahanies, Link Documents, Agreement of Sales, Legal Opinions, Valuation Report issued by M/S B . E . Reddy & Associates, Hyderabad and Location Sketch Map/Digital Survey Map of the Schedule Property, etc . , to the SECOND PARTY to verify the title and source of title, etc . On satisfying all the terms and conditions, the SECOND PARTY has agreed to purchase the afo ೦ esaid property th d from the FIRST PARTY. r \ _ ೦ _ db , _ ೦೦ ೦ lS2JLr ೦ H \ ld8 ೦ 1r ೦ , .. P/ 9 ೦ SS - U?e -

![](image_102.jpg)

:: 9 :: 16. That the Legal heir certificate for the deceased land owners will be obtained before the registration day, the same will be provided to the SECOND PARTY along with other documents at the time of registration and they will physically appear and sign the sale deeds at the time of registration in place of the deceased . 17. That the FIRST PARTY will hand over the possession of the scheduled property to the SECOND PARTY at the time of registration to pursue all the necessary developments and endeavours for this sale . 18. The FIRST PARTY assures the SECOND PARTY that the scheduled property is the absolute property of the land owners and that no other person has any right, title or interest over the same now or in the future . 19. The FIRST PARTY assures the SECOND PARTY that there are no further legal impediments to enter into this agreement with the SECOND PARTY and that the scheduled property is not subject to any further gift, alienation, transfer or any encumbrance of what - so - ever kind or nature and is free for sale in favour of the SECOND PARTY . 20. The FIRST PARTY assures the SECOND PARTY that they have not entered into any other agreement of sale or sales with any other third party and scheduled property is free for sale to the SECOND PARTY . 21. The FIRST PARTY assures to handover all the Original documents of title including the link documents, EC, Property Tax Receipts or any other to the SECOND PARTY at the · time of registration as per the norms and applicability . 22 . The FIRST PARTY will accept a relative reduction in the sale consideration agreed in this document, in case the extent of schedule property is less than what is stated in this agreement after official revenue survey of the property physically . ೦

![](image_103.jpg)

:: 10 :: 23. The FIRST PARTY and land owner, facilitated by Raghavendra Verita Spaces LLP, are willing to co - operate in case a land zone conversion is required by the SECOND PARTY. ARBITRATION CLAUSE: - 24. All disputes shall be resolv ೦ d through Arbitration and other ADR(Alternative Dispute Resolution) methods under Conciliation Act, 1 996(Amended in 2019) within Hyderabad, Telangana. Appropriate legal recourse the Arbitration and the jurisdiction of may be sought if Arbitration fails and the parties are unable to reach a consensus as a resolution to the competent court as per the provision of the Indian Law. SCHEDULE OF PROPERTY All the land admeasuring total 216 Acres (Refer ANNEXURE - A) of the scheduled property abutting to NH - 44 (Hyderabad to Nagpur Highway) situated at Village Chinnashivnoor, Mandal Chegunta of Medak District, Telangana, India, PIN : 502255 . The Schedule Property is bounded by : NORTH SOUTH EAST WEST NE I GHBOURS LAND NE I GHBOURS LAND R&B ROAD, NEIGBHBOURS LANDS & OPEN PLOTS i:;'.:derabad toNagp ೦ Highway @ K sh ೦೦ 1girlabadl 1 ... P/ 11

![](image_104.jpg)

:: 11 :: IN WITNESS WHEREOF the above - named FIRST and SECON D PARTIES herein have signed this Agreement of Sale on the da y, month and year aforementioned voluntarily with their own free will and consent and without any undue influence at HYDERABAD in the presence of the witnesses below mentioned . WITNESSES FIRST PARTY 1. CHENDIREDDY RAJIREDDY (Landlord & Representative) 2. J) SECOND PARTY M/ s MyRxWallet Prana Private Limited l)VENKATARATNAM POPPOPPU Director S - SC52 ೦ Q/ - - _ 2)SURESH SURA Director

![](image_105.jpg)

LIST OF DOCUMENTS ENCLOSED FIRST PARTY 1) ADHAR CARD OF THE FIRST PARTY. 2) PAN CARD OF THE FIRST PARTY. 3) LOCATION SKETCH MAP . 4) LIST OF DETAILS OF LAND OWNERS WITH SURVEY NUMBERS AND LAND EXTENT. 5) ADHAR CARD OF THE FIRST PARTY. 6) Certified copies of Pattadar Pass Books(Bhu Bharathi/Dharani), 7) Sale Deeds, ' 8) ECs, 9) All Pahanies, 10) Kasra Pahanies, 11) Link Documents(Sale Deeds and 13B Proceedings, etc), 12) Agreement of Sales, GPA and Consent letters, 13) Legal Opinions, 14) Valuation Report issued by M/S B.E.Reddy & Associates, Hyderabad, 15) Location Sketch Map/Digital Survey Map of the Schedule Property, etc., 16) All other documents related to the above land. 17) Bank account details/NEFT FORM of the FIRST PARTY, PATTADARS AND SPVs whichever is applicable. SECOND PARTY 1) ADHAR CARDS OF THE SECOND PARTY. 2) PAN CARDS OF THE SECOND PARTY 3) Company Registration Certificate issued by the ROC along with complete dossier, by - laws, List of the Directors, PAN/TAN/CIN and GST. 4) Board resolution for purchasing of the scheduled property. 5) Mother Company details., 6) Under Taking Certificate issued by the Mother Company /USA - MyRxWallet North America Corp. is 2475 S Jones Blvd, Ste 9, Las Vegas, Nevada, 89146. 7) Details if any to be given to the FIRST PARTY.

![](image_106.jpg)

Location Sketch Map: 9 @ M N 1 0 z..O 3 0 4 CJ ; ೦ 00 I I_.;} ೦ 00} ((I) 'I \ 03lX 0 \) \ t \ 1 ೦ HID (\) no, \ ; I, \ ll l ೦ V,: - .: II IJ SlVI mo (! \ \ ·1 ·Ill d \ 11 ೦ IUn)IS \ 011 VJO'I 5" ೦ '!, (;10 I 2.o I oo] Below are the details the Land owners with Survey numbers ೦ ೦ .i. 1 land extent:

![](image_107.jpg)

GTS ACR SY.NO. PPB&SD.NO. ACR GTS Name S.No. Group PPB - T0S0 - 2015 - 1398 4.5 9 PANKAJ MD 1 17 5 1551/2021 1 24 1 1552/2021 2 3.5 2 1719/2021 3 4.5 9 PPB - T0S0 - 2015 - 1400 10 ASHOKMD 4 0 1554/2021 1 24 3 1718/2021 2 32.S 3 399/2022 3 32.S 0 402/2022 4 28 1 396 28 23 - Aug 1 10 PPB - T0S0 - 2015 - 1399 36.5 10 KETANMD 0.5 1 1556/2021 1 25 2 1720/2021 2 0.5 6 400/2022 3 10.S 1 401/2022 4 36.5 10 PPB - T080 - 2015 - 1401 7 9 NITINAD 24 3 1558/2021 26 2 1721/2021 4 1 395 4 1 403 /2 022 U 1 397 7 4 1842/2022 23.5 1 396 35 5 11.5 1 398 0700 9 27 0 397 PPB - T080 - 20l5 - 1590 1 L KONDA MURALI ANKIREDDY 13 0 395 999/2023 1 0 400 0 1 400 PPB - T0S0 - 2015 - 1591 0 lNDLARADHA 0 1 395 PPB - T080 - 2015 - 1S92 0 l INDLA RAMASUBBA REDDY 20 ೦ 0 ೦ \ Ir 395 PPB - T0S0 - 2015 - 1702 20 0 ALAMNAWAZ 30 42 TOTAL GROUP - I • The landowners have authorized Mr. Cbeodireddy Rajireddy to act as their lawful representative for the purposes of this Agreement to Sale. Table 1: 12

![](image_108.jpg)

GTS ACR SY.NO . GTS A C R PPB&SD . NO . Name S.No . Group 20 0 395 PPB - TOSO - 2015 - 0897 9 2 MINNAKANTI PRASAD 2.17 9 II 34 0 400 1630/2021 8 1(52) 15 1 397 2373/2019 2 29 2 6063/2018 3 37 3 20 0 395 PPB - TOSO - 2015 - 0897 16 4 M.AMRUTHAMMA 10 738/2015 17 1(52) LINK: 540 / 2006, 191S/200S, 739/2015 , 702/2006, 1812/2005 3.3 0 400 PPB - TOSO - 2015 - 1492 3.2S 0 B.PRAVEEN KUMAR GOUD 11 10 1 44 PPB - TOSO - 2015 - 08S4 10 1 SUNKARIMOUNIKA GOUD 12 27 8 399 PPB - TOSO - 2015 - 1482 27 8 AYASHWANTH REDDY 13 27 8 1106/2016 0 2 400 AGPA 0 2 R SATISH KUMAR 14 2306/2007 BRAMESH YADAV MRAVIKUMAR PPB - TOSO - 2015 - 0445 14 0 K.LAXMANREDDY 15 14 0 406 14 0 269 / 2021 26 5 404 PPB - TOSO - 2015 - 0888 11 6 MANJUDEVI JAIN(PPB ON HIM) 16 25 0 406 11 6 5S88/2018 KALVA KA VITHA REDDY K.LAXMAN REDDY 17 1 398 PPB - TOSO - 2015 - 0526 17 1 KUMMARJ SAITAMMA 17 33 3 PAKA SATTAMMA 18 11 1 394 PPB - TOSO - 2015 - 1637 11 1 GURMILLA DEVENDER 11 1 394 PPB - TOSO - 2015 - 1635 11 1 SEETBA MADHU 11 1 394 PPB - TOSO - 2015 - 1636 11 l GUNDELLIYADAGIRI - PPB - TOSO - 2015 - 0526 20 0 UPPALA VENKATESHW ARLU 19 521 $1 \ Pr_ ೦೦ ೦ y ' \ ೦ ೦ : ೦ (V ೦ ೦ ೦೦೦ i l 3 S . SU7 ev -

![](image_109.jpg)

I I I TOIAL - GROIJP - 11 GRAND TOIAL(GP - 1&2) I I 1 1 I I I 1 ೦ GTS ACR SY .NO . GTS ACR PPB&SD.NO . Name S.No . Group PPB - T080 - 201S - 1416 20.5 11 CH RAJ] REDDY (11.05.5) 1 ill - A 404/2022 1590/2022 1615/2022 1841/2022 1843/2022 1845/2022 1846/2022 1858/2022 1865/2022 1574/2023 1772/2023 PPB - T080 - 2015 - 1543 21 0 J.SANTHOSH(HP) 2 5 0 390 5 0 30/2023 16 0 386 16 0 1469/2023 21 0 PPB - T080 - 2015 - 1584 4 0 P.SHASHANK 3 4 0 390 4 0 905/2023 PPB - T080 - 20IS - 1585 6 0 A.B.P ARDESffl 4 6 0 390 6 0 906/2023 21 0 383 PPB - T080 - 201S - 1401 7 1 NITINAD 5 26 0 383 1558/2021 PPB - T080 - 201S - 0426 31 3 G.SUDHEER REDDY 6 32 1 381 1448/2013 39 1 378 2488/2016 20 1 395 PPB - T080 - 2015 - 0826 20 2 MD. YOUSUF 7 816/2011 0 I 383 3481/2013 380 PPB - T080 - 2015 - 0481 4 2 M AMRUTHAMMA 8 \ ೦ lt . ೦ il ೦ 383 r ೦ r o I \ ೦ 738/2016 1 ೦ ೦೦ ೦ ೦ ೦ r

![](image_110.jpg)

0 2 378 PPB - T080 - 2015 - 0 2 MD.KHADIR 9 13B - MRO PROCEEDINGS 10 0 380 PPB - T080 - 2015 - 10 0 CB. SREEKANTH REDDY 10 4547/2025 3 . S 24 TOTAL GROUP - I PPB - T080 - 2015 - 169S 23.5 8 G.SAIAKHIL REDDY 11 Ill A PPB - T080 - 2015 - 1560 29 12 V.SUJEEIB 12 PPB - T080 - 2015 - 0087 39.5 11 P.JAGAN MOHAN REDDY 13 PPB - T080 - 2015 - 0677 18 11 GOPIDIVENKAT AKSHAYREDDY 14 PPB - T080 - 2015 - 0088 32 1 GOPIDI RAJJTHA 15 PPB - T080 - 2015 - 1292 0 2 VEDAMALA CHITRAREKHA 16 22 48 GROUP - Ill - A GTS ACR SY.NO. GTS ACR PPB&SD - 1'110. Name S.No. Group 377 PPB - T080 - 2015 - 0190 25.5 2 SANKEPALLY SAi BABA 17 ill - B 378 PPB - T080 - 2015 - 0213 25.5 2 SANKEPALLY RAMA DEVI 18 380 PPB - T080 - 2015 - 0807 1 1 MUKANUR SARITHA (VREDDY) 19 36 380 PPB - T080 - 2015 - 1255 20 1 SUNKARI RADBIKA 20 24 395 40 380 PPB - T0S0 - 2015 - 0151 39.5 0 SHEfKB BURANUDDIN 21 ೦ 0.5 ೦೦ ೦ PPB - T080 - 2015 - 0333 20.S 1 SHEfKH NOORJAHAN 22 Pr• ೦ ೦ 1 \ 20 l · ೦ ೦೦ ೦೦೦೦೦ , ೦ . 3U7 _ ,, 15

![](image_111.jpg)

0 1 383 PPB - T080 - 2015 - 0334 0 1 SHElKHKHAIRAT BEE 23 20 I 382 34 2 378 PPB - TOS0 - 2015 - 0143 38 4 KHANPUR TARA DEVI 24 24 I 379 20 0 382 34 1 382 PPll - T080 - 2015 - 1230 34 1 SJNGARAMAINA BABU 25 30 1 381 PPB - T080 - 2015 - 0563 30 1 SINGARM - VENKATESHAM 26 0 1 379 PPB - TOS0 - 2015 - 1552 0 1 SJNGRAMAINA MlJTHYALU 27 36 0 379 PPB - TOS0 - 2015 - 1692 36 0 SJNGRAMAINA SWAMY 28 15 0 380 PPB - TOS0 - 2015 - 1523 15 0 BHAYANI RAGHUPATI 29 15 0 380 PPB - T080 - 2015 - 0561 15 0 SHEIKH KHADIR 30 32 0 380 PPB - T080 - 2015 - uu 32 0 THAHARABEGAM 31 32 0 380 PPB - T080 - 20J 5 - 0905 22 0 MAHMOODA BEGAM 32 34 23 GROUP - lll - 8 ೦೦ ೦ ೦ GTS ACR SY . N O . PPB&SD . NO . GTS ACR Name S.No. Group PPB - TOS0 - 2015 - 0565 24.5 4 ALA ASGAR(7 - l) 32 IV 767/2 00 9 35 . 8 0 615/2022 2 0 19 /2 0 0 8 PPB - TOS0 - 2015 - 0566 22.S 10 SNEBAK S(l0 - 22.5) 33 1 675/ 2 010 YOGE S HTO S NEHAK PPB - TOS0 - 2015 - 1462 31.75 1 KUSHAL S(l - 31.75) 34 61 6/2 0 22 ೦ PPB - TOS0 - 2015 - 0854 15 2 SUMAN S(7.31) 35 F ೦೦ ' > ೦ . , 1 ೦ . ೦ , \ ! , 201 9 /2008 "V' < ೦ 7 6 7/2 00 9 •'Cl 1) \ i J ೦ ೦೦ l q :' I M s.s ,. , ... _ .:; lE

![](image_112.jpg)

33.25 115 GRAND TOTAL (GP - m. A. B&IV) 1.5 194 GRAND GRAND TOTAL (GP - I, II . III &IV) 0 216 ACTUAL 22 BALANCE I GROUP - lV 19 1 I I 1675/2010 I I I l 'i

![](image_113.jpg)

UNDERTAKING (TO WHOM - SO - EVER IT MAY CONCERNED) We the undersigned authorized signatories of M/S MyRxWallet North America Corp . is 2475 S Jones Blvd, Ste 9 , Las Vegas, Nevada, 89146 hereby under take that we have passed the board reso l ution to enter into the agreement of sale for purchase of an extent of 216 Acres agriculture land of the abutting to NH - 44 (Hyderabad to Nagpur H i g h way i . e . , No r th - South Corridor - Kashmir to Kanyakumari) situated at Village Chinnashivnoor, Mandal Chegunta of Medak District, Te l angana, I ndia, PIN : 502255 from Mr . CHENDIREDDY RAJI REDDY (AADHAAR NO . 9787 - 2345 - 09 11 & PAN : AMRPC 6639 G) S/o Late CH . BAPU REDDY, Age : 51 years, Occupation : Business . R/O H . NO . 1 - 4 - 177 / 10 / 4 , GREEENWOOD COLONY, OLD ALWAL, VENKATARAMANA COLONY , ALWAL, D I ST MEDCHAL - MALKAJGERY, HYDERABAD, TELANGANA, P I N - 500010 , Mobile : 7674014571 by our subsidiary company in India M/s MyRxWallet Prana Private Limited , Registered Office address is Wework , Raheja Mindspace, Sy . No . 64 , Building No . 9 , Madhapur, Shaikpet , H y derabad , Telangana, India, PIN : 500081 . CIN U 86900 - TS - 2025 - PTC - 201297 Represented by its Directors : (1) Mr . VENKATARATNAM POPPOPPU (Aadhaar No . 3179 - 3673 - 9502 , PAN NO . AILPP 4689 B AND DIN : 07812464) S/o Bulli Ramaiah Poppoppu , aged 54 years, Resident of H . No . 2 - 63 , Flat No . 204 , Block - B, Sai Durga avenue, Nizampet, Hyderabad, Telangana, PIN : 500090 and (2) Mr . SURESH SURA (Aadhaar No . 3869 - 5022 - 4901 , PAN No . BKIPS 1400 F AND DIN : 06777788) S/o Sura Venkateshwara Rao , aged 47 years, Resident of H . No . 3 - 6 - 54 , Flat No . 4 D, Anantha Sai Apartment, Vivekanandha Nagar Colony, Road No . 22 , Kukatpally, Hyderabad, Te l angana, PIN : 500072 to set up BIO - DATA CENTRE in INDIA . Now , we herein undertake and abide by the terms and conditions agreed and signed by our subsidiary company in India M/s MyRxWallet Prana Private Limited/Hyde r abad in the Agreement of Sale dated 09 . 08 . 2025 on our behalf . IN WITNESS WHEREOF we herein have signed this UNDERTAKING on the day, month and year aforementioned voluntarily with their own free will and consent and without any undue influence at Las Vegas, USA in the presence of the witnesses below mentioned. Note : - Tak e printout on their lett e r h e ad and s i gned by them duly notarized and send to u s in orig i nal through FED - EX as well a s share the sc a nned copy through ema il

## Ex1A-6

**Exhibit 6.7**

![](image_121.jpg)

I 600 ೦೦ dH•li.:tl TELANGANA I • Tran Id : 25081315162132720I Date: 13 AUG 2025, 03:25 PM Purchased By: VENKAT RATNAM POPPOPPU S/o BULLI RAMAIAH POPPOPPU Ri o HYDER.ABAD l'or \ Vhom MIS . MYR.XWAl, L ET PRANA PRNAIE L IMITED (1 BT 304087 c.Jrr t ೦ GOPA SREEMANTH LICENSED STAMP VENDOR Lie . No . 15 - 10.038 /2 019 R e n.No . 15 - 10 - 081 / 2025 ShopNo : 7 , Pl o t No : 44 , Serilingampaliy , Madhapur , Hyderabad P h 9703416341 AGREEMENT OF SALE 'lliis Agreement of Sale is made and executed on this the 16 th August 2025 at Hyderabad by and between : ೦ t . Arcbitha Raj Kumar Ittaboiena (Aadbaar No : 6144 2950 6533 , Pan No : AAHP 07396 Q, DIN no . 07575022), W/o Raj Kumar Yadav, age 47 years, Resident or : H . No . 168 / 3 rt ೦ Su . Imai Cottag ೦ ' 3 Jayanagar Colony, Meena Gardens, Hyderabad, Telangana - 500057 Hereinafter referred to as the VENDOR, which expression shall mean and include all their legal heirs , executors, successors , administrators, representatives, assignee of the first part . I AND I Mis MyRxWallet Prana Private Limited, Represented by its Directors ; 1 . VENKATA IIATNAM POPPOPPU (Aadhaar No : 3179 3673 9502 , PAN No : AILPP 4689 B, DIN : 0 J 812 % 4), S/o Bum Ramaiah Poppoppu, aged 54 years, Resident ofHNo 2 - 63 , Flat No 204 , Block - 11, Sai Durga Avenue, Nizampet, Hyderabad, Telangana, 500090. 2. Suresh S (Aadbaar No: 3869 5ff22 4901, PAN No: BKIPS1400F, DIN: 06777788), S/o Sura Venkateshwara Rao, aged 47 years, lt'esident ofHNo 3 - 6 - 54, Flat No 4D, Anatha Sai Apartment, Vivekanandba Nagar Colony, Road no ೦ • Kukatpally, Hyderabad, Telangaaa, 500072 r .k:::::IM:= - :: ::: - - - 1 ೦ - 5:5 I I

![](image_122.jpg)

Total Consultan Fee Total Land Price 120,00,000/ - 2% 60 Crore Total (INR) Price Per Acre No . Of Acres 60 Crore 6 Crore 10 Total (INR) Stamp - duty &Registration Cha1"2es Tota l Land Price 4,56,00,000/ - a mutual agreement to execute this sale of a total land extent admeasuring 10 Acres (Refer Table 1), situated at at Village KaUakal ,Manda! Manoharabad , Division Toopran , District Medak, State Telangana . Pin - 502110 , for a cumulative total sale consideration including the stamp duty, consultation fee , and the amount to be paid to the land owners would be Rs 65 , 76 , 00 , 000 INR, Rupees Sixty - Five Crore and seventy six Lakh Only (~ $75 , 58 , 62 . 0 i . e . , Seven Million Fifty five thousand eight Hundred sixty two and six cents US Dollars @INR 87 / -) . The details of this totalsum amount have been outlined below in the reference table . Reference table : Whereas the above - mentioned VENDOR is the nominated representative of the land owners of the scheduled property for the purpose of signing this agreement and to execute this agreement of sale on their behalf. The land owners who will be signing the sale deeds at the registrar office (Refer table 1) are the absolute owners and possessors of the scheduled property. Whereas the VENDOR is, Smt. Architha Raj Kumar lttaboiena as a individual , owning land parcel admeasuring 10 acres of the scheduled property , who have offered herein offered to sell the total 10 Acres (Refer Table 1), situated at at Village Kallakal , Mandal Manoharabad, Division Toopran , District Medak , State Telangana. Pin - 502110,in its entirety to the VENDEE for a total consideration of Rs 6 0, 00,00 , 000 INR, Rupees Sixty Crore, (6,896,552 $) calculated at Rs 6,00,00,000 INR, Six..Crores per acre (689,655 $). The VENDEE herein agreed to purchase the property for the said lump sum sale consideration from the VENDOR. 3

![](image_123.jpg)

Location Map: · - - - - - - - -- - , - s E w N SL NO Pan,c:ulars Sy NO ttl

![](image_124.jpg)

Purpo se Extent ACR - GTS Sy.No Particulars S . No Sale 12 - 05 330 1 For Sale 10 acres Out of which (in acres) On Lease 2 - 05 acres Balance (in acres) Below are the details the Land owner with Survey numbers & land extent: • The Individual Landowner Smt. Architha Raj Kumar lttaboiena to act as their lawful representative for the purposes of this Agreement to Sale. Table 1: ε I Note: The total extent of the land measures Acres 69 . 27 (Sixty - Nine Acres and Twenty - Seven Guntas), which is the absolute property of Smt . Architha Raj Kumar Ittaboiena . Out of the said total extent, an extent of Acres 12 . 05 {Twelve Acres and Five Guntas) comprised in Survey No . 330 is identified for sale . From the said extent , an area of Acres 10 . 00 (Ten Acres only) is agreed for sale under this Agreement . This Agreement of Sale further witnesses as follows : 1. The VENDEE will go ahead with the purchase and carry out the registration process of the scheduled property on or before 120 days from the date of this agreement , post which it is null and void . 2. The VENDEE will have to pay a Stamp and registration duty of 7 . 6 % of the total sale consideration to the Government of Telangana prior to the registration to book a slot at the sub - registrar / SRO office to carry out the registration of the sale deed . This amount would total to Rs 4 , 56 , 00 , 000 INR Rupees Four Crore Fifty - Six Lakh Only (~ $524 , 137 . 93 i . e . , Five Hundred Twemy - Four Thousand One Hundred Thirty - Seven Dollars and Ninety - Three Cents US Dollars @INR 87 / -) . 3. The said sale consideration does not include the consultation and facilitation fee payable to RAG HA VENDRA VERITA SPACES LLP towards facilitating the agreement of sale , which stands at 2 % of the total sale consideration plus 18 % applicable GST . The total payable fee would be Rs 120 , 00 , 000 INR , Rupees Sixty Laich Only (~ $137 , 931 . 03 i . e . , One Hundred thirty - seven Thousand Nine Hundred thirty one Dollars and Fifty - TwoC ೦ ts US Doi/or : s 87 1 -) 1 . 5

![](image_125.jpg)

4. The VENDEE will have to account for the out of pocket expenses to be paid at the time of registration of which will be handled by Raghavendra Verita Spaces LLP . 5. The Total sale consideration including the stamp duty . consultation fee and the amount to be paid to the landowners would be Rs 65 , 76 , 00 , 000 INR, Rupees Sixty - Five Crore and seventy six Lakh Only (~ $75 , 58 , 62 . 0 i . e . , Seven Million Fifty five thousand eight Hundred sixty two and six cents US Dollars@INR 87 / -) . 6. The said total sale consideration does not include the Land Zone/ Nala Conversion Fee that needs to be paid to the government or the facilitation charges that need to be paid to Raghavendra Verita Spaces LLP for taking care of the land zone conversion process , in case any portion of the proposed land needs to be converted to better suit the VENDEE's end utility . That the total land area of l 0 acres is valued at t 6 Crore per acre , amounting to a total consideration oft 60 Crore (USD 689 , 550) . For the purpose of statutory or contractual calculations for Nala conversion , @ 4 % of the total land value has been computed as Rs : 2 , 40 , 00 , 000 / - (Two - crore Forty Lakh) (USD - 275862 $) . Accordingly . 7. A breaking fee of 1 % will be applicable to the VENDOR or VENDEE in case of defaulting from either party with regards to this agreement of sale . 8. The Legal heir certificate for the deceased land owners will be obtained before the registration day, the same will be provided to the VENDEE along with other documents at the time of registration and they will physically appear and sign the sale deeds at the time of registration in place of the deceased . 9. Whereas the VENDORS will hand over the possession of the scheduled property to the VENDEE at the time of registration to pursue all the necessary developments and endeavour for this sale . 10. The VENDOR assures the VENDEE that the scheduled property is the absolute property of the land owners and that no other person has any right, title or interest over the same now or in the future . 11. The VENDOR assures the VENDEE that there are no further legal impediments to enter into this agreement with the VENDEE and that the scheduled property is not subject to any further gift, alienation , transfer or any encumbrance of whatsoever kind or nature and is free for sale in favour of the VENDEE . 12. The VENDOR assures the VENDEE that they have not entered into any other agreement of sale or sales with any other third party and scheduled property is freefor sale to the VENDEE . 13. The VENDOR assures to handover all the Original documents of title including the link documents, EC, property tax recipients or any other to the VENDEE at the time of registration . 14. The VENDOR indemnifies the VENDEE against all

![](image_126.jpg)

compensations, charges , that may be put by the VENDEE on account of any defect in title or Vendor's right to execute a sale/transfer of the property to the VEND EE/his nominee. 15. The VENDOR will accept a relative reduction in the sale consideration agreed in this document, in case the extent of schedule property is less than what is stated in this agreement after an official revenue survey of the property physically . 16. The VENDOR and land owner, facilitated by Raghavendra Verita Spaces LLP, are willing to cooperate in case a land zone conversion is required by the VENDEE SCHEDULE OF PROPERTY All the land admeasuring 10 Acres in total bearing survey no ' s detailed in table I , situated at Village Kallak : al , Mandal Manobarabad , Division Toopran , District Medak, State Telangana . Pin - 502110 . The schedu le property is bounded by : NORTH: Neighbors Land SOUTH: Sy.no. 329 EAST: Road Facing WEST: Neighbors Land IN WITNESS WHEREOF the above - named VENDOR and VENDEE have signed this Agreement of Sale on the day, month and year aforementioned with their own free will and consent in the presence of the witnesses below mentioned . WITNESSES : VENDOR : 1. ௭ / Smt: ARCBITHA RAJ KUMARIITABOIENA (Landlord) 2. 1 . Sri :VENKATA Director 7

![](image_127.jpg)

s. ೦ 2. Suresb S 8

## Ex1A-6

**Exhibit 6.8**

![](image_134.jpg)

l Tran l d : 2 ೦ 15194915388407 Q ate : 15 AUG 2025, 07:53 PM li'urcbaffll By: VEN K AT RATNAM POPPO P PU i'o B ULLIRAMAIAH POPPOP P U llio HYDE RB AD For Whom MIS . MYRXWALLET PRANA PR IV ATELIMITED I I AGREEMENT OF SALE a ANKARLA PRA LIKA LICENSED STAMP VENDOR LIC . NO . IS - 21 - 028/2025 REN.NO . NEW LICENSE H NO . 4 - 191/315 , NTR NAOAR, NJZAMPET , MEOCHAL M A L KAJGLRl DISTRIC T PH 9491033291 This t greement of Sale is made and executed on this the 16th day of August, 2025 at Hyderabad by and between ; • Mr Pandi Venkatesh (Aadbaar No: 511786512270, Pan No: AGQPP3764L, I S/o Pandi Advaiah , age 47 years , Resident of: Plot No 39/A, Chandra Nagar Colony, Rasoolpura, Secunderabad Hyderabad, Telangana - 500003. Hereinafter referred to as the VENDOR, which expres s ion shall mean and include all their legal heirs P executors , successors , administrators , representatives , assignee of the first part . I I Mis MyRxWaUet Prana Private Limited, Represented by its Directors; 1. • VENKATA RATNAM POPPOPPU (Aadhaar No:317936739502, PAN No: AILPP4689B, DIN: 07812464), S / o Bulli Ramaiah Poppoppu, aged 54 years, Re s ident AND a ೦ ೦ - r ೦೦ ೦ Ut'.fYdnt,adl ೦ • ೦ ೦ ೦ ೦ •

![](image_135.jpg)

ofH No 2 - 63, Flat No 204, Block - B, Sai Durga Avenue, Nizarnpet, Hyderabad , Telangana, 500090. 2. Suresh S (Aadbaar No: 3869 5022 4901, PAN No: BKIPS1400F, DIN: 06777788) , S/o Sura Venkateshwara Rao, aged 47 years, Resident of HNo 3 - 6 - 54, Flat No 4D, Anatha Sai Apartment, Vivekanandha Nagar Colony, Road no 22, Kuk:atpally, Hyderabad, Telangana, 500072. Hereinafter referred to as the VENDEES, which expression shall mean and include all its legal heirs, executors, successors, administrators, representatives , assignee of the second part. The VENDEES, VENDOR and other parties involved have come to a mutual agreement to execute this sale of a total land extent admeasuring 24,675 Square yards, situated at survey number 157/E/7/2, 157/E/7 /1, of Madharam village, Warga}, Siddipet District , for a cumulative total sale consideration including the stamp duty and consultation fee the amount to be paid to the land owners would be Rs 12,65,64,984 INR, Rupees twelve crore sixty five lakh sixty four thousand nine hundred eighty four Only(~ $1,454,769.93 i.e., 1.45 million USD, i.e, One Million four hundred fifty four thousand seven hundred sixty nine Dollars and ninety three cents @ Dollar Current price INR 87/ -) .. The details of this total sum amount have been outlined below in points 1 - 5. Whereas the above - mentioned VENDOR is the nominated representative of the land owners of the scheduled property for the purpose of signing this agreement and to execute this agreement of sale on their behalf. The land owners who will be signing the sale deeds at the registrar office (Refer table l) are the absolute owners and possessors of the scheduled property. Whereas the VENDOR is representing Mr Pandi Venkatesh, as a individual owning land parcel admeasuring 24,675 Square yards and property, 157/0/7/2, 157/D/7/1 ofMadharam village, Warga], Siddipet District, in it s entirety to the VENDEE for a total consideration of Rs 1 I, 54, 7 9, 000 (24,675 sq yards \* 4680 per sq yards) INR , Rupees eleven crore fifty four lakh seventy nine thousand only(~$1,327,344.82 i.e. , one million three hundred twenty seven thousands three hundred and forty four dollars and eighty cents Only@Current US Dollar price INR 871 -), calculated at 24675 \* 4680 per Sq yards. The VENDEE herein agreed to purchase the property for the said price as a sale consideration from the VENDOR. V 2

![](image_136.jpg)

Location Sketch Map: SITE PLANING SHOWING l ' ... ,,. . , , ೦ ,. ,., l l ,t .1 1 ೦ ... Ƈ /, .... - - . . . . - . , , - - · TotaJAzfA : 35 . SOGTS h ε , † ClieatName : I I _., ---- . l - - .iiw l.a - _.,... .._ , _.,........,. . . , ... .. II.Ult - l9.U Lt Cl - - l 3

![](image_137.jpg)

This Agreement of Sale further witnesses as follows: 1. The VENDEE will go ahead with the purchase and carry out the registration process of the scheduled property on or before 120 days from the date of this agreement, post which it is null and void . 2. The VENDEE will have to pay a Stamp and registration duty of 7 . 6 % of the total sale consideration to the Government of Telangana prior to the registration to book a slot at the s ub - registrar / SRO office to carry out the registration of the sale deed . This amount would total to Rs 87 , 76 , 404 INR Rupees Eighty seven lakh seventy six thousand four hundred four onl y, 100 , 878 . 20 USD, i . e . , one hundred thousand eight hundred seventy eight Dollars and twenty cents . (considered current market dollar price i . e . , INR 87 / -) . 3. The said sale consideration does not include the consultation and facilitation fee payable to RAGHAVENDRA VERITA SPACES LLP towards facilitating the agreement of sale, which stands at 2% of the total sale consideration plus 18% applicable GST. The total payable fee would be Rs 23,09,580 INR , Rupees Twenty three lakh nine thousand five hundred eighty Only. , ~26,546.89 USD @J.NR 87/ -), Twenty six thousand five hundred forty six Dollars and eighty nine cents (considered current market dollar price i.e., INR 871 -). 4. The VENDEE will have to account for the out of pocket expenses to be paid at the time ofregistration of which will be handled by Raghavendra Verita Spaces LLP. 5. The Total sale consideration including the stamp duty , consultation fee, and the amount to be paid to the landowners would be Rs 12 , 65 , 64 , 984 INR, twelve crore sixty five lakh sixty fQur thousand nine hundred eighty four Only (~ $1 , 454 , 769 . 93 i . e . , 1 . 45 million USD, One Million four hundred fifty four thousand seven hundred sixty nine Dollars and ninety three cents @Dollar Current price INR 87 / -) . 6. The said total sale consideration does not include the Land Zone Conversion Fee that needs to be paid to the government or the facilitation charges that need to be paid to Raghavendra Verita Spaces LLP for taking care of the land zone conversion process , in case any portion of the proposed land needs to be converted to better suit the VENDEE's end utility . S. S(5Jt:.

![](image_138.jpg)

7. A breaking fee of 1 % will be applicable to the VENDOR or VENDEE in case of defaulting from either party with regards to this agreement of sale . 8. The Legal heir certificate for the deceased land owners will be obtained before the registration day, the same will be provided to the VENDEE along with other documents at the time of registration and they will physically appear and sign the sale deeds at the time of registration in place of the deceased . 9. Whereas the VENDORS will hand over the possession of the scheduled property to the VENDEE at the time of registration to pursue all the necessary developments and endeavours for this sale . 10. The VENDOR assures the VENDEE that the scheduled property is the absolute property of the land owners and that no other person has any right, title or interest over the same now or in the future . 11. The VENDOR assures the VENDEE that there are no further legal impediments to enter into this agreement with the VENDEE and that the scheduled property is not subject to any further gift, alienation, transfer or any encumbrance of whatsoever kind or nature and is free for sale in favour of the VENDEE . 12. The VENDOR assures the VENDEE that they have not entered into any other agreement of sale or sales with any other third party and scheduled property is free for sale to the VENDEE . 13. The VENDOR assures to handover all the Original documents of title including the link documents, EC, property tax recipients or any other to the VENDEE at the time of registration . 14. The VENDOR indemnifies the VENDEE against all such losses , costs , damages , claims, compensations, charges , that may be put by the VENDEE on account of any defect in title or VENDOR's right to execute a sale / transfer of the property to the VENDEE/his nominee . 15. The VENDOR will accept a relative reduction in the sale consideration agreed in this document, in case the extent of schedule property is less than what is stated in this : ೦ :: ೦ =cial revenue swvey of ilie pr ೦೦

![](image_139.jpg)

16. The VENDOR and land owner, facilitated by Raghavendra Verita Spaces LLP, are willing to cooperate in case a land zone conversion is required by the VENDEE. SCHEDULE OF PROPERTY All the land admeasuring 24,675 Square yards, situated at survey number 157/D/7 /2, 157/0/7 / l , of Madhararn village, Warga ! , Siddipet District, NORTH: SOUTH: EAST: WEST: rN WITNESS WHEREOF the above - named VENDOR and VENDEE have signed this Agreement of Sale on the day , month and year aforementioned with their own free will and consent in the presence of the witnesses be l ow mentioned. WITNES ೦ ES.Je) 1. ೦ I \ J VENDO R : Mr Pandi Venkatesh (La ndlord) 2. VENDEES: S SU7,e_ ೦ 2.Mr. SURESB S 6

## Ex1A-6

**Exhibit 6.9**

**MYRXWALLET NORTH AMERICA CORPORATION**

*(a Wyoming corporation)*

**MUTUAL RESCISSION OF**

**DIRECTOR OF MERGERS AND ACQUISITION AND**

**BOARD MEMBER EMPLOYMENT AGREEMENT**

This Mutual Rescission of Director of Mergers and Acquisition and Board Member Employment Agreement (this "Rescission") is made and entered into as of the date last set forth below (the "Rescission Date"), by and between MyRxWallet North America Corporation, a Wyoming corporation (the "Company"), and Scherri A. Harps ("Ms. Harps"), each a "Party" and together the "Parties."

**<u>RECITALS</u>**

**A.** On or about March 1, 2026, a document titled "Director of Mergers and Acquisition and Board Member Employment Agreement" bearing an effective date of March 1, 2026 (the "**M&A Agreement**") was prepared and circulated for signature, and was thereafter executed by Olivia Trinh as Chairman and Chief Executive Officer of the Company, by Binh Do as President, Chief Financial Officer, and Director of the Company, and by Ms. Harps.

**B.** The M&A Agreement was generated from a generic executive employment template and was circulated for signature in error. The substantive arrangement intended by the Company and Ms. Harps was, and at all times has been, that Ms. Harps would serve solely as a non-employee Independent Director of the Company, and not as an officer, employee, or executive in any capacity, and would receive compensation solely on the terms of the Independent Director Appointment Agreement between the Parties dated March 1, 2026 (the "**Director Agreement**").

**C.** The M&A Agreement was never operated by either Party. No cash compensation was ever paid or accrued under Section 3.1 of the M&A Agreement; no equity grant was ever issued under Sections 3.2 or 3.3 of the M&A Agreement (the 35,000 shares of restricted common stock issued to Ms. Harps and recorded with the Company's transfer agent of record on March 10, 2026 were issued solely as the Initial Awards under the Director Agreement); no Milestone Incentive Plan sub-plan was ever established under Section 3.4 of the M&A Agreement; no payroll relationship was established; no IRS Form W-2 was issued; and Ms. Harps did not at any time perform services for the Company in the capacity of "Director of Mergers and Acquisition" or as an officer or employee of the Company.

**D.** The Parties intend by this Rescission to confirm in writing that the M&A Agreement was executed in error, was never intended to take effect, has never had operative force, and is rescinded *ab initio* as if it had never been executed.

**NOW, THEREFORE,** in consideration of the foregoing recitals, which are incorporated herein by reference, and of the mutual promises set forth below, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

**1. Rescission.** The M&A Agreement is hereby rescinded *ab initio*, is null and void, and shall be deemed never to have had any force or effect from its purported effective date of March 1, 2026, or otherwise. Neither Party has, or shall have, any rights, duties, obligations, or liabilities under the M&A Agreement, whether arising before, on, or after the Rescission Date.

**2. No Performance; No Compensation.** Each Party acknowledges and confirms that no compensation (cash, equity, or otherwise), benefits, expense reimbursements, severance, accelerated vesting, or other consideration has been paid, accrued, vested, owed, or earned under the M&A Agreement, and that no services have been rendered or performed by Ms. Harps under the M&A Agreement. The 35,000 shares of restricted common stock of the Company issued to Ms. Harps and recorded with Colonial Stock Transfer Co., Inc. effective March 10, 2026 were issued solely as the Initial Awards under the Director Agreement and not under the M&A Agreement, and the issuance and vesting of such shares are governed exclusively by the Director Agreement.

**3. Director Agreement Controls.** The Parties confirm that Ms. Harps's relationship with the Company at all times from and after March 1, 2026 has been, and shall continue to be, governed solely and exclusively by the Director Agreement, which sets forth the complete terms of Ms. Harps's service as a non-employee Independent Director of the Company, including her Initial Awards (25,000 shares as the Compensation Award and 10,000 shares as the Bonus Award, totaling 35,000 shares) and her deferred compensation arrangement (US$14,583.33 per month, capped at US$350,000 in the aggregate, payable upon the Funding Trigger Date as defined therein).

**4. Mutual Release.** Each Party, on behalf of itself or herself and its or her successors, assigns, heirs, and representatives, hereby releases, waives, and forever discharges the other Party (and the other Party's officers, directors, employees, agents, successors, and assigns) from any and all claims, demands, causes of action, damages, losses, costs, and liabilities of any kind or nature, whether known or unknown, that arise out of or relate to the M&A Agreement, in each case from the beginning of time through and including the Rescission Date.

**5. Independence Preservation.** The Parties confirm that this Rescission has the effect of confirming that Ms. Harps has at no time been an employee, officer, or executive of the Company, and that Ms. Harps's status as a non-employee Independent Director within the meaning of the listing standards of the Nasdaq Stock Market LLC and applicable rules of the U.S. Securities and Exchange Commission has been continuously preserved from March 1, 2026.

**6. Regulatory Disclosure.** Ms. Harps acknowledges that the Company will disclose this Rescission in its offering statement on Form 1-A, in any amendment thereto, and in such other filings made by the Company under applicable U.S. federal and state securities laws as may be required, and consents to such disclosure.

**7. Governing Law; Counterparts; Entire Agreement.** This Rescission shall be governed by the laws of the State of Wyoming without regard to its conflicts-of-law principles. This Rescission may be executed in counterparts, each of which shall constitute an original and all of which together shall constitute one and the same instrument. Signatures delivered electronically (including by PDF or DocuSign) shall be treated as original signatures. This Rescission, together with the Director Agreement, constitutes the entire understanding of the Parties with respect to the subject matter hereof and supersedes all prior agreements and understandings, written or oral, with respect thereto, including (without limitation) the M&A Agreement.

**IN WITNESS WHEREOF,** the Parties have executed this Mutual Rescission as of the date(s) set forth below.

**MyRxWallet North America Corporation**

By: <u>/s/ Olivia Trinh</u> 

Name: Olivia Trinh

Title: Chairman, Chief Executive Officer, and Interim Chief Financial Officer

Date: <u>05/08/2026</u> 

**Scherri A. Harps**

Signature: <u>/s/ Scherri A. Harps</u>

Date: <u>05/12/202</u>

***Note:*** *The M&A Agreement also bears the signature of Binh Do as President, Chief Financial Officer, and Director of the Company. Mr. Do voluntarily resigned from all positions with the Company effective March 10, 2026. As Mr. Do is no longer associated with the Company and the M&A Agreement is being rescinded ab initio, his execution is of no continuing effect, and his counter-signature on this Rescission is not required to give it full force.*

## Ex1A-6

**Exhibit 6.10**

**MyRxWallet North America Corporation**

*a Wyoming corporation*

 

 

**INDEPENDENT DIRECTOR APPOINTMENT AGREEMENT**

**FY-2026**

Director: Scherri A. Harps

Effective Date: March 1, 2026

**INDEPENDENT DIRECTOR APPOINTMENT AGREEMENT**

This **Independent Director Appointment Agreement** (this "**Agreement**") is made and entered into as of March 1, 2026 (the "**Effective Date**"), by and between **MyRxWallet North America Corporation**, a Wyoming corporation (the "**Company**"), and **Scherri A. Harps** (the "**Director**").

&nbsp;&nbsp;&nbsp;&nbsp;1. Position and Duties

**1.1 Title.** The Company hereby appoints the Director to serve as an Independent Director on the Company's Board of Directors (the "Board"), effective as of the Effective Date. The Director shall serve as a non-employee, non-management member of the Board.

**1.2 Duties.** The Director shall perform the duties customarily associated with service as an Independent Director of a Wyoming corporation, including attendance at meetings of the Board and any Board committee on which she serves, review of Board materials, and participation in Board deliberations and oversight functions. The Director agrees to comply with the Company's bylaws, committee charters, corporate governance guidelines, and codes and policies applicable to directors.

**1.3 Time and Manner of Service.** Service will include in-person and virtual meetings; reasonable travel may be required. The Director will devote the time reasonably necessary to fulfill her duties as an Independent Director.

**1.4 Independence.** The Board has determined that the Director qualifies as an "independent director" within the meaning of the listing standards of the Nasdaq Stock Market LLC and applicable rules of the U.S. Securities and Exchange Commission. The Director shall promptly notify the Board in writing of any fact, circumstance, or relationship that would or could reasonably be expected to affect such determination.

&nbsp;&nbsp;&nbsp;&nbsp;2. Term

**2.1 Term.** The Director's term of service under this Agreement shall commence on the Effective Date and continue for a period of one (1) year (the "Initial Term"). Thereafter, this Agreement will automatically renew for successive one-year terms (each, a "Renewal Term" and together with the Initial Term, the "Term") unless either party provides written notice of non-renewal at least thirty (30) days before the end of the then-current Term, or the Director's service ends earlier in accordance with Section 9 (Termination) or applicable law.

**2.2 Nature of Relationship.** The Director serves the Company solely in her capacity as a non-employee Independent Director. Nothing in this Agreement shall be construed to create an employment relationship, partnership, joint venture, agency, or independent contractor engagement for any purpose other than service as a

director, and the Director shall not hold herself out as an officer, employee, or agent of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;3. Compensation and Expenses

**3.1 Initial Equity Awards.** In consideration of the Director's service to the Company, and pursuant to a duly authorized resolution of the Board, the Director has received the following one-time grants of restricted common stock of the Company (collectively, the "Initial Awards"):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) **Compensation Award.** Twenty-Five Thousand (25,000) shares of restricted common stock as compensation for the Director's service as an Independent Director (the "Compensation Award"); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) **Bonus Award.** Ten Thousand (10,000) shares of restricted common stock as a one-time signing bonus in recognition of the Director's acceptance of appointment (the "Bonus Award").

The Initial Awards together total Thirty-Five Thousand (35,000) shares, were issued in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended, and applicable state securities exemptions, and have been recorded with the Company's transfer agent of record, Colonial Stock Transfer Co., Inc., effective March 10,

2026. The Initial Awards are subject to such restrictions on transfer as are applicable under federal and state securities laws and the Company's insider-trading and other applicable policies. The Initial Awards are fully vested upon issuance and are not subject to any continued-service vesting condition.

**3.2 Deferred Board Compensation.** In further consideration of the Director's service to the Company prior to the Company having sufficient operating capital to pay current cash compensation, the Company shall accrue, and pay on a deferred basis as set forth herein, the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) **Accrual Rate.** Commencing on the Effective Date and continuing through the Funding Trigger Date (as defined below) or the earlier termination of the Director's service, the Company shall accrue deferred compensation in favor of the Director at the rate of Fourteen Thousand Five Hundred Eighty-Three U.S. Dollars and Thirty-Three Cents (US$14,583.33) per month (the "Monthly Accrual"), prorated for any partial month and equivalent to an annualized rate of One Hundred Seventy-Five Thousand U.S. Dollars (US$175,000.00). The aggregate accrued obligation under this Section 3.2 (the "Deferred Compensation Balance") shall be reflected on the Company's books as an unfunded accrued liability in accordance with U.S. generally accepted accounting principles, including ASC 710.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) **Aggregate Cap.** Notwithstanding subsection (a), the Deferred Compensation Balance shall not exceed Three Hundred Fifty Thousand U.S. Dollars (US$350,000.00) in the aggregate (representing approximately twenty-four (24) months of Monthly Accrual), and no further accrual shall occur once such cap is reached unless and until the cap is increased by separate written action of the Board.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) **Funding Trigger Date.** The "Funding Trigger Date" means the first date on which the Company has received cumulative cash proceeds, in any combination of the following sources, of not less than Five Million U.S. Dollars (US$5,000,000.00) since the Effective Date: (i) net proceeds from the Company's offering of securities qualified under Regulation A of the Securities Act of 1933, as amended; (ii) net proceeds from any subsequent public or private financing transaction; or (iii) operating cash flow from revenue. The Company shall notify the Director in writing within ten (10) business days following the Funding Trigger Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) **Payment.** The Deferred Compensation Balance, plus any accrued interest under subsection (e), shall be paid in cash to the Director in twelve (12) equal monthly installments commencing on the first day of the month following the Funding Trigger Date, with each installment paid in cash on the first business day of the applicable month. Payment shall be reported on IRS Form 1099-NEC and shall be subject to such reporting and withholding as may be required by applicable law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) **Interest.** The Deferred Compensation Balance shall not bear interest. The parties acknowledge that this no-interest treatment is reflective of the Director's good-faith intent to support the Company during its development stage and is consistent with the deferred-compensation arrangements customarily extended by founding-stage independent directors.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) **Effect of Termination on Deferred Compensation.** If the Director's service terminates prior to the Funding Trigger Date for any reason other than termination by the Company for Cause, the Deferred Compensation Balance accrued through the date of termination shall remain a fixed obligation of the Company, payable in accordance with subsection (d) following the Funding Trigger Date, and the Director shall have no obligation to provide further service to receive such payment. If the Director's service is terminated by the Company for Cause, the Company's obligation to pay the Deferred Compensation Balance shall be forfeited; the Initial Awards shall remain vested and unaffected, having been fully vested upon issuance.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) **Section 409A.** The parties intend that the deferred compensation provided under this Section 3.2 either be exempt from Section 409A of the Internal Revenue Code of 1986, as amended ("Section 409A"), under the short-term deferral exception or comply with Section 409A, and this

Agreement shall be interpreted accordingly. Neither party guarantees the tax treatment of any payment hereunder, and each shall bear its own tax consequences.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) **Disclosure.** The Director acknowledges that the Company will disclose the material terms of this Section 3.2, including the Monthly Accrual, the Aggregate Cap, the Funding Trigger Date definition, and the outstanding Deferred Compensation Balance as of each balance sheet date, in the Company's offering statement, periodic reports, and other filings made under applicable U.S. federal securities laws.

**3.3 No Other Compensation.** Except as expressly provided in this Section 3 or in a separate written award agreement approved by the Board, the Director shall not be entitled to any other cash, equity, severance, or fringe benefit from the Company in connection with her service hereunder. The parties acknowledge that the Director is not an employee of the Company and is not entitled to participate in any Company employee benefit plan.

**3.4 Expenses.** The Company shall reimburse the Director for reasonable, documented business expenses incurred in performing Board duties, in accordance with the Company's expense reimbursement policy as in effect from time to time.

**3.5 Tax Reporting.** Compensation payable to the Director hereunder, including the Initial Awards and any deferred compensation, shall be reported on IRS Form 1099-NEC or other appropriate tax form for non-employee directors, as determined by the Company in accordance with applicable law.

&nbsp;&nbsp;&nbsp;&nbsp;4. Confidentiality and Company Materials

**4.1 Confidentiality.** The Director acknowledges that she will receive confidential, proprietary, and trade secret information of the Company and its affiliates (collectively, "Confidential Information"). The Director shall not disclose or use Confidential Information except as required to perform Board duties, and shall comply with Regulation FD and the Company's disclosure policies in all communications with persons outside the Company.

**4.2 Return of Property.** Upon cessation of service, the Director will promptly return or destroy all Company property and Confidential Information in her possession, with the exception of copies retained as required by law or for customary board record-keeping (subject to ongoing confidentiality).

&nbsp;&nbsp;&nbsp;&nbsp;5. Work Product

To the extent the Director creates works of authorship or materials specifically for the Company in her capacity as a director ("**Work Product**"), the Director hereby grants the Company an irrevocable, perpetual, worldwide, royalty-free license to use, reproduce, distribute, display, and create derivative works of such Work Product for Company purposes. This Section does not apply to the Director's pre-existing materials or general skills and know-how.

&nbsp;&nbsp;&nbsp;&nbsp;6. Non-Solicitation; No Non-Compete

**6.1 Non-Solicitation.** During the Director's service and for twelve (12) months thereafter, the Director shall not knowingly solicit for employment any executive-level employee of the Company with whom the Director worked in her capacity as a director, provided that general solicitations not directed at such persons are not prohibited.

**6.2 No Non-Compete.** In recognition of the Director's independent, part-time board role, the parties agree that no post-service non-competition covenant shall apply to the Director; provided, however, that the Director shall promptly disclose any actual or potential conflicts of interest and shall manage such conflicts in accordance with Company policy and applicable law.

&nbsp;&nbsp;&nbsp;&nbsp;7. Compliance with Policies; Insider Trading

The Director will comply with all Company policies applicable to directors, including codes of conduct, disclosure, and insider-trading policies. The Director will use any pre-clearance procedures established by the Company for trades in Company securities and will comply with any applicable trading windows and trading plans consistent with Company policy and applicable law, including Section 16 of the Securities Exchange Act of 1934, as amended, to the extent applicable.

&nbsp;&nbsp;&nbsp;&nbsp;8. Data Privacy and Regulatory Compliance

The Director agrees to handle Company personal and sensitive data in accordance with applicable law and Company policies. The Director shall not access, use, disclose, or retain any personal data except as necessary to perform her authorized Board duties on behalf of the Company. The Director acknowledges that the Company is engaged in healthcare technology and may handle protected health information subject to the Health Insurance Portability and Accountability Act of 1996, as amended ("HIPAA"), and that any access to such information by the Director shall be governed by HIPAA and the Company's privacy and security policies.

&nbsp;&nbsp;&nbsp;&nbsp;9. Termination

**9.1 By the Company.** The Company may terminate the Director's service for Cause (as defined in any award agreement applicable to her equity awards) or without

Cause at any time by written notice; provided, that any such termination shall be without prejudice to the Director's right to receive any compensation earned through the date of termination.

&nbsp;&nbsp;&nbsp;&nbsp;**9.2** **By the Director.** The Director may resign at any time upon written notice to the Company.

**9.3 Effect of Termination.** Upon cessation of service for any reason, any deferred compensation earned but unpaid through the date of termination will be paid in accordance with the Company's policies and applicable law. Equity awards will be treated in accordance with the Company's 2025 Director & Officer Equity Incentive Plan (as amended, the "Plan"), as applicable, and the applicable award agreement(s).

&nbsp;&nbsp;&nbsp;&nbsp;10. Change in Control

To the extent any award agreement entered into between the Company and the Director provides for accelerated vesting upon a Change in Control (as defined in the Plan or applicable award agreement), such acceleration shall be governed by, and given effect in accordance with, the terms of the Plan and the applicable award agreement, with performance-based awards (if any) treated as provided therein.

&nbsp;&nbsp;&nbsp;&nbsp;11. Securities Matters

The parties acknowledge that, as of the Effective Date, the Company has filed an offering statement on Form 1-A under Regulation A of the Securities Act of 1933, as amended, and that the Company's securities are not currently registered under Section 12 of the Securities Exchange Act of 1934, as amended. The shares granted as the Initial Awards have been issued in reliance on Section 4(a)(2) of the Securities Act and applicable state securities exemptions, and are "restricted securities" within the meaning of Rule 144. The Director represents that she is acquiring the Initial Awards for her own account, for investment, and not with a view to or for sale in connection with any distribution thereof, and that she is aware of the restrictions on transfer applicable to such shares. Following any change in the Company's reporting status or listing, awards and related practices will conform to applicable laws, exchange rules, the Plan, and Company policies.

&nbsp;&nbsp;&nbsp;&nbsp;12. Indemnification and Insurance

The Director shall be entitled to indemnification, advancement of expenses, and exculpation to the fullest extent permitted under the Wyoming Business Corporation Act and the Company's Articles of Incorporation and Bylaws as in effect from time to time, including with respect to claims arising out of her service as a director.

The Company shall use commercially reasonable efforts to maintain customary directors' and officers' liability insurance covering the Director on terms no less favorable than the coverage provided to other non-employee directors of the Company. The provisions of this Section 12 shall survive the termination of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;13. Dispute Resolution

**13.1 Governing Law.** This Agreement shall be governed by and construed in accordance with the laws of the State of Wyoming, without regard to its conflicts-of-law principles.

**13.2 Arbitration.** Any dispute arising out of or relating to this Agreement shall be resolved by final and binding arbitration administered by the American Arbitration Association under its Commercial Arbitration Rules. The seat and venue of arbitration shall be Cheyenne, Wyoming. Judgment on the award may be entered in any court of competent jurisdiction. Either party may seek temporary injunctive relief in a court of competent jurisdiction to protect Confidential Information or enforce restrictive covenants pending arbitration. Notwithstanding the foregoing, the Director's right to indemnification and advancement of

expenses pursuant to Section 12 may be enforced in any court of competent jurisdiction.

&nbsp;&nbsp;&nbsp;&nbsp;14. Notices

All notices under this Agreement shall be in writing and deemed given when delivered personally, sent by nationally recognized overnight courier, or emailed with confirmation, to the addresses below (or as updated by notice):

**If to the Company:**

MyRxWallet North America Corporation

Attention: Chairman and Chief Executive Officer

732 S. 6th Street, #5397

Las Vegas, Nevada 89101

Email: olivia@myrxwallet.app; executiveassistance@myrxwallet.io

**If to the Director:**

Scherri A. Harps Mobile: 909-200-7073

Email: scherriaharps@gmail.com

&nbsp;&nbsp;&nbsp;&nbsp;15. Miscellaneous

**15.1 Entire Agreement.** This Agreement, together with the Plan and any award agreements between the Company and the Director, constitutes the entire understanding of the parties and supersedes all prior discussions and agreements regarding the subject matter.

&nbsp;&nbsp;&nbsp;&nbsp;**15.2** **Amendments.** Any amendment must be in a writing signed by both parties.

**15.3 Assignment.** The Company may assign this Agreement to a successor; the Director may not assign her rights or obligations without the Company's prior written consent.

**15.4 Severability; Waiver.** If any provision is held invalid or unenforceable, the remainder of this Agreement shall remain in full force and effect. No failure or delay in enforcing any provision shall constitute a waiver thereof.

**15.5 Counterparts; Electronic Signatures.** This Agreement may be executed in counterparts, each of which shall be deemed an original and all of which together shall constitute one and the same instrument. Signatures delivered electronically (including by PDF or DocuSign or comparable e-signature platform) shall be treated as original signatures.

&nbsp;&nbsp;&nbsp;&nbsp;16. Signatures

IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date first written above.

**MyRxWallet North America Corporation**

By: <u>/s/ Olivia Trinh</u> 

Name: Olivia Trinh

Title: Chairman, Chief Executive Officer, and Interim Chief Financial Officer

Date: <u>05/08/2026</u> 

**Director**

Signature: <u>/s/ Scherri A. Harps</u>

Title: Independent Director

Date: <u>05/12/202</u>

## Ex1A-7

**Exhibit 7.1**

**Share Exchange Agreement**

**(SEA)**

by and among

**MyRxWallet North America Corporation**

("Acquirer")

A Wyoming Corporation

and

**MYRXWALLET DAO, LLC**

("Seller")

A Wyoming Corporation

September 22, 2025

**SHARE EXCHANGE AGREEMENT**

This Share Exchange Agreement (this "Agreement"), dated as of September 22, 2025, is entered into by and among MyRxWallet North America Corporation, a Wyoming corporation (the "Parent" or "Acquirer"), MyRxWallet DAO, LLC, a Wyoming limited liability company (the "Company" or "Acquiree"), and Chanh Trinh, an individual and the sole record and beneficial owner of 100% of the issued and outstanding membership interests of the Company (the "Shareholder").

Each of the foregoing may be referred to individually as a "Party" and collectively as the "Parties."

RECITALS

WHEREAS, the Shareholder owns 100% of the issued and outstanding membership interests (the "Company Interests") of the Company;

WHEREAS, the Parent desires to acquire from the Shareholder, and the Shareholder desires to transfer to the Parent, all of the Company Interests in exchange for an aggregate of Eighteen Million Five Hundred Eighteen Thousand Five Hundred Eighteen (18,518,518) newly issued shares of the Parent's common stock, par value $0.001 per share (the "Parent Shares"), valued at $27.00 per share, for an aggregate transaction value of Five Hundred Million U.S. Dollars (US $500,000,000);

WHEREAS, at the Closing, one-half of the Parent Shares (9,259,259 shares) shall be issued to Chanh Trinh, and the remaining one-half (9,259,259 shares) shall be issued to MyRxWallet DAO, Inc., a newly incorporated affiliate intended to serve as the long-term research, development, and governance foundation for the MyRxWallet DAO ecosystem (the "DAO Foundation");

WHEREAS, the Parties intend that the exchange of the Company Interests for the Parent Shares shall qualify as a tax-free reorganization within the meaning of Section 368(a)(1)(B) of the Internal Revenue Code of 1986, as amended (the "Code");

NOW, THEREFORE, in consideration of the foregoing recitals and the mutual covenants, representations, and warranties contained herein, the Parties agree as follows:

ARTICLE I

<u>Exchange of Shares</u>

SECTION 1.01. <u>Exchange by the Shareholders</u>. At the Closing (as defined in Section 1.03), the Shareholder shall transfer and assign to the Parent all of the Company Interests, free and clear of all liens and encumbrances. In consideration thereof, the Parent shall issue an aggregate of 18,518,518 fully paid and non-assessable shares of its common stock (the "Parent Shares"), allocated as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· 9,259,259 Parent Shares issued to Chanh Trinh; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· 9,259,259 Parent Shares issued to MyRxWallet DAO, Inc.

SECTION 1.02. <u>Consideration and Value.</u> The total transaction value shall be US $500,000,000, based on a per-share valuation of $27.00 for the Parent Shares.

SECTION 1.03. <u>Closing.</u> The Closing of the transactions contemplated by this Agreement (the "Closing") shall take place on such date and at such location as the Parties may mutually agree (the "Closing Date"). At Closing:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the Shareholder shall deliver to the Parent all instruments evidencing 100% ownership of the Company Interests, duly assigned for transfer;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) the Parent shall deliver share certificates (or electronic book entries) evidencing issuance of the Parent Shares to the Shareholder and MyRxWallet DAO, Inc.; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) the Parties shall execute such additional documents as may be required to give effect to this Agreement.

ARTICLE II

<u>Representations and Warranties of the Shareholders</u>

The Shareholders hereby represent and warrant to the Parent, as follows:

SECTION 2.01. <u>Good Title</u>. The Shareholders are the record and beneficial owners, and have good title to the Company Shares, with the right and authority to sell and deliver the Company Shares to the Parent as provided herein. Upon delivery of any certificate or certificates duly endorsed for transfer to the Parent, representing the same as herein contemplated and/or upon registering of the Parent as the new owner of the Company Shares in the share register of the Company, the Parent will receive good title to the Company Shares, free and clear of all liens, hypothecs security interests, pledges, equities and claims of any kind, voting trusts, trust agreements, shareholder agreements, prete-nom agreements and other encumbrances (collectively, "<u>Liens</u>").

SECTION 2.02. <u>Power and Authority</u>. All acts required to be taken by the Shareholders to enter into this Agreement and to carry out the Transactions have been properly taken. This Agreement constitutes a legal, valid and binding obligation of the Shareholders, enforceable against the Shareholders in accordance with the terms hereof.

SECTION 2.03. <u>No Conflicts</u>. The execution and delivery of this Agreement by the Shareholders and the performance by the Shareholders of their obligations hereunder in accordance with the terms hereof: (i) will not require the consent of any third party or any federal, state, provincial, local or foreign government or any court of competent jurisdiction, administrative agency or commission or other governmental authority or instrumentality, domestic or foreign ("<u>Governmental Entity</u>") under any statutes, laws, ordinances, rules, regulations, orders, writs, injunctions, judgments, or decrees (collectively, "<u>Laws</u>"); (ii) will not violate any Laws applicable to the Shareholders; and (iii) will not violate or breach any contractual obligation to which the Shareholders are a party.

SECTION 2.04. <u>No Finder's Fee</u>. The Shareholders have not created any obligation for any finder's, investment banker's or broker's fee in connection with the Transactions that the Company or the Parent will be responsible for.

SECTION 2.05. <u>Purchase Entirely for Own Account.</u> The Parent Shares proposed to be acquired by the Shareholders hereunder will be acquired for investment for their own account, and not with a view to the resale or distribution of any part thereof, and the Shareholders have no present intention of selling or otherwise distributing the Parent Shares, except in compliance with applicable securities laws.

SECTION 2.06. <u>Available Information</u>. The Shareholders have such knowledge and experience in financial and business matters that he are capable of evaluating the merits and risks of an investment in the Parent.

SECTION 2.07. <u>Non-Registration</u>. The Shareholders understand that the Parent Shares have not been registered under the Securities Act of 1933, as amended (the "<u>Securities Act</u>") and, if issued in accordance with the provisions of this Agreement, will be issued by reason of a specific exemption from the registration provisions of the Securities Act that depends upon, among other things, the bona fide nature of the investment intent and the accuracy of the Shareholders' representations as expressed herein. The non-registration shall have no prejudice with respect to any rights, interests, benefits and entitlements attached to the Parent Shares in accordance with the Parent charter documents or the laws of its jurisdiction of incorporation.

SECTION 2.08. <u>Restricted Securities</u>. The Shareholders understand that the Parent Shares are characterized as "restricted securities" under the Securities Act inasmuch as this Agreement contemplates that, if acquired by the Shareholders pursuant hereto, the Parent Shares would be acquired in a transaction not involving a public offering. The Shareholders further acknowledge that if the Parent Shares are issued to the Shareholders in accordance with the provisions of this Agreement, the Parent Shares may not be resold without registration under the Securities Act or the existence of an exemption therefrom. The Shareholders represent that they are familiar with Rule 144 promulgated under the Securities Act, as presently in effect, and understands the resale limitations imposed thereby and by the Securities Act.

SECTION 2.09. <u>Legends</u>. It is understood that the Parent Shares will bear the following legend or another legend that is similar to the following:

THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THESE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT SECURED BY SUCH SECURITIES.

and any legend required by the "blue sky" laws of any state to the extent such laws are applicable to the securities represented by the certificate so legended.

SECTION 2.10. <u>Accredited Investor</u>. The Shareholders are all "accredited investors" within the meaning of Rule 501 under the Securities Act.

ARTICLE III

<u>Representations and Warranties of the Company</u>

The Company hereby represents and warrants to the Parent, as follows

 

SECTION 3.01. <u>Organization, Standing and Power</u>. Each of the Company and its subsidiaries (the "<u>Company Subsidiaries</u>") is duly organized, validly existing and in good standing under the laws of the jurisdiction in which it is organized and in which it has a place of business and has the corporate power and authority and possesses all governmental franchises, licenses, permits, authorizations and approvals necessary to enable it to own, lease or otherwise hold its properties and assets and to conduct its businesses as presently conducted, other than such franchises, licenses, permits, authorizations and approvals the lack of which, individually or in the aggregate, has not had and would not reasonably be expected to have a material adverse effect on the Company, a material adverse effect on the ability of the Company to perform its obligations under this Agreement or on the ability of the Company to consummate the Transactions (a "<u>Company Material Adverse Effect</u>"). The Company is duly qualified to do business in each jurisdiction where the nature of its business or its ownership or leasing of its properties make such qualification necessary except where the failure to so qualify would not reasonably be expected to have a Company Material Adverse Effect. The Company has delivered to the Parent true and complete copies of the certificate of incorporation and bylaws of the Company and such other constituent instruments of the Company as may exist, each as amended to the date of this Agreement (as so amended, the "<u>Company Constituent Instruments</u>"), and the comparable charter, organizational documents and other constituent instruments of each Company Subsidiary, in each case as amended through the date of this Agreement.

SECTION 3.02.<u>Company Subsidiaries; Equity Interests</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)All the outstanding shares of capital stock or equity investments of each Company Subsidiary have been validly issued and are fully paid and nonassessable and are as of the date of this Agreement owned by the Company, by another Company Subsidiary or by the Company and another Company Subsidiary, free and clear of all Liens.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Except for its interests in the Company Subsidiaries, the Company does not as of the date of this Agreement own, directly or indirectly, any capital stock, membership interest, partnership interest, joint venture interest or other equity interest in any person.

SECTION 3.03. <u>Capital Structure</u>. The Company is the sole record and beneficial owner of all of the issued and outstanding capital stock of each Company Subsidiary. All outstanding shares of the capital stock of the Company and each Company Subsidiary are duly authorized, validly issued, fully paid and nonassessable and not subject to or issued in violation of any purchase option, call option, right of first refusal, preemptive right, subscription right or any similar right under any provision of the applicable corporate laws of Dubai, the Company Constituent Instruments or any Contract (as defined in Section 3.05) to which the Company is a party or otherwise bound. Except as set forth in this Section 3.03, there are not any bonds, debentures, notes or other indebtedness of the Company or any Company Subsidiary having the right to vote (or convertible into, or exchangeable for, securities having the right to vote) on any matters on which holders of Company Shares or the common stock of any Company Subsidiary may vote ("<u>Voting Company Debt</u>"). Except as set forth above, as of the date of this Agreement, there are not any options, warrants, rights, convertible or exchangeable securities, "phantom" stock rights, stock appreciation rights, stock-based performance units, commitments, Contracts, arrangements or undertakings of any kind to which the Company or any Company Subsidiary is a party or by which any of them is bound (a) obligating the Company or any Company Subsidiary to issue, deliver or sell, or cause to be issued, delivered or sold, additional shares of capital stock or other equity interests in, or any security convertible or exercisable for or exchangeable into any capital stock of or other equity interest in, the Company or any Company Subsidiary or any Voting Company Debt, (b) obligating the Company or any Company Subsidiary to issue, grant, extend or enter into any such option, warrant, call, right, security, commitment, Contract, arrangement or undertaking or (c) that give any person the right to receive any economic benefit or right similar to or derived from the economic benefits and rights occurring to holders of the capital stock of the Company or of any Company Subsidiary.

SECTION 3.04. <u>Authority; Execution and Delivery; Enforceability</u>. The Company has all requisite corporate power and authority to execute and deliver this Agreement and to consummate the Transactions. The execution and delivery by the Company of this Agreement and the consummation by the Company of the Transactions have been duly authorized and approved by the Board of Directors of the Company and no other corporate proceedings on the part of the Company are necessary to authorize this Agreement and the Transactions. When executed and delivered, this Agreement will be enforceable against the Company in accordance with its terms, subject to bankruptcy, insolvency and similar laws of general applicability as to which the Company is subject.

SECTION 3.05.<u>No Conflicts; Consents</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)The execution and delivery by the Company of this Agreement does not, and the consummation of the Transactions and compliance with the terms hereof and thereof will not, conflict with, or result in any violation of or default (with or without notice or lapse of time, or both) under, or give rise to a right of termination, cancellation or acceleration of any obligation or to loss of a material benefit under, or result in the creation of any Lien upon any of the properties or assets of the Company or any Company Subsidiary under any provision of (a) the Company Constituent Instruments or the comparable charter or organizational documents of any Company Subsidiary, (b) any material contract, lease, license, indenture, note, bond, agreement, permit, concession, franchise or other instrument (a "<u>Contract</u>") to which the Company or any Company Subsidiary is a party or by which any of their respective properties or assets is bound or (c) subject to the filings and other matters referred to in Section 3.05(b), any material judgment, order or decree ("<u>Judgment</u>") or material Law applicable to the Company or any Company Subsidiary or their respective properties or assets, other than, in the case of clauses (b) and (c) above, any such items that, individually or in the aggregate, have not had and would not reasonably be expected to have a Company Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Except for required filings with Canada and applicable "Blue Sky" or local securities commissions, no material consent, approval, license, permit, order or authorization ("<u>Consent</u>") of, or registration, declaration or filing with, or permit from, any Governmental Entity is required to be obtained or made by or with respect to the Company or any Company Subsidiary in connection with the execution, delivery and performance of this Agreement or the consummation of the Transactions.

SECTION 3.06.<u>Taxes</u>.

 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)The Company and each Company Subsidiary have timely filed, or have caused to be timely filed on their behalf, all Tax Returns required to be filed by them, and all such Tax Returns are true, complete and accurate, except to the extent any failure to file or any inaccuracies in any filed Tax Returns, individually or in the aggregate, have not had and would not reasonably be expected to have a Company Material Adverse Effect. All Taxes shown to be due on such Tax Returns, or otherwise owed, have been timely paid, except to the extent that any failure to pay, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect. There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company know of no basis for any such claim. No tax audit is in process or threatened and the Company has not received a notice of assessment from any tax authority indicating a tax assessment or recalculation of any taxes in any tax return previously filed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)The Company Financial Statements (as defined in Section 3.15) reflect an adequate reserve for all Taxes payable by the Company and the Company Subsidiaries (in addition to any reserve for deferred Taxes to reflect timing differences between book and Tax items) for all Taxable periods and portions thereof through the date of such financial statements. No deficiency with respect to any Taxes has been proposed, asserted or assessed against the Company or any Company Subsidiary, and no requests for waivers of the time to assess any such Taxes are pending, except to the extent any such deficiency or request for waiver, individually or in the aggregate, has not had and would not reasonably be expected to have a Company Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) For purposes of this Agreement:

"<u>Taxes</u>" includes all forms of taxation, whenever created or imposed, and whether of the United States or elsewhere, and whether imposed by a local, municipal, governmental, state, provincial, foreign, federal or other Governmental Entity, or in connection with any agreement with respect to Taxes, including all interest, penalties and additions imposed with respect to such.

"<u>Tax Return</u>" means all federal, state, provincial, local, provincial and foreign Tax returns, declarations, statements, reports, schedules, forms and information returns and any amended Tax return relating to Taxes.

SECTION 3.07. <u>Benefit Plans</u>. The Company does not have or maintain any collective bargaining agreement or any bonus, pension, profit sharing, deferred compensation, incentive compensation, share ownership, share purchase, share option, phantom stock, retirement, vacation, severance, disability, death benefit, hospitalization, medical or other plan, arrangement or understanding (whether or not legally binding) providing benefits to any current or former employee, officer or director of the Company or any Company Subsidiary (collectively, "<u>Company Benefit Plans</u>"). As of the date of this Agreement there are not any severance or termination agreements or arrangements between the Company or any Company Subsidiary and any current or former employee, officer or director of the Company or any Company Subsidiary, nor does the Company or any Company Subsidiary have any general severance plan or policy.

SECTION 3.08. <u>Litigation</u>. There is no action, suit, inquiry, notice of violation, proceeding (including any partial proceeding such as a deposition) or investigation pending or threatened in writing against or affecting the Company, any Company Subsidiary or any of their respective properties before or by any court, arbitrator, governmental or administrative agency, regulatory authority (federal, state, provincial, county, local or foreign), stock market, stock exchange or trading facility ("<u>Action</u>") that (i) adversely affects or challenges the legality, validity or enforceability of any of this Agreement or the Company Shares or (ii) could, if there were an unfavorable decision, individually or in the aggregate, have or reasonably be expected to result in a Company Material Adverse Effect. Neither the Company nor any Company Subsidiary, nor any director or officer thereof (in his or her capacity as such), is or has been the subject of any Action involving a claim or violation of or liability under federal, state or provincial securities laws or a claim of breach of fiduciary duty.

SECTION 3.09. <u>Compliance with Applicable Laws</u>. The Company and the Company Subsidiaries are in compliance with all applicable Laws, including those relating to occupational health, labor and safety and the environment, except for instances of noncompliance that, individually and in the aggregate, have not had and would not reasonably be expected to have a Company Material Adverse Effect. The Company has not received any written communication during the past two years from a Governmental Entity that alleges that the Company is not in compliance in any material respect with any applicable Law. This Section 3.09 does not relate to matters with respect to Taxes, which are the subject of Section 3.06.

SECTION 3.10. <u>Brokers; Schedule of Fees and Expenses</u>. Except for those brokers as to which the Company and Parent shall be solely responsible, no broker, investment banker, financial advisor or other person is entitled to any broker's, finder's, financial advisor's or other similar fee or commission in connection with the Transactions based upon arrangements made by or on behalf of the Company.

SECTION 3.11. <u>Contracts</u>. There are no Contracts that are material to the business, properties, assets, condition (financial or otherwise), results of operations or prospects of the Company and the Company Subsidiaries taken as a whole. Neither the Company nor any Company Subsidiary is in violation of or in default under (nor does there exist any condition which upon the passage of time or the giving of notice would cause such a violation of or default under) any Contract to which it is a party or by which it or any of its properties or assets is bound, except for violations or defaults that would not, individually or in the aggregate, reasonably be expected to result in a Company Material Adverse Effect.

SECTION 3.12. <u>Title to Properties</u>. The Company and the Company Subsidiaries do not own any real or immoveable property. Each of the Company and the Company Subsidiaries has sufficient title to, or valid leasehold interests in, all of its properties and assets used in the conduct of its businesses. All such assets and properties, other than assets and properties in which the Company or any of the Company Subsidiaries has leasehold interests, are free and clear of all Liens and except for Liens that, in the aggregate, do not and will not materially interfere with the ability of the Company and the Company Subsidiaries to conduct business as currently conducted.

SECTION 3.13. <u>Intellectual Property</u>. The Company and the Company Subsidiaries own, or are validly licensed or otherwise have the right to use, all patents, patent rights, trademarks, trademark rights, trade names, trade name rights, service marks, service mark rights, copyrights and other proprietary intellectual property rights and computer programs (collectively, "<u>Intellectual Property Rights</u>") that are material to the conduct of the business of the Company and the Company Subsidiaries taken as a whole. There are no claims pending or, to the knowledge of the Company, threatened that the Company or any of the Company Subsidiaries is infringing or otherwise adversely affecting the rights of any person with regard to any Intellectual Property Right. To the knowledge of the Company, no person is infringing the rights of the Company or s of the Company Subsidiaries with respect to any Intellectual Property Right.

SECTION 3.14. <u>Labor Matters</u>. There are no collective bargaining or other labor union agreements to which the Company or any of the Company Subsidiaries is a party or by which any of them is bound. No material labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company.

SECTION 3.15. <u>Financial Statements</u>. The Company has delivered to the Parent its financial statements for the years ended September 2025 and September 2026 (the "<u>Company Financial Statements</u>"). The Company Financial Statements have been prepared in accordance with generally accepted accounting principles applied on a consistent basis throughout the periods indicated. The Company Financial Statements fairly present in all material respects the financial condition and operating results of the Company, as of the dates, and for the periods indicated therein. The Company does not have any material liabilities or obligations, contingent or otherwise, other than (a) liabilities incurred in the ordinary course of business subsequent to February 28, 2021, and (b) obligations under contracts and commitments incurred in the ordinary course of business and not required under generally accepted accounting principles to be reflected in the Company Financial Statements, which, in both cases, individually and in the aggregate would not be reasonably expected to result in a Company Material Adverse Effect.

SECTION 3.16. <u>Insurance</u>. The Company and the Company Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Company Subsidiaries are engaged and in the geographic areas where they engage in such businesses. The Company has no reason to believe that it will not be able to renew its and the Company Subsidiaries' existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business on terms consistent with market for the Company's and the Company Subsidiaries' respective lines of business.

SECTION 3.17. <u>Transactions With Affiliates and Employees</u>. Except as set forth in the Company Financial Statements, none of the officers or directors of the Company and, to the knowledge of the Company, none of the employees of the Company is presently a party to any transaction with the Company or any Company Subsidiary (other than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real, immoveable, personal or moveable property to or from, or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee or partner.

SECTION 3.18. <u>Internal Accounting Controls</u>. The Company and the Company Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that (a) transactions are executed in accordance with management's general or specific authorizations, (b) transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain asset accountability, (c) access to assets is permitted only in accordance with management's general or specific authorization, and (d) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company has established disclosure controls and procedures for the Company and designed such disclosure controls and procedures to ensure that material information relating to the Company, including its subsidiaries, is made known to the officers by others within those entities. The Company's officers have evaluated the effectiveness of the Company's controls and procedures. Since December 31, 2016, there have been no significant changes in the Company's internal controls or, to the Company's knowledge, in other factors that could significantly affect the Company's internal controls.

SECTION 3.19. <u>Solvency</u>. Based on the financial condition of the Company as of the Closing Date (and assuming that the Closing shall have occurred), (a) the Company's fair saleable value of its assets exceeds the amount that will be required to be paid on or in respect of the Company's existing debts and other liabilities (including known contingent liabilities) as they mature, (b) the Company's assets do not constitute unreasonably small capital to carry on its business for the current fiscal year as now conducted and as proposed to be conducted including its capital needs taking into account the particular capital requirements of the business conducted by the Company, and projected capital requirements and capital availability thereof, and (c) the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its debt when such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt). The Company is not insolvent or bankrupt, and it has not filed for protection under applicable law. Moreover, there has been no petition in bankruptcy filed by the Company or against the Company.

SECTION 3.20. <u>Application of Takeover Protections</u>. The Company has taken all necessary action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar anti-takeover provision under the Company's charter documents or the laws of its jurisdiction of formation that is or could become applicable to the Shareholders as a result of the Shareholders and the Company fulfilling their obligations or exercising their rights under this Agreement, including, without limitation, the issuance of and the Shareholders' ownership of the Parent Shares.

SECTION 3.21. <u>No Additional Agreements</u>. The Company does not have any agreement or understanding with the Shareholders with respect to the transactions contemplated by this Agreement other than as specified in this Agreement.

SECTION 3.22. <u>Investment Company</u>. The Company immediately following the Closing will not have become, an "investment company" within the meaning of the Investment Company Act of 1940, as amended.

SECTION 3.23. <u>Absence of Certain Changes or Events</u>. Except as disclosed in the Company Financial Statements, from September 30, 2024 to the date of this Agreement, the Company has conducted its business only in the ordinary course, and during such period there has not been:

*Share Exchange Agreement September 2025*

 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)any change in the assets, liabilities, financial condition or operating results of the Company or any Company Subsidiary, except changes in the ordinary course of business that have not caused, in the aggregate, a Company Material Adverse Effect;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)any damage, destruction or loss, whether or not covered by insurance, that would have a Company Material Adverse Effect;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)any waiver or compromise by the Company or any Company Subsidiary of a valuable right or of a material debt owed to it;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)any satisfaction or discharge of any lien, claim, or encumbrance or payment of any obligation by the Company or any Company Subsidiary, except in the ordinary course of business and the satisfaction or discharge of which would not have a Company Material Adverse Effect;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)any material change to a material Contract by which the Company or any Company Subsidiary or any of its respective assets is bound or subject;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)any loans or guarantees made by the Company or any Company Subsidiary to or for the benefit of its employees, officers or directors, or any members of their immediate families, other than travel advances and other advances made in the ordinary course of its business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) any alteration of the Company's method of accounting or the identity of its auditors;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)any declaration or payment of dividend or distribution of cash or other property to the Shareholders or any purchase, redemption or agreements to purchase, redeem or retract any Company Shares;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)any issuance of equity securities to any officer, director or affiliate except pursuant to existing Company Shares option plans; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)any arrangement or commitment by the Company or any Company Subsidiary to do any of the things described in this Section 3.23.

SECTION 3.24. <u>Foreign Corrupt Practices</u>. Neither the Company nor any Company Subsidiary, nor, to the Company's knowledge, any director, officer, agent, employee or other person acting on behalf of the Company or any Company Subsidiary has, in the course of its actions for, or on behalf of, the Company (a) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity; (b) made any direct or indirect unlawful payment to any foreign or domestic government official or employee from corporate funds; (c) violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended; or (d) made any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment to any foreign or domestic government official or employee.

ARTICLE IV

<u>Representations and Warranties of the Parent</u>

The Parent hereby represents and warrants to the Company, as follows:

SECTION 4.01. <u>Organization, Standing and Power</u>. The Parent is duly organized, validly existing and in good standing under the laws of the State of Nevada and has full corporate power and authority and possesses all governmental franchises, licenses, permits, authorizations and approvals necessary to enable it to own, lease or otherwise hold its properties and assets and to conduct its businesses as presently conducted, other than such franchises, licenses, permits, authorizations and approvals the lack of which, individually or in the aggregate, has not had and would not reasonably be expected to have a material adverse effect on the Parent, a material adverse effect on the ability of the Parent to perform its obligations under this Agreement or on the ability of the Parent to consummate the Transactions (a "<u>Parent Material Adverse Effect</u>"). The Parent is duly qualified to do business in each jurisdiction where the nature of its business or the ownership or leasing of its properties make such qualification necessary and where the failure to so qualify would reasonably be expected to have a Parent Material Adverse Effect. The Parent has delivered to the Company true and complete copies of the certificate of incorporation of the Parent, as amended to the date of this Agreement (as so amended, the "<u>Parent Charter</u>"), and the Bylaws of the Parent, as amended to the date of this Agreement (as so amended, the "<u>Parent Bylaws</u>").

SECTION 4.02. <u>Subsidiaries; Equity Interests</u>. The Parent does not own, directly or indirectly, any capital stock, membership interest, partnership interest, joint venture interest or other equity interest in any person.

SECTION 4.03. <u>Capital Structure</u>. The authorized capital stock of the Parent consists of (1) 100,000,000 shares of common stock, par value $0.001 per share, of which (a) 100,000,000 shares are issued and outstanding (before giving effect to the issuances to be made at Closing), and (b) no shares of common stock are reserved by the Parent in its treasury; and (2) no shares of preferred stock, par value $0.001 per share, of which (a) no shares are issued and outstanding, and (b) no shares of preferred stock are reserved by the Parent in its treasury. No other shares of capital stock or other voting securities of the Parent are issued, reserved for issuance or outstanding. All outstanding shares of the capital stock of the Parent are, and all such shares that may be issued prior to the date hereof will be when issued, duly authorized, validly issued, fully paid and non-assessable and not subject to or issued in violation of any purchase option, call option, right of first refusal, preemptive right, subscription right or any similar right under any provision of the General Corporation Law of the State of Nevada, the Parent Charter, the Parent Bylaws or any Contract to which the Parent is a party or otherwise bound. There are not any bonds, debentures, notes or other indebtedness of the Parent having the right to vote (or convertible into, or exchangeable for, securities having the right to vote) on any matters on which holders of the Parent Shares may vote ("<u>Voting Parent Debt</u>"). Except as set forth above, as of the date of this Agreement, there are no options, warrants, rights, convertible or exchangeable securities, "phantom" stock rights, stock appreciation rights, stock-based performance units, commitments, Contracts, arrangements or undertakings of any kind to which the Parent is a party or by which it is bound (a) obligating the Parent to issue, deliver or sell, or cause to be issued, delivered or sold, additional shares of capital stock or other equity interests in, or any security convertible or exercisable for or exchangeable into any capital stock of or other equity interest in, the Parent or any Voting Parent Debt, (b) obligating the Parent to issue, grant, extend or enter into any such option, warrant, call, right, security, commitment, Contract, arrangement or undertaking or (c) that give any person the right to receive any economic benefit or right similar to or derived from the economic benefits and rights occurring to holders of the capital stock of the Parent. As of the date of this Agreement, there are no outstanding contractual obligations of the Parent to repurchase, redeem or otherwise acquire any shares of capital stock of the Parent. The Parent is not a party to any agreement granting any securityholder of the Parent the right to cause the Parent to register shares of the capital stock or other securities of the Parent held by such securityholder under the Securities Act. The stockholder list provided to the Company is a current stockholder list generated by the Parent's stock transfer agent, and such list accurately reflects all of the issued and outstanding shares of the Parent Shares as at the Closing.

SECTION 4.04. <u>Authority; Execution and Delivery; Enforceability</u>. The execution and delivery by the Parent of this Agreement and the consummation by the Parent of the Transactions have been duly authorized and approved by the Board of Directors of the Parent and no other corporate proceedings on the part of the Parent are necessary to authorize this Agreement and the Transactions. This Agreement constitutes a legal, valid and binding obligation of the Parent, enforceable against the Parent in accordance with the terms hereof.

SECTION 4.05.<u>No Conflicts; Consents</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)The execution and delivery by the Parent of this Agreement, does not, and the consummation of the Transactions and compliance with the terms hereof and thereof will not, conflict with, or result in any violation of or default (with or without notice or lapse of time, or both) under, or give rise to a right of termination, cancellation or acceleration of any obligationor to loss of a material benefit under, or to increased, additional, accelerated or guaranteed rights or entitlements of any person under, or result in the creation of any Lien upon any of the properties or assets of the Parent under, any provision of (a) the Parent Charter or Parent Bylaws, (b) any material Contract to which the Parent is a party or by which any of its properties or assets is bound or (c) subject to the filings and other matters referred to in Section 4.05(b), any material Judgment or material Law applicable to the Parent or its properties or assets, other than, in the case of clauses (b) and (c) above, any such items that, individually or in the aggregate, have not had and would not reasonably be expected to have a Parent Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) No Consent of, or registration, declaration or filing with, or permit from, any Governmental Entity is required to be obtained or made by or with respect to the Parent in connection with the execution, delivery and performance of this Agreement or the consummation of the Transactions, other than filings under state "blue sky" laws, as each may be required in connection with this Agreement and the Transactions.

SECTION 4.06.<u>Parent Financial Statements; Undisclosed Liabilities</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)<u>Financial Statements</u>. The Parent has delivered to the Company its financial statements from inception to October 2025 (the "Parent Financial Statements"). The Parent Financial Statements have been prepared in accordance with generally accepted accounting principles applied on a consistent basis throughout the periods indicated. The Parent Financial Statements fairly present in all material respects the financial condition and operating results of the Company, as of the dates, and for the periods indicated therein. The Parent does not have any material liabilities or obligations, contingent or otherwise, other than (a) liabilities incurred in the ordinary course of business subsequent to October 27, 2025, and (b) obligations under contracts and commitments incurred in the ordinary course of business and not required under generally accepted accounting principles to be reflected in the Parent Financial Statements, which, in both cases, individually and in the aggregate would not be reasonably expected to result in a Parent Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Except as set forth in the filed Parent Financial Statements, the Parent has no liabilities or obligations of any nature (whether accrued, absolute, contingent or otherwise) required by GAAP to be set forth on a balance sheet of the Parent or in the notes thereto.

SECTION 4.07. <u>Absence of Certain Changes or Events</u>. Except as disclosed in the Parent Financial Statements, from October 2024 to the date of this Agreement, the Parent has conducted its business only in the ordinary course, and during such period there has not been:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)any change in the assets, liabilities, financial condition or operating results of the Parent or any Parent Subsidiary, except changes in the ordinary course of business that have not caused, in the aggregate, a Parent Material Adverse Effect;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)any damage, destruction or loss, whether or not covered by insurance, that would have a Parent Material Adverse Effect;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)any waiver or compromise by the Parent of a valuable right or of a material debt owed to it;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)any satisfaction or discharge of any lien, claim, or encumbrance or payment of any obligation by the Parent, except in the ordinary course of business and the satisfaction or discharge of which would not have a Parent Material Adverse Effect;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)any material change to a material Contract by which the Parent or any of its assets is bound or subject;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)any material change in any compensation arrangement or agreement with any employee, officer, director or stockholder;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)any loans or guarantees made by the Parent to or for the benefit of its employees, officers or directors, or any members of their immediate families, other than travel advances and other advances made in the ordinary course of its business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)any declaration, setting aside or payment or other distribution in respect of any of the Parent's capital stock, or any direct or indirect redemption, purchase, or other acquisition of any of such stock by the Parent;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j) any alteration of the Parent's method of accounting or the identity of itsa uditors;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)any issuance of equity securities to any officer, director or affiliate (as defined in the Securities Act), except pursuant to existing Parent Shares option plans; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l)any arrangement or commitment by the Parent to do any of the things described in this Section 4.08.

SECTION 4.08.<u>Taxes</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Parent has timely filed, or has caused to be timely filed on its behalf, all Tax Returns required to be filed by it, and all such Tax Returns are true, complete and accurate, except to the extent any failure to file, any delinquency in filing or any inaccuracies in any filed Tax Returns, individually or in the aggregate, have not had and would not reasonably be expected to have a Parent Material Adverse Effect. All Taxes shown to be due on such Tax Returns, or otherwise owed, have been timely paid, except to the extent that any failure to pay, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)The Parent Financial Statements reflect an adequate reserve for all Taxes reflect an adequate reserve for all Taxes payable by the Parent (in addition to any reserve for deferred Taxes to reflect timing differences between book and Tax items) for all Taxable periods and portions thereof through the date of such financial statements. No deficiency with respect to any Taxes has been proposed, asserted or assessed against the Parent, and no requests for waivers of the time to assess any such Taxes are pending, except to the extent any such deficiency or request for waiver, individually or in the aggregate, has not had and would not reasonably be expected to have a Parent Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)There are no Liens for Taxes (other than for current Taxes not yet due and payable) on the assets of the Parent. The Parent is not bound by any agreement with respect to Taxes.

SECTION 4.09. <u>Absence of Changes in Benefit Plans</u>. There has not been any adoption or amendment in any material respect by the Parent of any collective bargaining agreement or any bonus, pension, profit sharing, deferred compensation, incentive compensation, stock ownership, stock purchase, stock option, phantom stock, retirement, vacation, severance, disability, death benefit, hospitalization, medical or other plan, arrangement or understanding (whether or not legally binding) providing benefits to any current or former employee, officer or director of the Parent (collectively, "<u>Parent Benefit Plans</u>"). As of the date of this Agreement there are not any employment, consulting, indemnification, severance or termination agreements or arrangements between the Parent and any current or former employee, officer or director of the Parent, nor does the Parent have any general severance plan or policy.

SECTION 4.10. <u>ERISA Compliance; Excess Parachute Payments</u>. The Parent does not, and since its inception never has, maintained, or contributed to any "employee pension benefit plans" (as defined in Section 3(2) of ERISA), "employee welfare benefit plans" (as defined in Section 3(1) of ERISA) or any other Parent Benefit Plan for the benefit of any current or former employees, consultants, officers or directors of the Parent.

SECTION 4.11. <u>Litigation</u>. There is no Action that (i) adversely affects or challenges the legality, validity or enforceability of any of this Agreement or the Parent Shares or (ii) could, if there were an unfavorable decision, individually or in the aggregate, have or reasonably be expected to result in a Parent Material Adverse Effect. Neither the Parent nor any subsidiary, nor any director or officer thereof (in his or her capacity as such), is or has been the subject of any Action involving a claim or violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty.

SECTION 4.12. <u>Compliance with Applicable Laws</u>. The Parent is in compliance with all applicable Laws, including those relating to occupational health and safety, the environment, export controls, trade sanctions and embargoes, except for instances of noncompliance that, individually and in the aggregate, have not had and would not reasonably be expected to have a Parent Material Adverse Effect. The Parent has not received any written communication during the past two years from a Governmental Entity that alleges that the Parent is not in compliance in any material respect with any applicable Law. This Section 4.12 does not relate to matters with respect to Taxes, which are the subject of Section 4.08.

SECTION 4.13. <u>Contracts</u>. There are no Contracts that are material to the business, properties, assets, condition (financial or otherwise), results of operations or prospects of the Parent taken as a whole. The Parent is not in violation of or in default under (nor does there exist any condition which upon the passage of time or the giving of notice would cause such a violation of or default under) any Contract to which it is a party or by which it or any of its properties or assets is bound, except for violations or defaults that would not, individually or in the aggregate, reasonably be expected to result in a Parent Material Adverse Effect.

SECTION 4.14. <u>Title to Properties</u>. The Parent has good title to, or valid leasehold interests in, all of its properties and assets used in the conduct of its businesses. All such assets and properties, other than assets and properties in which the Parent has leasehold interests, are free and clear of all Liens and except for Liens that, in the aggregate, do not and will not materially interfere with the ability of the Parent to conduct business as currently conducted. The Parent has complied in all material respects with the terms of all material leases to which it is a party and under which it is in occupancy, and all such leases are in full force and effect. The Parent enjoys peaceful and undisturbed possession under all such material leases.

SECTION 4.15. <u>Intellectual Property</u>. The Parent owns, or is validly licensed or otherwise has the right to use, all Intellectual Property Rights that are material to the conduct of the business of the Parent taken as a whole. No claims are pending or, to the knowledge of the Parent, threatened that the Parent is infringing or otherwise adversely affecting the rights of any person with regard to any Intellectual Property Right. To the knowledge of the Parent, no person is infringing the rights of the Parent with respect to any Intellectual Property Right.

SECTION 4.16. <u>Labor Matters</u>. There are no collective bargaining or other labor union agreements to which the Parent is a party or by which it is bound. No material labor dispute exists or, to the knowledge of the Parent, is imminent with respect to any of the employees of the Parent.

SECTION 4.17. <u>Transactions With Affiliates and Employees</u>. None of the officers or directors of the Parent and, to the knowledge of the Parent, none of the employees of the Parent is presently a party to any transaction with the Parent or any subsidiary (other than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Parent, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee or partner.

SECTION 4.18. <u>Internal Accounting Controls</u>. The Parent maintains a system of internal accounting controls sufficient to provide reasonable assurance that (a) transactions are executed in accordance with management's general or specific authorizations, (b) transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain asset accountability, (c) access to assets is permitted only in accordance with management's general or specific authorization, and (d) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Parent has established disclosure controls and procedures for the Parent and designed such disclosure controls and procedures to ensure that material information relating to the Parent is made known to the officers by others within those entities. The Parent's officers have evaluated the effectiveness of the Parent's controls and procedures. There have been no significant changes in the Parent's internal controls or, to the Parent's knowledge, in other factors that could significantly affect the Parent's internal controls.

SECTION 4.19. <u>Solvency</u>. Based on the financial condition of the Parent as of the Closing Date (and assuming that the Closing shall have occurred), (a) the Parent's fair saleable value of its assets exceeds the amount that will be required to be paid on or in respect of the Parent's existing debts and other liabilities (including known contingent liabilities) as they mature, (b) the Parent's assets do not constitute unreasonably small capital to carry on its business for the current fiscal year as now conducted and as proposed to be conducted including its capital needs taking into account the particular capital requirements of the business conducted by the Parent, and projected capital requirements and capital availability thereof, and (c) the currentcash flow of the Parent, together with the proceeds the Parent would receive, were it to liquidate all of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its debt when such amounts are required to be paid. The Parent does not intend to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt).

SECTION 4.20. <u>Application of Takeover Protections</u>. The Parent has taken all necessary action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar anti-takeover provision under the Parent's charter documents or the laws of its state of incorporation that is or could become applicable to the Shareholders as a result of the Shareholders and the Parent fulfilling their obligations or exercising their rights under this Agreement, including, without limitation, the issuance of the Parent Shares and the Shareholders' ownership of the Parent Shares.

SECTION 4.21. <u>No Additional Agreements</u>. The Parent does not have any agreement or understanding with the Shareholders with respect to the transactions contemplated by this Agreement other than as specified in this Agreement.

SECTION 4.22. <u>Investment Company</u>. The Parent is not, and is not an affiliate of, and immediately following the Closing will not have become, an "investment company" within the meaning of the Investment Company Act of 1940, as amended.

SECTION 4.23. <u>Certain Registration Matters</u>. The Parent has not granted or agreed to grant to any person any rights (including "piggy-back" registration rights) to have any securities of the Parent registered with the SEC or any other governmental authority that have not been satisfied.

SECTION 4.24. <u>Foreign Corrupt Practices</u>. Neither the Parent, nor to the Parent's knowledge, any director, officer, agent, employee or other person acting on behalf of the Parent has, in the course of its actions for, or on behalf of, the Parent (a) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity; (b) made any direct or indirect unlawful payment to any foreign or domestic government official or employee from corporate funds; (c) violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended; or (d) made any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment to any foreign or domestic government official or employee.

ARTICLE V

<u>Deliveries</u>

SECTION 5.01.<u>Deliveries of the Shareholders</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (a) Concurrently herewith the Shareholders are delivering to the Parent this Agreement executed by the Shareholders. At or prior to the Closing, the Shareholders shall deliver to the Parent:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) certificates representing their Company Shares; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) a duly executed share transfer power for transfer by the Shareholders of the Company
Shares to the Parent; and

SECTION 5.02.<u>Deliveries of the Parent</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Concurrently herewith, the Parent is delivering to the Shareholders and to the Company, a copy of this Agreement executed by the Parent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Promptly following the Closing, the Parent shall deliver to the Shareholders, certificates representing the Parent Shares.

SECTION 5.03.<u>Deliveries of the Company</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Concurrently herewith, the Company is delivering to the Parent this Agreement executed by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Concurrently herewith, the Company is delivering to the Parent the Board and Shareholders unanimous resolution to approve this Agreement.

ARTICLE VI

<u>Conditions to Closing</u>

SECTION 6.01. <u>Shareholders and Company Conditions Precedent</u>. The obligations of the Shareholders and the Company to enter into and complete the Closing is subject, at the option of the Shareholders and the Company, to the fulfillment on or prior to the Closing Date of the following conditions, any one or more of which may be waived by the Shareholders and the Company in writing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)<u>Representations and Covenants</u>. The representations and warranties of the Parent contained in this Agreement shall be true in all material respects on and as of the Closing Date with the same force and effect as though made on and as of the Closing Date. The Parent shall have performed and complied in all material respects with all covenants and agreements required by this Agreement to be performed or complied with by the Parent on or prior to the Closing Date. The Parent shall have delivered to the Shareholders and the Company, a certificate, dated the Closing Date, to the foregoing effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)<u>Litigation</u>. No action, suit or proceeding shall have been instituted before any court or governmental or regulatory body or instituted or threatened by any governmental or regulatory body to restrain, modify or prevent the carrying out of the Transactions or to seek damages or a discovery order in connection with such Transactions, or which has or may have, in the reasonable opinion of the Company or the Shareholders, a materially adverse effect on the assets, properties, business, operations or condition (financial or otherwise) of the Parent or the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)<u>No Material Adverse Change</u>. There shall not have been any occurrence, event, incident, action, failure to act, or transaction since __________ which has had or is reasonably likely to cause a Parent Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Deliveries</u>. The deliveries specified in Section 5.02 shall have been made by the Parent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)<u>Satisfactory Completion of Due Diligence</u>. The Company and the Shareholders shall have completed their legal, accounting and business due diligence of the Parent and the results thereof shall be satisfactory to the Company and the Shareholders in their sole and absolute discretion.

SECTION 6.02. <u>Parent Conditions Precedent</u>. The obligations of the Parent to enter into and complete the Closing are subject, at the option of the Parent, to the fulfillment on or prior to the Closing Date of the following conditions, any one or more of which may be waived by the Parent in writing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)<u>Representations and Covenants</u>. The representations and warranties of the Shareholders and the Company contained in this Agreement shall be true in all material respects on and as of the Closing Date with the same force and effect as though made on and as of the Closing Date. The Shareholders and the Company shall have performed and complied in all material respects with all covenants and agreements required by this Agreement to be performed or complied with by the Shareholders and the Company on or prior to the Closing Date. The Company shall have delivered to the Parent, if requested, a certificate, dated the Closing Date, to the foregoing effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)<u>Litigation</u>. No action, suit or proceeding shall have been instituted before any court or governmental or regulatory body or instituted or threatened by any governmental or regulatory body to restrain, modify or prevent the carrying out of the Transactions or to seek damages or a discovery order in connection with such Transactions, or which has or may have, in the reasonable opinion of the Parent, a materially adverse effect on the assets, properties, business, operations or condition (financial or otherwise) of the Parent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)<u>No Material Adverse Change</u>. There shall not have been any occurrence, event, incident, action, failure to act, or transaction since __________ which has had or is reasonably likely to cause a Company Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)<u>Deliveries</u>. The deliveries specified in Section 5.01 and Section 5.03 shall have been made by the Shareholders and the Company, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)<u>Financial Statements</u>. The Company shall have provided the Parent and the Shareholders with reasonable assurances that the Company shall have financial statements available to be incorporated into a private placement memorandum to assist in fundraising efforts following the Closing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)<u>Satisfactory Completion of Due Diligence</u>. The Parent shall have completed its legal, accounting and business due diligence of the Company and the Shareholders and the results thereof shall be satisfactory to the Parent in its sole and absolute discretion.

ARTICLE VII

<u>Covenants</u>

SECTION 7.01. DAO Foundation Conversion. The Parties acknowledge that MyRxWallet DAO, Inc. intends to reorganize and convert, within twelve (12) months following Closing, into a nonprofit or foundation entity under applicable corporate and tax laws (the "DAO Foundation"). The DAO Foundation shall serve as the research and development arm of the MyRxWallet ecosystem, supporting decentralized technologies, NFT infrastructure, tokenization rails, and governance initiatives. The Parent agrees to cooperate in good faith with such reorganization and to recognize the DAO Foundation as an affiliated strategic entity dedicated to ecosystem advancement, and acknowledges that the DAO Foundation may change its name at its discretion.

EXHIBIT A – Share Allocation Table

---

| | | | | |
|:---|:---|:---|:---|:---|
| Recipient | Entity Type | Shares Issued | Value per Share (USD) | Total Value (USD) |
| Chanh Trinh | Individual | 9259259 | $27.00 | $250000000 |
| MyRxWallet DAO, Inc. | Corporation (future foundation) | 9259259 | $27.00 | $250000000 |
| Total |  | 18518518 |  | $500000000 |

---

Prior to the Closing, the Parent and the Company will consult with each other before issuing, and provide each other the opportunity to review and comment upon, any press releases or other public statements with respect to the Agreement and the Transactions and shall not issue any such press release or make any such public statement prior to such consultation, except as may be required by applicable Law, court process or by obligations pursuant to any listing agreement with any national securities exchanges.

SECTION 7.02. <u>Fees and Expenses</u>. All fees and expenses incurred in connection with this Agreement shall be paid by the Party incurring such fees or expenses, whether or not this Agreement is consummated.

SECTION 7.03. <u>Continued Efforts</u>. Each Party shall use commercially reasonable efforts to (a) take all action reasonably necessary to consummate the Transactions, and (b) take such steps and do such acts as may be necessary to keep all of its representations and warranties true and correct as of the Closing Date with the same effect as if the same had been made, and this Agreement had been dated, as of the Closing Date.

SECTION 7.04. <u>Exclusivity</u>. Each of the Parent and the Company shall not (and shall not cause or permit any of their affiliates to) engage in any discussions or negotiations with any person or take any action that would be inconsistent with the Transactions and that has the effect of avoiding the Closing contemplated hereby. Each of the Parent and the Company shall notify each other immediately if any person makes any proposal, offer, inquiry, or contact with respect to any of the foregoing.

SECTION 7.05. <u>Access</u>. Each Party shall permit representatives of any other Party to have full access to all premises, properties, personnel, books, records (including Tax records), contracts, and documents of or pertaining to such Party.

SECTION 7.06. <u>Preservation of Business</u>. From the date of this Agreement until the Closing Date, the Company and the Parent shall operate only in the ordinary and usual course of business consistent with their respective past practices (provided, however, that Parent shall not issue any securities without the prior written consent of the Company), and shall use reasonable commercial efforts to (a) preserve intact their respective business organizations, (b) preserve the good will and advantageous relationships with customers, suppliers, independent contractors, employees and other persons material to the operation of their respective businesses, and (c) not permit any action or omission that would cause any of their respective representations or warranties contained herein to become inaccurate or any of their respective covenants to be breached in any material respect.

SECTION 7.07. <u>Additional Parent Shares for Note Conversion</u>. At Closing, the Parties acknowledge that there are no outstanding convertible debts or obligations of the Company as of the Closing Date requiring conversion or share issuance.

SECTION 7.08. <u>Reverse Split and Name Change</u>. After Closing, the Parties acknowledge that no reverse stock split, recapitalization, or post-Closing name change of the Parent is contemplated or required under this Agreement.

SECTION 7.09. <u>Cancellation of Shares</u>. At Closing but after the Parent Shares are issued, the Parties acknowledge that no share cancellation, redemption, or reduction of the Parent's outstanding common stock is contemplated or required in connection with this Agreement.

ARTICLE VIII

<u>Miscellaneous</u>

SECTION 8.01. <u>Notices</u>. All notices, requests, claims, demands and other communications under this Agreement shall be in writing and shall be deemed given upon receipt by the Parties at the following addresses (or at such other address for a Party as shall be specified by like notice):

If to the Parent, to:

Binh Do, President & CFO

2475 South Jones Blvd., Suite 9

Las Vegas \| Nevada \| 89146

If to the Company, to:

MyRxWallet North America Corporation

2475 South Jones Blvd., Suite 9

Las Vegas \| Nevada \| 89146

SECTION 8.02. <u>Amendments; Waivers; No Additional Consideration</u>. No provision of this Agreement may be waived or amended except in a written instrument signed by the Company, Parent and the Shareholders. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any Party to exercise any right hereunder in any manner impair the exercise of any such right.

SECTION 8.03. <u>Replacement of Securities</u>. If any certificate or instrument evidencing any Parent Shares is mutilated, lost, stolen or destroyed, the Parent shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof, or in lieu of and substitution therefore, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Parent of such loss, theft or destruction and customary and reasonable indemnity, if requested. The applicants for a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs associated with the issuance of such replacement Parent Shares. If a replacement certificate or instrument evidencing any Parent Shares is requested due to a mutilation thereof, the Parent may require delivery of such mutilated certificate or instrument as a condition precedent to any issuance of a replacement.

SECTION 8.04. <u>Remedies</u>. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, the Shareholders, the Parent and the Company will be entitled to specific performance under this Agreement. The Parties agree that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations described in the foregoing sentence and hereby agree to waive in any action for specific performance of any such obligation the defense that a remedy at law would be adequate.

SECTION 8.05. <u>Interpretation</u>. When a reference is made in this Agreement to a Section, such reference shall be to a Section of this Agreement unless otherwise indicated. Whenever the words "include," "includes" or "including" are used in this Agreement, they shall be deemed to be followed by the words "without limitation."

SECTION 8.06. <u>Severability</u>. If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any rule or Law, or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the Transactions contemplated hereby is not affected in any manner materially adverse to any Party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the Parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the Parties as closely as possible in an acceptable manner to the end that Transactions contemplated hereby are fulfilled to the extent possible.

SECTION 8.07. <u>Counterparts; Facsimile Execution</u>. This Agreement may be executed in one or more counterparts, all of which shall be considered one and the same agreement and shall become effective when one or more counterparts have been signed by each of the Parties and delivered to the other Parties. Facsimile execution and delivery of this Agreement is legal, valid and binding for all purposes.

SECTION 8.08. <u>Entire Agreement; Third Party Beneficiaries</u>. This Agreement (a) constitutes the entire agreement, and supersede all prior agreements and understandings, both written and oral, among the Parties with respect to the Transactions and (b) is not intended to confer upon any person other than the Parties any rights or remedies.

SECTION 8.09. <u>Governing Law</u>. This Agreement shall be governed by, and construed in accordance with, the internal laws of the State of Nevada, without reference to principles of conflicts of laws. Any action or proceeding brought for the purpose of enforcement of any term or provision of this Agreement shall be brought only in the federal or state courts sitting in Las Vegas, Nevada, and the parties hereby waive any and all rights to trial by jury.

SECTION 8.10. <u>Assignment</u>. Neither this Agreement nor any of the rights, interests or obligations under this Agreement shall be assigned, in whole or in part, by operation of law or otherwise by any of the Parties without the prior written consent of the other Parties. Any purported assignment without such consent shall be void. Subject to the preceding sentences, this Agreement will be binding upon, inure to the benefit of, and be enforceable by, the Parties and their respective successors and assigns.

/ Signature page follows /

IN WITNESS WHEREOF, the parties hereto have executed and delivered this Share Exchange Agreement as of the date first above written.

![](ex0701-sig.jpg)

## Ex1A-7

**Exhibit 7.2**

![](ex702-1.jpg)

... . - . . . • • • Share and Asset Purchase Agreement (SPA) By and among MyRxWallet Prana _ Private Limited ("Acquirer") MyRxWallet North America Corporation. A Wyoming Company . ("Acquirer's parent") And Clinrarc, Pvt. Ltd. An India Company ("Seller") September 24, 2025 . . • , • • , • • • . . . MyRxWallet North America Corporation 2475 South Jone s Blvd, Suite 9, L as Vegas, NV 89146 https: //M yRxWallet.io • • • • •

![](ex702-2.jpg)

• • .. DEFINITIVE PURCHASE AGREEMENT . . : , . . . . This Definitive Purchase Agreement (this " Agreement") i s entered into as of September 24, 2025, by and among Clinrarc, Pvt. Ltd. (t � e "Seller''), a company organized under the laws of India; MyRx:Wallet Prana, Private Limited (the "Acquirer") , a company organized under the laws of India; and the Acquirer's parent, MyRx:Wallet North A · merica Corporation, a C0(1'1pany organized under the laws of Wyoming. The Seller and the Acquirer are hereinafter collectively referred to as the " Parties " and individually as a "Party." • • RECITALS WHEREAS, upon the terms and subject to the cond i tions set forth herein, at the first effective time · of this Agreement (the 'First Effective Time '), Clinrarc Pvt . Ltd . shall become a subsidiary that is majority - owned and controlled by MyRx : Wallet Prana Private Limited (the 'Acquirer'), which shall serve as the acquiring entity . MyRx : Wallet Prana Private Limited is a · wholly owned subsidiary of MyRx:Wallet North America Corporation (the 'Parent'). Accordingly, the Parent shall indirectly control Clinrarc Pvt. Ltd. through the Acquirer (the 'Surviving Corporation'). WHEREAS, immediately following the First Effective Tfme, the Seller shall be treated as a majority - owned and conttolled subsidiary of the Acquirer, and the Acquirer shall continue as the surviving company (the "Surviving Corporation"); WHEREAS, the Board of Directors of the Seller � as unanimously: (a) determined that this Agreement and the transactions contemplated hereby (the "Transactions") are fair to and in the best interests of the Seller and its shareholders; (b) approved, ado(?ted, and declared this Agreement and the Transactions advisable; (c) directed that the adoption of this Agreement be submitted for requisite approval in accordance with applicable law; and (d) recommended the approval of this Agreement and the Transactions by the Seller's shareholders; WHEREAS, the Board of Directors of the Acquirer has una · nimously: (a) determined that this Agreement, including the issuance of Acquirer equity as consideration (the "Acquirer Share Issuance"), is fair to and in the best interests of the Acquirer and its shareholders; (b) approved, adopted, and declared this Agreement and the Transactions advisable; (c) recommended that the AGquirer approve the Acquirer Share Issuance and the related Transactions; WHEREAS, the Board of Directors 9f the Acquirer has unanimously approved, adopted , and declared advisable this Agreement and the Transactions. . : WHEREAS, · concurrently with the execution and delivery of this Agreement, the Acquirer, . in its capacity as the fl!ajority shareholder of the Seller (upon completion of the equity transfer), shall execute and deliver this Agreement and provide written consent to approve the Transactions contemplated herein. NOW, THEREFORE, in consideration of the foregoing, mutual covenants, representations, warranties, covenants and agreements contained in this Agreement, the Parties hereby agree as follows: ARTICLE I CERTAIN DEFINITIONS . . MyRxWallet North America Corporation 2 475 S ou th Jon es Blvd, S uit e 9, Las V egas , NV 8 9 146 h ttps: / /MyluWallet.io . ' . . .

![](ex702-3.jpg)

- . . 1.1 Certain Definitions: . .. · - - (a) The following terms, when used in this Agreement, shall have the respective meanings ascribed to them below: · "ACTION" means any claim, action, suit, inquiry, hearing, investigation or other proceeding. "AFFILIATE" means, with respect to a Person, any other . Person that, directly or indirectly, through one or more intermediaries, Controls, is controlled by or is under common Control with, such Person. For purposes of this definition, "CONTROL" (including, with correlative meanings, the terms "Controlled by" and "under common Control with") means the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of a Person, whether through the ownership of stock, as trustee or executor, by Contract or credit arrangement or otherwise . • - . • . ' ,• • . "ACQUIRER" has the meaning set forth in the preamble hereto. "AGREEMENT' has the meaning set forth.in the preamble hereto. "ANCILLARY AGREEMENTS" means the Bill of Sale and the IP Assignment. "ASSETS" has the meaning set forth in Section 2.1. "BUSINESS DAY" means any day other than Saturday, Sunday or any day on which banks in Las Vegas, Nevada are required or authorized to be closed. "CLOSING" ha · s the meaning set forth in Section 3.1. "CLOSING DATE" has the meaning set forth in Section 3.1. .. • • • "CONTRACT" means any agreement, lease, debenture _ , note, bond, evidence of Indebtedness, mortgage, indenture, security agreement, option or other contract or commitment (whether written or oral). "FIRST EFFECTIVE TIME" has the meaning set forth Section 2.1 to 2.5 . • • "EXCLUDED ASSETS" has the meaning set forth in Section 2.3. "EXCLUDED LIABILITIES" has the meaning set forth in Section 2.3. "GAAP" means United States generally accepted accounting principles as in effect from time to time, con � istently applied throughout the specified period and all prior comparable · periods. · . "GOVERNMENTAL ENTITY" means any government or political su _ bdivision thereof, whether foreign or domestic, federal, state, provincial, county, local, municipal or regional, or any other governmental entity, any agency, authority, department, division or instrumentality of any such government, political subdivision or other governmental entity, any court, arbitral . tribunal or arbitrator, and any nongovernmental regulating body, to the extent that the rules, regulations or orders of such body have the force of Law . • • . . MyRxWallet North America Corporation 2475 South Jones Blvd, Suite 9, Las Vegas, NV 89146 https://MyR.xWallet.io , • • • •

![](ex702-4.jpg)

... • "INDEBTEDNESS" means, as to any Person: (i) all obligations, whether or not contingent, of such Person for b _ orrowed money (includ . ing, without limitation, reimbursement . and all other obligatio11s with respect to surety bonds, letters of credit and bankers' • • acceptances, whether or not matured), (ii) all obligations _ o f such Person · evidenced by notes, bonds, debentures, capitalized leases or similar instruments, (iii) all obligations of such Person representing the balance c;>f deferred purchase price of property or services, (iv) all interest rate and currency swaps, caps, collars and similar agreements or hedging devices under which payments are obligated to be made by such Person, whether periodically or upon the happening of a contingency, (v) all indebtedness created or arising under any conditional sale or other title retention Contract with respect to property acquired by such Person (even though the rights and remedies of the seller or lender under such Contract in the event - of default are limited to repossession or sale of such property), (vi) all indebtedness secured by any Lien on any property or asset owned or held by such Person regardless of whether the indebtedness secured thereby shall have been assumed by such Person or is non - recourse to the credit of such Person, and (vii) all indebtedness referred to in clauses (i) through (vi) above of any other Person that is guaranteed, directly or indirectly, by such Person. "INTELLECTUAL PROPERTY" means: all (i) discoveries and inventions (whether patentable or unpatentable and whether or not reduced to practice), all improvements thereto, arid all United States, international, and . foreign patents, patent applicatrons (either filed or in preparation for filing), patent disclosures and statutory invention registrations, including all reissuances, divisions, continuations, continuations in part, extensions and reexaminations thereof, all rights therein provided by int � rnational treaties or conventions, (ii) trademarks, service marks, trade dress, logos, trade names, corporate names, and other source identifiers (whether or not registered) including all common law rights, all registrations and applications for registration (either filed or in preparation for filing) thereof, all rights therein provided by international treaties or conventions, and all renewals of any of the foregoing, (iii) all copyrightable works and copyrights (whether or not registered), all registrations and applications for registration thereof, all rights therein provided by international treaties or conventions, and all data and documentation relating thereto, (iv) confidential and proprietary information, trade secrets, know - how (whether patentable or nonpatentable and whether or not reduced to practice), processes and techniques, research and development information including patent and/or copyright searches conducted by Seller and/or any third party, ideas, technical data, designs, . drawings and specifications, (v) Software, (vi) coded values, formats, data and historical or ctJrrent databases, whether or not copyrightable, (vii) domain names, Internet websites or identities used or held for use by the Seller, (viii) other proprietary rights relating to any of the foregoing (including without limitation any and all associated goodwill and remedies against infringements thereof and rights of protection of an interest therein under the laws of all jurisdictions), and (ix) copies and tangible embodiments of any of the foregoing. "IP ASSIGNMENT" has the meaning set forth in Section 3.2(b). "KNOWLEDGE" means the actual or constructive knowledge after due inquiry of any current officer or manager of the Seller. • . . . . "LAWS" means all laws, statutes, rules, regulations, ordinances and other pronouncements h _ aving the effect of law of the United States, any foreign country or any domestic or foreign state, county, city or other political subdivision or of any Governmental · Entity. "LIABILITY" means all Indebtedness, obligations and other Liabilities of a Person, whether absolute , accrued, contingent, fixed or otherwise, and whether due or to become due (including for Taxes). _, • • • • • • • • MyRxWallet North America Corporation . 247 5 South Jon es Blvd, Suite 9, Las Ve gas, NV 8914 6 bttp s :/ /M y Rx Wa llet i o • . . . . •

![](ex702-5.jpg)

• • "LIEN" means any mortgage, pledge, assessment, security interest, lease, lien, adverse claim, 1e,1y, charge or .. other encumbrance of any kind , _ whether voluntary or involuntary (ir 1 cluding · any conditional sale Contract , titte · retention Contract Oi Contract committing to grant any of the foregoing). "LOSS" means all damages , fines, fees, penalties, deficiencies, losses and expenses (including, without limitation, all interest, · court costs, fees and expenses of attorneys, • accountants and other experts or other expenses of litigation or other proceedings or of any claim, default or assessment). . . . "MATERIAL ADVERSE EFFECr · means any material adverse effect on the condition, operations, business, prospects or results of sales of the � eller; PROVIDED, HOWEVER, that any adverse effect arising out of or resulting from the enterlng into of this Agreement or the consummation of the transactions contemplated hereby, shall be excluded in determining whether a Material Adverse Effect has occurred. . "ORDER" means any writ,judgment, decree, injunction or similar order · of any Governmental Entity (in each case whether preliminary or final). "PERSON" means any individu · a1, partnership, limited liability company, corporation, association, joint stock company, trust, estate, joint venture, unincorporated organization, Governmental Entity or any other entity of any kind. • "PURCHASE PRICE" has the meaning set forth in Section 2.1. "REPRESENTATIVES" means, with re � pect to any Person, the directors, officers, managers, employees, counsel, accountants and other authorized representatives of such Person. • • "SELLER" has the meaning · set forth in the preamble hereto. "SOFTWARE" mean � all computer software, including source code, object code, machine - readable code, HTML or other markup language, program listings, comments, user int � rfaces, menus, buttons and icons, web applications and all files, data, manuals, design notes, research and development documents, and other items and documentation related thereto or associated therewith. "SOLVENr means, with respect to the Seller, that (a) the Seller can pay its Liabilities, as they mature in the normal course of business, and (b) the fair value of the assets of the Seller is greater than the total amount of Liabilities of the Seller. "TAX RETURNS" means ?II returns and reports (including elections, claims, declarations, disclosures, schedules, estimates, computations and information returns) required to be supplied to a tax authority in any jurisdiction relating to Taxes. "TAXES" means all federal, state · , local and foreign income, profits, franchise, li � nse, social security, transfer, registration, estimated, gross receipts, environmental, customs duty, capital stock, severance, stamp, payroll, sales, employment, unemployment, disability, use, property, withh . olding, excise, production, value added, occupancy and other taxes, d . uties or assessments of any nature whatsoever together with all interest, penalties, fines and additions to tax imposed with respect to such amounts and any interest in respect of such penalties and additions to tax. • • MyRxWallet . North America Corporation 2475 South Jon es Blvd, Suite 9 , Las Vegas, NV 89146 https://MyRx.Walletio • • • • • • • •

![](ex702-6.jpg)

, ' "THIRD - PARTY CLAIM" has the meaning set forth in Section 7.2(a). , • • . . "TRANSFER TAXES" means all sales, · use, value added, excise, registration, • • - . documentary, stamps, transfer, real property transfer, recqrding, gains, stock transfer and other similar Taxes and fees. (b) For · purposes of this Agreement, except as otherwise expressly provided herein or unless the context otherwise requires: (i) words using the singular or plural number also include the plural or singular number, respectively, and the use of any gender herein shall be deemed t9 include the other genders; (ii) references herein to "Articles," "Sections," "subsections" and other subdivisions without reference to a document are to the specified Articles, Sections, subsections and other subdivisions of this Agreement; (iii) a reference to a subsection without further reference to a Section is a reference to such subsection as contained in the same Section in which the reference appears, and this rule shall alsq apply to other subdivisions within a Section or subsection; (iv) the words "herein," "hereof," "hereunder," "hereby" and other words of similar import refer to this Agreement as a who.le and not to any particular provision; · and (v) the words "include," "includes" and "including" are deemed to . be followed by the phrase "without limitation." All accounting terms used herein and not . expressly defined herein shall have the meanings given to them under GAAP. . . • • .. ARTICLE II DEFINITIVE PURCHASE AGREEMENT Section 2.1 - Execution of Agreement . This Definitive Purchase Agreement (this "Agreement"), dated as of September 4, 2025, is entered into by and among MyRxWallet Prana Private Limited (the "Acquirer"), a company organized under the laws of India, MyRxWallet North America Corporation, a company - • • organized under the laws of the State of Wyoming and the parent of the Acquirer (the "Parent"), and Clinrarc Pvt . Ltd . , a company organized under the laws of India (the "Acquiree or Seller") . WHEREAS, the Parties desire to enter into this Agreement for the purpose of effecting the acquisition of an eighty percent (80%) controlling interest in the Seller by the Acquirer, together with the Acquirer's concurrent equity commitment intended to support the Seller's post - closing operations and strategic expansion (the "Strategic Growth Capital Commitment"); and WHEREAS, the Parties have agreed that the aggr � ate purchase - price and Strategic • J Growth Capital Commitment (collectively, the "Transaction Consideration") shall be settled entirely through the issuance of 8 , 875 , 740 shares of common stock of the Acquirer, each having a deemed issue price of USO $84 . 50 per share, representing an implied total transaction value of approximately USO $750 , 000 , 000 , which valuation is established solely for purposes of this equity - based transaction ; and WHEREAS, the shares to be issued in connection with this Agreement (the "Cons{deration Shares") sha l l _ b e duly authorized, validly issued, fully paid, C?nd non - assessable, and shall be issued in accordance with all applicable provisions of United States securities and · corporate law, together with the rules and regulations promulgated thereunder. NOW, THEREFORE, in consideration of th � mutual covenants and agr.eements set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree to be bound by - the terms and conditions of this Agreement and to consummate the transactions contemplated herein in accordance with the provisions set f9rth below. • MyRxWallet North Americ · a Corporation 247 5 South Jones Blvd, Suite 9 , Las Vegas , NV 89146 bttp s:/ /MyRxWallet.io • I I ' • • • I I ' .I

![](ex702-7.jpg)

• • Section 2. 2 - Sale and Transfer of Equity Interests • . - . • • . Subject to the terms and conditi o ns · set forth in · this Agreement, the Seller hereby agree s · to sell, a s sign, transfer, and convey to the Acquirer, and the Acquirer hereby agrees to purchase from th e Seller, eighty percent (80 ƒ /o) of the total i s sued and out s tanding equity shares of Clinrarc Pvt. Ltd. (the "Shares"), s � c h Share s representing a controlling equity - interest in, and conferring majority ownership and voting control of, Clinrarc Pvt. Ltd. (the " Company"). • · , " Section 2.3 - Purcha s e Price , Share Issuance, and Performance Vesting Allocation of Transaction Consideration (a) Aggregate Consider � tion and Allocation • USO $50,000,000 (represented by approximately 591,716 Consideration Shares of the Ac quirer, each valued at a deemed issue price of USO $84.50 per share) shall represent the all - equity purchase consideration payable to · the Seller in exchange for eighty percent (80 ƒ /o) of the issued and outstanding equity interests of Clinrarc P v t � Ltd. , conferring upon the Acquirer a - controlling ownership and majority governance interest in the Company; and . . . • • USO $700 , 000,000 (represented by approximately 8,284,023 Consideration Shares of the Acquirer, each valued at a deemed issue price of USO $84.50 per share) shall represent the Strategic Growth Capital Commitment, to be deployed and allocated by the Acquirer in accordance with its board - approved roadmap to support Clinrarc Pvt. Ltd.'s data - center development, operational expansion, technology scaling , and industry growth initiatives. (b) Agreed Valuation Statement • The Parties hereby acknowledge and confirm the following with respect to the valuation underlying the Transaction Consideration: (i) The valuation set forth in this Agreement has been mutually d _ etermined by the Parties solely for the purposes of effecting this transaction and establishing the deemed issue price of the Consideration Shares ; (ii) Such valuation has not been derived from, nor is it supported by, any formal third - party valuation, appraisal, or independent financial opinion regarding the Company ' s financial condition, fair market value, or any other economic indicators; and (iii) For the avoidance of doubt, the agreed valuation shall be deemed final, binding, and conclusive as between the Parties, and shall not be subject to adjustment, renegotiation, or revision on account of any subsequent events or changes, including fluctuations in • currency exchange rates between the Indian Rupee and the U.S. Dollar occurring at or after the date of this Agreement. Nothing herein shall be construed to bind the Company or any tutu . re investor, shareholder , or affiliate to the per - share value agreed for purposes of this Transaction Consideration in any subsequent equity financing, capital raise, or valuation event. (c) Seller's Vesting Schedul e and P e rformance - Based Milestones. The Seller shall be entitled to vest a total of $60,000 , 000 in consideration shares, released in four tranches upon the achievement of the following milestones. All vesting shall be subject to • . . . . MyRxWallet North America Corporation 2475 So ll th J ones Bl vd, S uit e 9 , Las V egas , NV 89 14 6 https://MyRx W allet. i o • •

![](ex702-8.jpg)

,, validation and approval by the Parent and, where applicable , confirmation by an independent tevie \ - ' / committee or mvtual!y appointed advisor. .. . . . , _ Milestone 1: SEC Registration Statement Effectiveness and National Securities Exchange Listing •• • The Seller shall be entitled to $5,000,000 in consideration shares immediately upon the successful completion and effectiveness of the Parent's S - 1 registration statement and the Parent's national exchange listing debut. Milestone 2: Data Center Development Initiation & Governance Structures • The Seller shall be entitl � d to $15,000,000 in consideration shares upon: • Commencement of data center site development and construction, • Formation of all necess . ary committees for financial controls, project oversight, I I and auditability, • Ensuring every aspect of development is monitored and · all expenditures are • subject to audit, • Confirming all engaged stakeholders are appropriately licensed and bound by enforceable agreements, • • Securing governmental endorsement/support in alignment with relevant economic development agendas. The vesting of shares under this milestone is subject to verification of the Seller's achievement of the corresponding milestone criteria, which shall be established by audited financial statements or another mutually agreed form of independent review, and confirmed both by the Parent and any required ind � pendent review committee before release of the agreed amount to the Seller. Milestone 3: Progress & Performance Validation • The Seller shall be entitled to $15,000,000 in consideration shares upon: • Satisfactory completion of Milestone 2 requirements, • Demonstrable progress in data center construction and development in accordance with the Parent's goals , • Aggressive measures implemented for performance improvement, • Validation that all stakeholders maintain required performance standards, • Governmental support at or above anticipated levels . The vesting of shares under this milestone is � ubject to - verification of the Seller's achievement of the corresponding milestone criteria, which shall be established by audited financial statements or another mutually agreed form of independent review, and confirmed both by the Parent and any required independent review committee before release of the agreed amount to the Seller. Milestone 4 · : Project Completion & Exceptional Results _ . • The Seller shall be entitled to the final $15,000,000 tranche in consideration shares upon the successful completion of both data centers' construction and development. • An additional $10,000,000 reward shall be ve � ted if achievements e � ceed expectations and are deemed spectacular or extraordinary by the Parent and any independent review committee. • • • • • • MyRxWallet North America Corporation 2475 So uth Jones Bl vd; Sui t e 9, Las Vegas, NV 89146 http s : / /MyRxWalleLio • • • •

![](ex702-9.jpg)

• • • • The vesting of shares under this milestone is subject to verification of the Sellers achievement of the corresponding milestone criteria, which shall be established PY audited financial . . statements or another mutually agreed · form of independent review, and con · firmed both · by the • • • Parent and any required independent review committee before release of the agreed amount to the Seller. 2.4 Closing Term: The closing of the transaction (the "Closing") shall take place on or before October 26, 2025, or on such other date and time as may be mutually agreed upon by the Parties in writing. The Closing shall be deemed effective upon the completion of all condition's precedent and the mutual exchange of required deliverables, including the transfer of the Shares and issuance of the Consideration Shares. • • Issuance, Vesting, and Securities Compliance • Upon execution of this Agreement, the Acquirer shall promptly instruct - its duly appointed Stock Transfer Agent of record to initiate the issuance of the applicable equity consideration to the shareholders designated in writing by the Seller. • Equity shares that are immediately vested in accordance with the terms of this . Agreement shall be issued and delivered without delay, subject to applicable restrictions under federal and state securities laws. • • \ • Equity shares subject to a vesting schedule or escrow conditions shall be issued in book - entry form and held by the Transfer Agent or an appointed escrow agent, to be released in accordance with the agreed vesting milestones and any applicable escrow agreement. Transfer of Assets and Intellectual Property: As a condition precedent to Closing, the . Seller shall transfer, assign, and convey to MyRxWallet North America Corporation all right, title, and interest in and to all business assets of Clinrarc, Pvt. Ltd., Inc. related to its technology operations. Such assets include, without · limitation, all proprietary technology, software code, databases, trade secrets, product designs, trademarks, service marks, domain names, copyrights, patents, know - how, customer and vendor data, documentation, and any derivative works or improvements thereof. The transfer shall also include all tangible and intangible property, equipment, contracts, and goodwill necessary for the continued use, commercialization, and further de � elopment of the Clinrarc, Pvt. Ltd., Inc. technology platform by the Acquirer. All intellectual property assignments shall be executed in a form reasonably acceptable to both Parties, and any filings, registrations, or recordations required with governmental or regulatory agencies (including the USPTO or relevant IP offices) shall be completed promptly following Closing. . · 2.5 Legal Fees: Each . party shall be solely re . sponsible for the payment of its own legal fees and expenses incurred in connection with the negotiation, preparation, execution, and performance • of this Agreement, including the hiring and engagement of legal counsel. • • ARTICLE Ill THE CLOSING DATE AND TERMS • • • 3 . 1 Closing : The closing of the transactions contemplated hereby (the "CLOSING") shall take place contemporaneous with the execution of this Agreement on or prior to October 26 , 2025 (the "CLOSING DATE") . • • • . . . MyRxWallet North America Corporation 2475 South Jon e s Blv � Suite 9, Las Vegas , NV 89146 http s : // MyR.xWall et .io • • ' •

![](ex702-10.jpg)

• ,, • , , 3.2 Delivery of lte . ms by the Seller: The Seller shall deliver to the Acquirer at the Closing • the items listed · below: ..• • • , .. : " , , .. · . (a) All documentation necessary to effectuate the transfer of eighty percent (80%) of the issued and outstanding equity interests of Seller. to the Acquirer, through its designated stock transfer agent of record, shall be prepared, executed, and delivered within ? - day post - closing. OR The Seller shall engage a licensed Stock Transfer Agent or Chartered Accountant to issue an affidavit certifying that they represent the Seller, and that based on the structure of the transaction, seller shall deliver to acquirer documentation of majority ownership - with the provision prescribed herein. The affidavit shall be provided to the Acquirer's legal counsel prior to the Closing Date. {b) Concurrently, the Seller's representative (CPA) shall furnish documentation recognizing Acquirer, as the official majority shareholder of record, entitled to full governance rights and ownership of eighty percent (80%) of Seller, effective upon the execution of the Definitive Purchase Agreement. (c) Any required corporate resolutions, board consents, or share registers reflecting the transfer. • • • • (d) Any other agreements or instruments reasonably requested by the Acquirer to effectuate the terms of this Agreement (e) The acquiree shall initiate the organizatiori's name change within thirty (30) days of receiving the funds from the acquirer or its parent's. . (f) Any other documents and instruments as the Acquirer may reasonably request. • The Acquirer will issue the agreed - upon 591,716 common shares (equivalent to $50,000,000) to the Seller and separately 8,284,023 common shares (equivalent to $700,000,000) to the company upon the execution of this SPA, through its SEC - registered Stock Transfer Agent. The issuance of the . se shares constitutes de facto confirmation of the equity transaction a . n d satisfies all conditions required for Closing. Accordingly, all items shall be delivered directly to the Acquiree without escrow. 3.3 Delivery of Items by Acquirer: The Acquirer shall deliver to the Seller, within seventy - two (72) hours following the Closing, the following items: (a) Share Certificates or Book - Entry Confirmations issued by the Stock Transfer Agent of record, evidencing the issuance of the Acquirer's common shares representing the equity ownership interest in Acquirer, as set forth in this Agreement; and (b) Certificates or Official Receipts confirming the book - entry registration of such shares · in the name(s) of the Seller or designateq recipients, documentiQg ownership of the applicable Acquirer shares in accordance wit h . the terms of this Agre e . ment. • • • . . • . . . 3.4 Liquidity Rights Upon SEC Qualification of Form 1 - A Upon the SEC's issuance of a Notice of Qualification with respect to the Parent � s Offering Statement on Form 1 - A (the "Qualification Event"), the Parent shall reserve a portion of the authorized but unissued common shares covered under such Form 1 - A for the purpose of satisfying, in whole or in part, the remaining consideration payable to the Seller under this Agreement. Such shares, once issued, shall constitute newly issued, unrestricted, freely tradable securities, to the fullest extent permitted under applicable securities laws, and shall not . . MyRxWallet Nor:th America Corporation 2475 South Jones Blvd, Suite 9, Las Vegas , NV 89146 http s : l /MyRxWall e t.io • •

![](ex702-11.jpg)

t • • be subject to the vesting schedule or resale rest � ictions applicable to any non - registered Consideration Shares deliv e red at Clo$ir.g. • • .,.. r The Parties acknowledge their shared commercial intent that, upon the Qualification Event, the Seller shall have immediate access to liquidity, subject to standard regulatory and brokerage limitations. The Parent shall, where required, file any supplements or notices to the Form 1 - A to facilitate such issuance, and shall instruct its stock transfer agent to deliver the unrestricted shares electronically (DWAC or book - entry) within five (5) Business Days following the Qualification Event, subject only to customary anti - fraud and compliance procedures. . For clarity, the Parent is not acting as broker or selling agent for the Seller, and the Seller shall determine its own timing, pricing, and method of sale in compliance with applicable securities laws. Nothing in this Section shall impair the Parent's ability to manage offering timing, market conditions, or investor communications in good faith. . For the avoidance of doubt, the Part � es further acknowledge: • '• (a) The Seller shall be entitled to immediate access to liquidity with respect to such newly issued � nrestricted shares; (b) The Parent shall file any supplements, notices, or amendments to the Form 1 - A, if required, to facilitate sue � issuance; and (c) The Parent shall instruct its duly appointed stock transfer agent to deliver such shares via DWAC or book - entry electronic settlement within five (5) Business Days of the Qualification Event, subject to standard anti - fraud compliance review. . . Nothing in this Section shall obligate - the Parent to sell any shares on behalf of the Seller, and the Seller shall be solely respon · sible for determining the manner, timing, and method of any sale, including adherence to federal and state securities regulations and any volume limitations applicable to resales. . ARTICLE IV . . REPRESENTATIONS AND WARRANTIES OF THE SELLER · As an inducement to the Acquirer to enter into this Agreement, Seller represents and warrants to the Acquirer as follows: • • ' . . 4.1 Authorization: The Seller represents and warrants that it has conducted independent due diligence, fully understands the terms of this Agreement, and is entering into this transaction voluntarily and with informed consent. The Seller acknowledges and agrees that, upon execution of this Agreement, Seller, shall become a subsidiary of Acquirer. The Seller further represents that it has full power and - authority to execute and deliver this Agreement and � ny related Ancillary Agreements, and to perfo _ rm its obligations herel:fnder and thereunder. This Agreement and the Ancillary Agreements have been duly executed and delivered by the Seller an _ d, assuming the due at,Jthorization, execution · , . and delivery by the • Acquirer, constitute valid and legally binding obligations of the Seller, enforceable in accordance with their respective terms. • 4.2 Brokers and Legal Fees: Each Party shall be solely responsible for any and all legal, advisory, brokerag e - ,finder, accounting, or consulting fees it incurs in connection with the negotiation, execution, and consummation of the transactions contemplated by this Agreement, unless otherwise expressly agreed to in writing by the Parties. No agent, broker, finder, . . .. . . . . MyRxWallet North America Corporation 2475 South Jon es Blvd , Suite 9, Las Ve g a s , NV 89146 bttp s:/ /M y .R.. x \ Vallet. i o • •

![](ex702-12.jpg)

• ... . investment banker, financial advisor, or other similar intermediary shall be entitled to any fee , . .. commission, . or other compensation in connection with this . transaction based on any •· ·· •• arrangement · made by or on behalf of the other Party of any of its Affiliates: 4.3 Non - Contravention: Neither the execution, delivery or performance of this Agreement or the Ancillary Agreements, as applicable, nor the consummation of the transactions contemplated hereby or thereby will, with or without the giving of notice or the lapse of time or both, (i) violate any Law or Order or other restriction of any Governmental Entity to which the Seller may be subject or (ii) conflict with, result in a breach of, constitute a default under, result in the acceleration of any right or obligation under, create in any party the right to accelerate, terminate, modify, cancel, require any notice under or result in the creation of a Lien on any of the Assets under, any Contract to which the Seller is a party or by which it is bound and to which any of its Assets is subject. 4.4 Litigation: There is no pending or, to the Knowledge of the Seller, threatened Action against or affecting the Assets. Neither the Seller nor the Assets are subject to any Order restraining, enjoining or otherwise prohibiting or making illegal any action by the Seller, this Agreement or any of the transactions contemplated hereby. . . , . , - therefor. Sch e . dule 4.6 identifies the o . wner of each item list e . d thereon and, in the c . ase of . 4.5 Contracts: Except as set forth in Schedule 4.5, there are no executory contracts, commitments, agreements, or arrangements (whether written or oral, including but not limited to license agreements, development agreements, joint ventures, distribution arrangements, or strategic partnerships) to which any of the Assets are bound or subject, other than this Agreement. • The Seller further represents and warrants that if there exist any prior, existing, or anticipated contractual agreements - whether written, oral, formal, or informal - that (a) relate to the Assets or operations of Noah Bio - Bank Intelligence, Private Limited, and (b) have or may reasonably b � expected to have a material impact - financial, operational, or legal - on Clinrarc, Pvt. Ltd.or its business after the Closing, such agreements must be disclosed in full and delivered to the Acquirer as part of Schedule 4.5 prior to Closing. Failure to disclose any such agreement _ shall constitute a material breach of this Agreement and may result in appropriate remedies, including indemnification and potential termination rights, as provided elsewhere in this Agreement . 4.6 Intellectual Property: . Seller represents and warrants that • (a) Schedule 4 . 6 contains a list of all patents, trade names, trademarks and/or copyrights and all applications therefore owned by Seller with respect to the Assets and all licenses, if any, relating to the foregoing patents, trade names, trademarks and/or copyrights and all applications • registrations and applications, the application or registration number and date. The Seller has . . not taken any · action th . at could result in any of the registrations and � pplications for registration for the · Assets not being valid and in full force and effect. (b) Except as disclosed on Schedule 4.6, the Seller is the sole and exclusive owner of, and has good and marketable title to, all the Intellectual Property in and to the Assets, including the Intellectual Property set forth on Schedule 4.6, free and clear of all Liens. Except as disclosed on Schedule 4.6, the Seller has sole and exclusive right to develop, perform, use, create derivative works of, operate, reproduce, market, sell, license, display, distribute, publish . . MyRxWallet North America Corporation 2475 South Jones Blvd , Suite 9, Las Vegas, NV 89146 h ttps://M yRxWa ll e t. io • • • • • • •

![](ex702-13.jpg)

• • < , • . , .. , , I 1 l . , . . . • I , • and transmit the Intellectual Property in and to the Assets. Upon the Closing, except as disclosed on Schedule 4 . 6, the AGquirer will nave sole and exclusive right ; title � nd interest in and to the Intellectual Property in and to the Assets, such that the Acquirer shall thereafter have sole and exclusive rights to perform, reproduce, create derivative works of, develop, use, operate, market, sell, license, display, publish, transmit and distribute the Assets, free of all encumbrances. The Seller has taken reasonable measures to protect the proprietary nature of the Intellectual Property in and to the Assets and to maintain in confidence the trade secrets and confidential information that it owns or uses. Except as discl0sed on Schedule 4.6, no other Person . has any rights to any of Intellectual Property in and to the Assets and, to the knowledge of the Seller, no other Person is infringing, violating or misappropriating any of the Intellectual Property in and to the Assets. (c) With respect to the Seller's Intellectual Property contributed to the Assets, such Intellectual Property does not infringe upon, violate or constitute a misappropriation or any Intellectual Property or other right of any other Person. In addition, to Seller's knowledge, none of the activities or business presently cond . ucted by the Seller with respect to the Assets _ infringes or violates, or constitutes a misappropriation of any Intellectual Property · or other right of any other Person. Neither the Seller nor any Affiliate of . the Seller has received any written complaint, claim or notice alleging any such infringement, violation or misappropriation. Further, neither the Seller nor any - Affiliate of the Seller has disclosed to any Person, any product formula or design, or any portion or aspect of any product formula or design, which is part of the Assets, including Intellectual Property. . - . . . . . • - . . . • . . 4.7 Title to Assets: Except as to Intellectual Property (which warranty is � ntained in Section 4.6): (i) the Seller has good a _ nd marketable title to all of the Assets free and clear of all Liens; (ii) this Agreement and the instruments of transfer to be . executed and delivered pursuant hereto will effectively vest in the Acquirer good and marketable title to all of the Assets free and clear of all Liens; (iii) and no Person other than the Seller has any ownership interest in any of the Assets. , • • ' • • • • . I • . ' . . - - ·. 4.8 Investment Representations: Seller and those receiving shares in Acquirer represent and warrant that: (a) Seller and those receiving the shares are aware of the Acquirer's business affairs and financial condition and has acquired sufficienf information about Acquirer to reach an informed and knowledgeable decision to acquire the shares that constitute the Purchase Price. Seller and those receiving the shares also acknowledge that they are relying solely on their own counsel for legal advice, and not on any statements or representations of Acquirer or its legal counsel or agents for legal advice with respect to this investment or the transactions contemplated by this Agreement. ,, . 1 l . . ' (b) Seller and those receiving shares are acquiring the shares for investment for their own account only and not with a view to, or for resale in connection with, any "distribution" thereof within the meaning of the 1933 Act or under any applicable provision of state law. Seller and those receiying the shares do not have any present intent_ion to . transfer the shares to any person or entity. Seller and those receiving the share are aware that their investment in Acquirer is a speculative inve � tment that has limit e _ d l iquidity and is subject to the risk of complete loss. Seller and those receiving the share are able, without impairing their financial condition, to hold the shares for an indefinite period and to suffer a complete loss of its investment in the shares. . . (c) Seller and those receiving shares understand that the shares that comprise the Purchase Price have not been registered under the 1933 Act by reason of a specific exemption therefrom, which , exemption depends upon, among other things, the bona fide nature of Seller's investment intent as expressed herein. I • . . MyRxWallet North America Corporation 2475 South Jones Blvd, Suite 9, Las Vegas, NV 89146 h ttp s : / /MyRxWalle t .io •

![](ex702-14.jpg)

> f • • (d) · The Seller and af1y individual or entity receiving s . hares pursuant to this A † reement , . . . . - ·' acknowledge and agree that the shares oeing issued are " restricted securities" under applicable - � Indian securities laws, including the Companies Act, 2013, the Companies (Prospectus and Allotment of Securities) Rules, 2014, and where applicable, the SEBI (Issue of Capital and Disclosure Requirements) Regulations, as amended. Pursuant to these laws and rules, recipients may be required to hold the shares for a specified period and may not transfer, sell, or otherwise dispose of such shares unless such transfer complies with all applicable Indian corporate, securities, and exchange control laws, including approvals or exemptions under the Foreign Exchange Management Act, 1999 (FEMA) and/or RBI guidelines, where applicable. To the extent that U.S. securities laws become relevant (e.g., in the context of a subsequent listing in the U.S. or an offerin_g under Rule 144 or Regulation S), the Seller and recipients understand that the shares may also be treated as "restr i cted securities" under · the U.S. Securities Act of 1933, and may not be resold or transferred in the United States absent registration or an available exemption. The Acquirer shall have no obligation to register the shares with the U.S. Securities and Exchange Commission (SEC) or qualify them under state securities laws,. and any exemption · that may apply could be subject to conditions beyond the control of the Seller or recipients. ARTICLEV REPRESENTATIONS AND WARRANTIES OF THE ACQUIRER As an inducement to the Seller to enter into this Agreement, the Acquirer represents and warrants to the Seller as follows: 1. Authorization: The Acquirer has full power and authority to execute and deliver this Agreement and the Ancillary Agreements, as applicable, and to perform its obligations hereunder and thereunder. This Agreement and the Ancillary Agreements have been duly executed and de livered by the Acquirer and, assuming the due authorization, execution and delivery hereof and thereof by the Seller, constitute the valid and legally bi _ nding obligations of the Acquirer enforceable in accordance with their respective t � rms. Acquirer is a Private Limited Company organized under the laws of the State of Telangana, India, in good standing, and has obtained all consents and other approvals necessary under Telangana law, its Articles of Incorporation, and its Bylaws necessary for the execution, delivery and performance of this Agreement and the An . cillary Agreements. 2. Non - Contravention: (a) Neither the execution, delivery or performance of this Agreement or the Ancillary Agreements, as applicable, nor the consummation of the transactions contemplated hereby or thereby will, with or without the giving of notice or the lapse of time or both, violate any Law or Order o � other restriction of any Governmental Entity t9 which the Acquirer m _ ay be subject. . {b) The execution and delivery of this Agreement and the Ancillary Agreement �, as • • • • • • applicable, by the Acquirer does not, and the performance of this Agreement and the Ancillary Agreements by the Acquirer and the consummation of the transactions contemplated hereby and thereby will not, require any consent, approval, authorization or permit of, or filing with or notification to, any Governmental Entity. . 5.3 Brokers and Legal Fees: Each Party shall be solely responsible for any and all legal, advisory, brokerage, finder, accounting, or consulting fees it incurs in connection with the . • MyRxWallet North America Corporation 24 75 So uth J o n es Blvd, Suite 9, Las V eg as, NV 89146 http s: / /M.y Rx. W all e t.i o l • • I • l

![](ex702-15.jpg)

• • • - negotiation, execution, and consummation of the transactions contemplated by this Agreement, unle$S o therwise expr e ssly agreed to in writi11g by the Parties. • .. • . . - No agent, broker, finder, investment banker, financial advisor, or other similar intermediary shall be entitled to any fee, commission, or other compensation in connection with this transaction based on any arrangement made by or on behalf of the other Party or any of its Affiliates. , ARTICLE VI • CONDITIONS TO OBLIGATION TO CLOSE • • 1. Conditions to Closing by the Acquirer: The obligation of the Acquirer to effect the transactions contemplated hereby is subject to the satisfaction or waiver by the Acquirer of the following conditions: (a) The representations and warranties of certain of the Seller set forth in this Agreement shall be true and correct in all material respects, with respect to representations and warranties not qualified by materiality, or · in all respects, with respect to representations and warranties qualified by materiality, as of the date . of this Agreement and as of the Closing Date as though made on _ and as of the Closing qate. (b) The Seller shall have performed in all material respects the covenants required to be performed by it under this Agreement at or prior to the Closing Date. (c) The Seller shall have executed and delivered each of the Ancillary Agreements, as applicable. (d) There shall be no effective or pending Law or Order that would prohibit the Closing, and the Seller shall have obtained all necessary approvals of any Governmental Entities in connectio �_ with the transactions contemplated hereby and by the Ancillary Agreements. • (e) The Seller shall have delivered each of t � e items described in Section 3.2. . . (f) Seller shall have conducted its business only in the ordinary course and shall not have acquired or agreed to acquire as part of the business all or any substantial portion of the assets or business of any other business organization by merger or consolidation, stock purchase or asset purchase without Acquirer's approval in writing. • • . . (g) Seller shall have completed the approval of this Agreement and Ancillary Agreements as required under its articles of organization, operating agreements, and the laws of the jurisdictions where it is subject. (h) There were no appraisal rights (dissenter's rights) asserted by any owner of Seller in connection with this transaction. 6 . 2 CONDITIONS TO CLOS � NG BY THE SELLER . The obligation of the S � ller to effect the transactions contemplated hereby is subject to the satisfaction or waiver by the Seller of the following conditions : (a) The representations and warranties of the Acquir � r set forth in this Agreement shall be true and correct in all material respects, with respect to representations and warranties not qualified by materiality, and in all respects, with respect to representations and warranties qualified by materiality, in each case as of the date of this Agreement and as of the Closing Date as though made on and as of the Closing Date. ' I I , l . • l • ; • ; • I ' . . MyRxWallet North America Corporation 2475 South Jon es Blvd, Suit e 9, Las Veg as, NV 8914 6 https://MyR.x W allet .i o I ! •

![](ex702-16.jpg)

• • • ' (b) The Acquirer shall _ have performed in all material respects the covenants required to be performetf' by it unde r . t h i s . . Agreemen t at or prior to the Closing Date. · .. . · r • . . • • ' . . (c) The Acquirer shall have executed and delivered each of the Ancillary Agreements, as applicable. ' (d) There shall be no effective or pending Law or Order that would prohibit the Closing, and the Acquirer shall have obtained all necessary approvals of any Governmental Entitfes in . connection with the transactions contemplated hereby and by the Ancillary Agreements. (a) The Acquirer shall have delivered each of the items described in Section 3.3. ARTICLE VII POST - CLOSING COVENANTS . . . r • ••• • • • • . . . . - . • • 7.1 Transfer Taxes: Notwithstanding anything herein to the contrary, Acquirer shall be liable for and · shall pay any Transfer Taxes or other similar tax imposed in connection with the transfer of the Assets pursuant to this Agreement. The party responsible under applicable Law for remitting any such tax shall _ pay and remit such t ax _ o n a timely basis and, jf such party is the Seller, the Seller shall notify t � e Acquirer of the amount of such tax, and the Acquirer shall promptly pay to the Seller the amount of such tax. 7.2 Further Action: From and after - the Closing, each party her � to shall execute and deliver any documents and take all further actions as may reasonably be required to implement the provisions of this Agreement and the Ancillary Agreements, and to give effect to the transactions contemplated herein and therein. This includes ensuring that the Acquirer obtains effective ownership and control of the Assets. , . • ' . " . . . . ' ARTICLE VIII MISCELLANEOUS - · • • • . 8.1 Survival: Notwithstanding any right of the Acquirer (whether or not exercised) to investigate the affairs of the Seller _ or any right of any party (whether or not exercised) to investigate the accuracy of the representations and warranties of the other party contained in this Agreement or the waiver of any condition to Closing, each of the parties hereto has the right to rely fully upon the representations, warranties, covenants and agreements of the other contained in this Agreement. The representations, warranties, covenants and agreements of the parties hereto contained in this Agreement and any certificate or other document provided hereunder or • thereunder will survive the Closing. 8.2 No th � rd - party Beneficiaries: The terms and provisions of this Agreement are intended solely for the benefit of the Parties hereto and their respective successors and permitted assigns, and it is not the intention of the Parties to confer third - party beneficiary rights, and this Agreement does not confer any such rights, upon any other Person. . . . . 8.3 Entire Agreement: This Agreement (including the Exhibits and the Schedules heret o _) . constitute th _ e entire agreement between the Parties hereto with respect to the subject matter hereof and thereof and supersede any prior understandings, agreements or representations by or between the Parties hereto, written or oral, with respect to such subject matter. . . 8.4 Succession and Assignment: This Agreement shall be binding upon and inure to the benefit of the Parties named herein and their respective successors and permitted assigns. No Party hereto may assign either this Agreement or any of its rights, interests or obligations hereunder without the prior written approval of the other Parties hereto. • . . . MyRxWallet North America Corporation 2475 South Jones Blvd, Suite 9, Las Vegas, NV 89146 https: / /MyR.xWallet.io • • • • • • • • • r

![](ex702-17.jpg)

• • • • C r 8.5 Drafting: The Parnes have participated jointly in the negotiati o n ar:td drafting of this Agreement and, in the event an ambiguity or que s tion of intent or interpretation arises, this Agreement shall be construed as if drafted joi _ ntly by the Parties and no presumption or burden of proof shall arise favoring or disfavoring any Party by virtue of the authorship of any of the provisions of this Agreement. • . unless such amendment is in writing and signed by each of the Parties hereto. No waiver by any Party hereto of any default, misrepresentation or breach of warranty or covenant hereunder, whether intentional or not, shall be deemed to extend to any prior or subsequent default, mi s representation or breach of warranty or covenant hereunder or affect in any way any rights arising by virtue of any prior or subsequent such occurrence. No waiver shall be valid unless f - such waiver is in writin g - and signed by the Pa r - ty against whom such w - aiver is sought to be enforced. 8.6 Governing Law: This Agreement shall be governed by, and construed in accordance with � the laws of the State of Wyoming, and in State of Telangana, Hyderabad, India, without giving effect to any choice of law or conflict of law provision or rule that would cause the application of the Laws of any jurisdiction other than the State of Wyoming and State of Telangana, Hyderabad, India. . . 8. 7 Amendments and Waivers: No amendment of any provision of this Agreement shall be valid . . . . . . , • • • 8.8 Severability: If any provision of this Agreement is held to be illegal, invalid or unenforceable under any present or future Law, and if the rights or obligations of any Party hereto under this Agreement will not be materially and adversely affected thereby, (a) such provision will be fully severable, {b) this Agreement will be construed and enforced as if such illegal, invalid or unenforceable provision had never comprise � a part hereof, (c) the remaining provisions . of this Agreement will remain in full force and effect and will not be affected by the illegal, invalid or unenforceable provision or by its severance here from and (d) in lieu of such illegal, invalid or unenforceable prov _ ision, there will be added automatically • as a part of this Agreement a legal, valid and enforceable . provision as similar in terms of such illegal, invalid or unenforceable provision as may be possible. . . - • I - . • 8.9 Expenses: Except as otherwise expressly set forth herein or therein, each of the Parties hereto will bear its own costs and expenses (including legal fees and expenses) incurred in connection with this Agreement , the Ancillary Agreements and the transactions contemplated hereby or thereby, whether the transactions contemplated hereby or thereby are consummated. 8.1O Incorporation of Exhibits and Schedules: The Exhibits, Annexes and Schedules identified • in this Agreement are incorporated herein by reference and made a part hereof. Unless otherwise specified, no information contained in any numbered Schedule shall be deemed to be contained in any other numbered Schedule unless explicitly included therein {by cross reference or otherwise) . �.11 Specific Performa � ce: The Partie s hereto _ agree that irreparable c;jamage would occur if � ny provision of this Agreement was not performed in accordance with the terms hereof and that the Parties shall be e · ntitled to specific performance of the terms hereof in additiqn to any other remedy available to them at law or equity. 8 . 12 H � adings: The descriptive heading s contained in this Agreement are included for . convenience of reference only and shall not affect in any way . the meaning or interpretation of this Agreement . • • • . . . MyRxWallet North America Corporation 247 5 S ou th J o n es Bl v d, S uit e 9, Las V egas, NV 89 14 6 https :/ /MyR,x \ Valle t. io ' . . • • • • • •

![](ex702-18.jpg)

. . • 8.13 Counterparts: This Agreement may be executed in one or more counterparts, and by the different Parties hereto in , separate counterparts, each of which when · executed shall be d � emed to be an original but all of whrch taken together shall constitute one and the same agreement. 8.14 Written Confirmation & SEC Complian _ ce: (a) Formal Acknowledgment & Acceptance . The Seller shall provide a written confirmation or formal acceptance of this Agreement within [ 7 ] business days of execution . Such confirmation shall expressly acknowledge that this Agreement is binding, enforceable, and an integral part of the transaction . , (b) SEC Incorporation Rights. Upon receipt of the · written confirmation, � he Buyer shall have the right to incorporate this Agreement into any of its SEC Registration Statement to notify the Securities and E � change Commission (SEC) that this transaction is part of a planned Primary or Secondary Offering, or combination of both subjects to market conditions and regulatory approvals. • · (c) No Further Seller Approval Required. The Selle . r shall not unreasonab l . . y . withhold, delay, or co . ndition such confirmat - ion. The Seller acknowledges that the Buyer is under regulatory obligations to disclose this Agreement as part of its SEC registration process and agrees to cooperate in good faith. 8.15 Reg _ istration Rights: At or immediately following the Closing, the Parties shall enter into a Registration Rights Agreement (the "RRA"), in substantially the form attached hereto as Exhibit F, granting the Seller (and any designated share recipients) customary demand registration, piggyback registration, and Form S - 3 shelf registration rights, together with allocation of expenses, blackout periods, lock - ups, and indemnification provisions, each consistent with U.S. securities law and industry practice. The RRA shall govern the Seller's right to request that the Acquirer file, register, qualify, or make effective one or more resale registration statements under the Securities Act of 1933 with respect to the Consideration Shares, subject · to customary underwriter and regulatory limitations. • ARTICLE IX TERMINATION • • • 1. Termination Rights: This Agreement may be terminated at any time under the following conditions: (a) Mutual Termination. By mutual written consent of both Buyer and Seller with a prior written notice o f _ 30days. (b) Any material or non - mater - ial, tangible or intangible changes impacting the normal business ope � ations immediately upqn execution of the Dennitive Purchase Agree(Jlen • t shall constrtute a Material Adverse Effect , requiring reassessment of contractual _ obligations and may be subject to breach of contractual agreement. . • (c) Failure to Satisfy Closing Conditions. By either Buyer or Seller, if the Closing Conditions have not been satisfied by "Closing Date", unless the failure is due to the breach or failµre of the party seeking termination. (d) Breach by Seller. By - Buyer, if the Seller breaches any material representation, warranty, or covenant and fails to cure such breach within 60 days after receiving · written . . . . MyRxWallet North America Corporation 2475 South Jon es Blvd, Suite 9, Las Ve g as , NV 89146 http s://My R x.Wallet. i o • . . •

![](ex702-19.jpg)

• • ' ' .. notice. (e) Regulatory Prohibition. By either Buyer or Seller, if the transaction is prohibited · by law or regulatory order from any applicable governmental authority. (f) Material Adverse Change. By Buyer, if a Material Adverse Change occurs that negatively impacts the financial condition, business operations, or assets of the Seller before Closing. • • ... . (g) · Buyer's Non - Payment. By Seller , if Buyer fails to deliver near the Purchase Price or other required consideration as agreed in this purchase agreement. 9.2 Effect of Termination: : If this Agreement is terminated in accordance with this section: (a) All obligations of the parties under this A greemen t _ shal l immediately terminate, · except those expressly stated to survive termination (e.g., · Confidentiality, Governing Law, Dispute Resolution). • I . . . • (b) If termination occurs due to a material breach, the non - breaching party shall hav e · t he • right to pursue remedies available under law or equity. ; ' . . 1 i . , . , . : (c) Any funds, deposits, or escrowed amounts shall be returned or distributed in accordance with the Agreement . ARTICLE X INDEMNIFICATION AND REMEDIES .. . . . , •• • , · • 10.1 Indemnification by Seller The Seller hereby agrees to indemnify, defend , and hold harmless the Acquirer and its affiliates, officers, directors, employees, agents, successors, and assigns (each an "Acquirer Indemnified Party") from and against any and all losses, damages, liabilities, costs, expenses (including reasonable attorneys' fees) , claims, demands, action �, or proceedings ("Losses") incurred or sustained by any Acquirer Indemnified Party arising out of or relating to: .. . •. . . • (a) any breach of any representation, warranty, covenant, or agreement of the Seller contained in this Agreement or any ancillary document; (b) any failure by the Seller to perform any post - closing obligations as set forth herein; (c) any liability relating to , resulting from, or arising out of the Seller's ownership, conduct, or operations of Clinrarc, Pvt. Ltd., Inc. prior to Closing, including taxes , third - party claims , or employee matters. . . 10.2 Indemnification by Acquirer • . . ' The Acquirer agrees to indemnify , d e fend, and hold harmless the Seller and its affiliates, officers, directors, employees, agents, successors, and assigns (each a "Seller Indemnified Party") from and against any and all Losses incurred or sustained by any Seller Indemnified Party arising out of or relating to: • • • • . . . . . MyR:xWallet North America Corporation . 2475 South J o n es Blvd, S ui te 9 , Las Ve gas, NV 8914 6 https://M y RxWal l et. i o ' J I I I I I I I •

![](ex702-20.jpg)

• • • • • • (a) any breach by the Acquirer of any representation, warranty, cov e nant, or agreement contained in this Agreement or any ancilla ry .' document ; . • . ... • • . . . ,.. ., • (b) any liability relating to operations of Clinrarc , Pvt. Ltd., Inc. following the Closing (except as expressly retained by Seller). 10.3 Procedures and Limitations · (a) Notice and Defense. The Party seeking indemnification (the "Indemnified Party") shall promptly notify the indemnifying party (the "Ind e mnifying Party") in writin · g of any claim , action, or occurrence for which indemnification is sought. The Indemnifying Party shall have the right to assume the defense and control of any claim, subject to Indemnified Party's right to participate at its · own expense. .. • • (b} Baskets and Caps. Indemnification obligations of either Party shall be subject to a · threshold (" basket'} of · $100,000 and a maximum aggregate liability ("cap " } of $5,000,000 , except in the case of fraud, willful misconduct, or claims arising from a breach of a fundamental obligation (where caps shall not .apply). • - . . . • (c} Survival . The indemnification rights and obligations set forth in . this Article X shall survive the Closing fo r a period of twenty - four (24) months, except claims arising from fraud or willful misconduct, which shall survive indefinitely . (d} Remedies Not Exclusive. , The indemnification and remedies provided under this Article X are in addition to and not exclusive of any other rights or remedies available at law or in equity. • • • ARTICLE XI POST - CLOSING • , • • • 10.1 Following Closing: (a} Name Change. Within thirty (30} days following the Closing, the Board and shareholders of the Company shall approve a name change from C/inrarc Private Limited to Bio Intelligence Private Limited, subject to Registrar of Companies (ROC) approval under the Companies Act, 2013. . . (b) Formation of Bio Intelligence Corporation (U.S.). · Following � he Closing, either the Parent (MyRxWallet North America Corporation} or the Company (Bio Intelligence Private Limited}, acting through its board and authorized representatives, shall cause to be forrned a United S t ates corporation under the law � of the State of Wyoming to be named "Bio Intelligence Corporation " (the "U.S. Bio Entity"). The U.S. . Bio Entity shall be structured as a majority - own � d sub s idi a ry of th _ e Parent and shall serve as the United States operating and commercialization vehicle for the Bio Intelligence business, including cloud infrastructure , data center operations, Al workloads , partnerships, and revenue contracts conducted within the United States. For clarity, the corporate ownership chain following formation shall be: MyRxWallet North America Corporat i on (Parent, Wyoming) • • • • . . MyRxWallet North America Corporation . 2 4 75 So u th J o n es B l v d, S uit e 9, La s Vegas , NV 89 1 46 https://MyR.xWallet.io • I f • -- -

![](ex702-21.jpg)

• • • . • \ • � Bio Intelligence Corporation (U.S. Subsidiary, Wyoming) � MyRxWallet Prana Pri ' ض ate Limited (India Subsidiary) • · :! - + Bio Intelligence Private Limited (formerly ' Clinrarc Pvt. : Ltd., India Op � rations) Nothing in this Agreement shall be construed to imply that the U.S. Bio Entity supers � des, merges with, or replaces th � Company's Indian corporate identity or jurisdiction of incorporation. The Parties agree to execute any intercompany · services, licensing, IP · assignment, or transfer pricing arrangements as recommended by international tax counsel following Closing. {c) Post - Closing Stock Issuance Mechanics (CoreWeave - Structured). The Parties acknowledge that the Consideration Shares issued at Closing are being issued in a private placement exempt from registration under the U.S. Securities Act of 1933 in reliance on Section 4(a){2) and, as applicable, Rule 506 of Regulation D and/or Regulation S. Such shares will be "restricted securities" at the time of issuance and shall bear applicable legends. _ - Upon the SEC's qu � lification of the Parent' � offering statement on form 1 - A (the . "Qualified Offering"),. the Parent shall reserve and make available to the Seller, from the shares qualified under the Form 1 - A, an allocation of Parent common stock having an aggregate value · of USD $52,000,000 {the "Qualified Tranche"). The Qualified Tranche shall be issued at the per - share price set forth in the Qualified Offering (the "Qualified Offering Price"). • • The n':,Jmber of shares comprising the Qualified Tranche shall be determined by dividing USO $52,000,000 by the Qualified Offering Price {rounded down to the nearest whole share). The Qualified Tranche shall be issued as part of the Qualified Offering, an d - ,to the maximum extent perm • itted under the Form 1 - A qualification and applicable securities laws, shall be issued without restrictive legends and in a form eligible for electronic settlement through the Parent's stock transfer agent. · · For clarity, the ability of the Seller to resell, transfer, or otherwise dispose of any shares received pursuant to this Section shall be subject to (i) applicable securities laws, (ii) the Registration Rights Agreement (Exhibit F), (iii) any stabilization, lock - up, or compliance protocols applicable to the Qualified Offering, and (iv) standard transfer agent and broker - dealer procedures. No assurance is provided regarding the trading liquidity, volume, market depth, or resale timing of such shares. . • For purposes of this Agreement, a "Qualified Liquidity Event" means: (i) the qualification of the Parent's offering statement - on Form 1 - A by the SEC, • (ii) the effectiveness of a registration statement on Form S - 1 or Form S - 3, or (iii) the initial listing of Parent's common stock on either a national securities exchange or the OTC mar k - et. • . . . • • . . . • No representation is � ade that any such Qualified Liquidity Event will occur on any . particu · lar timeline. Th � timing · of any · resale of shares issued under � his Section shall remain subject to applicable securities laws, the Registration Rights Agreement (Exhibit F}, transfer agent compliance, and any underwriter or market stabilization activity, where applicable. • • • • • 1 • [Signature page follows] . MyRxWallet North America Corporation 2475 South Jone s Blvd, Suite 9, Las Vegas , NV 89146 http s://MyRxWallet.io • . ; ! I • I • • • ' • I ! I l •

![](ex702-22.jpg)

• • • • • .. IN WITNESS WHEREOF, the parties hereto have executed1his Agreement as of the day and year first above written. ,. • .. Acquirer: • Signature: _ MyRxWallet Nort � America Corporation Name: Binh Do Title: President & CFO Address: 2475 South Jones Blvd., Suite 9 Las Vegas, Nevada 89146 Email: · binh@myrxwallet.app Mobile: 408.797.8043 f mobile Main: 725.546 . 8686 • Date: . . Acquirer: . Signature: _ MyRxWallet North America Corporation Name: Olivia Trinh Title: Chairman & CEO Address: 2475 South Jones Blvd., Suite 9 Las Vegas , Nevada 89146 Email: olivia@myrxwallet.app Mobile: Main: • Dat e: • : • . Acquiree: �1/.f' - y - � t3" . Signature: �' Clinrarc Pvt. Ltd. . Name: Swetha Tattari . Title: . Co - Managing Director . . Email: swetha.tattari@gmail.com Phone: +91 9863727393 I D . ate : Q.,o l \ 2 - - �2.5 . Acquiree: , Signature: _ Name: . . Karna Golla Mahesh Kumar Yadav Title: Co - Managing Director Email: Phone: Dat e: Acquiree: Signature: - I• /' �· �_ ._,,, I _;, '": j \ c, ¥ ... \ . - -- , �- - • Clinrarc Pvt. Ltd. Name: Dr. Pandi Venkatesh Title: Managing Director Address: P NO 39/A, Chandra Nagar Rasoolpura Road, Hyderabad, Secunderabad, Telangana , India ," 5000003 Email: venkat@noahtherapeutics.com Phone:+91 - 9440383778 . . • • • • MyRxWallet North America Corporation 2475 So uth Jon es Blv d , Suite 9, Las Vegas, NV 891 4 6 bttps: //MyRx Wallet.io • • •

![](ex702-23.jpg)

• • • • EXHIBITS ... . • . . . . .. • - . •• Exhibit F - Registration Rights Agreement (RRA) • . , ' ' . ' • , . ' . , · . t " •) • . ' . • . • • • . • • • . . . . • ' , - . " ' . . • • .. • . , . .. . . : Exhibit A - Board Resolution Approving Sale of Clinrarc Pvt. Ltd. Exhibit B - Share Issuance Certificate and Book - Entry Confirmation Exhibit C - Bill of Sale and IP Assignment Agreement Exhibit D - Audited Financial Statements of Clinrarc Pvt. Ltd. Exhibit E - Performance Vesting and Milestone Release Confirmation Procedures • • • • • • • MyRxWallet North Americ a · c o r por at io n 2475 South Jon es Blvd, Suite 9, Las Vegas, NV 89146 https://MyR.,x Wallelio • . • • , • • . . • ---- -

## Ex1A-7

**Exhibit 7.3**

![](e0703-1.jpg)

DEFINITIVE SHARE PURCHASE AGREEMENT (SPA) BY AND AMONG MYRXWALLET PRANA, PVT. L TO. an India register company (..AcquIrer") (a Subsi iary of MYRXWALLET f \ ORTH AMERICA CORPORATION) AND OAH THERAPEUTICS PVT. LTD , an India register company ("Sell r") June 17, 2025 MyRxWallet Prana Private Limited A subsjdiery of MyRxWiLllet North Amettea Coq,oration Un iled States of Am � rlea

![](e0703-2.jpg)

OEFINJTIVE SHARE PURCHASE AGREEMENT This D finltive Share Purchase Agroornanl (th s "A,greemem•J Is ente - 1ed Into as of June 17, 2025 by and amo g MyRxWanet Pratia Pflvale Limited . a company incorporated under the laws of lnd · B pursuant to the Compan i es Act, 2013 (the 'Acquirer"}. a d a majorlty - owr)ad subsidiary of 1yRxWallet North Am rfca Corp � allor, (th �"A.cq ire r Parenf'), and Noah Th rapeutlcs Priva e ti m • ed, a company imxxporated urtder the laws of India (the •s ner"). Tho Acq lror and lh8 Saller are hereinafter collectively referred to as the "Parties 0 and indi VR:lually as a "Party ," RECITALS � EREAS . the Seifer i s the legal end beneficia l owner of 100% of t ho issood and outstandiTig equity shares of Noah Th rapeutlcs Priv a te Limited (the "Company") ; WHEREAS, the Acqulrer desires to purchaoo, and the Sel ler de si re6 to sell, seventy percent (70%) of the equity shares of the Company, on t he tern,s and subj ect to the condilions set forth in this Agreement (1he 'Transaction··); WHEREAS, the Parties desire to set forth the t8ITTIS and conditions upon which such sale and purchaso shall be con$ummated; NOW , EREFORE, in cons·deration of the mutual covenants and agrooments oonlained herefn an d fo r other good and val able COl'ls.l ra Ion, the rec eipt and sufficiency of which are hornby acknowledged, U,e Parties agree as follows: G:) STRATEGIC BENEFITS OF ACQUIRING NOAH THERAPEUTICS, Contract Research Organization (CRO) Acquiring Noah , Contract Researcti Organization (CRO). provldos MyRxWallet lh a transrormat ive oppo,tunity to optimize drug d&volopm t enhance innovation , and seCtJre long - term competitive advantage . This ac ul J lion scrategicalfy aligns cl i nica l development of MyRxVva Ue t �' th business objectives, eoob ing pha,ma and biotQch to increase efficiency, p otect tor � assets , and lead in an illc roaslngly oomplex global R&0 environment. 1 . Speed to Market • Acoelerated Drng Developmant: Noah has established processes, global site networks, and expe n¢e personne l , enabling faster cun · ca l trial execution . • Reg latory Expenise: Noah btlng s trong regulato ry know - ho \ v, he plng Mvlgare complex approval processes efficiently across global markets . MyRxWallet Prana Private Limited A $Ub ldlar � of MyRxWellet North Amerre:s Corporation United State,s o Aniorica

![](e0703-3.jpg)

2. Cost Efficiency hlft from fixed intetnal R&D costs to • Reduced Flx9d Cost : oal \ allows MyRxWalt l t a more variable model � ith better scalab · lity. • Opera • al Synergies: Integratlon may reduoe dupl.cation In pr - oject management, data mindling, 81 \ d administrative tasks. 3. Increased Control and Customiza n • Alignment of Priorities : A rulty CN ned CRO \ II prlorill:t:e i nlemel pipel i nes, align timehnes, and 9hare strategic goals . • Tailored Capabilities : Ernibles customization of SOPs, l&ehr ology platforms, and trief d lgns to mea sped ,c drug dev Joprnent strateg · es . 4. Cotnpatl ve A antaga • V rt e I I ntegration : Control over tile fuII R&D cnain from discovery to commercl.allzatlon ca create a susfainabto com tltlve edge . • Diffe - re tiated Off rings : Noah could beoome a profit center by offering seNices to external clients wh i le s \ Jpporting interna.J pipelines. 5. Access to Talen and 1 frastructure • Global Reach and Networks : Acquiring Noah l nc lud � r;1coess to g(obaJ trjaf sites, nvestlga o r s , and patlec,t popula · ons . • Experienoed Wo �:dorce : Offers i mmet � tI$t ic l l"IS, etter co trol over cllnlcal data , reducing risk of data loss , leakage, or misuse . , IP SeCtJrity : Reduoes risk of nteJla toal roperty leakage that can occu whtil wor I n g with externaJ vendors . 7. Scalablllty and F � xlbilily • Scslabl OperatiollS : Noah infrastructure can support both er;Jrly - Cage and late - stage trials across multiple geograp los a d dlcalions . • Thorap ulfc Expertise : Nqc1h has specialized experiencB In key therapeutic areas, whicti can b � l eversged across e development portfolio . 8. Stra egio PO$ition i ng for Innovation • New Tech o ogy lntegra n : MyRxWalle can deploy digi al lleatth tools. AJ/ML In dets a n alysis , &Centralized tria l models , and MyRxWall l - E H R olu i s . MyRxWallet Prana Private Limited A subsidiary of MyRxW llct North America Corporation United Stabts of America

![](e0703-4.jpg)

• Real - \ , 'orld Evidence {RW) Capabir ies � Noah enables tighter lntegre � on o resl Nortd data into clinical development NOW, HEREFORE, in consideration of the repres, .ntatlons , w rrantie , and covenants h reiri oorilained, and for other good and valuable conslde lions, the rece· and sufficiency o which are h reby acknowledged , the paroes hereto agree as follO \ vs: ARTICLE I CERTAJN OEFINlTIONS 1. Certain Definitions: (a) The follo ving terms, w,en used in 1tlls Agreement, ehRU heve the respective meanings ascribed to them be l ow: 'ACTION" mean any c m, aotion, suit, inqu i ry, hearing lnvostlgauon or other proc 9d r.g, ,. AF IUA mea11s, with respect to a Person, allY other Per on that. directly or indirectly, through one or more lnterrnedi.aries, Controls . is co trorled by or Is under oommon Control with, suet, Pe SOfl, or pYrposes of this de fi · n tIon , 'CONTROL• (incJIJding. with correlative meanings, the terms •co troll&d by" and under common Control with) m ans lhe posses 'on, directly or indrrectly, of the pov to dJrect Of cause he drre • n of ttle management ƒ ' policies of a Person. whether through the ownersh i p of stock, as trustee or executor, by Contract r credit arrangement or otherwise . "ACQUIRER" has ti rr Bar1.ir19 et forth in e preamble hereto. AGRE ENT'' has the aanir"lg set forth in the preamble her - eto . 'ANC � LLARY AGREEMENTS" means the BIii of SaJe and the IP Assignment. •ASSETS" l \ as he meaning se forth in Section 2 . 1 . BUSINESS DAY" means any day other than Saturday, Sunday or any day on which ba ks in as Vegas, Nevada are requJred or authoriz.ed to be closed. "CLOSING ha ttle m aning set forttl in Section 3.1, "CLOSING DATE" h13s the meaning se forth in Section 3.1. MyRxWaJlet Prana Private Limited A subsidiary of MyR'x.W llot North America Corporation United States of America

![](e0703-5.jpg)

� CONTRACT means any a reatnenl, lease, debenture, note, bond, cvld81 \ C8 of Ind btoo.n ss , rnortgage, indenture, seoori y agreement , optlol' ot oU,er contract or oommitment (whettler wri en or oral). •EXCLUDED ASSETS" ha the meaning set forth in Section 2,3 . ·excLUDED L IABILITIES'' has ti" \ m , ng set forth in Section 2 . 3. GAAP• means United States generally accopted a<: 01 . mUng principles as in effect fro time to time, consrs - tently applied throughout the specified period and all prior oompara e periods . "GOVERN ENT AL ENTITY.. means any government or political subd j vislon thereo , wh8 her orelgl' \ r dorries · c , federal, state. proviocial. county, loca l, munic · paJ or regional or any other governmental en ty , any agency, authority depanmcnt, divis · on ƒ ' Instrumentality of any suet govemtnenl, political subdivision or oU - .er goOJornmenta l en ity, any court. arbitral trib \ Jnal or arbi rator , and any nongovarnm nuil regulating body, o thee nt thi;lt the rules, regulations or ord rs of ucti body ave the force of Law . "INDEBTED ES$" means, as to any Person : () a I obllg ions, whether or no con ngant. of su!;'h Person for borrow&d mone �(Including, wittiout li mitation, rclmbursemen and all other obligations v U, respecl t o surety bonds , letters of croolt and bankers' acceptancas, whether or not matured), (ii} all obligalioos of Sl>Ch Person evidenced by not �. bonds, deben res, capctaJized leases ƒ ' i rnilar instruments, (iii} all obligatlons of such Person represontlng the baJance of dererred purchas price of coperty o se r vices . (iv) all i t r, st f ale and c1 . .arrency swaps, caps. ooJlars and slrn �$r agr � ments or hedging dovlc9S under w ich payments are obligat8d to be made by su - ch Person. wheth petlodlcally or upon the happening of a contln ncy, (v) all ifldebledness created or arlslt' \ g unde ar1y conditional saJ or other tit e Mlenllor1 Contract with respect to properly cqulred by such Pernon (even though the rlgh sand remedies of the - sol r or le nde r under such Contract i n the ev � rit of dafauf are lrmited to repossession or sale or such property), (vi) alt Jndebtedness secured l>y any Lian on any property or asset owned Of held by such Person regardless of whether the indebtedness secured th reby stt.a II have been assumed by such Perso or is noll - recourse to tho crodlt of such Person, an (vii) alJ indcbt dness referred to · n clauses {i) th11 9h ('JI) bove o any other Perso that s 9u ranleed , directly or i irectly, by suet Person. • JNTELLECTUAL PROPERTY" means : all (i) dlsooveries and inven ons (whetllor pat nta le or unpatenta le and ether oc r)t>l reduced to pra · ce}, all ,mprovtimenls - thereto , nd all un · ed States , international, and oreign patents. pate t applic tions (eith er led or in preparatioo for nl i ng). pate nt discios res and statutory inv ntion registra ions, incfud l l'lg all r · ssuanees. divisions. continuations , tin.uations in pert ex cnsions and raexa ir,ations thereof, all rig ts therein provided by intematio I treaties o oo VE?ntions , {ii) trademarks. service marks . trade dre s, logos . trade names. corpcrata mes , and other source den If a s (whether or not registered) including all common law igh s . all reg i strations end applictJtions for registration (either fl or in p r eparation for - rmll9) thereof, all rights therein provided by in tematlonal traa • $ or conve n · ons, and all rnoQWals o any o the foregoing, (iJI) all copyrightable worts an d copy . hls (Nhether or not reglstcrod) , al regiStretions an d appllcatlons for registration ther � o f, �, • hts here i n prov i ded by Jnlem tional treaties or conv n ns, and all data and documentatio relatin g th • elo, (1 v} confidential and proprietary information, trade MyRxWa ll et Prana Private Limited A su �,dlar}' of MyRxWallet North America Corporation Unft cl Staten, of America

![](e0703-6.jpg)

saCtets, know•how {whether pa antable or nonpatentablo and whether or not reduced to practice), processe a tech iques, research and development informatlol \ lnolud"il"9 patent andlor copyright searches conducted by Seller and/or any tl'lird party. ideas, tcchnJcal data, designs, drawings and s � cifications, (v) Software, (vi) coded values, forma s, data and historic I or current databasos. whether or not copyrightable, (Vii) domain names, Int m � ebsites or identities us d or held for use by th Sel t , (vi"') otfler proprl tary rights retatil"9 to any of lhe fofi going (inciuding without lim tat on riy and an associated goodwill and remedies agait,s infringements thereof ood ,ights o protection of an interest therein under the l � v,s of all jurisdictions). and (ix) copies and tangible embodiments of any of the forogolng. "IP ASSIGNMENT' has U,e meaning set forth in Section J.2(b). "KNOWLEDGE'' mean tile a � tual or constru · va knowledge after duo inquiry of any curre t officar or manager of the Seller. � LAWS' means all laws, sta1u � s. rules, reguJatlol \ s, 0rdir1aoces and other prono noemant � having the effect of law of e un · teo States, any foro gn co1111try or any domestic or foreign state, county, city or otfler political subdlvl Ion or of a y Govemmentat En tty. "LIABILITY" means all Indebtedness. obllgatlons arid other Liabilities of a Per$on, whether � bsolute, accr �- eo. conting nt, ri � ed or o herwise, and vhethar due or to become - due (incl ding for Taxes). "LIEN" means any mart age, pledge, assessment, s � curity interest, lease, II n, adverse claim. levy, charge or other encumbranc of any kind . whetfler voruntary or lnvo f untary (irtcllJd i ng any condition sal Contr:.ict, title reten• Contract ot C - ontl"flct oomm , tting to grant a y of the foregoing) . oss � means all damages , fir � e , fees, penalties, doficlencles, losses and expenses {including without lfmltallon, all in ere - st, court oosts, foes and expenses of attorneys accountants alld other experts or otho expenses of litigation or other proceed rigs or of any c; im, defauI or assessment). "MATERIAL ADV RSE EFFECT' means any mate lal adverse effect on the condition, operations, buslne , pros.pects or results of sales of the Selle. PROVIDED HOWEVE:R, tha any adverse effect arisJng out of 0t resulting from the entering into of this Agreement or the consummation of tt a transactions contemplated h reby, shall be excluded in de rmlnlng vh u,e a Materi I Adverse Effect has occurt8d. 'OROER means any wri judg ent, d ree, injunction or si !Jar ord8' o ijf' \ Y Gover me tal En · y (in each case /he her prelim · nary or final). ·•p RSON' means any individual. part.n rship , I mited liability co pan>·· ocrporation, association. joint stock company, trust. estate, joint ve ture, un c;orpora ed organization, Governmental f:ntl or any other eJltity of any kind . •PURCHASE PRICE" has the meaning set f; th In Section 2.1 . MyRxWa ll et Prana Privat Limited A subsidiary of MyRxWallet Nor1h Amerle:1 Corporation Unrted State$ of America

![](e0703-7.jpg)

· REPRESENTATIV S means, with resp ct to any Person, the directors, officers, manag � rs, employees Ź counsel , acoountanls and othei - autho.rlzed representatives of such Person . SEUER" has the meaning set forth in e preamble hereto . 0 $0flWARE' mea s all computer software, Including source cod , obj ct code, machine - readable code HTML or other martcu language , program listlng , comments, user in erfaoos, met'lus - , buttons and Icons, web applica · oos and a l l files , data , anu.als , design notes, research and dev loprnent documents , and o ,er i ems and document lion related thereto or assoc i led ttlerewith . "SOLVENT" me.ans, wi h rcspgct to tne Serler, tha (a) the SelJ r can pay its liab " litl , as they mature in tfle nonnal oourae of bus · ness, and (b} ,a fair va ue of the assets of the Seller is greater han he total amount of Liabllitles of lhe Seirer . "TAX RETURNS" ar 'l s all re:t1rllS and reports (Incl ing elections, claims, declarations , dlsclosur'eS, schedules. estlmat , computations and information returns) requ red to be ppl i ed lo a tax authority In any Jutisdicoon relatlng to Taxes . "TAXES" meal' \ s a � I federal, stat , local and foreign irtcome, profits , franchise, license. social securtty , transfer. rogls atlon , es · mated , gross rec i pts, enviroomental, cu.stoms duty, ca aJ stock, EtVer nee . stamp , pay r oll , sales , employment , un mployment , disability, use, property , withholding. excise, production, value add d oocupancy and other tax , duties or assessment or any nature whatsoove , together vith all interes t pena · l es , fines and addllioos to ta)(imposed witl'l res � t to $- \ Jch amounts and any Interest in respec of such pena lt ies and additions to tax. "THIRD - PARTY CLAI "has the mean i ng se t fi h in Section 7.2(a). 'TRANSFER TAXES• ' m ans ijll sales. use , value addod e)(clse, registration , documentary, stamps tran fer, real property transfe reoording, gains , stock tra ns f r nd o her similar Taxe � and fees. (b) For purpose s of his Agreement excep a o en'ltSe expressly pro 1ded herein or unless e context ottlerw i se requires : (i) words usir>g th singular or plural number also · nclude the plural or singular nurtlber, respe • ely, and t he usa or any gender herein shall be deemett to incfud lh$ other genders ; (i i) referenc s ere ' n to "Articles,· ' ' Sections ,' "subsections" and olher subdivisions wi hout ref nee to a document are to ti peel ' ed A · ctes, Sections, subsections and other subdivisions o this Agroomtit"lt �(iii) a reference to a subsection wet out further referenee to a Soctloo i s a referenoe to such subsoctlon a contained in the same SeC1ion In which he reference appears, and th i s rule shall also apply to othor subdl · s1ons w · hin a Section or subsection: (iv) th vtord& ''herei , ' "hereof," "hcrouncter," hereby" and o herv10

![](e0703-8.jpg)

ARTICLE II OEFINITIVE SHARE PURCHASE AGREEMENT Section 2.1 - Execu ·on of Agreoment This D fin bVe Share Purchase Agreement (this ''Agreement"), dat d as of Ju 17, 2025, Js entered into by and be !/een MyRxWallet Prana Private Limited (the "Acquirer"), a company proposed to be incorporated under the Companies Aclof 2013 , as amended, India, and No � h Therapeutics Private Limited (the "Seller''), a company organi4 d under the la of India . WHEREAS the considera · on for ttle acquisition shall be payabl& solely in the form of equity, speclflcally through the i ssuance of 843,750 common stock of MyRxWallet Prana , Private Limited, valued at INR 2,064 (USD 24) per share 1 which shaJI oonsti te the agreed and fixed va l uation or the purposes of this equity � sed transaction . Section 2.2 - Purchase a d Sale of Shares Subject to the terms and wnditions sot forth In th f s Agreement t e Sofler hereby agrees to sell , a � slgn. transfer, .:Jnd convey to the Acq irer , an ·he Acqu i r r agre � s to pure ase from the Seller, seventy percent {70'¾) of the lola l issued a, d o tstandmg equity shares of Noah Therapeutics Private Limited (the Shares), represeotrng a oontrolllng eq ity i tere t and majority shareholde In the Company . S c on 2.3 - Purchase Price and Share lssuanc The aggregate purchase price for e Shares shall be satisfied enti re ly throug the Issuance of 843,750 common stock of the Aoqulter (the "Consideration Shares"} , each valued at INR 2,064 (USO $24) por oornmon share. The Consideration Shares shall be uly authorized, validly issued , fully paid, and non - assessable, and shall be issued in accordance with the appricable provisions of Indian securities and corporate law , including the Comp nies Act , 2013 , India, and a l l relevant rules and regulations thereunder. These shares shalf be issue

![](e0703-9.jpg)

oonstitute the agre d fixed value for the purposes of this equity - based transaction al a per - share value of INR 2 064 (USO $24). The Parties further acknowledge and oonfirm tha : • Th i s valuation has been mutually agreed upon solely tor the purposes of th · s transaction ; • It is not based on any formal third - party valuatlon. appraisal, or independent financial assessment of the Company's condition, marke value, or any other economic factors; and • For the avofdance of doubt. the agreed valuation shall be treated as final and binding and shaU no be adjusted or renegotiated basao on fluctuations in currency exchange rates be en the Ind Ian Rupee and the U . S . DoJlar at or after the date of this Agreement. Furthermore , the Parties affirm at they have each independently evatuated the transac · on and are not relying on any representations or warranties regarding the vaJue of the shares beyo d the mutual agreement as axpr ssty set forth herein: (a) Acquisition Consideration The total acquisition considera · on shaU consist of 843,750 common stock of MyRxWalfe Prana, Private Limited, having an ag eed I lernal valua ion of INR 174. Crores {t 174,15,00,000 - Rupees One Hundred Seventy - Four C res . Fifte Lakhs Only) (USO $20,250,000). se shares shall be allocated as follows : • Listing Day Ves · ng : The Seller shall receive 125,200 oomrnon stock {mternally valued at I R 25 Crores and 80 Lakhs / USO $3,000.000}, which shall vest immediately upo1 tJ1e ffecti e c 1mencement o trading of MyRxWallet North America Corporation's commons ock on a natJonaJ securities exchange or quotation system pursuant to a Dire Public Usting (DPL'') (the 0 Llsting Date") . These shares shall become el i gible for trading publicly upon such listing, subject to applicable securities regulations and any fi quired compliance or transfer restrictions . • Milestone - Based Vesting: The Sefler·s rema i n i ng 125,200 common stock (also fnternally valued at INR 25 Crores 80 Lakhs / USD $3,000,000) shafl vest In four (4 quaf installments of twenty - five peroent (25o/c) e ery six (6) mon s over a period of tvventy - four {24) months following the Listing Oa . Theses a es s alt b subj ct to the Securfties and Excha ge ommission's appl i cable lock - up restrlc ions and shall be held i escrow by tf'le Acquirers legal oou sel or another rnut alfy agreed - upon designated escrow agent. The shares shall b � reJeased to e S lier in accordance w th the agr ed ves ng schedule, and dis ursed at eac distributlot1 interval, subject to customary administrative and d i sburseme t fees. (b) Strategic Equity Growth Alloc - atlon • A total of 500,000 com mo11 stock of the Acquirer, havl g an i erna I valuation of approximat ly INR 103 Cro 20 Lakhs (t103,20 . 00 ,0 00 - R pees One MyRxWallet Prana Private Limited A sub lcflary of MyRxWaUet North America Corporation Unttc *![](e0703-10.jpg)

Hundred Torno Croros, and T � enty Lakhs Only) (USD S12,00O,0O0). shall be designated as "Strategic E � uity Growth Allocation", These shares shall be reinvested into the Seller and its operations, under the direction and strategic oversight of e Acq lrer's parent, MyRxWaltet North Amenca Corporation . • The Strategic Equity Growth Allocation shall be utilized to s pport Noah Therapeutics' worldng capitaJ needs , operational expenditures, and strategic growth Initiatives, including but not limited to mergers and a oq ui itions . U S marke entry, and modernizatio of manufacturing and research facil ties . al l 1 accordance with he Acqu rer's board - approved flnanelal and development roadmap. • These shares shaU be issued immediately upon exeet1tio11 of this Definitive Shari Purchase Agreement (SPA} and shall remain restricted secur • i s wit in the meaning or applicable Indian securit i es laws . The issuance, holding. and transfer of these shares shall be subject to compliance � ith the Companies Act . 2013 inclu ing but not l t mlted to Section 42 (Private P f acement) a n d S ction 62(1){c} (Preferentiat Allotment) , as well as the applicable rules framed t • ereunder, including the Companies (Prospectus and Allotment of Securities) Rules, 2014 : • In add i tion, the shares shall be governed by all applicable provis · on � of the Securities and Exchange Board of lndia (� EBI} regulations, as amended, a d, where apprlcable , e Fore g Exchange Manageme t Act . 1999 (FEMA) and relevant ot · i ca ti ons issued by the Reserve Ba k of India (RBI), • No transfer or disposition of these s ares shal I be pe m li tted unless al I regulatory approvals and co d tions nder Indian law, including filings with the R gistrar of Companies and applicable RBI permissions (i required), have been satisfled . • The shares may bear a restrictive legend ind i cating sue Ii ilat i ons, an d the Seller ag ees to comply with all legaJ requirements under Indian s curities and corporate law prior to a y proposed transfer . (c) Employee Equity Retention Plan As part of the u - ansaction. a total equity pool not to exceed INR 4.30 Crores { pproximately US $500,000}, representing up to 20,833 commons ock of the Acqu i rer . shall be reserved for allocation to elig i ble employees of r eoord of the Seller as of tt1e Clos i ng Date, These shares shall beg anted u der the Acquirers Employee Equity Retention Ptan and will be subjoct to the following terms : 1 . The shares shall be distributod among all qualifying employees of record, unless otherwise deteonined by the Acqufrer's Board of Di rec tors in accordance wi app l icable � mployment levels. responsibilities, o r tenure - bas , ed criteria. MyRxWallet Prana Private Limited A subsidiary of � yRxWsllet North America Corporation United States of America

![](e0703-11.jpg)

2. The allocation will foJlow a vesting schedule tied to continued employment , with vesting occurring i n the following milestones: Iii. i . End of Year 1 : 5 , 208 common stock, equivalent to INR 1 , 07 , - 50 , 000 (lncfan Rupees One Crore, Seven Lakhs and Fifty Thousand only or US $125 , 000 , based on a price of INR 2 , 064 per oommon stock . II . End of Year 3 : 7 , 812 common stock, equ i valent to INR 1 , 61,25,000 (I dian R pees One Crore, Sixty - One akhs and Twenty - Five thousand only) or USO $187,500, based on a prjce of INR 2,064 per common stock. End of Year 5 : 7,812 co mon sock, equ ival ent to INR 1 , 6 ,25 1 000 (Indian Rupees - One Crore, Sixty - One Lakhs and T • - 1enty - Five Thousand only) or USD S187,500 . based on a price of INR 2,064 per common stoc . 3. AJI equity awards shall be governed by th terms and conditions of the Aoquirer's Employee Equity Retention Plan and, to the extent appticabJe, in accordance with Ind ia n regulatory standards, including those set forth under e SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 . 4. lnd ivld uaJ award agreements, vesUng te r ms, exercise cond, tio s (If appticab l e) . and any imp l ications shalf be communicated to eactl eligibre employee fo l lowing the Closing Date, and shall be executed in accordance with the Acquirer's standard equity award practices. (d) Assumption of Liabilities The Buyer assumes all curr nt liabllftles net of cas receivables and incl d i ng I nventories o tstandl og as of t h e record date, tot a ling approx! nate ty INR 15,05,00 ,000 (R pees Fifteen Crores and Five Lakhs Only) (US $1 , 750,000) eq ivalent to 72,916 common stock , (e) Seller's Vesting Schedule and Perfonnance - Based MIiestones Each mi !&stone shal I serve as a condition precedent the vesting of th e corresponding share tranche. The vesting shalf proceed in four (4) equaI installments of 31,250 common tock very six (6) month , subj ct to h ac i v nt of m tually agreod milestones : • MIiestone 1 (Months 0 - 6) - I nltlal Integratlo n and Strategle P l anning : Within th first six (6) mo lhs following the Closing Dat e, tha Sell r shall support the MyRxWallet Prana Private Limited A subsiQiary of MyRxWatlet North Americ= - Corpo1'8tion U lftcd Stat of Amcrk

![](e0703-12.jpg)

lntegra on of 0 \ e acqu i red assets Into Acquirers ecosystem , i ncluding cultural and governance alignment, strategic planni g for mergers and acqu 1 s · i ans, revenue enhancement initiatives, employee stock ownership plans (ESOPs) , and foundational preparations for ure capital rals � or spin - offs. Upon satisfactory completion of Mi lgstone 1 , as determined by the Aoquirer i n good faith, 31,250 common stock shalt vest at the end of Month 6. • MIiestone 2 (Months 7 - 12} - Exeoution of Growth Strategies : During his phase, the Seller shall assist 1ith execu ·ng the s rateglc g r owth pfan, 1 nduding trac ng measurable outcomes of 1he acquisition, ovaluating cul raJ and techoofogy i tegration, achieving revenue growth targets of at l east 2x to10x , and [nitla · ng capital raising efforts. Upon comp le lion of Mlleslone 2, a the end of ri., onth 12 . co mon stock 31 , 250 shall vest. • Milestone 3 (Months 13 - 18) - Spinoff Preparation and Consol dated Impact RevJew : This milestone involves a consolidated review of Miloston s 1 and 2 , confirmation of their succossful completion, and the preparation for a strategic splnoff of the Seller, subsi iary . Upon oompletlon of Milestone 3 , at the end of Month 18, an additional 31,250 common stock shalI vest. • Final Milestone 4 (Months 19 - 24) - Seller IPO Preparation : Upon the satisfactory completion o all prior milestones. and active p eparation for an initial public offering {IPOJ in cittior t a Uni ed States of Ame · ca, In d ia, or bo 1 Jurisdictions, the remaining balance of vested shar s . 31,250 commons ock s all be rel asoo in full to the Seller . The Seller acknowledges that vesting Is s ctly performance - based and contingent upon the Acquirer's reasonable determ i nation that tne above milestones have been me i. Closing Term : The closing of the transaction (the Clos i ng") shall take place on or before June 20, 2025, or on such oth - er da e and time as may be mutually agreed upon by the Part i es l n writing . The Closing shall be deemed effective upon the completion of al I conditions pracodont and the mu al exchange of required deliverables. i ncluding e transfer of the Shares and issuance of the Co siderati Shares . Issuance, Vesting and SoctJrlt' s Con,plianc;e • Upon ex.ecut i on of this Agreement , the Acquire stiall pro o y in s t cl i t s duly a · po nled stock Transfer / \ geri of record o nitlat lt e issuat1c of the <;1pp ' ica I equ - y co :sideration to the $ha aholders designatec in writi g bi the Seller . MyRxWallet Prana Private Limited A cubgidiary of MyRxWallet North America CofJ)oratlon United States o Amcr'lea

![](e0703-13.jpg)

• Eq ity sharBS that ar& mtr \ ed i ately v sled in accordance • h the terms of his Agreement shall be issued and delivered wi hout delay, subjoct to applicable restrictions under federal and state securities laws. • Equity shares subJoct to a vos · ng schedule or escro•N oonditions sha1I be issued in book - en.try form ahd held by the rans er Agent or an ap ointed escrow agent, to be released in accordilnce with the agreed vesting mllestones and any appl able !llseto �, agreemen . 2 . 5 Assump · on of Liabirtles : The Acquirer shall assume, and shaJI not be deemed ,o a ume, any llabl ltl so, obligations o the Sel er e � ceeding the specified amount herein INR 15,05 , 00,000 (Indian Rupees Fifteen Crores and Five Lakhs only) (US $1 , 750 ,000) urval nt to 12,916 co mon stock, wfle her no vn or known . disclosed or undlsclos, d . conti11ge11 or otherv ise, including but not J I I ed to any Ta.x Lisbilities, deb{s, cla i ms , lawsui s , or contractual obll aHons axi Ing prior or of the Closing Date. Any liabi rties no spe<:i • ed h ... rcin and oxcoo - d ttie ar c>unt s ' II amain the so l �<1nd xcl JS ve , spo slblllty of the S lier. 2 , 6 Excluded Assets: Th i s provision applies only to asse � o vned by tie oc,n,pa y . Pen;onal assets of the Sellers or af"ly rnem o' th Board of Ƒ · rectors, ;ncluding tho e pledged as oollaleral wiUl e ls rng lenders or banking lnstiru ·ans, a e expressly excludocJ from mis transaction . Such personal assets shaJI rnmain s so{ proper - ty ;Jnd re � PQn ibitity o their re pectlve ners. 2.7 Exe ded Liabilities: The,e ar&no Exclucled U � bir ·es. 2.8 Legal Fees : Each party shall be sol ly tespoh i e tor lhe payment of i own lega l fees and expenses inet1rrea in connection with the negotiation, pr para lion, x utlon, n performanoo of Is Agr ment, irclud i ng the hiring arid engagement o legat counsel. ARTICLE Ill THE CLOSING DATE ANO TERMS 1. Closing : The clo Ing of lhe trQ &actions OCJl empla ec hereby (the • Cl OSI NG·) shalJ ta u place conte poraneous with 1he exec Ion of this Agree r nent ur I ur µ1101 tu J r 10 20 2025 (the ·cL.OSING DATE"), 2. DeUvery of Items by the Seifer: ne Seller sllell derwer to the Acquirer at t e Clos i ng the items listed below: (a) All documentation neoessary to ffectuat& he tr � n fer o Seventy peroent {70%) of 1he Issued and oulstandi119 equily interests of SELLER. to the Acqulror, thmugh Its de lgnated stock transfer ag t of rooord. shaJI be pMpared, exec:uted, and delivered within 7 - - 0ay post • closlng . OR The Soller sh al I engage a licensed Stock Transfer Agent or Charterad Acoountaot to · ssue a affidavit oerttfying that they represent the S Uar, and that based on the structure of the transac ·011, t e s are transfer shall be exeouted and deliver upon SEC confirmation of e buyers' S - 1 "Effective" and shares have is declaro MyRxWallet Prana Private Limited A subsldlaty ot MyRXWallet North America Corporatron United States of America

![](e0703-14.jpg)

unrestricted shares. Th affidavit shall be provided to lhe Acq irer's legal co nsoJ p rio to the Closing Date. (b) Cooculi ently , the Sellers representa · ve (CPA) shall furnish documentatiofl recogniz.i Acquirer, as the official majority sharetiolder of reoc,)ld , entitled to fuU governance gl11s at1d owoors f , - p of - Seventy perc.:enl (70%) of Seller. effective upon e execution of the De itive Shar Pu rch ase Agreement . (c) Any required cof'J)orate resolutions, board consent , or share registers reflec · ng the transfer ; (d) Any other agreements or I nstruments reasonably requested by the Aoquirer to effectuate the terms of thIs Agreement (e) 81 \ Y other documen nd mstruments as 1he Acquirer m,Hy 1'1.:1 onably req e t The Acq Ir - will issue the ag. - eed - upon 843.750 common stock to the Sel r and separately to the company upon th eJ \ ng Items: (a) Share Certificatas or Book - Entry Con atlons l.ss ed by the Stock Tra srer Age of r � oord , evidencing the issuance or the Acquirer's common stock representing the equity ownership ; terest i n Acqulrer, as set for1h in th s A911 0 ent ; and {b) Certificates or O cial Receipts oot1f 1 rml g tho book entry registralion of such shares in ttie name(s) of the Sellar or d s · nated rec i pients, dooum � m :j ng ownership of thP. appl.c:abl Acquirer shares r n ccord noe with the terms of is Agreerr1 e1 . ARTICLE I V REPRESEN T ATIONS ANO WARRANT I ES OF THE SELLER As an induoernent to the Acqulr

![](e0703-15.jpg)

dal ered by the Seller and. ossumlng the due authorization . execution . a delive - ry by the Aoq irer, constitute valld and legally bind i ng obugatiorlS of the S I enforceable in acoordance with the ' r re pective tem,s . 2. B kers and Legal Fees : ach P � rty shall be sole[y spor slble lor a11y and al l legal advisory , brokerage , ir,der, acoounting, con lJlt i � fees i t incurs in conn c on v 1 l 1he nogouanM. execution, and consumma on of the transactio 0011 emplated y th Agreement, unless otherwise expressly agreed to In writing by the Parties . No agen, broker, nder . inv strn nt ban er. flnancial advisor. or other simi la r ntermediary shall be entitled to a y fee, commission, or othe compensation In connection with this transaction based on a y ammgemerit made by or o behal of the other Party 0< any of Its AffilJates . 3. Non � Contravention : Neither the exeCtJtion , delivery or perfomiance of this Agreement ct he Anci lary Agreements. as applicable, n r the collSummation of th transactions oon emplated hereby or thsreb,y · 11, vith or vithou the glvlng of no ce or the lapse of time or both, (I) vlolal any Law or Order or other restncllon of c1ny Go,• mental Entity to ,c the Seller may be subject or (ii) con 1(;1 wi , resul in a breach of. constltu1e default nder, esult in tho ace I ration of any right or obligation under, cteate Ir Any party the • ht to ace I ratti. terminate , modify . cancel. require a y n orc e v der or esult in the crQa .)(I

![](e0703-16.jpg)

(a) Schedule 4.6 conti:!ln.s a list of all pcrtents, trade "ames, trademarks and/or oopyrighls and all applic lions therefor owned by Seirer with respect to th Ass ts and alt lioenses if any relating to the foregoing patents trade names � traderr rks a /or copyrights an aII applicat ons therefor . ScheduJa 4.6 Ida llries the owner of each i tem listed thereon and , Int.no cas � of re,gisfrations and appl1calions, the application or registration number and data . ha Seller has not taken any action that could rosutt in arw of tl1e r&glslratlo s ar'ld applictllions or registration for the Asoots not heir � valid and In full fOr'CA and effect. {b) Except as d i sclosed on Sch dule 4 . 6, the Sell r is t o sole and exclus i ve o �81' of , and has good nd m fk ta l e tiUe o, en the In ellectual Properly in and to he Assets , inciud i ng the Intellectual Property set forth on Sciledule 4 . 6, free a11d clear of all ens. Except as lsclose on Schedule 4 .6. the Sel f e, has sole and ex.elusive ri ht to dev � lop, perform, use, create derivative works of, operate, reproduce, market self, license, display, distribufe . publish and ttan mit tho lnt oJ lcctual Property In and lo the Assets . Upon the Closing, excopt as isclose on Sche le 4 . 6, the Acqu 1 rer � i l l have sole and exclu ive ri9 t, Litle and lt1lerest In and to lhe lntcllectua l Property · n and o the Asse , such tt \ et the Aoquirer sha11 lhereaftar ave sole ar c,l xciuslvQ rlgh to perform, re produce . create derivative wor1ts of , develop use. operate, market, sell, rcense, d splay, publl h, transm ta d distr i bute the Assets, free of all enc mb ances . The Seller has taken reasonable measures o prote<.l l � propr'le ary nature of the Intellectual Property in and to the Assets and to ainta i n in confidef'!ce ttte trade secrets a � d confidential in formation hat i owns or u - ses . Exoe as d i sclos on Schedule 4 .6. no other Persoo has any rights to any of I tellectual Property ir and o the Assets an , to the ledg of the Seller, no other Parso Is lofrlnglng, l olating or misappropriating any of the Jntellectuaf Property irs and to the Assets. {c -) Wi h respeci to the Sal els lnlellat;1ual Prnp&rty cort buted to e Assets . such Intellectual Property does not infringe upc>n, violete or ootistitute.a misappropriation of any Intellectual Prope y or other right of any o·her Person . tn addition , to SelJer' knowledge, nooa or th � lvlti or business prese Uy conducted by ths Sell r with respect to the Assets infringes or violates , or constitutes a misapprcp ' ation of , any lntelrectual Ptoperty or olh r right of any o r Parson. Neithe r the Seller nor any Affiliate of the Seller has received any written complai11t c � im or no � ce alleg i any such nHngern nt, vlola on or misappropriation . Further. neither t e Seller nor any Affiliate of the Seller has d . closed to any Person, any produ orm la or des · gn, or any portion or aspect of any product formula or design . wnich is part o e Assets, incfu - ding Intellectual Property . 7. Tille to Assets: Except as to Intellectual Property (, ich wa r ranty is co taineo in Section 4.6) : (i) the Selle has good and marKe b f e title Lo all o f t he Assets fre - e a11d clear of al I Lien �· (" i) th · s Agreement aoo the i ns uments of transfer to � e executed and der ere - d JJU s ant hereto wlll effectlvely vest I e Acqulrer goo a d 1arketab1 e ti � to a l l of the Assats free anc clear' of all Lfe11s; {in) end no Person other tha,i he Sel r has any ownership in erest in any o he Assets . 8. Investment Representations: Seller and those ,eceivir,g shc:1 a in A - cquket r ptesent and varran lhal: (a) Se J ler a d hose receiving the shares are aware of the Acquirer's business affairs ano financial condition a d has acqu i red su cient information abou Acquirer to reach an nformed and knowledgeable decision to acquire \ he hares that t:onstitute the Pur'chase Ptioe. Seller and MyRxWallet Prana Private Limited A subsidiary of MyRxWatlet North America Corp«atlon Unlted States of Amcrlc �

![](e0703-17.jpg)

ttlose receiving the shares a1so ackrloWledge lhat lhey are relying sol ly on their own counsel for legal advice, and no on any statements Cl(representa1iollS of Aoquirer or its legal counsel or agents ror legal advice v · th re p t lo tlll nv � tment o the transactions oont&mplated by is Agreement. (b) Seller and those re - ceivi119 shares are acquiring the shares or I vestm t for their own account ori and not vith c1 view to , or Or' resale r n con, oclion with . any "d1str but1onr tnercof W l ltiln the meaning of the 1933 Act or u der any appficable provision o state l aw . Seller a d those receivirtg the sbares do not havG any pr s nt I tentlon to transfer 1he shares to any pe,son or enti y . Seller and those reoeivir,g the share re awere that their lnv � slmt1nt ul Acqu1rt1(I � spaculativ Investment that has limited liq idity and i s subject to the risk or oompJete loss Se ler and those receiving the share are able. v.tithout impairing their financic1I condition. to hol the shar - es for an indefinite period and to suffer a complete Joss of Its rnvestment in the shares. (c) Seller and those receiving shares understand ttia the shares that oomprise Cha Purcltasa Prioe have r'lot been 1"4:!gi!i et d und tho 1933 Act by reason o a specific exemption therefrom , vhich exem pti on dep8llds upon, among olh r lhlngs. Cha bon � fide naturo of Seller's Investment It t nt as €lXl)(CSSOO herein. (d) he Seller afld any individual or entity receiving shares p � rsuanl to this Agreement scknawladge and agr � ti ,at the shares belng issu d are � stricted secu iti - es under a icable I ndrat1 se<:umies laws, including tl',e Corn , ani s Acl, 2013. he Co panlss (P ospoct s and Allotment of Securities) Rules, 2014. and where applicable , the SEBI (lss1.Je of Cap"4:!I an"d o · sclosute Raqu l rements) R99ulatlons. as amen d. Pu rs anl to thi!!se laws end rules, recipients may be roq ired to ho the s ares for a s ecified pefiod and may not transfer, sen, or o he �• e dispoaa o such share � ut1lass sucl1 transf8r cornpllos wltti aH applfcabae Indian corporate, seoorities, and exchange control law , • � ludlng spprovals or � xemptlons und r the Foreign Ex.change �. an:agomcnt Act. 1999 (FEM) and,'or RB I guidelines, where applicable . Tot e exteflt Ulat U . S . securities iaW$ become relevant (. g . , In th context of a subsequent listing in the U.S. or an offertng under Rure 144 or Regula lion S) , the Seller and recipients understand t1'1at the sha, s may also bs treated as "restricted securities" under tt,e U . S . Securities A.cl of 1933 . and may not be resold or transferred i r'l tile Un i ted State - s absent registration or an a ia i lable exemption . The Acqui rer s all have no ob igation to r'e{} I 181' th � shares wilh the U . S . Secvrities and Exchange Commlssron {SEC) o r qualify them under sate securities laws, and any exemption hat may apply could be subject 1o oondrlions beyo id he cor rol of tba Selle, or fi cipien s. ARTICLEV REPRESENT ATJONS AND WARAANTl£S OF THE ACQUIRER As an inducement to th Seller to ant r Into Is A9roemc t, t e Acqui er epresents aino warrants to the Seirer as follows : 5.1 Authorization: The A �4ul r er has full o er and authority to execute and der er thi Agreement a d the Ancillary Agreements, as app • able, and to perform Its llgatlons h reunder and e,eundor. This Agl'{lamcmt and the Ancillary Agreements have been duly MyRxWallet Prana Private Limited A t.ubsldlary of M � RxWallot North Amor �� Corpor � tlon United States of America

![](e0703-18.jpg)

e>eecuted and de livered by lhe Aoqu i rer an - d, assuming the due � lJthorlzalion, ex&eutlon and del very hereof and ttloreof by the Seller. constirute 1he valid and legally binding oblig,at»ons of the Acquirer enforceable in aocory aoo thereby II not , r u ire any conscn approval, aulhon:tatioll or perm t of, or fll i AQ with or notification to . any GovernmentQ Entity. 3. Brokers and Legal Fees: Each Party shall be solely respon!.iblA for any and all legal. advi � y, brokerage . fuldec, acoountir,g, or oohaul1Jn � f s • t lncu,s • n connec ion witti he negotiation, execution, and summation of lhe transactio s oontem IJlted by th is Agreoment. unless othsrwise expressly agree to in wt'i i g by Pa · � s . Tne Acq irer has a Master Agl'eemont wlth the - agent/finder for th is - · pe<;ific tran action.. The agerlV nder shall be compensated pursuar,t t Mas or Ag eement. o a<.;1ent, broker. finder , investment ban er, financial advisor . or other s · milar intermediary shall be entitled to any fee, commission, Of ot er compensation in connection with this 1ransac · on Stid on any arrangem.., t made by or on be alt of e other Party or any of it Afftllates. A,RTICLE:VJ CONDITIONS TO OBLIGATION TO CLOSE 1. Conditions to Closing by e Acqui rer : The obliga · on of the Aoquirer to effect tho transactions contern plate here y Is subject to the satisractio:n ot waive r by the Acqu i rer of Ule followi conditions: (a) The representations and warranties of certain of the Seller set fo rth In this Agreement shall be lrue , md o0tr t In all material respects . · wit re p c t to ropresentations a d warrant s r'lot q uactfled by aterial � ty , or in aH respects, vith re spect to rep r esenta ion$ and � am:inties qualified by ma erlal ty as of th daka oft is Agreernen and as of the Closing Date as 1hougt maoo on and as of the cosing oa ce. (b) The Seller shall t,ave JM3rformed in aa mate r ial e pact the covenants require<l 1o ba performed by .it under this Agreemen at or p,lor to the Closing Date . MyRxWallet Prana Private Limited A subsidiary of MyRxWallet North Amenea Corporation United States of Amorlca</P

![](e0703-19.jpg)

(c} Th S lier shall have exocutcd and dcflverod each of the Anclllary Agl"QQmonts, as applicable . {d) There shall be no effective or pending Law or Order - that would profl ' bit the CIOslng , and the Saller shall h.ave obtained all necessary approvals of any Governmental ntl • in connectlo with the transactions contemplated hereby and by the Ancillary Agreements . (8) Tne Seller shall have delivered each of 1he i erns described In S � clion 3.2 . (f) Seller shalr have conducted its bu ir1ess only IJ1 th ordinary course and shall no1 have acquired or a mod o acquire as pa of the busm s all or any substantial ponioo of :he assots or business of any other business organization by merger o oo solidatioo, ·tock purchase or asse purchase without Acqulrer' ppr'oval In writing. (g) Seller shall have com tad Ul.C approval of this Agreeme - n t c:1r1d Anclllary Agreements as r � ulred under its articles of orgamzatlon , opera ·n - g agreements, and th � la vs of the,urf sdlctions where it is sul>Ject. (h} There - . re no appraisal r ights (dissenter's rights) asserted by any owner of Se ler iri connection with tti' s tr � n actlo . 6 . 2 CONDITIONS TO CLOSING BY THE SELLE R The obligation or the Sel � to fl c t the tr nsactiofls contemplate her by I � subject to the satisfaction walv : r by the Se ler o f the follov ir 19 collditions : (a) he representations arid warrantlos o the Acquirer set fo 1111 this Agreeme t shall bo true and correct In all material respects, with respoct to representationi:. ;:md varranties not quallficd by m teria r y and In all respects, witfl respect lo r prnsontations and var anlies qualified by ma erlallty, in ach case a of 1e dat of i s Agreer - nen and Hs of Clos,rg Date as oagh ma e on and as of the Closing 0a1 . (b) The Aoqu , rer sha l l ha e performed in all mat r al respects the covenant r'eqo 1 rod to be p rformed by it under i.s r mofl a or prior to the Clos i ng Oat . (c} The Aequl'8r sr.all have execu ed and d lvare

![](e0703-20.jpg)

1. Transfer Taxes; Not \ • hstnnding anything herein to the oontrary, Aoquirer shall be liable for and shall pay imy Transfer Taxes or other similar tax i mposed in connecoon with the transfer of the Assets pursuan to his Agreement. The party re..pon bis under applica b e Law for remitting any such tax shal pay and remit such tax on a timely basi and, If such party Is tho Sollor, tho Seller hall notify tho Acqulrer of the amount of such ta;c, and the Acquirer shaJI pl'OmpUy pay to tne SelffW the amount of u e h tax. 2. Further Action : From and after the Closing, each party hereto shaJI execute and deliver any documents and take au rurthef a • ns as may reasonably be required to implement the provisions of this Agreement and the Ancillary Agreer e ts . and to g i ve e ·ect to ttie transac f ons cont mplatcd herein and therein . is inclu - de • e surin that the Acqulrer obtains effective ow11ership an control of th Assets. ARTICLE VIII M ISC€1.LAN EOUS 1. Survival : Notwithstaf')ding any right ofthe Acqu · rer (whether or notei

![](e0703-21.jpg)

effect to any choke o law or conflict of law provlsio11 or rule that would cause lhe applioation of the Laws of any juri sdiction other than the S ate of Wyom • ng and St<1to of Telan9El11o, Hyder � bad , India . 7. Amendments and Waivers ; No amendment of any provlsloo of thii:J Agreemen shall be valld unless such amendment i s in vrltlng and signed by eE1ctl of the Parties hereto. Now - av by any Party hereto o any default. lsr&p esentation or breach of warranty or covenant hereund r. whethQ - f Intentional or not. s all be deemed to extend to any prior or $1Jbsequent def au It, misreprese taoon or breach of varranty or oovel \ 8J'lt hereunder or affect in any way any rights arising by virtue of any prlo or su s � ue11t such oocurrence . No waiver shalr be valid unlaS$ uoh wa · er i in \ lri rng and signed by the Party against whom sud'I waiver · sought to be enforced . 8. Severability : If any pro · sIon o1 his Agreement · s held to be illegal invalid or unM orce.ible unde any present or future Law al \ d if th& rlgh s or obligations of ny Par y he eto un<.Jsr th s Agr'i:!e.. - ,e it · 11not be mate ally ar \ (J adverse1y affected thereby , (a) � ch p ovision will be fu ly severable, (b) th · s Agreement, · 11 be oonstruea and en·orced as if such ii egal inva l id or unenforceabl provlsjon had never cooip isad a part heroof, (c} th r maining provisions of this Agreement · 11remain in f II force and effect and will no be affected by e illegal , inv lld or' unenforceable provision or by its severance here from a11d (d) in lieu of suet, illegal, invalid or unenforceable provia·on, th - ere wi boadded automatically aa a part of is Agreement a legal . valid e11d enforoea le provision · m · Iar in 1 rms o such ill � gal, invar or unen orc � ab e provision as may be possibte . 8.9 Expenses : Except as atherw J a expr sly set forth hereµ, o there n, ch of the Parties holllto w i ll bear its own costs and expenses (inctuding iegai fees and expenses) incUJrcd i n connection with U Is Agreer ar)t tt Y Ancillary A J nte11ts ar)d 1he lr'ar sections oontemplated hereby or 1tiereby , whether the tra sa - ctions oontemplated hereby or thereby are consummated. 10. lncorpor � t1on of Exh i bits and Schedules · he xhi i , Annexe and Sched les identified in ttlis Agreemen are incorporated herein by ref erenee and nado a part h reo . Unloss othcl' \ vlso speciflod, no Informa on oontalnod I an �, nur bera

![](e0703-22.jpg)

(a) ormal Acknowledgment & Acceptance . The Seller shall provid a wr tt n confirmation or formal acceptance of 1 hi s Agr m nt � iltlin [7] busine$S c ys of execuUon. Such confirmation shall expressly acknO \ eclge f: at this Agreement is binding, enforceabla , and an nt grnl � rt of the transactiofl , {b) SEC S.1 In egration . Upon r'8C � lpl of th written confirmation, the Buyer shall have the right to Incorporate this Agreement Into its S - 1 Reg · stration Statement to notify the Securities and Exchange Commissioo (SEC) that th i s transaction ls pa of a planned Secondary Offering . svbjeci to market oondnions and regulatory approvats . (c} o Fu her Seller Approval R u i red . Tho Se l ler shall not unreasonably , · thhol , delay . Or' oondltlon such con ation e Seller 8(;:i(flO \ edges tha tho Buyer is under regulatory obligation to d i s - c lo e th s Agreement as pa of i s SEC registra Of'I process and agrees to cooperate i n good fai h . ARTICLE IX TERMINATION 1. T ermina � on Rights : This A9ree e n t may b tem,inated at any t i me under the follQwir \ g conditions : (a} M tual Term i nli.tlor,. By mu ual vriuen consent of both Buyer a'ld Se ll er vi 1 a priur vritten notice vit i n 15 days upon execu .i o " or t his SPA. {b) Any meteri I or non - rnEilar..a.l tang Ible or i tangibfe changes i mps ting the norm I business operations immedia ely upon ex u o of e Definitive Sha e Purchase Agreement shall oons · tute a Mate,lal Adverse Effect, quiring reasse sm nt of contractuaI obligations and may be subject to b r each of contractual agreemen '" (c) Failure to Satisfy Clo · i t � g Condltons . By cl er Buyer o r Se ll er • , the Closing Candltlons have not been satisfied by "Closing Dale \ uh le s s t1c falJure i due to e breach or f ilure of the party seeking termination . (d) Breach by Seller. By Buyer . if he S I brea es any mat · a1 rep r esentation , watranty , or oovonant and fails to cure such breach within 60 da)'$ aft r r lvmg ,vritten otice . (�) Rogu J atory Proh i bition . By either Buyer or Se ll er, 1r th nsactlon Is prohibited by law pr regulato, - y on.let from any appficab governmental authority . (f) Material Adverse Change . By B ye . If a Ma t e rl .:.1 1 Mvors o Change occurs t t negatively Impacts the finan ci al condition, b siness operations - , or a sets of the Seller before Closing . {g) Buyer's Non - Payrn nt. By Sell r If Buyer fail to deliver near t e Purchase ti O r' o her r qulr d con · dera ·on as agreed in this pur c hase agre,em nt. MyRxWallet Prana Private Limited A subsidiary of lllyRxWallet North America Corporation Unit d $t3tes ot AmerJc - a

![](e0703-23.jpg)

9 . 2 Effoct of Termination : If this - Agreement is te rminate In SCOC>tdanoo with this section : (a) All obligations of the parties under this Agreament shall Immediately terminate , e oep tho e expressly stated to survive termina · on {e . g . , Confi entlality , Gover ing Law, Dispute Resolution). {b) lf terminaliot1 occurs due to a material breach , the non - breaching party shall have th right to pursue re edies available under law or e *![](e0703-24.jpg)

IN WlTNESS WHEREOF. the parties hereto ave executed th i s Agra ment as oft e day and year first above written. ACQUIRER: Signature : _ Binh Do, Chief Financial Officer MyRxWallet North Arnerlca Corpora • n 24 75 South Jones Blvd, Suite 9 Las Vagas , NV 89146 Un i ted Sta es of America Email : binh@myrxwalle . app https;//nwtxwallet lo Phone �408 . 797 . 8043 Dated : _ SELLER: �/:1•• l � Signa re: _, '1f_'"" "" _ Dr . P. Venkalesh Managing Director oah Therapeutics Pvt . Ltd . D.No . 7 - 1..645/A. Erragadtje, Sanath N gar Near Shilparamam, Madhapur Hyderabad, 500018 Telangana, lndi Email: venkal@noah erapeutlcs . co t https:// oah erapeu ics.com DIN : o 66 3C6 �1 PAN : A,G, a Pp 3, 1 G c... L Phone : +91 - 9440383778 Dated : 19 A"" - " "'l - <> ,_ Signature: - �- ----- - Klshore K., Managing Director MyRxWallet Prana, Pvt. Ltd . 2475 South Jones Blvd, Su i te 9 Las Vegas, NV 89146 United States of America mail: klshore myrxwa lle1 . app https �//myrxwal let.io Mobile : 408 . 966.1400 Dated : 06.11712025 SELLER : Signature : r -- �- - � N.Upendra Di r ector Noah Therapeutics Pvt. Ltd. D . No . 7 - 1 - 645/A, Erragadda Senath Nagar, Near Shilparamam , Madhapur Hyderabad 1 500018 Telanga na, I d i a Email· upendra@noa therapeutics . co h. ps :/ /noahtherapeutics.com D I N : Cb , '5"5" 1 8 PAN : A I eN 6 ƒ 94 - N Phone : +91 - 9177 2445 Dated: 19 ': i t;, Cl .S 0.2.r MyRxWallet Prana Private Limited A subsJdlary of MyRxWallat North America Corporation Unlted States of America*

## Ex1A-10

**Exhibit 10.1**

**MYRXWALLET NORTH AMERICA CORPORATION**

**POWER OF ATTORNEY**

*Form 1-A — Regulation A Offering Statement Under the Securities Act of 1933, as Amended*

KNOW ALL PERSONS BY THESE PRESENTS, that each of the undersigned officers and directors of MyRXWallet North America Corporation, a Wyoming corporation (the "Company"), whose principal executive offices are located at 732 S. 6th Street, #5397, Las Vegas, Nevada 89101, does hereby constitute and appoint Olivia Trinh, the Company's Chairman, Chief Executive Officer, and Interim Chief Financial Officer, as such person's true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person and in such person's name, place, and stead, in any and all capacities, to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) sign, execute, and deliver the Company's Offering Statement on Form 1-A filed with the United States Securities and Exchange Commission (the "Commission") pursuant to Regulation A under the Securities Act of 1933, as amended (the "Securities Act"), and the rules and regulations promulgated thereunder (the "Offering Statement"), together with any and all exhibits, schedules, and other documents filed as part thereof or in connection therewith;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) sign, execute, and deliver any and all amendments (including post-qualification amendments), supplements, or other modifications to the Offering Statement, including any exhibits, schedules, and other documents filed as part thereof or in connection therewith;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) sign, execute, and deliver any and all other documents required by the Commission or by applicable law in connection with the Offering Statement or the offering described therein, including without limitation offering circular supplements, annual reports, and other periodic or current reports filed by the Company with the Commission in connection with the offering;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) take any and all actions that such attorney-in-fact and agent deems necessary, appropriate, or advisable in connection with any of the foregoing; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) file the Offering Statement, and any and all amendments, supplements, and other documents described above, with the Commission electronically through the Commission's Electronic Data Gathering, Analysis, and Retrieval system ("EDGAR") or by such other means as may be required or permitted by the Commission.

Each of the undersigned hereby grants to said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection with the foregoing, as fully to all intents and purposes as the undersigned might or could do in person, and each of the undersigned hereby ratifies and confirms all that said attorney-in-fact and agent, or his or her substitute or substitutes, shall do or cause to be done by virtue of this Power of Attorney.

This Power of Attorney shall be effective as of the date of execution by the undersigned and shall remain in full force and effect until revoked by the undersigned in a signed written instrument delivered to the Company; provided, however, that this Power of Attorney shall automatically terminate upon the earlier of: (i) the termination or withdrawal of the Offering Statement; or (ii) the completion of the offering described in the Offering Statement and all required post-qualification filings in connection therewith.

This Power of Attorney shall not be affected by the disability or incapacity of the undersigned.

This Power of Attorney may be executed in one or more counterparts, each of which shall be deemed an original and all of which together shall constitute one and the same instrument. Electronic signatures shall be deemed valid and binding to the same extent as original ink signatures.

**IN WITNESS WHEREOF**, each of the undersigned has executed this Power of Attorney as of the date set forth opposite his or her name below.

**PRINCIPAL EXECUTIVE OFFICER, PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER, AND CHAIRMAN**

---

| | |
|:---|:---|
| Signature: | <u>/*s/ Olivia Trinh*</u>_________________________________ |
| Name: | Olivia Trinh |
| Title: | Chairman, Chief Executive Officer, and Interim Chief Financial Officer<br> *(Principal Executive Officer and Principal Financial and Accounting Officer)* |
| Date: | June 18, 2026 |

---

**DIRECTOR**

---

| | |
|:---|:---|
| Signature: | <u>/*s/ Scherri A. Harps*</u> |
| Name: | Scherri A. Harps |
| Title: | Independent Director |
| Date: | June 18, 2026 |

---

*This Power of Attorney is filed as Exhibit 10.1 to the Offering Statement on Form 1-A of MyRXWallet North America Corporation filed with the United States Securities and Exchange Commission pursuant to Regulation A under the Securities Act of 1933, as amended.*

**ACKNOWLEDGMENT OF ATTORNEY-IN-FACT**

The undersigned hereby acknowledges her appointment as attorney-in-fact pursuant to the foregoing Power of Attorney and her authority to act on behalf of each of the foregoing persons in connection with the Form 1-A Offering Statement of MyRXWallet North America Corporation and all amendments, supplements, and related filings thereto.

---

| | |
|:---|:---|
| Signature: | <u>/*s/ Olivia Trinh*</u> |
| Name: | Olivia Trinh |
| Title: | Chairman, Chief Executive Officer, and Interim Chief Financial Officer |
| Date: | June 18, 2026 |

---

*This Power of Attorney is executed and delivered in connection with the Offering Statement on Form 1-A of MyRXWallet North America Corporation. Nothing herein shall be construed to limit or restrict the authority of the Board of Directors of the Company or any duly authorized officer thereof to act independently in any capacity on behalf of the Company.*

## Ex1A-11

**Exhibit 11.2**

**<u>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</u>**

We consent to the incorporation by reference in this Offering Circular on Form 1-A of our report dated January 22, 2026 with respect to the financial statements of MyRxWallet North America Corporation for the years ended September 30, 2025.

/S/ Lateef Awojobi

LAO PROFESSIONALS

(PCAOB ID 7057)

Lagos, Nigeria

June 19, 2026

## Ex1A-12

**Exhibit 12.1**

---

| | | |
|:---|:---|:---|
| ![](image_001.jpg) | **BUSINESS LEGAL ADVISORS, LLC**<br> 14888 Auburn Sky Drive, Draper, UT 84020<br> (801) 634-1984<br> brian@businesslegaladvisor.com<br>| <br> Brian Higley<br> Attorney at Law<br> Licensed in Utah |

---

June 22, 2026

MyRXWallet North America Corporation

732 S. 6th Street

#5397

Las Vegas, Nevada 89101

**Re: Regulation A Offering Statement on Form 1-A — Opinion as to Legality of Securities**

Ladies and Gentlemen:

We have acted as legal counsel to MyRXWallet North America Corporation, a Wyoming corporation (the "**Company**"), in connection with the preparation and filing of the Company's Offering Statement on Form 1-A (File No. [●]) (as amended and supplemented from time to time, the "**Offering Statement**"), filed with the United States Securities and Exchange Commission (the "**Commission**") pursuant to Regulation A under the Securities Act of 1933, as amended (the "**Securities Act**"), and the rules and regulations promulgated thereunder. The Offering Statement relates to the offer and sale of up to 882,127 shares of the Company's common stock, par value $0.0001 per share (the "**Shares**"), at a price of $85.00 per Share, for maximum gross proceeds of up to $74,980,795 (the "**Offering**").

This opinion letter is furnished to you pursuant to the requirements of Item 17 of Form 1-A and is filed as Exhibit 12.1 to the Offering Statement.

**I. DOCUMENTS REVIEWED**

In connection with rendering this opinion, we have examined and relied upon, among other things, the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the Offering Statement on Form 1-A, including the Offering Circular forming Part II thereof, and all exhibits
filed or to be filed therewith;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) the Amended and Restated Articles of Incorporation of the Company, as filed with the Wyoming Secretary
of State on March 10, 2026 (the "**Articles of Incorporation** "), filed as Exhibit 2.1 to the Offering Statement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) the Bylaws of the Company, as currently in effect (the "Bylaws"), filed as Exhibit 2.2 to the
Offering Statement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) resolutions of the Board of Directors of the Company authorizing the Offering, the issuance of the Shares,
and the execution, delivery, and performance of the Subscription Agreement (the "**Board Resolutions** ");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) a certificate of the Company's Chairman and Chief Executive Officer, Olivia Trinh, as to certain factual
matters (the "**Officer's Certificate** "); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) such other corporate records, documents, instruments, certificates, and matters of law as we have deemed
necessary or appropriate as the basis for the opinions expressed herein.

**II. ASSUMPTIONS**

In rendering this opinion, we have assumed, with your permission and without independent investigation:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the genuineness of all signatures on all documents examined by us;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) the authenticity of all documents submitted to us as originals and the conformity to originals of all
documents submitted to us as copies;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) the legal capacity of all natural persons executing documents;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) that the Articles of Incorporation and Bylaws reviewed by us are currently in full force and effect and
have not been amended, restated, or otherwise modified since the dates of the versions reviewed by us;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) that the Board Resolutions reviewed by us are true, complete, and accurate, have not been rescinded, revoked,
or modified, and remain in full force and effect as of the date hereof;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) that the Officer's Certificate is accurate in all material respects as of the date hereof;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) that the Shares will be issued against full payment of the Offering Price of $85.00 per Share in accordance
with the terms of the Offering Statement and the Subscription Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) that prior to the issuance of the Shares, the Offering Statement shall have been duly qualified by the
Commission pursuant to Regulation A under the Securities Act; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) that no stop order suspending the qualification of the Offering Statement shall have been issued and no
proceedings for that purpose shall be pending or threatened by the Commission as of the date of any issuance of Shares.

**III. OPINION**

Based upon the foregoing examination, assumptions, and qualifications set forth herein, and subject to the limitations stated below, it is our opinion that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.** The Company is a corporation duly organized, validly existing, and in good standing under the laws of
the State of Wyoming and has the requisite corporate power and authority to execute and deliver the Offering Statement and to consummate
the transactions contemplated thereby.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.** The Shares have been duly authorized by all requisite corporate action of the Company and, when issued
and delivered by the Company against payment therefor in accordance with the terms of the Offering Statement and the Subscription Agreement,
will be validly issued, fully paid, and non-assessable shares of common stock of the Company under the Wyoming Business Corporation Act.

**IV. QUALIFICATIONS AND LIMITATIONS**

The foregoing opinions are subject to the following qualifications and limitations:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) **Scope of Law.** This opinion is limited solely to the Wyoming Business Corporation Act (Wyoming
Statute Title 17, Chapters 16 and 17) and, to the extent applicable, the federal securities laws of the United States. We express no opinion
with respect to the laws of any other jurisdiction, including the laws of any other state, the laws of any foreign country, or any local
laws.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) **No Opinion on Federal Securities Law Compliance.** We express no opinion as to the compliance
of the Offering with the registration or qualification requirements of the Securities Act, the Securities Exchange Act of 1934, as amended,
or the rules and regulations of the Commission thereunder, or with respect to any state securities or "blue sky" laws, except
to the extent expressly stated herein. We note that the Offering is being conducted pursuant to the qualification of the Offering Statement
under Regulation A of the Securities Act, and the qualification of the Offering Statement is a condition to the release of this opinion
as provided below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) **No Opinion on Tax Matters.** We express no opinion regarding any federal, state, local, or foreign
tax consequences of the Offering or the issuance or ownership of the Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) **Reliance on Certificates and Representations.** We have relied, without independent verification,
upon the certificates, representations, and warranties of officers and directors of the Company as to factual matters. We have conducted
no independent investigation of any factual matters.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) **Good Standing.** Our opinion as to good standing is based solely upon the website for the Wyoming
Secretary of State, which speaks only as of this date. We have made no further investigation as to the good standing of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) **Authorized Shares.** Our opinion that the Shares will be validly issued is subject to the condition
that, at the time of issuance of each Share, the Company shall have a sufficient number of authorized but unissued shares of common stock
available for issuance under its Articles of Incorporation to cover such issuance. As of the date of the Offering Circular, the Company's
Articles of Incorporation authorize 750,000,000 shares of common stock, par value $0.0001 per share. We have made no independent determination
as to the number of shares reserved, issued, or committed for issuance at any particular time and express no opinion as to whether sufficient
authorized shares will be available at any given future date, particularly in light of the potential issuance of shares upon conversion
of the Company's outstanding promissory notes, payment of interest thereon in stock, and future equity awards and issuances.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) **No Undertaking to Update.** We assume no obligation to update or supplement this opinion to
reflect any change in law, facts, or circumstances that may occur after the date hereof.

**V. CONSENT**

We hereby consent to the filing of this opinion letter as Exhibit 12.1 to the Offering Statement and to the reference to our firm in the Offering Circular under the headings "*Legal Matters*" and "*Experts*." In giving this consent, we do not hereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission promulgated thereunder.

This opinion letter is rendered solely for your benefit in connection with the Offering and may not be relied upon by any other person or entity, or used for any other purpose, without our prior written consent.

---

| | |
|:---|:---|
| <br> Very truly yours,<br>**BUSINESS LEGAL ADVISORS, LLC** | <br> Very truly yours,<br>**BUSINESS LEGAL ADVISORS, LLC** |
| By: | */s/ Brian Higley* |
|  | Brian Higley, Esq. Attorney at Law<br> 14888 Auburn Sky Drive Draper, Utah 84020<br> (801) 634-1984<br> brian@businesslegaladvisor.com |

---

## Add

**Exhibit 15.1**

![](ex15-1.jpg)

MyRxWallet North America Corporation Blockchain - Secured, Patient - Controlled EHR Platform Investor Presentation — Maxim Group LLC Regulation A+ Offering \| June 2026 $74.98M Max Offering $85.00 Price / Share 882,127 Shares Offered 317/317 ONC Inferno Pass IMPORTANT: This presentation does not constitute an offer to sell or solicitation to buy securities. Offering statement filed but not yet qualified by the SEC. No commitment may be accepted prior to qualification. See full disclosures on next slide. CONFIDENTIAL — FOR INSTITUTIONAL USE ONLY \| CIK: 0002041886 \| EIN: 33 - 1503628 \| myrxwallet.io

![](ex15-2.jpg)

IMPORTANT DISCLOSURES — PLEASE READ BEFORE PROCEEDING REGULATION A — NOT YET QUALIFIED An offering statement on Form 1 - A has been filed with the SEC (CIK: 0002041886) but has not yet been qualified. This presentation does not constitute an offer to sell or a solicitation to buy any securities. No money or consideration is being solicited. No commitment, binding or otherwise, may be accepted prior to qualification. Any offer may be withdrawn at any time before acceptance after the date of qualification. FORWARD - LOOKING STATEMENTS This presentation contains forward - looking statements subject to risks and uncertainties that could cause actual results to differ materially. Statements regarding future milestones, listings, revenue, acquisitions, certifications, grants, and similar matters are forward - looking. No assurance can be given that any forward - looking statement will prove correct. The Company undertakes no obligation to update such statements. GOING CONCERN / DEVELOPMENT STAGE MyRxWallet is a development - stage company with no revenues, no commercialized product, and no established public trading market . Independent auditors have expressed substantial doubt about the Company's ability to continue as a going concern . Past performance of any referenced transaction or market is not indicative of future results . NO GOVERNMENT ENDORSEMENT References to SAM.gov, UEI, CAGE Code, ONC Inferno, eRA Commons, and Grants.gov are factual recitations of registration and application status only. They do not imply endorsement, approval, or affiliation by any U.S. government agency, including HHS, NIH, ONC, DHS, SBA, or the SEC. This presentation has not been filed as a Rule 255 solicitation - of - interest communication and is intended solely for limited institutional use. Prospective investors must review the full offering circular on EDGAR before investing. KEY RISK FACTORS — Summary (See Full Form 1 - A for Complete Disclosure) ● Development - stage: no revenues, no product, going concern doubt expressed by auditors භ Noah Therapeutics SPA not yet closed; Noah is not currently a subsidiary ● No public trading market; may be illiquid indefinitely; Form 8 - A and OTCQB not guaranteed භ CEO controls ~71.48% of voting power; investors have limited ability to influence decisions ● $1.147B related - party notes (CEO - controlled); conversion would significantly dilute shareholders භ No minimum offering; no escrow; may raise far less than $74.98M ● India land (~$104.2M cash): title only upon full payment; no assurance of closing

![](ex15-3.jpg)

Company Overview Who We Are & What We Build MyRxWallet North America Corporation is a Wyoming - incorporated, development - stage healthcare technology company building patient - controlled Electronic Health Records (EHR) — secured by blockchain, compliant with FHIR and ONC standards, and designed to give patients greater data access and control. Founded October 2024 \| Wyoming Corporation Headquarters Las Vegas, Nevada (Commercial Virtual Office) Structure Parent + 3 Active Subsidiaries + VC Arm ONC Certified 317/317 Inferno (g)(10) Pass — April 17, 2026 (inferno.healthit.gov) Federal IDs UEI: MVKQW9DKKGB8 \| CAGE: 20KM5 \| SAM.gov Active Auditor LAO Professionals (PCAOB - Registered) Our Mission Your health story belongs to you. We believe every patient deserves the right to own, control, and benefit from their own medical records — not surrender them to systems that profit in their absence. MyRxWallet exists to return that power to the people it was always meant for, secured by blockchain and built on the conviction that true healthcare begins with patient autonomy. Platform Highlights (Development Stage) FHIR R4 - compliant EHR — patient & provider portals Blockchain - secured records (Hyperledger Fabric 2.5 LTS) AI - driven clinical decision support (in development) Tokenized consent framework (planned; subject to legal/ regulatory review) HIPAA & ONC (g)(10) compliance architecture

![](ex15-4.jpg)

The Problem & Our Solution Healthcare Data Is Broken — We Intend to Fix It THE PROBLEM Patients have limited ownership or control over their health records Fragmented data silos prevent coordinated, efficient care Healthcare data breaches expose millions of patients annually Providers spend significant time on administrative inefficiencies Patient data is monetized by systems — patients typically don't share in that value Interoperability gaps block meaningful care coordination THE MyRxWallet SOLUTION Development Stage Patient portal with real - time access to health data Blockchain - anchored immutable records (Hyperledger Fabric) HIPAA / GDPR / ONC (g)(10) compliance architecture AI - powered health insights & clinical decision support (in development) Tokenized data consent framework (planned; subject to legal/regulatory review) Provider workflow: scheduling, prescriptions, care coordination

![](ex15-5.jpg)

Platform Architecture & Key Features ONC - Certified. FHIR - Native. Blockchain - Secured. ONC Inferno (g)(10) Standardized API Test Suite v8.0.0 — 317 / 317 Tests PASSED \| April 17, 2026 \| inferno.healthit.gov Patient Portal Real - time lab, imaging & prescription access Appointment scheduling & telehealth integration 2FA encrypted login with biometric options AI - driven personalized health insights (in development) Prescription refill management & reminders Immutable blockchain record of each update Provider Workflow Appointment & care coordination tools Prescription management + e - prescribing Role - Based Access Control (RBAC) Complete audit trail via blockchain CDS (clinical decision support) integration Analytics, reporting & coding assistance Blockchain & AI Layer Hyperledger Fabric 2.5 LTS infrastructure (live) Blockchain - based patient identity layer Smart - contract consent controls (planned) Token - based incentive framework (planned; subject to legal review) FHIR R4 - compliant interoperability APIs AI predictive modeling (in development)

![](ex15-6.jpg)

Corporate Structure Parent Company + Integrated Subsidiary Ecosystem MyRxWallet North America Corporation Wyoming, USA \| CIK 0002041886 \| Parent / Registrant MyRxWallet Prana Private Limited India (Hyderabad) 100% Wholly - Owned APAC operations, land program, biobank, CRO acquisition MyRxWallet DAO, LLC Wyoming, USA 100% Wholly - Owned Technology backbone — EHR software, blockchain, AI, IP licensing MyRxWallet Venture Capital Inc. Wyoming, USA 100% Wholly - Owned Strategic M&A arm, formed March 2026 Controlled Under MyRxWallet Prana Private Limited: Bio - Blockchain Intelligence Pvt. Ltd. Majority / Controlling — ACQUIRED November 2025 Consideration: 8,875,740 NAC shares (~$750M aggregate, Board - determined; no formal third - party appraisal). Biobank, genomics, blockchain biomedical data intelligence. Noah Therapeutics Pvt. Ltd. 70% SPA — NOT YET CLOSED CRO based in Hyderabad. SPA dated June 17, 2025. Noah is NOT currently a subsidiary. SPA may not close on expected terms or at all. Independent pharma MSA in place (not yet a Company obligation).

![](ex15-7.jpg)

India Infrastructure Acquisition Program Hyperscale Health - Data Campus & Biobank — Pending Closing, Contingent on Offering Proceeds IMPORTANT: Prana does NOT currently own any of these land parcels. Cash consideration of ~$104.2M has not been paid. Title transfers only upon FULL cash payment from offering proceeds. Closings are not assured and may not occur on expected terms or at all. Status Cash Remaining Total Value Agreed Date Property / Location AoS executed; extended via Affidavit 12/11/2025; 1% IPO closing penalty if applicable ~$83.5M ~$83.6M Aug 9, 2025 216 Acres — Medak District, Telangana (NH - 44 corridor, hyperscale data center site) AoS executed; ~$855K stamp duty payable to Govt of AP upon closing ~$12.2M ~$12.2M Aug 20, 2025 147.07 Acres — Vemulapalli Farms Andhra Pradesh (Bio - Blockchain counterparty) AoS executed; title at sub - registrar upon full cash payment ~$7.0M ~$7.1M Aug 16, 2025 10 Acres — Medak District, Telangana (Logistics & biobank specimen facility) AoS executed; title at sub - registrar upon full cash payment ~$1.45M ~$1.45M Aug 16, 2025 5 Acres — Siddipet District, Telangana (Logistics center / warehouse / mixed - use) Agreement to Lease; no title transfer; quarterly rent only ₹41K/acre/mo (qtly, after 12 mos) Lease Aug 15, 2025 41 Acres — Medak, Telangana (LEASE) 30 - year term, solar - power logistics Total Pending Cash Consideration (Sale Agreements): ~$104.2 Million — payable from offering proceeds; no assurance closings will occur.

![](ex15-8.jpg)

Strategic Acquisitions: CRO & Biobank Intelligence Building the Integrated Healthcare Ecosystem Noah Therapeutics Pvt. Ltd. Type Contract Research Organization (CRO) — Hyderabad, Telangana, India Status 70% SPA signed June 17, 2025 — ACQUISITION NOT YET CLOSED Consideration 843,750 NAC shares (~$20.25M aggregate) Partial Xfer 572,916 + 125,200 shares issued Sept 19, 2025 Minority 30% held by original Noah Therapeutics promoters (unaffiliated) MSA Independent pharma MSA in place (not yet an obligation of the Company) Why Noah? Accelerated drug development with established global site networks Integrates CRO clinical data into the MyRxWallet EHR ecosystem Regulatory expertise for complex international pharma approvals Bio - Blockchain Intelligence Pvt. Ltd. f/k/a Clinrarc Services Pvt. Ltd. Type Biobank + blockchain biomedical data intelligence Status Majority/controlling interest acquired — November 2025 (CLOSED) Consideration 8,875,740 NAC shares (~$750M aggregate, Board - determined; no formal third - party appraisal) Land Anchor Counterparty for 147 - acre Vemulapalli Farms (Andhra Pradesh) Infrastructure Biobank vaults, EHR integration, cloud data centers, IoT logistics Standards ISO 9001, CLIA, HIPAA, GDPR, ICH - GCP (planned upon completion) Strategic Role in the Ecosystem: Anchors genomic database + AI - powered analytics capabilities Enables personalized medicine through bio - blockchain data integration Expands IP portfolio across life sciences and precision diagnostics

![](ex15-9.jpg)

MyRxWallet Prana — India Operations & Capitalization Strategy The Operating Engine for APAC Healthcare Infrastructure Capitalization of Prana MyRxWallet Prana Pvt. Ltd. was initially capitalized via issuance of NAC common stock valued at approximately $250M at the Board - determined price of $84.50/share. This equity capitalization is not equivalent to cash, but serves four critical strategic purposes: Establishes Prana's balance sheet for financing and strategic partnerships in India Enables equity - for - equity acquisition structures without immediate cash outlay Provides documented equity value for engagement with Indian government authorities Creates the capitalization framework to be supplemented with offering proceeds Board Valuation Basis: The Board valued NAC common stock at $84.50/share based on its assessment of the strategic asset base including ~$104M in committed land agreements. This is NOT based on a formal third - party appraisal. Market price, if and when traded, may differ materially. ~$250M Prana Initial Capitalization (NAC shares) ~$104.2M Pending Land Cash Consideration ~$750M Bio - Bank Acquisition Consideration (shares) ~$20.25M Noah Therapeutics SPA Consideration 70% stake Noah Therapeutics (pending close) 100% Prana Owned by NAC (Parent)

![](ex15-10.jpg)

The Offering Regulation A+ Tier 2 \| Primary - Only \| Best Efforts \| Not Yet Qualified Offering Terms Issuer: MyRxWallet North America Corporation Jurisdiction: Wyoming Corporation Offering Type: Regulation A+ Tier 2 (primary - only) Shares Offered: 882,127 shares of common stock Price Per Share: $85.00 Max Gross Proceeds: ~$74,980,795 Net Proceeds: ~$74,930,795 (after ~$50K offering expenses) Min Investment: $500 (may be waived) No Escrow: Best - efforts; funds available immediately Shares Outstanding: 280,352,363 (pre - offering, Colonial - confirmed) Fully Diluted: 289,532,363 (incl. 10,557,000 reserved note conversion) Conversion Price: $125.00/share (Amended Promissory Notes) Transfer Agent: Colonial Stock Transfer (Tyler Napier) Auditor: LAO Professionals (PCAOB - Registered) Promissory Note Structure Noteholder: MyRxWallet Corporation (CEO - controlled) Principal: $850,000,000 Amended Promissory Note Noteholder 2: Z the Future, LLC (CEO - controlled) Principal 2: $297,500,000 Amended Promissory Note Interest Rate: 7.5% per annum Conversion: $125.00/share; 10,557,000 shares reserved Note Repayment: Management expects conversion to equity, not cash repayment Capital Structure Snapshot Authorized Common: 750,000,000 shares (Wyoming) Authorized Preferred: 100,000,000 shares Issued & Outstanding: 280,352,363 (pre - offering) Treasury Shares: 2,943,000 Reserved (Notes): 10,557,000 Fully Diluted: 289,532,363 Post - Offering Outstanding: 281,234,490 (if all shares sold) Counsel: Business Legal Advisors LLC (Brian Higley) All cap figures per Colonial Stock Transfer as of March 24, 2026 (authoritative source).

![](ex15-11.jpg)

Use of Proceeds Net Proceeds: ~$74.93M \| Strategic M&A - Led Deployment \| Management Retains Broad Discretion Allocation at Maximum Offering Strategic M&A / Acquisitions 70% EHR Platform Development 10% Working Capital 10% Legal / Accounting / Regulatory 5% Land Acquisition Deposits 5% 100% ~$75.0M 50% ~$37.4M 10% ~$7.4M Use of Proceeds $74,980,795 $37,490,440 $7,498,105 Gross Proceeds ($50,000) ($50,000) ($50,000) Less: Offering Expenses $74,930,795 $37,440,440 $7,448,105 Net Proceeds $52,451,557 $26,208,308 $5,213,674 Strategic M&A (70%) $7,493,080 $3,744,044 $744,811 EHR Development (10%) $7,493,080 $3,744,044 $744,811 Working Capital (10%) $3,746,540 $1,872,022 $372,405 Legal/Accounting/Reg (5%) $3,746,540 $1,872,022 $372,405 Land Acq. Deposits (5%) At 10% – 25% funding: proceeds directed to EHR development, working capital & partial deposits. Full land acquisition closing requires substantially full offering proceeds. Management retains broad discretion over allocation. No minimum offering; actual proceeds may be substantially less than the maximum.

![](ex15-12.jpg)

Leadership Team Founder - Led, Mission - Driven Execution Olivia Trinh Founder \| Chairman \| CEO \| Interim CFO Age: 21 \| Appointed: August 2025 Founded MyRxWallet from the ground up in October 2024 — concept through SEC Regulation A+ filing Leads all operations: platform development, SEC compliance, federal grants, and India subsidiary program Assumed Interim CFO role March 2026 upon co - founder resignation; maintained continuity without interruption Devotes ~95% of professional time exclusively to the Company CEO of MyRxWallet Corporation ($850M note) and Managing Director of Z the Future, LLC ($297.5M note) — both CEO - controlled related - party noteholders Beneficial ownership: ~71.48% of voting power (controlling shareholder) Academic background: public health and business administration (University of Nevada, Reno) Scherri A. Harps Age: 62 \| Appointed: March 1, 2026 \| 35,000 shares awarded Serves as the Company's sole independent director Deferred compensation: $14,583.33/month (capped $350K), payable upon Funding Trigger Date Independence preserved continuously from March 1, 2026 per Nasdaq standards Planned Future Hires Permanent CFO (post - qualification, subject to funding) Additional independent directors (Nasdaq requirements) Executive officers in Sales, Clinical Ops & Engineering Board intends to recruit additional independent directors, a permanent CFO, and executive officers following Reg A qualification and receipt of sufficient offering proceeds. No assurance as to timing or terms.

![](ex15-13.jpg)

Path to Market & Development Roadmap Key Milestones — Subject to Qualification, Regulatory Approval & No Assurance of Completion Oct 2024 Revenue & India Land OTCQB Form 8 - A Reg A Reg A Under 317/317 ONC Company Scale Closings Application (concurrent) Qualification SEC Review Inferno Pass Founded Apr 2026 Jun 2026 Q3 2026\* Q3 2026\* Q3 2026\* Q4 2026\* 2027+\* \* Forward - looking milestones — no assurance these will be achieved on the indicated timeline or at all. Phase 1: Core Platform (Deployed) Patient portal live at myrxwallet.io Provider portal at visual parity APIs, Hyperledger blockchain infra live ONC Inferno 317/317 pass — April 2026 Phase 2: AI & Blockchain Integration AI clinical decision support tools (in development) Blockchain module certification (ONC) Telehealth & patient engagement features Backend provider workflow completion Phase 3: Commercial & Global Expansion India campus construction (subject to funding) Noah CRO integration (subject to SPA closing) WOSB / 8(a) SBA certifications (pending) Nasdaq uplisting (targeted 2027 – 2028; not guaranteed)

![](ex15-14.jpg)

Market Opportunity Multi - Billion Dollar Intersection of EHR, Blockchain & Precision Medicine (Third - Party Estimates) $38.5B+ Global EHR Market (2024 est.) Projected ~$105B by 2030 $89B+ Healthcare AI Market (2025 est.) Growing at 45%+ CAGR $8.5B+ Healthcare Blockchain Market (2026 est.) Fastest - growing HIT segment $49B+ Global CRO Market (2025 est.) Driven by pharma R&D outsourcing Market size figures are third - party estimates. The Company's actual addressable market may differ materially. Market size does not indicate expected revenue, share, or returns. MyRxWallet Competitive Differentiators (Development Stage — Not Yet Commercially Deployed) ONC - Certified 317/317 Inferno (g)(10) pass — April 2026. One of the key technical credentials for EHR interoperability. Patient Data Control Blockchain - secured, patient - permissioned consent architecture vs. traditional hospital - controlled systems. Planned Data Monetization Token - based patient incentive model under development; subject to applicable legal and regulatory review prior to launch. Global Ecosystem (Planned) India CRO + biobank + U.S. EHR — subject to SPA closing, land acquisition, and funding. AI - First Architecture Purpose - built AI for clinical insights and predictive modeling; AI features in active development.

![](ex15-15.jpg)

Key Risk Factors Development - Stage Company — Material Risks Disclosed in Form 1 - A (CIK: 0002041886) This is a development - stage company with no revenues, no current market for its shares, and no assurance the offering will be completed or that land acquisitions will close. Independent auditors have expressed substantial doubt about the Company's ability to continue as a going concern. Investors should read the full risk factors in the Form 1 - A before investing. Development Stage No revenues . No commercialized product . No assurance platform will be successfully developed or that users will adopt it . Going concern doubt expressed by independent auditors . No Trading Market No established public trading market. A trading market may never develop. Shares may be illiquid indefinitely. Form 8 - A and OTCQB application are planned but not guaranteed. India Land Acquisitions Prana does NOT currently own any of the land parcels (~$104.2M pending cash consideration). Title transfers only upon full cash payment. No assurance closings will occur. Noah SPA Not Closed Noah Therapeutics acquisition has NOT closed. Noah is not currently a subsidiary. The SPA may not close on expected terms or at all. Related - Party Notes $1.147B in related - party promissory notes held by CEO - controlled entities. Conversion would significantly dilute existing shareholders. Authorized shares may be insufficient. Concentrated Ownership CEO Olivia Trinh controls ~71.48% of voting power. Investors have limited ability to influence corporate decisions. Board Concentration Board currently consists of only two members. Limited independent oversight. Additional directors to be recruited post - qualification. No Minimum Offering No escrow; no minimum raise. Company may close with far less than $74.98M, limiting its ability to fund land acquisitions or full platform development.

![](ex15-16.jpg)

MyRxWallet North America Corporation Redefining Healthcare Data Ownership — One Patient at a Time 317/317 ONC Inferno (g)(10) Pass — April 17, 2026 (inferno.healthit.gov) Reg A+ Tier 2 — 882,127 shares at $85.00 \| Max proceeds ~$74.98M \| Not yet qualified by the SEC India hyperscale health - data campus + CRO + biobank ecosystem — pending funding and closing Blockchain - anchored, AI - powered, FHIR - native patient data platform (development stage) Form 8 - A planned concurrent with qualification — subject to SEC qualification; not guaranteed Contact Olivia Trinh \| Founder, Chairman, CEO & Interim CFO olivia@myrxwallet.io \| 725.217.7853 \| myrxwallet.io 732 S. 6th Street, #5397, Las Vegas, Nevada 89101 This presentation is for informational purposes only and does not constitute an offer to sell or solicitation to buy securities. Offering statement not yet qualified by the SEC. No commitment may be accepted prior to qualification. All investments involve risk. Prospective investors should read the full Offering Circular on EDGAR (CIK: 0002041886) before investing. References to SAM.gov, UEI, CAGE Code, ONC certifications, and federal programs do not imply government endorsement.

## Add

**Exhibit 15.2**

![](image_018.jpg)

MyRx Wallet MyRxWallet North America Corporation Your Health Data. Your Control. Your Consent. ONC (g)(10) INFERNO CERTIFIED 317 / 317 Sub - Tests PASS · April 17, 2026 Same federal certification required of Epic & Oracle $150B+ Healthcare IT Market TAM 317/317 ONC Inferno PASS $75M Reg A Max Raise $0 Outside Funding Raised Regulation A Tier 2 Offering \| CIK: 0002041886 \| Las Vegas, NV \| myrxwallet.io MyRxWallet North America Corporation \| myrxwallet.io \| Confidential

![](image_019.jpg)

Important Disclosures — Please Read Before Proceeding REGULATION A — RULE 255 REQUIRED NOTICE (VERBATIM PER SEC REGULATION) NO MONEY OR OTHER CONSIDERATION IS BEING SOLICITED, AND IF SENT IN RESPONSE, WILL NOT BE ACCEPTED. NO OFFER TO BUY CAN BE ACCEPTED AND NO PART OF THE PURCHASE PRICE CAN BE RECEIVED UNTIL THE OFFERING STATEMENT IS QUALIFIED BY THE U.S. SECURITIES AND EXCHANGE COMMISSION. ANY SUCH OFFER MAY BE WITHDRAWN OR REVOKED, WITHOUT OBLIGATION OR COMMITMENT OF ANY KIND, AT ANY TIME BEFORE NOTICE OF ITS ACCEPTANCE GIVEN AFTER THE DATE OF QUALIFICATION. AN INDICATION OF INTEREST IN RESPONSE TO THIS ADVERTISEMENT WILL INVOLVE NO OBLIGATION OR COMMITMENT OF ANY KIND. NOT AN OFFER TO SELL This document is a preliminary overview for informational purposes only. It does not constitute an offer to sell or a solicitation of an offer to buy any securities. The Company's Draft Offering Statement on Form 1 - A (CIK 0002041886) was submitted to the SEC on February 17, 2026 and has not been qualified. No securities may be sold, and no commitment to purchase may be accepted, until the Offering Statement is qualified by the Commission. GOING CONCERN / RISK OF LOSS The Company has incurred operating losses since inception and has not generated revenue. The Company's independent auditors have expressed SUBSTANTIAL DOUBT about the ability to continue as a going concern. Investment in this offering involves a HIGH DEGREE OF RISK. You may lose your ENTIRE INVESTMENT. This offering has no minimum amount; proceeds may be insufficient to fund operations. The Company should be viewed as a high - risk, speculative investment. FORWARD - LOOKING STATEMENTS All revenue projections, customer targets, milestone timelines, and product development plans contained herein are forward - looking statements based on management estimates involving significant assumptions and uncertainties. Actual results may differ materially. The Company undertakes no obligation to update these statements. Investors should refer to the complete Risk Factors section of the Offering Statement (CIK 0002041886) on EDGAR prior to making any investment decision. MyRxWallet North America Corporation \| CIK 0002041886 \| Form 1 - A Offering Statement (Not Yet Qualified) \| Confidential

![](image_020.jpg)

O U R S T O R Y At 21 , she earned the same federal certification Epic and Oracle hold. Olivia Trinh is a full - time Public Health student at the University of Nevada, Reno. During her summer internships at primary care and OB/GYN clinics in her hometown of Las Vegas, she watched patients leave appointments empty - handed — unable to access records they had a legal right to. She came home with a question no one had answered: what if patients actually owned their health data? F E D E R A L C E R T I F I C A T I O N 317/317 ONC (g)(10) Inferno PASS April 17, 2026 — the certification Epic and Oracle Health hold. Most healthcare IT startups never reach it. G O V E R N M E N T R E A D Y ACTIVE SAM UEI · CAGE Code UEI MVKQW9DKKGB8 · CAGE 20KM5. WOSB - eligible. SBA 8(a) in process. Federal procurement eligibility is active. P U B L I C C O M P A N Y SEC CIK 0002041886 Wyoming C - corp, Form 1 - A on file, PCAOB - audited financials, independent director seated. OTCQB - ready. F E D E R A L T A I L W I N D Jan 2026 CMS - 0057 - F enforcement Federal mandate creates compulsory demand for exactly what we built. FHIR API + TEFCA filed April 2026. The fundability question: A college student. $0 in outside funding. A full course load. And still — a federally certified, SEC - registered healthcare company. What does she build with capital, a team, and full attention? MyRxWallet North America Corporation · CIK 0002041886 · Offering Statement Under SEC Review — Not Yet Qualified

![](image_021.jpg)

MyRx Wallet The Problem: America's Healthcare Data Crisis Three compounding failures creating a $30B+ annual cost burden 01 Patients Don't Own Their Data Hospitals, insurers & legacy EHRs profit from patient records — selling, licensing & restricting access without consent. No mechanism for patients to carry, control or monetize their own clinical history. 280K+ Practices lacking enterprise EHR 02 No Affordable Certified EHR ONC (g)(10) certification is a legal prerequisite for Medicare/Medicaid incentive payments — yet EHR software costs $500K – $5M to implement. 76% of physicians & 1,400+ FQHCs are locked out. $30B+ Annual adverse drug event costs 03 Federal Mandates With No Solution CMS - 0057 - F (effective Jan 1, 2026) requires all Medicare/Medicaid payers to support FHIR - based patient access or face CMS penalties. The mandate is law. The affordable certified vendor doesn't exist — yet. 1,400+ FQHCs required to use certified EHR MyRxWallet North America Corporation \| myrxwallet.io \| Confidential

![](image_022.jpg)

MyRx Wallet The Solution: One Certified Platform, Three Breakthroughs MyRxWallet Platform — Built on Hyperledger Fabric · ONC (g)(10) Certified · Patient - Owned F O R PAT I E N T S • • • • Blockchain NFT identity credential (MyRx - ID) — permanent, patient - owned Portable health record access on any device from any provider Consent - gated data marketplace: earn 85% of every pharma/research data sale AI Health Sentinel: real - time medication, lab & drug interaction monitoring F O R P R O V I D E R S • • • • Full ONC (g)(10) FHIR R4 EHR DEA EPCS controlled substance e - Rx CCM billing: $62.28/patient/month Drug provenance via DSCSA F O R F E D E R A L / F Q H C s MyRxWallet North America Corporation \| myrxwallet.io \| Confidential • • • • ONC Inferno 317/317 PASS TEFCA participant (national data network) CAGE 20KM5 + SAM.gov registered WOSB eligible (SBA 8(a) in process)

![](image_023.jpg)

MyRx Wallet Why Now: Three Forces Converging in 2026 The window is 12 – 18 months wide. All three forces are current, not coming. F O R C E 1 Federal Mandate Now In Effect CMS - 0057 - F took effect January 1, 2026. Every Medicare/Medicaid payer must support FHIR - based patient access — or face CMS financial penalties. This is current law, not a coming regulation. Providers need certified EHR software today. L AW I N E F F E C T: J A N 1 , 2 0 2 6 F O R C E 2 Epic's Dominance Creating Defection Pressure Epic raised prices 23% in 2024. Industry surveys show 67% of small practices find current EHR costs 'prohibitive.' We are priced 80 – 90% below Epic and offer the same federal certification. The defection window is open. E P I C + 2 3 % P R I C E I N C R E A S E : 2 0 2 4 F O R C E 3 Post - COVID FQHC Funding Surge HRSA received $7.5B+ for FQHCs under the American Rescue Plan. These centers must use ONC - certified EHR under federal grant terms. The money has been allocated. The affordable certified vendor does not exist — until now. $7 . 5 B H R S A F Q H C F U N D I N G MyRxWallet North America Corporation \| myrxwallet.io \| Confidential

![](image_024.jpg)

MyRx Wallet Traction: Built Bootstrapped. Federally Certified. Zero outside capital. Every achievement below was self - funded. Federal EHR certification. Epic/Oracle spent $1M – $15M. We did it bootstrapped. ONC (g)(10) Inferno — 317/317 PASS Apr 17, 2026 Patient portal, provider portal, FHIR API, blockchain audit operational. Full EHR Platform Live Apr 2026 Apr 2026 CAGE 20KM5 + SAM.gov UEI: MVKQW9DKKGB8 Federal contract eligible today — most healthcare startups never reach this. Apr 2026 TEFCA Participant Application Submitted National health data network — same Epic/Cerner connect to; rare for pre - revenue company. Apr 2026 MyRxWallet North America Corporation \| myrxwallet.io \| Confidential USCDI v7 Element 703 Filed with ONC Novel national blockchain patient identity standard — if adopted, every EHR vendor must integrate. Apr 2026 DEA EPCS Audit Initiated (Schellman) Controlled substance e - prescribing — opens 30%+ more prescriber TAM. May 2026 Pepperdine MFC Quarter - Finals Advanced to quarter - finals — external validation of business model strength.

![](image_025.jpg)

MyRx Wallet Market Opportunity: $150B+ TAM, Federal Mandate Floor TAM $150B+ SAM $2.1B SOM $52M Independent Physician Practices 280,000 practices · 76% lack enterprise EHR · $299 – $599/month SaaS Federally Qualified Health Centers 1,400+ centers · 32M patients · $7.5B HRSA funding · $30K – $200K/year contracts CMS Promoting Interoperability $1B+ incentive payments tied to ONC - certified EHR use Patient Data Marketplace $5.3B by 2027 · 25% CAGR · 15% platform fee on consented research sales Federal Prime Contracts VA, IHS, CMS · $500K – $5M sole - source contracts via 8(a) pathway MyRxWallet North America Corporation \| myrxwallet.io \| Confidential

![](image_026.jpg)

MyRx Wallet Business Model: 4 Revenue Streams, All Recurring Designed for ROI - positive customer economics — CCM billing model offsets platform cost at scale. 1 SaaS Subscription • • • • Solo Provider: $299/month Small Practice: $799/month FQHC / Health Center: $2,499/month Federal / Enterprise: $100K – $500K/year Entry tier ($9,999/year) is below federal procurement threshold — no RFP required 2 CCM Billing Platform Fee • • • • CMS pays providers $62.28/patient/month MyRxWallet charges 10% fee = $6.23/patient/month 500 CCM patients → $37K/year for provider + $3.7K for us Passive, recurring, scales with provider patient panel CCM module designed to offset platform cost on a per - patient basis 3 Blockchain Gas Micro - Fees • • • • Every data access event = $0.001 micro - fee 1,000 providers п 50 daily events = $50/day Scales automatically with platform adoption Near - zero per transaction; significant at volume Zero marginal cost to us — pure margin at scale 4 MyRxWallet North America Corporation \| myrxwallet.io \| Confidential Patient Data Marketplace • • • • Patient sets price floor for consented data Pharma / biotech / research institutions pay directly Patient earns 85%; MyRxWallet earns 15% fee Fully HIPAA - compliant; patient - activated only Market size: $5.3B by 2027, growing 25% CAGR

![](image_027.jpg)

MyRx Wallet Competitive Advantage: Architecture Cannot Be Bolted On Legacy EHRs cannot add blockchain - native patient credentials without rebuilding their database. This is an architectural moat. DrChrono athenahealth Oracle/Cerner Epic MyRxWallet Feature 㾐 㾐 㾐 㾐 ض ONC (g)(10) Inferno PASS غ غ غ غ ض Blockchain Patient Identity غ غ غ غ ض Patient Data Ownership + Marketplace غ غ غ غ ض Hyperledger Fabric Immutable Audit غ ✓ (add - on) ✓ (extra fee) ✓ (extra fee) ض CCM Billing Module (CMS revenue) غ غ Partial Partial ض DSCSA Drug Provenance Tracking غ غ غ غ ض WOSB / SBA 8(a) Eligible $199/mo (ltd) $350+/mo $200K+ impl. $500K+ impl. $299/mo Price for Small Practice MyRxWallet North America Corporation \| myrxwallet.io \| Confidential

![](image_028.jpg)

MyRx Wallet Go - to - Market: Federal - First, Then Expand P H A S E 1 — Y E A R 1 FQHC Beachhead Strategy Legally required to use ONC - certified EHR · HRSA - funded (money is available) · Entry tier ($9,999) is below federal procurement threshold — no RFP, single decision - maker, 30 - day close C H A N N E L S : • • • • NVPCA — 15 Nevada FQHCs targeted via NVPCA channel CPCA — 300+ California FQHCs TACHC — 70+ Texas FQHCs HRSA Site Visit contacts — 1,400 grantees TARGET: 10 – 20 FQHC contracts · $300K – $1M ARR P H A S E 2 — Y E A R 2 Independent Physician Expansion 76% of 280K practices are without enterprise EHR · Digital CAC ~$200 – $400 vs FQHC $5K – $8K · CCM billing drives ROI - positive sales conversation C H A N N E L S : • • • Google Ads : ONC - certified EHR small practice Content/SEO : CMS Promoting Interoperability incentives Revenue cycle management channel partners TARGET: 500 practices + 50 FQHCs · $900K ARR P H A S E 3 — Y E A R 3 Federal Prime Contracts FedRAMP + SBA 8(a) unlocks sole - source contracts up to $5.5M · IHS (170 federal facilities) WOSB set - aside eligible · ARPA - H SBIR ($600K non - dilutive) C H A N N E L S : • • • • FedRAMP Marketplace visibility SBA 8(a) sole - source awards IHS agency procurement ARPA - H SBIR Phase I TARGET: First federal prime contract · $500K+ ARR MyRxWallet North America Corporation \| myrxwallet.io \| Confidential

![](image_029.jpg)

MyRx Wallet Team: Built by a Rare Founder OT Olivia Trinh Founder · Chairman · CEO · Interim CFO Age 21 · University of Nevada, Reno · B.S. Public Health · Minor: Business Administration Zero outside capital — at 21 Built the entire platform from $0 bootstrapped to ONC federal certification while enrolled full - time Full - stack engineering FastAPI · React · Hyperledger Fabric · NGINX/systemd — solo, no technical co - founder ONC (g)(10) Certified Navigated 317/317 Inferno PASS without a CTO, co - founder, or outside firm Federal compliance stack SAM.gov · CAGE · TEFCA · USCDI v7 standard filing — self - executed Regulatory expertise 45 CFR Part 164 (HIPAA) · CMS PI · DEA 21 CFR 1311 · DSCSA WOSB & SBA 8(a) Vietnamese - American woman founder · Presumptively eligible · 8(a) in process SH Scherri A. Harps Independent Director · Appointed Mar 1, 2026 20+ Years Sales Leadership Contract negotiation · Client relationship management Fortune 500 Experience Lennar Corporation (NYSE:LEN) · 5+ years as licensed real estate broker Academic Background B.S. Economics & Finance · University of Southern California P L A N N E D H I R E S (P o s t - O ff e r i n g) Chief Technology Officer / Technical Co - Founder $80K – $100K + equity FQHC & Federal Sales Representative $60K base + commission MyRxWallet North America Corporation \| myrxwallet.io \| Confidential

![](image_030.jpg)

MyRx Wallet Financial Projections: Projected Path to Profitability Conservative organic projections based on specific customer unit economics. Noah Therapeutics acquisition pending. Total ARR by Year Year 1 Year 2 Year 3 5000000 4500000 4000000 3500000 3000000 2500000 2000000 1500000 1000000 500000 0 SaaS ARR CCM + Other Year 3 Year 2 Year 1 Metric 100+ 50 10 FQHC Customers 2,000 500 50 Small Practices $3.8M $900K $180K SaaS ARR $299K $75K $0 CCM Billing Fees $500K+ $200K $0 Federal Contracts $100K $25K $0 Data Marketplace $4.7M $1.2M $180K Total ARR ~80% ~78% ~75% Gross Margin ~$140K ~$75K ~$35K Monthly Burn Path to cash - flow positive: 20 FQHCs + 200 small practices = $1.72M projected ARR vs. $840K burn → projected cash - flow positive at Month 14 – 16 post - funding. MyRxWallet North America Corporation \| myrxwallet.io \| Confidential Forward - Looking Statements: All projections are management estimates subject to significant uncertainty. Actual results may differ materially. See Risk Factors in the Offering Statement (CIK 0002041886).

![](image_031.jpg)

MyRx Wallet Regulatory & IP: An 18 – 36 Month Moat ACTIVE ONC (g)(10) Inferno PASS — 317/317 Federal EHR certification · Legal requirement for Medicare/Medicaid providers ACTIVE FHIR R4 + SMART on FHIR Live Federal data exchange standard · Required under CMS - 0057 - F (Jan 2026) APPLIED TEFCA Participant Applied National health data network — same network Epic/Cerner connect to ACTIVE CAGE 20KM5 + SAM.gov Active (UEI: MVKQW9DKKGB8) Federal contracting eligibility — gates all government revenue FILED USCDI v7 Element 703 Filed with ONC Novel blockchain patient identity standard — if adopted, becomes compliance requirement IN PROGRES S DEA EPCS (21 CFR Part 1311) Audit In Progress (Schellman) Controlled substance e - prescribing — opens ~30% additional prescriber TAM PLANNED FedRAMP Authorization In Preparation Required for federal cloud - hosted contracts (VA, IHS, CMS) PLANNED MyRxWallet North America Corporation \| myrxwallet.io \| Confidential SOC 2 Type II Planned Enterprise / payer sales prerequisite — unlocks major health system contracts

![](image_032.jpg)

MyRx Wallet The Ask: Regulation A Tier 2 Public Offering Raising Up To $75,000,000 Regulation A Tier 2 \| $85.00 per share \| CIK: 0002041886 OFFERING STATEMENT UNDER SEC REVIEW — NOT YET QUALIFIED No commitment may be accepted prior to qualification U S E O F P R O C E E D S Platform ecosystem acquisitions DEA EPCS, FedRAMP, SOC 2 Team, operations, infrastructure SEC compliance, IP filings Strategic M&A (70%) EHR Platform Development (10%) Working Capital (10%) Legal / Regulatory (5%) Land Acquisition — India (5%) $52.50M $7.50M $7.50M $3.75M $3.75M Prana data center infrastructure 1 8 - M O N T H M I LE S T O N E S PO S T - F U N D I N G DEA EPCS Certified Opens full prescriber market (+30% TAM) SOC 2 Type II Complete Unlocks enterprise + payer sales channel FedRAMP Ready Designation Visible to all federal agencies on marketplace 10 – 20 Paying FQHC Customers Signed Revenue base established, referenceable clients $1.2M ARR Path Established Conservative; full offering proceeds accelerate further ARPA - H SBIR Phase I Submitted $600K non - dilutive potential (July 2026 deadline) S - 1 Filing Initiated Path to OTCQB → Nasdaq uplisting MyRxWallet North America Corporation \| myrxwallet.io \| Confidential

![](image_033.jpg)

MyRx Wallet Your Health Data. Your Control. Your Consent. 317/317 ONC Inferno PASS $68,300 F&F Equity Round 5 Federal Registrations $150B+ Healthcare IT TAM Olivia Trinh — Founder & CEO MyRxWallet North America Corporation \| myrxwallet.io \| Confidential olivia@myrxwallet.io \| info@myrxwallet.io \| 702.546.8686 Website myrxwallet.io \| ehr.myrxwallet.io/docs ONC Inferno Verification inferno.healthit.gov (info@myrxwallet.io) Contact & Verify SAM.gov UEI MVKQW9DKKGB8 CAGE Code 20KM5 SEC CIK 0002041886

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 1-A

### REGULATION A OFFERING STATEMENT
### UNDER THE SECURITIES ACT OF 1933

### Item 1. Issuer Information

**Exact name of issuer:** MYRXWALLET NORTH AMERICA Corp

**Jurisdiction of Incorporation/Organization:** WY

**Year of Incorporation:** 2024

**CIK:** 0002041886

**I.R.S. Employer Identification Number:** 33-1503628

**Primary Standard Industrial Classification Code:** 7374

**Total number of full-time employees:** 0

**Total number of part-time employees:** 0

**Address of Principal Executive Offices:** 732 S. 6TH STREET, #5397, LAS VEGAS, NV 89101

**Company Phone:** 702-546-8686

**Person to contact:** Business Legal Advisors, LLC

### Financial Statements

**Balance Sheet Information**

| Metric                                   | Amount    |
|:---|:---|
| Cash and Cash Equivalents                | $48998.00 |
| Investment Securities                    | $0.00     |
| Accounts and Notes Receivable            | $0.00     |
| Property, Plant and Equipment (PP&E)     | $0.00     |
| Total Assets                             | $48998.00 |
| Accounts Payable and Accrued Liabilities | $13177.00 |
| Long-Term Debt                           | $0.00     |
| Total Liabilities                        | $13177.00 |
| Total Stockholders' Equity               | $35821.00 |
| Total Liabilities and Equity             | $48998.00 |

**Statement of Comprehensive Income Information**

| Metric                                    | Amount     |
|:---|:---|
| Total Revenues                            | $0.00      |
| Costs and Expenses Applicable to Revenues | $39533.00  |
| Depreciation and Amortization             | $0.00      |
| Net Income                                | $-39533.00 |
| Earnings Per Share - Basic                | 0.00       |
| Earnings Per Share - Diluted              | 0.00       |

**Auditor Information**

| Metric          | Amount            |
|:---|:---|
| Name of Auditor | LAO Professionals |

### Outstanding Securities

| Class                        |   Outstanding |     CUSIP | Publicly Traded   |
|:---|---:|---:|:---|
| Common Stock                 |     283295363 | 000000000 | N/A               |
| N/A                          |             0 | 000000000 | N/A               |
| Convertible Promissory Notes |    1147500000 | 000000000 | N/A               |

### Item 2. Issuer Eligibility
- [x] The issuer certifies that all of the statements in this part are true.

### Item 3. Application of Rule 262
- [x] The issuer certifies that it is not disqualified and has not been involved in any disqualifying event.

### Item 4. Summary Information Regarding the Offering

**Tier:** Tier2

**Financial Statement Status:** Audited

**Type of Securities Offered:** Equity (common or preferred stock)

**Is this a delayed or continuous offering?** Yes

**Was or is the offering to take place within one year after qualification?** Yes

**Was or is the offering to commence within two days after qualification?** No

**Is this a best efforts offering?** Yes

**Was there any solicitation of interest?** No

**Are there any resale securities by affiliates of the issuer?** No

**Offering Amounts**

| Description                                                     | Amount       |
|:---|:---|
| Number of securities offered                                    | 882127       |
| Number of securities outstanding                                | 280352363    |
| Price per security                                              | $85.00       |
| Issuer's aggregate offering price                               | $74980795.00 |
| Aggregate offering price of securities held by security holders | $0.00        |
| Aggregate price of securities offered concurrently              | $0.00        |
| Total aggregate offering price                                  | $74980795.00 |

**Anticipated Fees**

| Service Provider   | Name                         | Fees      |
|:---|:---|:---|
| Auditor            | LAO Professionals            | $8062.50  |
| Legal              | Business Legal Advisors, LLC | $15000.00 |
| Promoters          |  |  |

**Estimated Net Proceeds to the Issuer:** $74980795.00

### Item 5. Jurisdictions in Which Securities are to be Offered

- All States and Territories

### Item 6. Unregistered Securities Issued or Sold Within One Year

**Name of Such Issuer:** MyRXWallet North America Corporation

**Title of Securities Issued:** Common Stock

**Total Amount of Securities Issued:** 49626919

**Amount of such securities sold by principal security holders:** 0

**Aggregate consideration:** The aggregate consideration is $2,676,276,960.25, calculated by multiplying the number of shares issued in each completed transaction during the trailing twelve-month period by the Board-determined per-share price applicable to such transaction, as confirmed by the Company's transfer agent of record (Colonial Stock Transfer Co., Inc.). Of such issuances, 5,555,556 shares issued to DineNamics, Inc. on October 20, 2025 (Colonial Stock Transfer Log No. 120806) were subsequently cancelled on February 20, 2026 (Colonial Stock Transfer Log No. 122707) in connection with the termination of the DineNamics acquisition; net shares issued and currently outstanding from these transactions: 44,071,363.

**Basis for aggregate consideration:** —

**Securities Act Exemption:** Shares were issued pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended.